**EFFECTIVE**
**Version**
**Updated: 06/03/16**

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include:
"A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives"

From Act 127 passed in 2002

The following pages contain:

- The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories.
- The therapeutic classes of drugs which have clinical criteria for Prior Authorization may or may not be subject to a preferred agent.
- Within both of these categories there may be drugs or even drug classes that are subject to Quantity Limit Parameters.

Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non-preferred agents have been included and are listed in the right-hand column. Any drug not listed as preferred in any of the included categories requires Prior Authorization.

| | | |
|---|---|---|
| **GHS/Change Healthcare**<br>**PRESCRIBER Call Center:**<br>PA Requests<br>Tel: 1-844-679-5363; Fax: 1-844-679-5366<br>Note: Fax requests are responded to within 24 hrs.<br>For Urgent requests, please call GHS/Emdeon Directly | **GHS/Change Healthcare**<br>**PHARMACY Call Center:**<br>PA Requests<br>Tel: 1-844-679-5362<br>Available for assistance with claims processing | **GHS/Change HealthcareSr. Account Manager:**<br><br>Michael Ouellette, RPh<br>Tel: 802-922-9614<br>Fax:<br>E-Mail: mouellette@ghsinc.com |
| **DVHA Medical Staff:** | **DVHA Pharmacy Unit Staff:** | **DVHA Pharmacy Administration:** |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

Drugs highlighted in yellow denote a change in PDL status.

To search the PDL, press CTRL + F

**EFFECTIVE**
**Version**
**Updated: 06/03/16**

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)


| | | |
|---|---|---|
| *Medical Director*<br>J. Scott Strenio, M.D.<br>Tel: 802-871-3194 | Stacey Baker<br>Tel: 802-879-5912<br>Fax: 802-879-5651<br>E-Mail: stacey.baker@vermont.gov | *Director of Pharmacy Services*<br>Nancy Hogue, Pharm. D.<br>Tel: 802-879-5611<br>Fax: 802-879-5651<br>E-mail: nancy.hogue@vermont.gov |




This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

Drugs highlighted in yellow denote a change in PDL status.

To search the PDL, press CTRL + F

EFFECTIVE
Version
Updated: 06/03/16

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

## Contents


ACNE AGENTS ..... 7
ADHD AND NARCOLEPSY CATAPLEXY MEDICATIONS ..... 10
ALLERGEN IMMUNOTHERAPY ..... 15
ALPHA1-PROTEINASE INHIBITORS ..... 16
ALZHEIMER'S MEDICATIONS ..... 16
COX-2 INHIBITORS ..... 17
ANALGESICS ..... 18
ANEMIA: HEMATOPOIETIC/ERYTHROPOIETIC AGENTS ..... 25
ANKYLOSING SPONDYLITIS: INJECTABLES ..... 27
ANTI-ANXIETY: ANXIOLYTICS ..... 28
ANTICOAGULANTS ..... 29
ANTICONVULSANTS ..... 31
ANTIDEPRESSANTS ..... 34
ANTI-DIABETICS ..... 39
ANTI-EMETICS ..... 44
ANTI-HYPERTENSIVES ..... 48
ANTI-INFECTIVES ANTIBIOTICS ..... 58
ANTI-INFECTIVES ANTIFUNGAL ..... 66
ANTI-INFECTIVES ANTIMALARIALS: QUININE ..... 68
ANTI-INFECTIVES ANTI-VIRALS ..... 69
ANTI-MIGRAINE TRIPTANS ..... 71
ANTI-OBESITY ..... 73
ANTI-PSYCHOTIC ATYPICAL & COMBINATIONS (CHILDREN < 18 YEARS OLD) ..... 74
ANTI-PSYCHOTIC ATYPICAL & COMBINATIONS (CHILDREN > 18 YEARS OLD) ..... 78




This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

Drugs highlighted in yellow denote a change in PDL status.

To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

ANTI-PSYCHOTIC: TYPICALS ..... 85
BONE RESORPTION INHIBITORS ..... 86
BOTULINUM TOXINS ..... 88
BPH AGENTS ..... 90
CARDIAC GLYCOSIDES ..... 91
CHEMICAL DEPENDENCY ..... 92
GASTROINTESTINAL AGENTS: CONSTIPATION/DIARRHEA, IRRITABLE BOWEL SYNDROME-CONSTRIPATION, SHORT BOWEL SYNDROME, OPIOID INDUCED CONSTIPATION ..... 93
CONTRACEPTIVES ..... 95
CORONARY VASODILATORS/ANTIANGINALS/SINUS NODE INHIBITORS ..... 99
CORTICOSTEROIDS: ORAL ..... 101
COUGH AND COLD PREPARATIONS ..... 102
CYSTIC FIBROSIS MEDICATIONS ..... 102
DERMATOLOGICAL AGENTS ..... 104
DESMOPRESSIN: INTRANASAL/ORAL ..... 111
DIABETIC TESTING SUPPLIES ..... 112
EPINEPHRINE: AUTO-INJECTOR ..... 112
ESTROGENS: VAGINAL ..... 113
FIBROMYALGIA AGENTS ..... 113
GASTROINTESTINAL ..... 114
GAUCHER'S DISEASE MEDICATIONS ..... 120
GOUT AGENTS ..... 121
GROWTH STIMULATING AGENTS ..... 122
HEMOPHILIA FACTORS ..... 124
HEPATITIS C AGENTS ..... 125
HEREDITARY ANGIOEDEMA MEDICATIONS ..... 126
IDIOPATHIC PULMONARY FIBROSIS (IPF) ..... 127
IMMUNOLOGIC THERAPIES FOR ASTHMA ..... 127



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

Drugs highlighted in yellow denote a change in PDL status.

To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

INTERLEUKIN (IL)-1 RECEPTOR BLOCKERS ..... 129
IRON CHELATING AGENTS ..... 130
LIPOTROPICS: ..... 130
MISCELLANEOUS ..... 136
MOOD STABILIZERS ..... 141
MUCOSAL COATING AGENTS ..... 142
MULTIPLE SCLEROSIS MEDICATIONS ..... 142
MUSCLE RELAXANTS, SKELETAL ..... 143
NEUROGENIC ORTHOSTATIC HYPOTENSION ..... 145
NUTRITIONALS, LIQUID ORAL SUPPLEMENTS ..... 146
ONCOLOGY: ORAL (select) ..... 147
OPHTHALMICS ..... 147
OTIC ANTI-INFECTIVES ..... 154
OVER THE COUNTER (OTC) MEDICATIONS ..... 155
PANCREATIC ENZYME PRODUCTS ..... 155
PARATHYROID AGENTS ..... 155
PARKINSON'S: NON ERGOT DOPAMINE RECEPTOR AGONIST ..... 156
PHOSPHODIESTERASE-4 (PDE-4) INHIBITORS ..... 158
PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS ..... 159
PLATELET INHIBITORS ..... 159
POST-HERPETIC NEURALGIA AGENTS ..... 160
PSORIATIC ..... 161
PULMONARY AGENTS ..... 163
PULMONARY ARTERIAL HYPERTENSION MEDICATIONS ..... 172
RENAL DISEASE: PHOSPHATE BINDERS ..... 173
RESTLESS LEG SYNDROME MEDICATIONS ..... 174
RHEUMATOID, JUVENILE & PSORATIC ARTHRITIS: IMMUNOMODULATORS ..... 174
SILIVA STIMULANTS ..... 177



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

SEDATIVE/HYPNOTICS ..... 177
SMOKING CESSATION THERAPIES ..... 179
TESTOSTERONE: TOPICAL ..... 180
THROMBOPOIETIN RECEPTOR AGONISTS ..... 181
URINARY ANTISPASMODICS ..... 182
VAGINAL ANTI-INFECTIVES ..... 183
VITAMINS: PRENATAL MULTIVITAMINS ..... 184



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **ACNE AGENTS** | | |
| **ORAL AGENTS** | | |
| DOXYCYCLINE MONOHYDRATE 50MG, 100MG CAPS<br>DOXYCYCLINE MONOHYDRATE SUSP 25MG/5ML<br>MINOCYCLINE 50MG 100MG CAPS<br><br>ISOTRETINOIN† CAP<br>(AMNESTEEM, CLARAVIS, MYORISAN) | Adoxa®* (doxycycline monohydrate) 150mg tab<br>Doryx (doxycycline hyclate) tabs<br>Doxycycline 50mg, 75mg, 100mg, 150mg tabs<br>Doxycycline 75mg, 150mg caps<br>Oracea® (doxycycline monohydrate) 40 mg cap<br>Vibramycin®* (doxycycline hyclate) 100 mg cap<br>Vibramycin®* (doxycycline hyclate) suspension<br>Vibramycin® (doxycycline calcium) syrup<br>All other brands<br><br>Eryped® (erythromycin ethylsuccinate)<br>Erythrocin (erythromycin stearate)<br>PCE Dispertab® (erythromycin base)<br>All other brands<br><br>Minocycline 50mg, 75mg, 100mg tabs<br>Solodyn® (minocycline) tabs ER<br>E.E.S.® (erythromycin ethylsuccinate)<br>Eryped® (erythromycin ethylsuccinate)<br>ERY-TAB® (erythromycin base, delayed release)<br>Erythrocin (erythromycin stearate)<br>Erythromycin Based<br>Erythromycin Ethylsuccinate (E.E.S. ® , Eryped®)<br>PCE Dispertab® (erythromycin base) | **Non-preferred doxycycline/minocycline products:** patient has had a documented side effect, allergy, or treatment failure with a preferred doxycycline/minocycline. If a product has an AB rated generic, the trial must be the generic formulation.<br>**Oracea:** patient has a diagnosis of Rosacea AND patient has had a documented side effect, allergy, or treatment failure with both a preferred doxycycline and minocycline.<br>**Vibramycin Suspension, Syrup:** patient has a medical necessity for a liquid dosage form AND a documented failure of preferred doxycycline suspension.<br>**Erythromycin products:** patient has had a documented side effect or treatment failure with at least two preferred products.<br>**Tetracycline products:** patient has had a documented side effect, allergy, or treatment failure with at least two preferred products..<br>**Absorica/Zenatane:** patient has had a documented side effect, allergy, or treatment failure with at least two isotretinoin preferred products. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | Tetracycline 250mg, 500mg cap<br>Absorica® (isotretinoin) capsules<br>Zenatane cap (isotrentinoin)<br>All other brands | |
| **TOPICAL ANTI-INFECTIVES** | | |
| BENZOYL PEROXIDE PRODUCTS<br>BENZOYL PEROXIDE †<br>2.5%,5%, 10% *G*,<br>*5%, 6%,7%, 10% CL*;<br>10%*C*;<br>5%, 10% *L*;<br>5.3%, 9.5% F<br><br>CLINDAMYCIN PRODUCTS<br>CLINDAMYCIN 1% *S, G, L, P,F* †<br><br>ERYTHROMYCIN PRODUCTS<br>ERYTHROMYCIN 2% *S, G, P* †<br><br>SODIUM SULFACETAMIDE PRODUCTS<br><br>COMBINATION PRODUCTS | Benzepro 5.3%, 9.8% F; 6% P; 7% CL<br><br>PanoxylG; 10% B, 4% CL<br>All other brands<br><br>Cleocin-T®* (clindamycin) 1% S, P, L, G<br><br>All other brands<br><br>Erygel®* (erythromycin 2% G)<br>All other brands<br><br>Klaron®* (sodium sulfacetamide 10% L)<br>Sodium Sulfacetamide 10% *L*†<br><br>All other brands<br><br>Benzaclin® (clindamycin/benyoyl peroxide)<br><br>Azelex® (azelaic acid 20%C)<br>DUAC® (clindamycin/benzoyl peroxide) gel | **Single ingredient products:** patient has had a documented side effect, allergy, or treatment failure with two preferred products including one from the same sub-category, if there is one available. If a product has an AB rated generic, there must have been a trial of the generic.<br>**Combination products:** patient has had a documented side effect, allergy, or treatment failure with generic erythroymycin/benzoyl peroxide. (If a product has an AB rated generic, there must have been a trial of the generic.) AND patient has had a documented side effect or treatment failure on combination therapy with the separate generic ingredients of the requested combination product, if applicable.<br>**Azelex:** the diagnosis or indication is acne AND patient has had a documented side effect, allergy, or treatment failure with two generic topical anti-infective agents (benzoyl peroxide, clindamycin, erythromycin, erythroymcin/benzoyl peroxide, )<br>**Limitations:** Kits with non-drug products are not covered<br><br>**Onexton :** Prior authorization and be available to the few patients who are unable to tolerate or who have failed on preferred medications. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| ERYTHROMYCIN / BENZOYL PEROXIDE†<br><br><u>OTHER</u><br><br>*C=cream,CL=cleanser, E=emulsion, F=Foam, G=gel, L=lotion,O=ointment, P=pads, S=solution, W=wash, B=bar* | Benzamycin®* (erythromycin/benzoyl peroxide)<br>Onexton® (clindamycin/benzoyl peroxide)<br>Sodium Sulfacetamide/Sulfur C*L, C, P, E,*†<br>Sodium Sulfacetamide/Sulfur *W* †<br><br>Sumaxin ® (sulfacetamide/sulfur*L,P,W*)<br>Rosula®* (sulfacetamide/sulfur P, W)<br>All other brands<br><br>Aczone® (dapsone 5% G)<br><br>All other brands any topical acne anti-infective medication | |
| **TOPICAL - RETINOIDS** | | |
| TRETINOIN† *(specific criteria required for ages <10 or >34)* 0.025%, 0.05%, 0.1% *C*; 0.01%, 0.025% *G*<br>AVITA® (tretinoin)<br>FABIOR® (tazarotene 0.1% F)<br>TAZORAC® (tazarotene) 0.1% *C, G*<br><br>C= *cream*, G=*gel* | All brand tretinoin products (Atralin® 0.05% G, Retin-A®*, Retin-A Micro® 0.1%, 0.04%, etc.)<br><br>Tretinoin microsphere† (compare to Retin-A Micro®) 0.1%, 0.04%<br><br>adapalene† (compare to Differin®) 0.1% C, G, 0.3% G<br>Differin® (adapalene) 0.1% C, G; L 0.3% G<br><br>Avage® (tazarotene) ♣ | **Brand name tretinoin products and generic tretinoin microsphere:** diagnosis or indication is acne vulgaris, actinic keratosis, or rosacea AND patient has had a documented side effect, allergy, or treatment failure with a preferred generic topical tretinoin product. If a product has an AB rated generic, the trial must be the generic formulation.<br><br>**Differin** (brand) and adapalene (generic): diagnosis or indication is acne vulgaris, actinic keratosis, or rosacea AND patient has had a documented side effect, allergy, or treatment failure with a preferred generic topical tretinoin product AND the request is for the brand product, the patient has had a documented intolerance to a generic adapalene product.<br>**Tretinoin** (age < 10 or > 34): diagnosis or indication is acne vulgaris, actinic keratosis, or rosacea. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | Renova® (tretinoin) ♣<br>Solage® (tretinoin/mequinol) ♣<br>Tri-Luma® (tretinoin/hydroquinone/fluocinolone) ♣<br>Veltin® (clindamycin/tretinoin) G<br>♣ Not indicated for acne. Coverage of topical retinoid products will not be approved for cosmetic use (wrinkles, age spots, etc.). | **Limitations:**<br>Coverage of topical retinoid products will not be approved for cosmetic use (wrinkles age spots, etc.) (i.e. Avage, Renova, Solage, Tri-Luma). |
| **TOPICAL - ROSACEA** | | |
| FINACEA® (azelaic acid) 15% *G* , F<br>METRONIDAZOLE† 0.75% *C, G, L*<br><br>*C=cream, F=Foam, G=gel, L=lotion* | All brand metronidazole products (MetroCream®* 0.75% *C*, Metrogel® 1% *G*, MetroLotion®* 0.75% *L*, Noritate® 1% *C* etc.)<br>Metronidazole† 1% *G*<br>Soolantra® (ivermectin) | **Brand name metronidazole products,** metronidazole 1% gel (generic) and Soolantra: diagnosis or indication is roacea AND patient has had a documented side effect, allergy or treatment failure with a preferred generic topical metronidazole product. If a product has an AB rated generic, there must have also been a trial of the generic formulation.<br>**Limitations**: The use of Mirvaso (brimonidine topical gel) for treating skin redness is considered cosmetic. Medications used for cosmetic purposes are excluded from coverage. Mirvaso topical gel has not been shown to improve any other symptom of rosacea (e.g. pustules, papules, flushing, etc) or to alter the course of the disease. |
| **ADHD AND NARCOLEPSY CATAPLEXY MEDICATIONS** | | |
| **SHORT/INTERMEDIATE ACTING** | | |
| DEXMETHYLPHENIDATE † (compare to Focalin®) | Evekeo® (amphetamine sulfate)<br>Focalin® (dexmethylphenidate) | **Focalin:** patient has a diagnosis of ADD, ADHD or narcolepsy AND patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient is also on Focalin |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| METADATE ER® (compare to Ritalin® SR)<br>METHYLIN® (compare to Ritalin® )<br>METHYLIN® ER (compare to Ritalin® SR)<br>METHYLPHENIDATE † (compare to Ritalin®)<br>METHYLPHENIDATE SR † (compare to Ritalin ® SR)<br>AMPHETAMINE/DETROAMPHETAMINE † (compare to Adderall®)<br>DEXTROAMPHETAMINE IR† (Zenzedi 5 or 10 mg, formerly Dexedrine®) | Ritalin®* (methylphenidate)<br>Ritalin SR®* (methylphenidate SR)<br>Adderall®* (amphetamine/dextroamphetamine)<br>Desoxyn® (methamphetamine)<br><br>Dextroamphetamine sulfate† 1 mg/ml oral solution<br>Methamphetamine † (compare to Desoxyn®)<br>Procentra® (dextroamphetamine sulfate) 1 mg/ml oral solution<br>Zenzedi® (dextroamphetamine IR) 2.5 mg, 7.5 mg, 15 mg, 20 mg, 30 mg tablets | XR and the prescriber is adding a shorter acting dosage form. OR patient has had a documented side-effect, allergy, or treatment failure on Methylin or methylphenidate. AND In addition, for approval of brand name Focalin, the patient must have had a documented intolerance to generic dexmethylphenidate.<br>**Ritalin and Ritalin SR**: patient has a diagnosis of ADD, ADHD, or narcolepsy. AND patient has had a documented intolerance to the preferred equivalent. For Ritalin SR these are Methlyin ER, Metadate ER, or methylphenidate SR. For Ritalin these are Methylin or methylphenidate.<br>**Adderall:** patient has a diagnosis of ADD, ADHD, or narcolepsy. AND patient has had a documented intolerance to the preferred generic equivalent.<br>**Methamphetamine and Desoxyn:** Given the high abuse potential of methamphetamine and Desoxyn, the patient must have a diagnosis of ADD, ADHD or narcolepsy and have failed all preferred treatment alternatives. In addition, for approval of brand name Desoxyn, the patient must have had a documented intolerance to generic methamphetamine.<br>**Procentra, dextroamphetamine oral solution:** patient has a medical necessity for an oral liquid dosage form. (eg. Swallowing disorder). AND if the request is for Procentra, the patient has a documented intolerance to the generic equivalent.<br>**Zenzedi:** the prescriber provides clinical rationale explaining why other generic dextroamphetamine oral tablet products are not suitable alternatives.<br>**Evekeo**: patient has a diagnosis of ADHD or narcolepsy AND the patient has had a documented side-effect, allergy, or treatment failure of at least 3 preferred agents, including one of each two distinct chemical entity (amphetamine/dextroamphetamine,methylphenidate). |
| **LONG ACTING** | | |
| **Methylphenidate Products**<br>**Oral**<br>FOCALIN® XR (dexmethylphenidate SR 24 HR | Aptensio®XR (methylphenidate DR 24HR IR/.ER, 40:60%) | **Aptensio XR, Metadate CD, Ritalin LA, and Methylphenidate CR, Methylphenidate SR 24 HR:** patient has a diagnosis of ADD, ADHD or narcolepsy. AND patient has been started and stabilized on the requested |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| IR/ER, 50:50%)<br><br>METHYLPHENIDATE SA OSM IR/ER, 22:78%† (compare to Concerta®) (authorized generic, labeler code 00591 is only preferred form)<br><br>**Oral Suspension**<br>QUILLIVANT XR® (methylphenidate IR/ER, 20:80%) (*QL = 12 ml/day)*<br><br>**Transdermal**<br>DAYTRANA® (methylphenidate patch) (*QL = 1 patch/day)*<br><br>**Amphetamine Products**<br>**Oral**<br>ADDERALL XR® (amphetamine/dextroamphetamine SR 24 HR, IR/ER, 50:50%)<br>DEXTROAMPHETAMINE 24 hr SR† (compare to Dexedrine CR®)<br><br>VYVANSE® (lisdexamfetamine) *(QL = 1 cap/day)* | Concerta®* (methylphenidate SA OSM IR/ER, 22:78%)<br>Dexmethylphenidate SR 24 HR IR/ER, 50:50% † (compare to Focalin XR®)<br>Metadate CD® (methylphenidate CR, IR/ER, 30:70%)<br>methylphenidate CR, IR/ER, 30:70% (compare to Metadate CD®)<br>Methylphenidate SA OSM IR/ER, 22:78% (compare to Concerta®) (non-authorized generic forms)<br>Methylphenidate SR 24 HR, IR/ER, 50:50%† (compare to Ritalin LA®)<br>Ritalin LA® (methylphenidateSR 24 HR, IR/ER, 50:50%)<br>Amphetamine/dextroamphetamine SR 24 HR, IR/ER, 50:50% † (compare to Adderall XR®)<br>Dexedrine CR®* (dextroamphetamine 24 hr SR) | medication (Note: samples are not considered adequate justification for stabilization) OR patient has had a documented side-effect, allergy, or treatment failure on Focaline XR or Methylphenidate SR OSM. AND for approval of generic methylphenidate CR or methylphenidate SR 24 HR, the patient must have had a documented intolerance to the brand equivalent.<br>**Concerta and non-authorized generic:** patient has a diagnosis of ADD, ADHD, or narcolepsy. AND patient has had a documented intolerance to authorized generic Methylphenidate SA OSM.<br>**Dexedrine CR**: patient has a diagnosis of ADD, ADHD, or narcolepsy. AND patient has had a documented intolerance to the preferred generic equivalent.<br>**Amphetamine/dextroamphetamine** SR 24 HR (generic) dexmethylphenidate SR 25 HR IR/ER (generic): patient has a diagnosis of ADD, ADHD, or narcolepsy. AND patient must have a documented intolerance to the brand name equivalent. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **MISCELLANEOUS** | | |
| GUANFACNIE ER (Intuniv®) | Modafinil (compare to Provigil® ) **(not approvable for ADHD in children age ≤12)** ***(Max days supply = 30 days)***<br>*Qty limit: 100 mg = 1.5 tablets/day;200 mg = 2 tablets/day*<br>*Maximum Daily Dose = 400 mg*<br>Nuvigil® (armodafinil)<br>*Qty limit: 50 mg = 2 tablets/day; 150 mg/200 mg/250 mg = 1 tablet/day*<br>Provigil® (modafinil) ***(not approvable for ADHD in children age ≤12).***<br>*Qty limit: 100 mg = 1.5 tablets/day;200 mg = 2 tablets/day*<br>*Maximum Daily Dose = 400 mg* ***(Max days supply = 30 days)***<br>Clonidine extended release †(compare to Kapvay®)<br>*Qty limit = 4 tabs/day*<br>Intuniv® (guanfacine extended release) Tablet *Qty limit = 1 tablet/day*<br>Kapvay® (clonidine extended release) Tablet *Qty limit = 4 tablets/day*<br>Strattera® (atomoxetine)<br>*Qty limit:10, 18, 25 and 40 mg = 2 capsules/day*<br>*60, 80 and 100 mg = 1 capsule/day*<br>*FDA maximum recommended dose = 100 mg/day*<br>Xyrem® (sodium oxybate) oral solution<br>*Qty limit = 540 ml/30 days* | **Nuvigil®:** Narcolepsy, excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (adjunct to standard treatment): The patient is > 17 years old AND The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient has had a documented side-effect, allergy or treatment failure to a CNS stimulant or has a contraindication for use of these agents (e.g. substance abuse history). Nuvigil® will not be approved for sleepiness associated with shift work sleep disorder, idiopathic hypersomnolence, excessive daytime sleepiness, fatigue associated with use of narcotic analgesics, or for ADHD (for any age patient).<br>**Provigil®, Modafinil**: Narcolepsy, Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (adjunct to standard treatment), fatigue associated with multiple sclerosis, fatigue associated with the treatment of depression or schizophrenia: The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.)OR The patient has had a documented side-effect, allergy or treatment failure to a CNS stimulant or has a contraindication for use of these agents (e.g. substance abuse history) AND if the request is for modafinil, the patient has a documented intolerance to brand Provigil ADHD age >12: The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient has a documented treatment failure, due to lack of efficacy, to two long-acting CNS stimulants or the patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate -to-severe anxiety, substance abuse) to one Long -acting CNS stimulant. AND The patient has had a documented side-effect, allergy, or treatment failure to Strattera® AND if the request is for modafinil, the patient has a documented intolerance to brand Provigil.<br><br>**Provigil®/Modafinil** will not be approved for sleepiness associated with shift work |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | sleep disorder, idiopathic hypersomnolence, excessive daytime sleepiness, fatigue associated with use of narcotic analgesics, or for ADHD in children age ≤12.<br>**Intuniv:** patient has a documented intolerance to generic guanfacine ER<br>**Kapvay, Clonidine ER:** patient has a diagnosis of ADD or ADHD. AND patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization). OR patient has a documented treatment failure, due to lack of efficacy, to 2 long-acting CNS stimulants (Metadate CD, Ritalin LA, Focalin XR, Adderall XR, Methylphenidate SA OSM, Vyvanse and Daytrana) OR patient has had a documented side-effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety) to 1 long-acting CNS stimulant (Metadate CD, Ritalin LA, Focalin XR, Adderall XR, Methylphenidate SA OSM, Vyvanse or Daytrana) OR there is a question of substance abuse with the patient or family of the patient. AND the patient has been trialed on clonidine IR with at least a partial response but needs and extended duration formulation to maximize the clinical benefit. AND for approval of generic clonidine ER, patient must have had a documented intolerance to the brand equivalent.<br>**Strattera:** patient has a diagnosis of ADD or ADHD. AND patients has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient has a documented treatment failure, due to lack of efficacy, to 2 long-acting CNS stimulants (Metadate CD, Ritalin LA, Focalin XR, Adderall XR, Methylphenidate SA OSM, Vyvanse and Daytrana) OR patient has had a documented side effect, allergy, or direct contraindication (e.g. comorbid tics, moderate-to-severe anxiety) to 1 long-acting CNS stimulant (Metadate CD, Ritalin LA, Focalin XR, Adderall XR, Methylphenidate SA OSM, Vyvanse and Daytrana). OR there is a question of substance abuse with the patient or family of the patient OR family will choose to decline therapy if a stimulant must be trialed. OR patient's need for drug therapy is primarily in early AM and evenings in the home environment.<br>**Limitations:** Kapvay dose pack not covered - prescribe multiple strengths individually. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **ALLERGEN IMMUNOTHERAPY** | | |
| | Grastek® *(QL = 1 tablet/day)*<br>Oralair® *(QL = 1 tablet/day)*<br>Ragwitek® *(QL = 1 tablet/day)* | **Clinical Criteria**<br><br>**All agents in class**<br>• Prescriber must provide the testing to show that the patient is allergic to the components in the prescribed therapy and must provide a clinically valid rationale why single agent sublingual therapy is being chosen over subcutaneous therapy<br>• Treatment must start 12 weeks before expected onset of pollen season and only after confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen (Ragwitek), timothy grass or cross-reactive grass pollens (Grastek), or any of the 5 grass species contained in Oralair<br>• Have an auto-injectable epinephrine on-hand<br><br>**Grastek additional criteria:**<br>• Patient age ≥5 years and ≤65 years<br><br>**Oralair additional criteria:**<br>• Patient age ≥10 years and ≤65 years<br><br>**Ragwitek additional criteria:**<br>• Patient age ≥18 years and ≤65 years |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **ALPHA1-PROTEINASE INHIBITORS** | | |
| | Aralast NP®<br>Glassia®<br>Prolastin-C®<br>Zemaira®<br>**Maximum days supply per fill for all drugs is 14 days** | **Criteria for Approval:** The indication for use is treatment of alpha1 -proteinase inhibitor deficiency-associated lung disease when all of the following criteria are met: Patient's alpha1 -antitrypsin (ATT) concentration < 80 mg per dl [or < 11 micromolar] AND patient has obstructive lung disease as defined by a forced expiratory volume in one second (FEV1) OF 30 - 65% of predicted or a rapid decline in lung function defined as a change in FEV1 of > 120 mL/year. AND medication is being administered intravenously (inhalation administration will not be approved) AND patient is a non-smoker OR patient meets above criteria except lung function has deteriorated beneath above limits while on therapy. |
| **ALZHEIMER'S MEDICATIONS** | | |
| **CHOLINESTERASE INHIBITORS** | | |
| DONEPEZIL† (compare to Aricept®) tablet *(QL = 1 tablet/day)*<br><br>EXELON® (rivastigmine) Capsule *(QL = 2 capsules/day)*<br><br>**SOLUTION**<br><br>EXELON® (rivastigmine) Oral Solution | Aricept® (donepezil) Tablet *(QL = 1 tablet/day)*<br>galantamine† tablet § (compare to Razadyne®) Tablet<br>galantamine ER† capsule § (compare to Razadyne ER®)<br>Razadyne® (galantamine) Tablet<br>Razadyne ER® (galantamine) Capsule<br>rivastigmine† (compare to Exelon®) capsule *(QL = 2 capsules/day)*<br>Aricept® ODT (donepezil) *(QL = 1 tablet/day)*<br>Donepezil ODT † (compare to Aricept® ODT) | **Galantamine Tablet, Galantamine ER Capsule, Razadyne Tablet, Razadyne ER Capsule:** diagnosis or indication for the requested medication is Alzheimer's disease. AND patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization) OR patient had a documented side effect, allergy or treatment failure to donepezil and Exelon. AND if the product has an AB rated generic, the patient has a documented intolerance to the generic.<br>**Aricept:** diagnosis or indication for the requested medication is Alzheimer's disease. AND the patient has a documented intolerance to the generic product.<br>**Galantamine Oral Solution, Razadyne Oral Solution:** diagnosis or indication for the requested medication is Alzheimer's disease. AND patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization) OR the patient had a documented side effect, allergy or treatment failure to Exelon Oral Solution. AND if the product |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **TRANSDERMAL**<br><br>EXELON® (rivastigmine transdermal) Patch *(QL = 1 patch/day)* | *(QL = 1 tablet/day)*<br>galantamine† (compare to Razadyne®) Oral Solution<br>Razadyne® (galantamine) Oral Solution | has an AB rated generic, the patient has a documented intolerance to the generic.<br>**Aricept ODT, Donepezil ODT:** diagnosis or indication for the requested medication is Alzheimer's disease. AND medical necessity for a specialty dosage form has been provided. AND if the request is for donepezil ODT, the patient has a documented intolerance to the brand product.<br>**Rivastigmine Oral Capsule:** diagnosis or indication for the requested medication is Alzheimer's disease. AND patient has a documented intolerance to the brand Exelon product. |
| **NMDA RECEPTOR ANTAGONIST** | | |
| NAMENDA® (memantine) Tablet<br>NAMENDA® XR (memantine ER) Oral Capsule *(QL = 1 capsule/day)*<br>NAMENDA® (memantine) Oral Solution | | |
| **CHOLINESTERASE INHIBITOR/NMDA COMBINATION** | | |
| | Namzaric® (donepezil/memantine) Capsule (QL = 1 capsule/day) | **Namzaric:** Clinically compelling reason why the individual ingredients of donepezil and Namenda cannot be used |
| **COX-2 INHIBITORS** | | |
| **Clinical PA Required**<br>CELECOXIB† *(QL = 2 caps/day)* | Celebrex® (celecoxib) *(QL = 2 capsules/day)* | **Celebrex:** patient does not have a history of a sulfonamide allergy. AND patient has had a documented side effect, allergy, or treatment failure to two or more preferred generic NSAIDS and has had a previous trial of generic celecoxib. OR patient is not a candidate for therapy with a preferred generic NSAID due to one of the following: patient is 60 years of age or older, patient has a history of GI bleed and has had a previous trial of generic celecoxib, patient is currently taking an anticoagulant (warfarin or heparin) and has had a previous trial of generic celecoxib, Patient is currently taking an oral corticosteroid and has had a |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | previous trial of generic celecoxib, and Patient is currently taking methotrexate and has had a previous trial of generic celecoxib. |
| **ANALGESICS** | | |
| **MISCELLANEOUS: TRANSDERMAL PATCH** | | |
| **Note:** Please refer to "Analgesics: Long Acting Narcotics" for Duragesic® and fentanyl patch | Lidocaine 5% patch† (compare to Lidoderm®) *(QL = 3 patches/day)*<br>Lidoderm® Patch (lidocaine 5 %) *(QL = 3 patches/day)*<br>Qutenza® Patch (capsaicin 8 %) *(QL =4 patches/90 days)*<br>(Note: Please refer to Analgesics: COX IIs and NSAID s for topical NSAIDS) | **Lidoderm, Lidocaine Patch:** diagnosis or indication is neuropathic pain/post-herpetic neuralgia AND patient has had a documented side effect, allergy, treatment failure or contraindication to 2 drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class AND patient has had a documented side effect, allergy, treatment failure or contraindication to Lyrica, OR patient has a medical necessity for a transdermal formulation (ex. dysphagia, inability to take oral medications), AND if the request is for generic lidocaine patch, the patient has had a documented intolerance to the brand product.<br>**Qutenza:** diagnosis or indication is post-herpetic neuralgia AND patient has had a documented side effect, allergy, treatment failure or contraindication to 2 drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class AND patient has had a documented side effect, allergy, treatment failure or contraindication to Lyrica AND patient has had a documented side effect, allergy treatment failure or contraindication to Lidoderm OR patient has a medical necessity for transdermal formulation (ex. dysphagia, inability to take oral medications) AND patient has had a documented side effect, allergy, treatment failure or contraindication to Lidoderm. |
| **OPIOIDS: SHORT ACTING** | | |
| ACETAMINOPHEN W/CODEINE† (compare to Tylenol® w/codeine)<br>ACETAMINOPHEN W/HYDROCODONE† | Abstral® (fentanyl) Sublingual Tablets<br>Acetaminophen w/codeine: *all branded products*<br>Acetaminophen w/hydrocodone: *all branded products*<br>*(QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day, 7.5/750 = 5 tablets/day)* | **Butorphanol Nasal Spray:** documented site effect, allergy, treatment failure, or contraindication to codeine, hydrocodone, morphine, & oxycodone (all 4 generic entities) as single or combination products. OR is unable to use tablet or liquid formulations.<br>**Abstral, Actiq, fentanyl transmucosal, Fentora, Lazanda, Subsys:** indication of |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| (compare to Vicodin®, Lorcet®, Maxidone®, Norco®, Zydone®)<br>*(QL 5/500 = 8 tablets/day, 10/500 = 8 tablets/day, 7.5/750 = 5 tablets/day)*<br>ACETAMINOPHEN W/OXYCODONE†<br>(compare to Percocet®)<br>*(QL 10/650 = 6 tablets/day)*<br>ASPIRIN W/CODEINE†<br>ASPIRIN W/OXYCODONE† (compare to Percodan®)<br>BUTALBITAL COMP. W/CODEINE† (compare to Fiorinal® w/codeine)<br>CODEINE SULFATE†<br><br>DIHYDROCODEINE COMPOUND† (compare to Synalgos-DC®)<br>ENDOCET® (oxycodone w/ acetaminophen)<br>ENDODAN® (oxycodone w/ aspirin)<br><br>HYDROCODONE† (plain, w/acetaminophen, or w/ibuprofen)<br>(some exceptions apply)<br>HYDROMORPHONE† tablets (compare to Dilaudid®)<br>*First fill limited to 14 days' supply* | Acetaminophen w/hydrocodone (compare to Xodol®) *(QL=13 tablets/day)*<br>Acetaminophen w/oxycodone: *all branded products (QL 10/650 = 6 tablets/day)*<br>Actiq® (fentanyl lozenge on a stick: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg, 1600 mcg)<br>Anexsia®* (acetaminophen w/hydrocodone)<br>Butorphanol Nasal Spray† (Qty Limit = 2 bottles/month)<br>Capital® w/codeine* (acetaminophen w/codeine)<br>Cocet® /Cocet Plus® (acetaminophen w/codeine) *(QL 30/650 or 60/650 = 6 tablets/day)*<br><br>Combunox®* (oxycodone w/ ibuprofen)<br>Demerol* (meperidine)<br><br>Dilaudid®*(hydromorphone) tablets<br>*First fill limited to 14 days' supply*<br>*(Qty limit = 16 tablets/day)*<br>Dilaudid-5®(hydromorphone) oral solution *First fill limited to 14 days' supply*<br>fentanyl citrate transmucosal† (compare to Actiq®)<br>Fentora® (fentanyl citrate buccal tablets)<br>Fioricet® w/codeine*(butalbital/acetaminophen/caffeine/codeine)<br>Hydrocodone-Acetaminophen Soln 10-325 Mg/15ml | cancer breakthrough pain AND patient is opioid tolerant AND is on a long acting opioid formulation AND is 18 years of age or older (Actiq 16 years of age or older) AND prescriber is registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program AND member has had a documented treatment failure with or intolerance to 2 of the following 3 immediate release treatment options: morphine, hydromorphone or oxycodone. OR is unable to use tablet or liquid formulations AND if the request is for brand name Actiq, member has a documented intolerance to generic fentanyl transmucosal.<br>**Dilaudid - 5 Oral Solution, Hydromorphone Oral Solution:** member has had a documented side effect, allergy or treatment failure with oxycodone oral solution and morphine oral solution OR has been started and stabilized on another dosage form of hydromorphone AND if the request is for the branded product, patient has a documented intolerance to the generic product.<br>**Nucynta, Opana, Oxymorphone**: member has had a documented side effect, allergy, or treatment failure to at least two of the following 3 immediate release generic short acting narcotic analgesics - morphine, hydromorphone, or oxycodone AND if the request if for brand Opana, member has a documented intolerance to generic oxymorphone.<br>**Oxycodone (generic) Capsules:** member has a documented intolerance to generic oxycodone tablets.<br>**Oxecta:** prescriber provides a clinically valid rationale why the generic immediate release oxycodone cannot be used AND member has a documented side effect, allergy, or treatment failure to at least 2 other preferred short acting narcotic analgesics. NOTE: a history of substance abuse does not warrant approval of Oxeta (oxycodone IR) since a clear advantage of this product over preferred short acting opioids in this population has not been established.<br>**Ultram, Ultracet:** member has a documented intolerance to the generic formulation<br>**Rybix ODT:** member has a medical necessity for a disintegrating tablet formulation (i.e. swallowing disorder)<br>**Xartemis XR:** diagnosis is acute pain AND member has a documented side effect, allergy, or treatment failure to at least 2 short acting opioids not requiring prior |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| *(Qty limit = 16 tablets/day)*<br>MEPERIDINE† (compare to Demerol®) (30 tabs or 5 day supply)<br>MORPHINE SULFATE†<br>MORPHINE SULFATE† (compare to Roxanol®)<br>OXYCODONE† (plain)<br>*First fill limited to 14 days' supply*<br>*(For tablets, Qty limit = 12 tablets/day)*<br>OXYCODONE† (w/acetaminophen or w/ibuprofen)<br>ROXICET® (oxycodone w/ acetaminophen)<br>TRAMADOL† (compare to Ultram®) *(Qty Limit = 8 tablets/day) (Age ≥ 16)*<br>TRAMADOL/APAP† (compare to Ultracet®) *(Qty Limit = 8 tablets/day)* (Age ≥18)<br>ZAMICET† ( Hydrocodone-Acetaminophen Soln 10-325 Mg/15ml) | Hydromorphone† oral soln (compare to Dilaudid-5®)<br>*First fill limited to 14 days' supply*<br>Ibudone®* (hydrocodone w/ ibuprofen)<br>Lazanda® (fentanyl) Nasal Spray<br>Liquicet® (hydrocodone w/ acetaminophen)<br>Lorcet®* (also HD, PLUS) (hydrocodone w/ acetaminophen)<br>Lortab®*(hydrocodone w/ acetaminophen)<br>Magnacet® (oxycodone w/ acetaminophen)<br>Maxidone®*(hydrocodone w/ acetaminophen)<br>Meperidine† (Qty > 30 tabs or 5 day supply)<br>Norco®*(hydrocodone w/ acetaminophen)<br>Nucynta® (tapentadol)<br>Opana® (oxymorphone)<br>Oxycodone† (plain) capsules<br>First fill limited to 14 days' supply<br>(Qty limit = 12 capsules/day)<br>Oxymorphone† (compare to Opana®)<br>Panlor DC® (acetaminophen/caffeine/dihydrocodeine)<br>Pentazocine w/acetaminophen†<br>Pentazocine w/naloxone†<br>Percocet®*(oxycodone w/ acetaminophen)<br>Percodan®* (oxycodone w/aspirin)<br>Reprexain®* (hydrocodone w/ ibuprofen)<br>Roxanol®*(morphine sulfate)<br>Rybix® ODT (tramadol ODT) (Qty Limit = 8 tablets/day)<br>Subsys® (fentanyl) Sublingual Spray | approval, one of which is oxycodone w/ apap AND prescriber must provide a compelling clinical reason why an extended release product is required for treatment of acute pain.<br>**Other Short acting Opioids:** member has had a documented side effect, allergy, or treatment failure to at least 2 medications not requiring prior approval. (If a product has an AB rated generic, one trial must be the generic)<br>**PA Requests to Exceed QL for Oxycodone IR or Hydromorphone IR:** if dose consolidation is not possible (i.e. use of higher strength dosage form), all requests will be referred to the DVHA Medical Director for review unless the medication is being prescribed for pain related to an oncology diagnosis which will be approved by the Clinical Call Center.<br>**Limitations:** APAP containing products: daily doses that result in > 4 grams of apap/day will reject for PA; Meperidine 75mg/ml injection no longer available - 25mg/ml, 50mg/ml and 100mg/ml available. Brand name Demerol 75mg/ml and 100mg/2ml not covered - no generic equivalents. Roxicodone (oxycodone) tablets not covered - product does not offer Federal rebate. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | Synalgos DC®*(dihydrocodeine compound)<br>Talwin®* (pentazocine) and branded combinations<br>Trezix® (acetaminophen/caffeine/dihydrocodeine)<br>Tylenol® #3*,#4*(acetaminophen w/codeine)<br>Tylox®*(oxycodone w/ acetaminophen)<br>Ultracet® (tramadol w/ acetaminophen) (Qty Limit = 8 tablets/day)<br>Ultram®* (tramadol) (Qty Limit = 8 tablets/day)<br>Vicodin®*(hydrocodone w/acetaminophen)<br>Vicoprofen®*(hydrocodone w/ ibuprofen)<br>Xartemis XR® (oxycodone w/acetaminophen) (Qty Limit = 4 tablets/day)<br><br>Xodol® (hydrocodone w/acetaminophen)<br>Xolox® (oxycodone w/ acetaminophen)<br><br>Zydone®*(hydrocodone w/acetaminophen) | |
| **OPIOIDS: LONG ACTING** | | |
| **TRANSDERMAL**<br>BUTRANS (buprenorphine) TRANSDERMAL SYSTEM<br>*(QL = 2 patches/14 days) (Maximum 14 day fill)*<br><br>**Fentanyl**<br>FENTANYL PATCH† (compare to Duragesic®)<br>12 mcg/hr, 25 mcg/hr, 50 mcg/hr (*QL=15 patches/30 days)*<br>FENTANYL PATCH† (compare to Duragesic®)<br>75 mcg/hr, 100 mcg/hr (*QL=30 patches/30 days)* | Duragesic®* (fentanyl patch) 12 mcg/hr, 25 mcg/hr, 50 mcg/hr<br>(QL=15 patches/30 days)<br>Duragesic®* (fentanyl patch) 75 mcg/hr, 100 mcg/hr<br>(QL= 30 patches/30 days)<br><br>Exalgo® (hydromorphone XR) tablet<br>(*QL= 30 tablets/30 days (8 mg, 12 mg, 16 mg tabs), 60 tablets/30 days (32 mg tabs)*<br>hydromorphone XR† (compare to Exalgo®) tablet | **CLINICAL CONSIDERATIONS:** Long acting opioid dosage forms are intended for use in opioid tolerant patients only. These tablet/capsule/topical medication strengths may cause fatal respiratory depression when administered to patients not previously exposed to opioids. LA opioids should be prescribed for patients with a diagnosis or condition that requires a continuous, around-the-clock analgesic. LA opioids should be reserved for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. LA opioids are NOT intended for use as 'prn' analgesic. LA opioids are NOT indicated for pain in the immediate post-operative period (the first 12-24 hours following surgery) or if the pain is mild, or not expected to persist for an extended period of time. LA opioids are not |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| **ORAL**<br>BUPRENORPHINE<br>**All products require PA.**<br>HYDROMORPHONE<br>**All products require PA.**<br><br>METHADONE<br>**All products require PA**<br><br>**MORPHONE**<br>MORPHINE SULFATE CR 12 hr† tablet (compare to MS Contin®, formerly Oramorph SR®) *(QL=90 tablets/strength/30 days)*<br><br>EMBEDA® (morphine sulfate/naltrexone hydrochloride) Capsules *(QL=2 capsules/day)*<br><br>**TRAMADOL**<br>**All products require PA.** | *(QL= 30 tablets/30 days (8 mg, 12 mg, 16 mg tabs))*<br><br>Dolophine® (methadone) tablets<br>Methadone† (compare to Dolophine®) 5 mg, 10 mg tablets<br>Methadone† oral solution 1 mg/ml (no PA required for patient less than 1 year old)<br>Methadone† oral concentrate 10 mg/ml<br><br>****Maximum initial daily dose all products = 30 mg/day****<br><br>Avinza® (morphine sulfate beads SR 24hr) Capsules *(QL= 30 capsules/strength/30 days)*<br><br>Kadian® (morphine sulfate XR) *(QL= 60 capsules/strength/30 days)*<br>MS Contin®* (morphine sulfate CR 12 hr) Tablets *(QL=90 tablets/strength/30 days)*<br>Morphine sulfate SR 24hr† capsule (compare to Kadian®) *(QL= 60 capsules/strength/30 days)*<br>Morphine sulfate SR beads 24hr† capsule (compare to Avinza®) *(QL= 30 capsules/strength/30 days)*<br>Oxycodone ER† (compare to OxyContin®) *(QL= 90 tablets/strength/30 days)* | intended to be used in a dosage frequency other than FDA approved regimens. Patients should not be using other extended release opioids prescribed by another physician. Prescribers should consult the VPMS (Vermont Prescription Monitoring System) to review a patient's Schedule II - IV medication use before prescribing long acting opioids.<br>**Brand Duragesic Fentanyl Patches:** patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term treatment and for which alternative treatment options are inadequate AND the patient has had a documented intolerance to generic fentanyl patches.<br>**Methadone Tablet:** Patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (Note: Methadone products, when used for treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed ONLY by certified opioid treatment programs as stipulated in 42 CFR 8.12, NOT retail pharmacy) AND patient has had a documented side effect, allergy, or treatment failure to morphine sulfate CR 12 hr tablets AND the initial methadone daily dose does not exceed 30mg AND for approval of brand Dolophine tablets, the patient must have a documented intolerance to the equivalent generic tablet.<br>**Methadone Liquid:** patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (Note: Methadone products, when used for treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed ONLY by certified opioid treatment programs as stipulated in 42 CFR 8.12, NOT retail pharmacy) AND the patient has been started and stabilized on the requested oral liquid medication OR patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (Note: Methadone products, when used for treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed ONLY by certified opioid treatment programs as stipulated in 42 CFR 8.12, NOT retail pharmacy) AND the initial methadone daily dose does not exceed 30mg AND the patient must have a medical necessity for an oral liquid (i.e. swallowing disorder, inability to take oral medications). |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **<u>HYDROCODONE</u>**<br>**All products require PA.** | OxyContin® (Oxycodone ER) *(QL= 90 tablets/strength/30 days)*<br>Opana ER® (oxymorphone ER) (crush resistant) *(QL=60 tablets/strength/30 days)*<br>Oxymorphone ER *(QL=60 tablets/strength/30 days)*<br>Nucynta ER® (tapentadol ER) *(QL=2 tablets/day)*<br>Conzip® (tramadol ER biphasic release) Capsule *(QL = 1 capsule/day)*<br>Tramadol SR† (compare to Ultram ER®) *(Qty Limit = 1 tablet/day)*<br>Tramadol ER biphasic-release® Capsule *(Qty Limit = 1 capsule/day)(150 mg strength)*<br>Tramadol ER biphasic-release† tablet (formerly Ryzolt®) *(Qty Limit = 1 tablet/day)*<br>Ultram ER® (tramadol SR 24 hr) *(Qty Limit = 1 tablet/day)*<br>Hysingla ER® w/abuse deterrent properties (hydrocodone bitartrate) *(Qty Limit = 1 tablet/ day)*<br>Zohydro ER® (hydrocodone bitartrate) | **Conzip, Tramadol ER biphasic-release Capsule, Tramadol ER biphasic-release Tablet, Tramadol ER/SR, Ultram ER:** member has had a documented treatment failure to a preferred short-acting tramadol product. In addition, for approval of tramadol ER biphasic-release capsule or tablet or Ultram ER, the patient must have a documented intolerance to generic tramadol ER/SR.<br>**Oral Non-Preferred (except methadone & tramadol containing products):** patient has a diagnosis of severe pain that requires daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate AND the patient has had a documented side effect, allergy, or treatment failure to morphine sulfate CR 12hr tablet (generic) AND generic fentanyl patch. (If a product has an AB rated generic, there must have been a trial of the generic). NOTE: A history of substance abuse does not warrant approval of Opana ER (crush resistant) since a clear advantage of this product over preferred long-acting opioids in this population has not been established.<br>**Hysingla ER/Zohydro ER:** Available with PA for those unable to tolerate any preferred medications. All requests will go to the DVHA Medical Director for approval.<br>**Limitations:** Methadone 40mg dispersible tablet not approved for retail dispensing. Methadone 2mg/ml oral solution not covered - use 1mg/ml generic oral solution. Opana ER (crush resistant): a history of substance abuse does not warrant approval of Opana ER (crush resistant) since a clear advantage of this product over preferred long-acting opioids in this population has not been established. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **NSAIDS** | | |
| **ORAL**<br>**SINGLE AGENT**<br>DICLOFENAC POTASSIUM† DICLOFENAC SODIUM† (compare to Voltaren®)<br>ETODOLAC† (formerly Lodine®)<br>ETODOLAC ER†<br>FLURBIPROFEN†<br>IBUPROFEN† (compare to Motrin®)<br><br>INDOMETHACIN†(formerly Indocin®, Indocin SR®)<br>INDOMETHACIN ER†<br>KETOPROFEN†<br>KETOPROFEN ER†<br>KETOROLAC† (formerly Toradol®)<br>*(QL = 20 doses/5 day supply every 90 days)*<br>MECLOFENAMATE SODIUM† MELOXICAM† tabs (compare to Mobic®)<br>NABUMETONE†<br>NAPROXEN† (compare to Naprosyn®)<br>NAPROXEN ENTERIC COATED† (compare to EC-Naprosyn®)<br>NAPROXEN SODIUM† (compare to Anaprox®, Anaprox DS®,<br>Naprelan®) | Anaprox DS®* (naproxen sodium)<br>Cambia® (diclofenac potassium) packet for oral solution<br>*(QL = 9 packets/month))*<br>Daypro®* (oxaprozin)<br>EC-Naprosyn® * (naproxen sodium enteric coated)<br>Feldene®* (piroxicam)<br>Fenoprofen 400mg cap<br>Fenoprofen† 600 mg tab<br>Indocin®* (indomethacin) suspension , suppository<br>mefenamic acid† capsules (compare to Ponstel®)<br>meloxicam suspension<br>Mobic® (meloxicam) suspension<br>Mobic®* (meloxicam) tablets<br><br>Nalfon® (fenoprofen) 400 mg capsules<br>Naprelan®* (naproxen sodium)<br>Naprosyn®* (naproxen sodium)<br>Ponstel® (mefenamic acid)<br>Tivorbex (indomethacin) capsules (QL=3 caps/day)<br>Vivlodex® (meloxicam) capsules<br>Voltaren XR®* (diclofenac sodium SR)<br>Zipsor® (diclofenac potassium)<br>Zorvolex® (diclofenac) Capsules<br>*(QL = 3 capsules/day)* | **Arthrotec, diclofenac/misoprostol, Duexis:** patient has a documented side effect or treatment failure to 2 or more preferred generic NSAIDs OR patient is not a candidate for therapy with a preferred generic NSAID mono-therapy due to one of the following: patient is 60 years of age or older, Patient has a history of GI bleed, Patient is currently taking an oral corticosteroid, Patient is currently taking methotrexate AND patient is unable to take the individual components separately AND if the request is for brand Arthrotec, the patient has a documented intolerance to the generic equivalent.<br>**Cambia:** drug is being prescribed for treatment of acute migraine attacks AND patient has had a documented side effect or treatment failure to 2 or more preferred generic NSAIDs, one of which must be generic diclofenac OR drug is being prescribed for treatment of acute migraine attacks AND patient has a requirement for an oral liquid dosage form (i.e. swallowing disorder, inability to take oral medications) AND patient has had a documented side effect or treatment failure with the generic ibuprofen suspension and the generic naproxen suspension.<br>**Flector Patch, Pennsaid, Diclofenac 1.5% Topical Solution:** diagnosis or indication is osteoarthritis or acute pain caused by minor strains, sprains, and contusions AND patient has had a documented side effect or inadequate response to Voltaren gel OR patient is not a candidate for therapy with a preferred generic NSAID due to one of the following: Patient is 60 years of age or older, Patient has a history of GI bleed, Patient is currently taking an oral corticosteroid, Patient is currently taking methotrexate OR patient has a documented medical necessity for a topical/transdermal formulation (ex. dysphagia, inability to take oral medications), AND for approval of Pennsaid 1.5%, the patient has had a documented intolerance to the generic equivalent.<br>**Sprix:** indication or diagnosis is moderate to moderately severe pain. AND patient has had a documented inadequate response or intolerance to generic ketorolac tablets. OR patient has a documented medical necessity for the specialty dosage form (i.e. inability to take medication orally (NPO)). |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| OXAPROZIN† (compare to Daypro®)<br>PIROXICAM† (compare to Feldene®)<br>JLINDAC†<br>**INJECTABLE**<br>KETOROLAC † Injection (formerly Toradol®) *(QL = 1 dose per fill)*<br><br>**NASAL SPRAY**<br><br>**All products require PA.**<br><br>**TRANSDERMAL**<br>**All products require PA.**<br><br>**NSAID/ANTI-ULCER**<br>**All products require PA.**<br>Note: Please refer to "Dermatological: Actinic Keratosis Therapy" for Solaraze® or Diclofenac 3% Gel | Sprix® (ketorolac) Nasal Spray<br>*(QL = 5 bottles/5 days – once every 90 days)*<br>diclofenac† (compare to Pennsaid®) 1.5 % Topical Solution<br><br>Flector® (diclofenac) 1.3 % Patch *(QL = 2 patches/day)*<br>Pennsaid® (diclofenac) 2% Topical Solution<br>Voltaren® (diclofenac) 1 % Gel<br>Arthrotec® (diclofenac sodium w/misoprostol)<br>diclofenac sodium w/misoprostol† (compare to Arthrotec® )<br>Duexis® (ibuprofen/famotidine)<br>*(QL = 3 tablets/day)*<br>Vimovo® (naproxen/esomeprazole)<br>*(QL = 2 tablets/day)* | **Tivorbex:** patient has had a documented side effect, allergy, or treatment failure to 4 or more preferred generic NSAIDs, including generic indomethacin.<br>**Vivlodex®:** patient has had a documented side effect, allergy, or treatment failure to 4 or more preferred generic NSAIDs, including generic meloxicam.<br>**Voltaren Gel, Diclofenac 1% Gel:** diagnosis or indication is osteoarthritis or acute pain caused by minor strains, sprains, and contusions. AND patient has had a documented side effect or treatment failure with at least 2 preferred generic NSAIDs. OR patient is not a candidate for therapy with a preferred generis NSAID due to one of the following: Patient is 60 years of age or older, Patient has a history of GI bleed, Patient is currently taking an oral corticosteroid, Patient is currently taking methotrexate OR patient has a documented medical necessity for a topical/transdermal formulation (ex. dysphagia, inability to take oral medication). For approval of generic Diclofenac 1% gel, the patient must have had a documented intolerance to Brand Voltaren.<br>**Vimovo:** patient has had a documented side effect or treatment failure to 2 or more preferred generic NSAIDs OR patient is not a candidate for therapy with a preferred generis NSAID due to one of the following: Patient is 60 years of age or older, Patient has a history of GI bleed, Patient is currently taking an oral corticosteroid, Patient is currently taking methotrexate AND patient is unable to take naproxen and a preferred proton pump inhibitor, separately.<br>**Zipsor, Zorvolex:** patient has had a documented intolerance to diclofenac tablets. AND patient has had a documented side effect, allergy, or treatment failure to 4 or more preferred generic NSAIDs.<br>**All other PA requiring NSAIDs:** patient has had a documented side effect or treatment failure to 2 or more preferred generic NSAIDS. (If a product has an AB rated generic, one trial must be the generic.) |
| **ANEMIA: HEMATOPOIETIC/ERYTHROPOIETIC AGENTS** | | |
| ***PREFERRED AFTER CLINICAL CRITERIA ARE MET*** | Epogen® (epoetin alpha) | **Aranesp, Procrit:** diagnosis or indication for the requested medication is anemia due to one of the following: Chronic kidney disease/renal failure, Post-renal |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| ARANESP® (darbepoetin alfa)<br>PROCRIT® (epoetin alpha) | Mircera® (methoxypolyethylene glycol-epoetin beta) | transplant, Use of zidovudine for the treatment of human immunodeficiency virus (HIV) (other causes of anemia, such as iron/folate/vitamin B12 deficiency have been eliminated), Surgery patients at high risk for perioperative blood loss, Cancer chemotherapy, Use of ribavirin or interferon therapy for Hepatitis C, Myelodysplastic syndrome. Hemoglobin level at initiation of therapy is <10 g/dL OR for patients currently maintained on therapy, hemoglobin leven is < 11 g/dL in dialysis patients with chronic kidney disease, < 10 g/dL in non-dialysis patients with chronic kidney disease, or < 12 g/dL in patients treated for other indications<br>**Epogen:** diagnosis or indication for the requested medication is anemia due to one of the following: Chronic kidney disease/renal failure, Post-renal transplant, Use of zidovudine for the treatment of human immunodeficiency virus (HIV) (other causes of anemia, such as iron/folate/vitamin B12 deficiency have been eliminated), Surgery patients at high risk for perioperative blood loss, Cancer chemotherapy, Use of ribavirin or interferon therapy for Hepatitis C, Myelodysplastic syndrome. Hemoglobin level at initiation of therapy is <10 g/dL OR for patients currently maintained on therapy, hemoglobin leven is < 11 g/dL in dialysis patients with chronic kidney disease, < 10 g/dL in non-dialysis patients with chronic kidney disease, or < 12 g/dL in patients treated for other indications. AND patient has had a documented side effect, allergy, or treatment failure to both Aranesp and Procrit.<br>**Mircera:** The diagnosis or indication for the requested medication is anemia due to chronic kidney disease/renal failure AND Hemoglobin level at initiation of therapy is <10g/dl OR For patients currently maintained on therapy, hemoglobin level is ≤11 g/dL in dialysis patients with chronic kidney disease, ≤10 g/dL in non-dialysis patients with chronic kidney disease, or ≤12 g/dL in patients treated for other indications AND The patient has had a documented side-effect, allergy, or treatment failure to both Aranesp and Procrit |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| **ANKYLOSING SPONDYLITIS: INJECTABLES** | | |
| ****Self-injectables (Enbrel®, Cimzia®, Humira® and Simponi®) must be obtained through Specialty Pharmacy Provider, Briova** Length of Authorization: Initial PA 3 months; 12 months thereafter** | | |
| ***PREFERRED AFTER CLINICAL CRITERIA ARE MET***<br><br>ENBREL® (etanercept)<br>*Qty Limit = 4 syringes/28 days(50 mg), 8 syringes/28 days (25 mg)*<br><br>HUMIRA® (adalimumab)<br>*Qty Limit = 2 syringes/28 days* | Cimzia® (certolizumab pegol)<br>*(Quantity limit = 1 kit/28 days (starter X 1, then regular))*<br>Cosentyx® (secukinumab) subcutaneous (*Quantity limit = 8 pens or vials month one, then 4 pens or vials monthly)*<br><br>Remicade® (infliximab)<br><br>Simponi® (golimumab) Subcutaneous<br>*Qty Limit = 1 of 50 mg prefilled syringe or autoinjector/28 days)* | **Humira:** patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Humira. OR patient has a confirmed diagnosis of AS, and conventional NSAID treatment and DMARD therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried. Notes: Approval should be granted in cases where patients have been treated with infliximab but have lost response to therapy.<br>**Enbrel:** patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on Enbrel. OR diagnosis is AS, and conventional NSAID treatment and DMARD therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried.<br>**Cimzia, Cosentyx, Remicade, Simponi:** patient has a diagnosis of ankylosing spondylitis (AS) and has already been stabilized on the medication being requested OR diagnosis is AS, and conventional NSAID treatment and DMARD therapy (e.g. methotrexate therapy) resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried. AND the prescriber must provide a clinically valid reason why BOTH Humira and Enbrel cannot be used.<br>**Additional criteria for Cosentyx and Simponi:** Patient must be ≥ 18 years of age. Safety and efficacy has not been established in pediatric patients.<br><br>* Patients with documented diagnosis of active axial involvement should have a trial with two NSAIDs, but a trial with DMARD is not required. If no active axial skeletal involvement, then NSAID trial and a DMARD trial are required (unless otherwise contraindicated) prior to receiving Humira, Cimzia, Cosentyx, Enbrel, |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | Remicade, or Simponi. |
| **ANTI-ANXIETY: ANXIOLYTICS** | | |
| **BENZODIAZEPINE** | | |
| CHLORDIAZEPOXIDE† (formerly Librium®)<br>CLONAZEPAM† (compare to Klonopin®)<br>*(QL = 4 tabs/day except 2 mg ( QL = 3 tabs/day))*<br><br>CLONAZEPAM ODT† (formerly Klonopin Wafers®)<br>*(QL = 4 tabs/day except 2 mg (QL = 3 tabs/day))*<br>CLORAZEPATE† tabs (compare to Tranxene T®)<br>DIAZEPAM† (compare to Valium®)<br><br>LORAZEPAM† (compare to Ativan®)<br>*(QL = 4 tablets/day)*<br><br>OXAZEPAM† (formerly Serax®) | alprazolam† (compare to Xanax®)<br>*(QL = 4 tablets/day)*<br><br>alprazolam ER†, alprazolam XR® (compare to Xanax XR®)<br>*(QL = 2 tablets/day)*<br>alprazolam ODT† (compare to Niravam®)<br>*(QL = 3 tablets/day)*<br><br>Alprazolam Intensol® (alprazolam concentrate)<br>Ativan®* (lorazepam)<br>*(QL = 4 tablets/day)*<br><br>Diazepam Intensol® (diazepam concentrate)<br>Klonopin®* (clonazepam)<br>*(QL = 4 tabs/day except 2 mg (QL = 3 tabs/day))*<br>Lorazepam Intensol® (lorazepam concentrate)<br><br>Niravam® (alprazolam ODT)<br>*(QL = 3 tablets/day)* | **Non-preferred Benzodiazepines (except for alprazolam ODT, Klonopin Wafers, Niravam & Intensol Products):** patient has a documented side effect, allergy, or treatment failure to at least 2 preferred benzodiazepine medications. (If a product has an AB rated generic, there must also be a trial of the generic formulation)<br>**Alprazolam ODT and Niravam:** patient has a documented side effect, allergy, or treatment failure to at least 2 preferred benzodiazepine medications. (If a product has an AB rated generic, there must also be a trial of the generic formulation). OR patient has a medical necessity for disintegrating tablet administration (i.e. inability to swallow tablets) AND patient has a documented side effect, allergy or treatment failure to clonazepam ODT.<br><br>**Alprazolam Intensol, Diazepam Intensol, and Lorazepam Intensol:** patient has a medical necessity for the specialty dosage form (i.e. swallowing disorder). AND the medication cannot be administered by crushing oral tablets. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | Tranxene T®* (clorazepate tablets)<br>Valium®* (diazepam)<br>Xanax® (alprazolam)<br>*(QL = 4 tablets/day)*<br>Xanax XR® (alprazolam XR)<br>*(QL = 2 tablets/day)* | |
| **NON-BENZODIAZEPINE** | | |
| BUSPIRONE† (formerly Buspar®)<br>HYDROXYZINE HYDROCHLORIDE† (formerly Atarax®)<br>HYDROXYZINE PAMOATE† (compare to Vistaril®) (all strengths except 100 mg)<br>MEPROBAMATE† (formerly Miltown®) | Hydroxyzine Pamoate† (100 mg strength ONLY) (compare to Vistaril®)<br>Vistaril®* (hydroxyzine pamoate) | **Hydroxyzine Pamote 100mg strength ONLY:** patient is unable to use generic 50mg capsules<br>**Vistaril:** patient has a documented intolerance to the generic formulation.<br>**PA Requests to Exceed QL:** all requests will be referred to the DVHA Medical Director for review unless (a) the medication is being prescribed for acute alcohol withdrawal for a maximum 10 day supply or (b) the patient has been started and stabilized on the requested quantity for treatment of a seizure disorder. |
| **ANTICOAGULANTS** | | |
| **ORAL** | | |
| **Vitamin K Antagonist**<br>WARFARIN † (compare to Coumadin®) | Coumadin®* (warfarin) | **Coumadin:** patient has been started and stabilized on the requested medication OR patient has had a documented intolerance to generic warfarin. |
| **Direct Thrombin Inhibitor**<br>PRADAXA® (dabigatran etexilate)<br>*(Quantity Limit = 2 capsules/day)* | Savaysa® (edoxaban) *(Quantity limits=1 tablet/daily* | **Savaysa:** Diagnosis or indication is nonvalvular atrial fibrillation or the indication is treatment of DVT or PE following 5-10 days of parenteral anticoagulation or the indication is reduction of risk of recurrent DVT or PE following initial therapy AND creatinine clearance is documented to be < 95 ml/min AND prescriber has provided another clinically valid reason why generic warfarin, Pradaxa, Xarelto |
| **Factor Xa Inhibitor** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| Eliquis® (apixaban)<br>*(Quantity Limit = 2 tablets/day)*<br>*(Quantity limit 5mg = 4 tablets/day for 7 days if indication is treatment of DVT or PE)(followed by 5 mg twice daily)*<br>XARELTO® (rivaroxaban)<br>*(10mg- Quantity Limit = 1 tablet/day, maximum 30 day supply to complete total 35 days/every 180 days)*<br>*(15m & 20mg -Quantity Limit = 1 tablet/day)*<br>*(Quantity limit 15 mg = 2 tablets/day for 21 days if indication is treatment of DVT or PE) ( followed by 20mg once daily)*<br>Starter Pack (15 mg/20 mg)<br>*(Quantity Limit = 51 tablets/30 days)* | | or Eliquis cannot be used. A yearly creatinine clearance is required with renewal of PA request |
| **INJECTABLE** | | |
| **UNFRACTIONATED HEPARIN INJECTABLE**<br>HEPARIN†<br><br>**LOW MOLECULAR WEIGHT HEPARINS INJECTABLE**<br>ENOXAPARIN † (compare to Lovenox®)<br>*(QL = 2 syringes/day calculated in ml volume)*<br>FRAGMIN® (dalteparin) | n/a<br><br>LOVENOX® (enoxaparin) *(QL = 2 syringes/day calculated in ml volume)*<br>Innohep® (tinzaparin) | **Arixtra:** patient has a documented intolerance to generic fondaparinux.<br>**Lovenox:** patient has a documented intolerance to generic enoxaparin<br>**Innohep:** diagnosis is treatment of acute, symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism, administered in conjunction with warfarin sodium AND patient does not have a bleeding disorder or documented heparin-induced thrombocytopenia (HIT) AND prescriber must provide a clinically valid reason why one of Lovenox, Fragmin, or fondaparinux cannot be used OR patient has been started and stabilized on the requested medication in conjunction with warfarin |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| **SELECTIVE FACTOR XA INHIBITOR INJECTABLE**<br>FONDAPARINUX† (compare to Arixtra®) | Arixtra®* (fondaparinux) | |
| **ANTICONVULSANTS** | | |
| **ORAL** | | |
| CARBAMAZEPINE† (compare to Tegretol®)<br>CARBAMAZEPINE extended release † (compare to Tegretol XR®)<br>CARBATROL® (carbamazepine)<br>CELONTIN® (methsuxamide)<br>CLONAZEPAM† (compare to Klonopin®)<br>*QL = 4 tablets/day*<br>CLONAZEPAM ODT† (formerly Klonopin Wafers®)<br>*QL = 4 tablets/day*<br>CHLORAZEPATE† (compare to Tranxene-T® Tablets<br>DEPAKOTE SPRINKLES® (divalproex sodium caps)<br>DIAZEPAM† (compare to Valium®)<br>DILANTIN® (phenytoin)<br>DIVALPROEX SODIUM † (compare to Depakote®)<br>DIVALPROEX SODIUM ER† (compare to Depakote ER®) | Aptiom® (eslicarbazepine acetate)<br>*QL = 1 tab/day (200, 400 and 800 mg) and 2 tabs/day (600 mg)*<br>Banzel® (rufinamide)<br>*QL = 8 tabs/day (400 mg) and 16 tabs/day (200 mg)*<br>Banzel® (rufinamide) oral suspension<br>*QL = 80 ml/day (3,200 mg/day)*<br>Depakene®* (valproic acid)<br>Depakote®* (divalproex sodium)<br>Depakote ER®* (divalproex sodium)<br>divalproex sodium capsules † (compare to Depakote Sprinkles®)<br>felbamate† (compare to Felbatol®)<br>Felbatol® (felbamate)<br>Fycompa® (perampanel) tablets *QL = 1 tablet/day*<br>Keppra®* (levetiracetam) tablets, oral solution<br>Keppra XR® (levetiracetam extended release)<br>Klonopin®* (clonazepam) | **Depakene, Depakote, Depakote ER, Keppra tabs or oral solution, Klonopin, Klonopin Wafers, Lamictal tabs or chew tabs, Mysline, Neurontin caps, tabs, sol, Tegretol XR (200mg & 400mg), Topamax tabs, Topamax sprinkles, Trileptal tabs, Zarontin, Zonegran:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization) OR patient has had a documented intolerance to the generic equivalent of the requested medication.<br>**Benzel:** diagnosis or indication is treatment of Lennox-Gastaut Syndrome. AND patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants used for the treatment of Lennox-Gastaut syndrome (topiramate, lamotrigine, valproic acid) AND for approval of the oral suspension, patient must be unable to use Benzel tabs (i.e. swallowing disorder)<br>**Felbamate, Felbatol:** patient information/consent describing aplastic anemia and liver injury has been completed AND patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization). Additionally, if brand is requested, the patient has a documented intolerance to the generic product. OR diagnosis is adjunctive therapy of partial-onset seizures or Lennox-Gastaut seizures and the patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least THREE preferred anticonvulsants. Additionally, if brand is requested, the patient has a documented intolerance to the generic product. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| EPITOL† (carbamazepine)<br>ETHOSUXAMIDE† (compare to Zarontin®)<br>GABAPENTIN† 100 mg, 300 mg, 400 mg capsules, 600 mg, 800 mg tablets, 250 mg/5 ml oral solution (compare to Neurontin®)<br>GABITRIL® (tiagabine)<br>LAMOTRIGINE† chew tabs (compare to Lamictal® chew tabs)<br>LAMOTRIGINE† tabs (compare to Lamictal® tabs)<br>LEVETIRACETAM† tabs (compare to Keppra® tabs)<br>LEVETIRACETAM† oral soln (compare to Keppra® oral soln)<br>OXCARBAZEPINE† tablets (compare to Trileptal®)<br>OXCARBAZEPINE † oral suspension (compare to Trileptal®)<br>PEGANONE® (ethotoin)<br>PHENYTEK® (phenytoin)<br>PHENYTOIN† (compare to Dilantin®)<br>PHENYTOIN EX† cap (compare to Phenytek®)<br>PRIMIDONE† (compare to Mysoline®)<br>TEGRETOL XR® (carbamazepine) 100 mg ONLY<br>TOPIRAMATE ER<br>TOPIRAMATE† tabs (compare to Topamax® tabs)<br>TOPIRAMATE† sprinkle caps (compare to Topamax® | *QL = 4 tablets/day*<br>Lamictal®* tabs (lamotrigine tabs)<br>Lamictal®* chew tabs (lamotrigine chew tabs)<br>Lamictal ODT® (lamorigine orally disintegrating tablets)<br>Lamictal XR® tablets (lamotrigine extended release)<br>lamotrigine ER† (compare to Lamictal XR®)<br><br>levetiracetam ER† (compare to Keppra XR®)<br>Lyrica® (pregabalin) § cap *(Quantity Limit = 3 capsules/day)*<br>Lyrica® (pregabalin) oral solution<br>Mysoline®* (primidone)<br>Neurontin®* (gabapentin) capsules, tablets and solution<br>Onfi® (clobazam) Oral Suspension 2.5 mg/ml *(Quantity limit = 16 ml/day)*<br>Onfi® (clobazam) Tablets *(Quantity Limit = 3 tabs/day (10 mg), 2 tabs/day (20 mg))*<br>Oxtellar® XR (oxcarbazapine ER) tablet<br>Potiga® (ezogabine) tablets *(Quantity limit = 9 tablets/day (50mg), 3 tablets/day (all others)*<br>Qudexy® XR (topiramate) capsules<br>Sabril® (vigabatrin)<br>Tegretol®* (carbamazepine) | **Divalproex sodium capsules (sprinkles) and tiagabine generic:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization). OR patient has had a documented intolerance to the brand name product.<br>**Keppra XR, Lamictal XR, lamotrigine ER, levetiracetam ER, Oxtellar XR:** patient has been unable to be compliant with or tolerate twice daily dosing of the immediate release product. Additionally, if brand Keppra XR or Lamictal XR is requested, the patient has a documented intolerance to the generic product.<br>**Lamictal ODT:** medical necessity for a specialty dosage form has been provided AND lamotrigine chewable tabs cannot be used.<br>**Lyrica caps, Lyrica oral solution:** patient has a diagnosis of epilepsy OR patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine or Savella, if medication is being used for fibromyalgia. (This indication not processed via automated step therapy). OR if the diagnosis is for post-herpetic neuralgia or neuropathic pain, there is a documented side effect, allergy or treatment failure to TWO drugs from the following: tricyclic antidepressant, gabapentin, or SNRI, AND if the request is for the oral solution, the patient is unable to use Lyrica capsules (i.e. swallowing disorder)<br>**Onfi:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization) OR diagnosis or indication is adjunctive treatment of Lennox-Gastaut Syndrome. AND patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants used for the treatment of Lennox-Gastaut syndrome (topiramate, lamotrigine, valproic acid) OR diagnosis or indication is adjunctive treatment of refractory epilepsy (may include different types of epilepsy) AND patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least THREE preferred anticonvulsants.<br>**Fycompa, Potiga:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| Sprinkles)<br>VALPROIC ACID† (compare to Depakene®)<br>ZONISAMIDE† (compare to Zonegran®) | Tegretol XR® (carbamazepine) (200 and 400 mg strengths)<br>tiagabine† (compare to Gabitril®)<br>Topamax®* (topiramate) tablets<br>Topamax®* (topiramate) Sprinkle Capsules<br>Tranxene-T®* (clorazepate) tablets<br>Trileptal®* tablets (oxcarbazepine)<br>TRILEPTAL® oral suspension (oxcarbazepine)<br>Trokendi XR® (topiramate SR 24hr) Capsules<br>*(Quantity limit = 2 caps/day (200mg), 1 cap/day all others)*<br>Valium®* (diazepam)<br>Vimpat® (lacosamide) tablets, oral solution<br>Zarontin®* (ethosuxamide)<br>Zonegran®* (zonisamide) | stabilization) OR diagnosis is adjunctive therapy or partial-onset seizures OR diagnosis is adjunctive therapy for primary generalized tonic-clonic seizures (Fycompa only) AND the patient has had a documented side effect, allergy, treatment failure, inadequate response, or a contraindication to at least TWO preferred anticonvulsants. Sabril: prescriber and patient are registered with the SHARE program AND diagnosis is infantile spasms OR patient is > 16 years old and the indication is adjunctive therapy in refractory complex partial seizures and failure of THREE other preferred anticonvulsants.<br>**Trileptal oral suspension:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization). OR patient has had a documented intolerance to the generic product.<br>**Trokendi XR, Qudexy XR:** patient has failed treatment with topiramate ER<br>**Vimpat:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization) OR diagnosis is monotherapy adjunctive therapy of partial-onset seizures and the patient has had a documented side effect, allergy, treatment failure/inadequate response or a contraindication to at least TWO preferred anticonvulsants AND if the request is for the oral solution, the patient is unable to use Vimpat tables (eg. swallowing disorder).<br>**PA Requests to Exceed QL for clonazepam/clonazepam ODT or Klonopin**: all requests will be referred to the DVHA Medical Director for review unless the patient has been started and stabilized on the requested quantity for treatment of a seizure disorder. |
| **RECTAL** | | |
| DIASTAT® (diazepam rectal gel) | Diazepam rectal gel | **Diazepam Rectal Gel:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization) OR patient has had a documented intolerance to Diastat rectal gel. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **ANTIDEPRESSANTS** | | |
| **MAO INHIBITORS – Length of Authorization: Duration of Need for Mental Health Indications** | | |
| PHENELZINE SULFATE (compare to Nardil®)<br>*FDA maximum recommended dose = 90 mg/day*<br>TRANYLCYPROMINE (compare to Parnate®)<br>*FDA maximum recommended dose = 60 mg/day* | EMSAM® (selegiline) *(QL = 1 patch/day)*<br>Marplan® (isocarboxazid)<br>Nardil®* (phenylzine)<br>*FDA maximum recommended dose = 90 mg/day*<br><br>Parnate®* (tranylcypromine)<br>*FDA maximum recommended dose = 60 mg/day* | **Marplan:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization). OR patient has had a documented side effect, allergy, or treatment failure to phenelzine and tranylcypromine.<br>**Nardil, Parnate:** patient has had a documented intolerance to generic equivalent product.<br>**EMSAM:** patient has had a documented side effect, allergy, or treatment failure with at least 3 antidepressants from 2 of the major antidepressants classes (Miscellaneous, SNRIs, SSRIs, and Tricyclic Antidepressants). OR patient is unable to tolerate oral medication.<br>**Limitations:** Chlordiazepoxide/amitriptyline and amitriptyline/perphenazine combinations are not covered. Generic agents may be prescribed separately. |
| **MISCELLANEOUS - Length of Authorization: Duration of Need for Mental Health Indications, 1 Year for Other Indications** | | |
| BUDEPRION® SR/BUPROPION SR† (compare to Wellbutrin SR®) *FDA maximum recommended dose = 400mg/day*<br>BUDEPRION XL/BUPROPION XL† (compare to Wellbutrin XL®)<br>*FDA maximum recommended dose = 450 mg/day*<br>BUPROPION† (compare to Wellbutrin®) | Aplenzin® (bupropion hydrobromide) ER tablets<br>*Quantity Limit = 1 tablet/day*<br>Brintellix® (vortioxetine) Tablet<br>*Quantity Limit = 1 tablet/day*<br>Forfivo XL® (bupropion SR 24hr) 450 mg tablet<br>*FDA maximum recommended dose = 450 mg/day*<br>*Quantity Limit = 1 tablet/day*<br>Oleptro® (trazodone) ER tablets<br>*Quantity Limit = 2 tablets/day (150 mg) or 1 tablet/day* | **Aplenzin:** The patient has had a documented inadequate response to Budeprion XL/bupropion XL AND The patient has had a documented side effect, allergy, or in adequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories (may be preferred or non-preferred)<br>**Forfivo XL**: The patient is unable to take the equivalent dose as generic bupropion XL<br>**Oleptro:** The diagnosis for use is MDD (major depressive disorder). AND The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| *FDA maximum recommended dose = 450 mg/day*<br>MAPROTILINE† (formerly Ludiomil®)<br>*FDA maximum recommended dose = 225 mg/day*<br>MIRTAZAPINE† (compare to Remeron®)<br>*FDA maximum recommended dose = 45 mg/day*<br>MIRTAZAPINE RDT† (compare to Remeron Sol-Tab®)<br>*FDA maximum recommended dose = 45 mg/day*<br>NEFAZODONE† (formerly Serzone®)<br>*FDA maximum recommended dose = 600 mg/day*<br>TRAZODONE HCL† (formerly Desyrel®)<br>*FDA maximum recommended dose = 600 mg/day* | *(300 mg)*<br>Remeron®* (mirtazapine)<br>*FDA maximum recommended dose = 45 mg/day*<br>Remeron Sol Tab®* (mirtazapine RDT)<br>*FDA maximum recommended dose = 45 mg/day*<br>Viibryd® (vilazodone) Tablet<br>*Quantity Limit = 1 tablet/day*<br>Wellbutrin®* (bupropion)<br>*FDA maximum recommended dose = 450 mg/day*<br>Wellbutrin SR®* (bupropion SR)<br>*FDA maximum recommended dose = 400mg/day*<br>Wellbutrin XL®* (bupropion XL)<br>*FDA maximum recommended dose = 450 mg/day* | patient has a documented treatment failure/inadequate response to immediate release trazodone.<br>**Remeron, Remeron SolTab, Wellbutrin, Wellbutrin SR, and Wellbutrin XL:** The patient has had a documented intolerance to the generic formulation of the requested medication.<br>**Brintellix, Viibryd:** The diagnosis or indication is MDD AND The patient has had a documented side effect, allergy, or inadequate response (defined by at least 4 weeks of therapy) to at least 3 different antidepressants from the SSRI, SNRI, and/or Miscellaneous Antidepressant categories (may be preferred or non-preferred). Document clinically compelling information supporting the choice of a non-preferred agent on a General Prior Authorization Form. After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a lookback through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria. |
| **SNRI - Length of Authorization: Duration of Need for Mental Health Indications, 1 Year for Other Indications** | | |
| VENLAFAXINE ER† capsule (compare to Effexor XR®) *FDA maximum recommended dose = 225 mg/day, Quantity limit = 1 capsule/day (37.5 mg & 75 mg)* | Cymbalta® (duloxetine) Capsule<br>*FDA maximum recommended dose = 120 mg/day(MDD and GAD), 60 mg/day all others*<br>*Quantity limit = 2 capsules/day*<br>Desvenlafax ER (desvenlafaxine fumarate SR 24hr) Tablet<br>*FDA maximum recommended dose = 400 mg/day,*<br>*Quantity limit = 1 tablet/day (50 mg tablet only)*<br>Desvenlafaxine ER® (desvenlafaxine base SR)<br>*FDA maximum recommended dose = 400 mg/day,* | **Venlafaxine IR:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories (may be preferred or non-preferred).<br>**Venlafaxine ER tablet (generic), Venlafaxine ER tablet (brand), Effexor XR Capsule (brand):** The patient has had a documented intolerance to generic venlafaxiner ER caps.<br>**Fetzima, Pristiq:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | *Quantity limit = 1 tablet/day (50 mg tablet only)*<br>Duloxetine† (compare to Cymbalta®) Capsule<br>*FDA maximum recommended dose = 120 g/day(MDD and GAD), 60 mg/day all others Quantity limit = 2 capsules/day*<br>Effexor XR® (venlafaxine XR) capsule<br>*FDA maximum recommended dose = 225 mg/day, Quantity limit = 1 capsule/day (37.5 mg & 75 mg)*<br>Fetzima® (levomilnacipran ER) capsule<br>*FDA maximum recommended dose = 120 mg/day*<br>*Quantity limit = 1 capsule/day*<br>Fetzima® (levomilnacipran ER) capsule titration pack<br>*(QL = 1 pack per lifetime)*<br>*FDA maximum recommended dose = 120 mg/day*<br>Irenka 40mg (duloxetine) capsules *FD maximum recommended dose = 120g/day (MDD and GAD), 60mg/day all others, QL = 2 caps/day.*<br>Khedezla® (desvenlafaxine base SR)<br>*FDA maximum recommended dose = 400 mg/day, Quantity limit = 1 tablet/day (50 mg tablet only)*<br>Pristiq® § (desvenlafaxine succinate SR)<br>*FDA maximum recommended dose = 400 mg/day, Quantity limit = 1 tablet/day (50 mg tablet only)*<br>Venlafaxine ER®† tablet<br>*FDA maximum recommended dose = 225 mg/day, Quantity limit = 1 tablet/day (37.5 mg & 75 mg)*<br>Venlafaxine ER† tablet<br>*FDA maximum recommended dose = 225 mg/day,* | stabilization.) OR The diagnosis or indication is Major Depressive Disorder (MDD) AND The patient has had a documented side effect, allergy, or inadequate response to at least 3(three) different antidepressants from the SSRI, SNRI, TCA and/or Miscellaneous Antidepressant categories, one of which must be Venlafaxine ER capsule (may be preferred or non-preferred).<br>**Desvenlafaxine ER, Khedezla:** The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories, one of which must be venlafaxine ER capsule (may be preferred or non-preferred) AND The patient has had a documented intolerance with Pristiq.<br>**Duloxetine:**<br>Depression: The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient has had a documented side effect, allergy, or inadequate response to at least 2 different antidepressants from the SSRI, SNRI and/or Miscellaneous Antidepressant categories, one of which must be venlafaxine ER capsule (may be preferred or non-preferred).<br>Generalized Anxiety Disorder: The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient has had a documented side effect, allergy, or inadequate response to at least TWO different antidepressants from the SSRI, SNRI and/or TCA categories (may be preferred or non-preferred) or ONE antidepressant from the SSRI, SNRI and/or TCA categories (may be preferred or non-preferred) and buspirone.<br>Neuropathic pain: The patient has had a documented side effect, allergy, or treatment failure to TWO drugs in the tricyclic antidepressant (TCA) class and/or anticonvulsant class. (this indication not processed via automated step therapy).<br>Non-neuropathic musculoskeletal pain (osteoarthritis, chronic low back pain): The patient has had a documented side effect, allergy, inadequate response or contraindication to acetaminophen (Tylenol®) AND at least TWO nonsteroidal anti-inflammatory drugs (NSAIDs) (oral and/or topical). (this indication not processed via automated step therapy) Fibromyalgia: The patient has had a |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | *Quantity limit = 1 tablet/day (37.5 mg & 75 mg)*<br>venlafaxine IR †§ (previously Effexor®)<br>*FDA maximum recommended dose = 225 mg/day* | documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine, Lyrica® or Savella®.(this indication not processed via automated step therapy) Document clinically compelling information supporting the choice of a non-preferred agent on a General Prior Authorization Form. After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a lookback through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria.<br>**Cymbalta, Irenka:** Must meet criteria for duloxetine (above) AND have a clinically compelling reason why the dosing needs cannot be accomplished with generic duloxetine. |
| **SSRIs – Length of Authorization: Duration of Need for Mental Health Indications, 1 Year for Other Indications** | | |
| CITALOPRAM† (compare to Celexa®)<br>*FDA maximum recommended dose = 40 mg/day*<br><br>ESCITALOPRAM† (compare to Lexapro®) TABLETS<br>*FDA maximum recommended dose = 20mg/day*<br>*QL = 1.5 tabs/ day (5mg & 10mg tabs)*<br><br>FLUOXETINE† (compare to Prozac®) CAPSULES, SOLUTION<br>*FDA maximum recommended dose = 80 mg/day*<br><br>FLUVOXAMINE† (formerly Luvox®)<br>*FDA maximum recommended dose = 300 mg/day*<br><br>PAROXETINE tablet† (compare to Paxil®)<br>*FDA maximum recommended dose = 60 mg/day*<br><br>SERTRALINE† (compare to Zoloft®) | Brisdelle® (paroxetine)<br>*Quantity Limit = 1 capsule/day*<br>Celexa®* (citalopram)<br>*FDA maximum recommended dose = 40 mg/day*<br>escitalopram† solution (compare to Lexapro® solution)<br>*FDA maximum recommended dose = 20 mg/day,*<br>Fluoxetine®Tablets<br>*FDA maximum recommended dose = 80 mg/day*<br>fluoxetine† 90 mg (compare to Prozac Weekly®)<br>*FDA maximum recommended dose = 90 mg/week*<br>Lexapro® (escitalopram)<br>*FDA maximum recommended dose = 20 mg/day,*<br>*Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)*<br>fluvoxamine CR† (compare to Luvox CR®) | **Celexa, Lexapro, Paxil tablet, Prozac, Zoloft:** The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs. (One trial must be the generic formulation of the requested medication.)<br>**Brisdelle:** The indication for use is moderate to severe vasomotor symptoms (VMS) associated with menopause. AND The patient has tried and failed generic paroxetine.<br>**fluvoxamine CR:** The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs. (One trial must be generic fluvoxamine IR.)<br>**Pexva, Paroxetine CR, and Paxil CR:** The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs. (One trial must be generic paroxetine.) AND If the request is for Paxil CR, the patient has a documented intolerance to paroxetine CR.<br>**Paroxetine suspension, Paxil suspension, Escitalopram solution, Lexapro solution:** The patient has a requirement for an oral liquid dosage form. AND The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs. If the request is for the brand product, the patient also has a documented intolerance to the generic equivalent. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| *FDA maximum recommended dose = 200 mg/day,*<br>*Quantity limit = 1.5 tabs/day (25 mg & 50 mg tabs)* | *FDA maximum recommended dose = 300 mg/day,*<br>*Quantity limit = 2 capsules/day*<br>paroxetine suspension† (compare to Paxil® susp)<br>*FDA maximum recommended dose = 60 mg/day*<br>Paroxetine CR† (compare to Paxil CR®)<br>*FDA maximum recommended dose = 75 mg/day*<br>Paxil®* (paroxetine) *FDA maximum recommended dose = 60 mg/day*<br>Paxil® suspension (paroxetine)<br>*FDA maximum recommended dose = 60 mg/day*<br>Paxil CR® (paroxetine CR)<br>*FDA maximum recommended dose = 75 mg/day*<br>Pexeva® (paroxetine)<br>*FDA maximum recommended dose = 60 mg/day*<br>Prozac®* (fluoxetine)<br>*FDA maximum recommended dose = 80 mg/day*<br>Prozac Weekly® (fluoxetine)<br>*FDA maximum recommended dose = 90 mg/week*<br>Sarafem® (fluoxetine pmdd)<br>*FDA maximum recommended dose = 80 mg/day*<br>Zoloft®* (sertraline)<br>*FDA maximum recommended dose = 200 mg/day,*<br>*Quantity limit = 1.5 tabs/day (25 mg & 50 mg tabs)* | **Sarafem**: The patient had a documented side effect, allergy, or treatment failure with 2 preferred SSRIs, one of which must be fluoxetine capsules.<br>**Fluoxetine tablet:** Prescriber must provide a clinically compelling reason why the patient is unable to use capsules<br>**Fluoxetine 90mg, Prozac Weekly:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient failed and is not a candidate for daily fluoxetine. AND The prescriber provides clinically compelling rationale for once-weekly dosing. AND If the request is for Prozac Weekly, the patient has a documented intolerance of fluoxetine 90 mg capsules.<br>Document clinically compelling information supporting the choice of a non-preferred agent on a General Prior Authorization Form.<br>After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a lookback through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria. |
| **TRICYCLICS – Length of Authorization: Duration of Need for Mental Health Information, 1 Year for Other Indications** | | |
| AMITRIPTYLINE† (formerly Elavil®)<br>*FDA maximum recommended dose = 300 mg/day* | Anafranil®* (clomipramine)<br>Norpramin®* (desipramine) | **Tricyclics (TCAs) (Brands with generic equivalents):** The patient has had a documented side effect, allergy, or treatment failure to 2 or more TCAs not requiring prior authorization. One trial must be the AB rated generic formulation. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

Drugs highlighted in yellow denote a change in PDL status.

To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| AMOXAPINE† (formerly Asendin®)<br>CLOMIPRAMINE† (compare to Anafranil®)<br>DESIPRAMINE† (compare to Norpramin®)<br>DOXEPIN† (formerly Sinequan®)<br>IMIPRAMINE† (compare to Tofranil®)<br>*FDA maximum recommended dose = 300 mg/day*<br>IMIPRAMINE PAMOATE† (compare to Tofranil PM®)<br>NORTRIPTYLINE† (formerly Aventyl®, compare to Pamelor®)<br>NORTRIPTYLINE Oral Solution<br>PROTRIPTYLINE† (compare to Vivactil®) | Pamelor®* (nortriptyline)<br>Surmontil® (trimipramine)<br>Tofranil®* (imipramine)<br>*FDA maximum recommended dose = 300 mg/day*<br>Tofranil PM®* (imipramine pamoate)<br>Vivactil®* (protriptyline) | OR The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) AND The patient has had a documented intolerance to the generic formulation.<br>**Surmontil:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization). OR The patient has had a documented side effect, allergy, or treatment failure to one or more preferred TCAs.<br>**Limitation:** Chlordiazepoxide/amitriptyline and amitriptyline/perphenazine combinations not covered. Generic agents may be prescribed separately. Document clinically compelling information supporting the choice of a non-preferred agent on a General Prior Authorization Form.<br>After a 4-month lapse in use of a non-preferred agent for a mental health indication, or if there is a change in therapy, a lookback through claims information will identify the need to re-initiate therapy following the PDL and clinical criteria. |
| **ANTI-DIABETICS** | | |
| **ALPHA-GLUCOSIDASE INHIBITORS** | | |
| ACARBOSE† (compare to Precose®)<br>GLYSET® (miglitol) | Precose®* (acarbose) | **Precose:** patient must have a documented intolerance to generic acarbose |
| **BIGUANIDES & COMBINATIONS** | | |
| **SINGLE AGENT**<br>METFORMIN† (compare to Glucophage®)<br>METFORMIN XR† (compare to Glucophage XR®)<br>RIOMET® (metformin oral solution)<br>**COMBINATION** | Fortamet® (metformin ER Osmotic)<br>Glucophage®* (metformin)<br>Glucophage XR®* (metformin XR)<br>Glumetza® (metformin ER) | **Fortamet, Glucophage XR, Glumetza, Metformin ER osmotic:** patient has had a documented intolerance to generic metformin XR (if product has an AB rated generic, there must have been a trial of the generic)<br>**Glucophage, Glucovance, Metaglip:** patient has had a documented side effect, allergy OR treatment failure with at least one preferred biguanide OR biguanide combination product (if a product has an AB raged generic, the trial must be the |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| GLIPIZIDE/METFORMIN† (compare to Metaglip®)<br>GLYBURIDE/METFORMIN† (compare to Glucovance®) | Metformin ER Osmotic† (compare to Fortamet®)<br>Glucovance®* (glyburide/metformin)<br>Metaglip ®* (glipizide/metformin) | generic) |
| **DIPEPTIDYL PEPTIDASE (DPP-4) INHIBITORS** | | |
| ***PREFERRED AFTER CLINICAL CRITERIA ARE MET***<br><br>**SINGLE AGENT**<br>JANUVIA® (sitagliptin) § *(Quantity Limit = 1 tablet/day)*<br>ONGLYZA® (saxagliptin)§ *(Quantity limit=1 tablet/day)*<br><br>**COMBINATION**<br>JANUMET® (sitagliptin/metformin) § *(Quantity Limit = 2 tablets/day)*<br>KOMBIGLYZE XR® (saxagliptin/metformin ER) § *(Quantity limit=1 tab/day)* | ***NON-PREFERRED AFTER CLINICAL CRITERIA ARE MET***<br><br>Nesina® (alogliptin) *(Quantity limit=1 tablet/day)*<br>Tradjenta® *(linagliptin) (Quantity limit=1 tab/day)*<br>Janumet XR® (sitagliptin/metformin ER) *(Qty limit=1 tab/day of 50/500 mg or 100/1000 mg or 2 tabs/day of 50/1000 mg)*<br>Jentadueto® (linagliptin/metformin) *(Quantity limit=2 tabs/day)*<br>Kazano® (alogliptin/metformin) *(Quantity limit=2 tabs/day)*<br>Oseni® (alogliptin/pioglitazone) *(Quantity limit=1 tab/day)* | **Januvia, Onglyza:** patient has had a documented side effect, allergy, contraindication OR treatment failure with metformin<br>**Nesina, Tradjenta:** patient has had a documented side effect, allergy, contraindication OR treatment failure with metformin AND patient has had a documented side effect, allergy OR treatment failure with at least one preferred DDP-4 agent.<br>**Janumet:** patient has had an inadequate response with Januvia OR Metformin monotherapy OR patient has been started and stabilized on Januvia and Metformin combination therapy.<br>**Kazano:** patient has had a documented side effect, allergy OR treatment failure with at least one preferred DDP-4 combination agent.<br>**Janumet XR:** patient has had an inadequate response with Januvia OR Metformin/Metformin XR monotherapy OR patient has been started and stabilized on Januvia and Metformin/Metformin XR combination therapy AND patient is unable to take Januva and Metformin/Metformin XR as the individual |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | separate agents.<br>**Jentadueto:** patient has had an inadequate response with Tradjenta OR Metformin monotherapy OR patient has been started and stabilized on Tradjenta and Metformin combination therapy AND the patent is unable to take Tradjenta and Metformin as the individual separate agents.<br>**Kombiglyze XR:** patient has had an inadequate response with Onglyza OR Metformin/Metformin XR monotherapy OR Patient has been started and stabilized on Onglyza/Metformin XR combination therapy.<br>**Oseni:** patient is unable to take Nesina and Actos (pioglitazone) as the individual separate agents (after meeting clinical criteria for each individual agent) |
| **INSULINS** | | |
| **RAPID-ACTING INJECTABLE**<br>HUMALOG® (insulin lispro)<br>NOVOLOG® (Aspart)<br>**SHORT-ACTING INJECTABLE**<br>HUMULIN R® (Regular)<br>NOVOLIN R® (Regular)<br>**INTERMEDIATE-ACTING INJECTABLE**<br>HUMULIN N® (NPH)<br>NOVOLIN N® (NPH)<br>**LONG-ACTING ANALOGS INJECTABLE**<br>LANTUS® (insulin glargine)<br>LEVEMIR® (insulin detemir) | **AFREZZA® INHALED (insulin human)**<br>Apidra® (insulin glulisine)<br>**TOUJEO® (insulin glargine)**<br>TRESIBA® FLEXTOUCH (insulin degludec) | **Apidra:** patient has had a documented side effect, allergy OR treatment failure to Novolog or Humalog<br>**TOUJEO**:<br>• Diagnosis of diabetes mellitus<br>**AND**<br>• Prescription is initiated by an Endocrinologist<br>**AND**<br>• The person is currently on insulin glargine U100 and cannot achieve glycemic control (defined as hemoglobin A1c ≤ 7%) because dose increases cannot be tolerated due to at least one severe low blood sugar event (requiring assistance from another) despite attempts at manipulating dosing time or splitting the dose.<br>**TRESIBA FLEXTOUCH:** Diagnosis of diabetes mellitus AND prescription is initiated in consultation with an Endocrinologist AND the patient must have documented treatment failure with BOTH preferred agents. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **MIXED INSULINS INJECTABLE**<br>HUMULIN 70/30® (NPH/Regular)<br>NOVOLIN 70/30® (NPH/Regular)<br>NOVOLOG MIX 70/30® (Protamine/Aspart)<br>HUMALOG MIX 50/50® (Protamine/Lispro)<br>HUMALOG MIX 75/25® (Protamine/Lispro) | | **AFREZZA INHALED INSULIN:**<br>• Baseline PFT with FEV1 ≥ 70 % predicted<br>• Patient does not have underlying lung disease (Asthma, COPD)<br>• Patient is a non-smoker or has stopped smoking more than six months prior to starting Afrezza<br>• Patient is currently using a long-acting insulin<br>• Patient has failed to achieve HbA1c goal (defined as ≤ 7%) on a short-acting insulin in combination with a long-acting insulin<br>• Initial approval is for 3 months and improved glycemic control must be documented for further approvals<br><br>**Diabetes Mellitus Type 2 additional criteria**<br>Patient is intolerant to, or is not a candidate for, or has failed to achieve HbA1c goal, (defined as ≤ 7%) despite therapy with two or more oral hypoglycemic agents |
| **MEGLITINIDES** | | |
| **Single Agent**<br>NATEGLINIDE† (compare to Starlix®)<br><br>COMBINATION | Prandin® (replaglinide)<br>repaglinide† (compare to Prandin®)<br>Starlix®* (nateglinide)<br><br>Prandimet® (repaglinide/metformin) | **Starlix:** patient has had a documented intolerance to generic nateglinide.<br>**Prandin, Repaglinide:** patient has been started and stabilized on the requested medication OR patient has had a documented side effect, allergy OR treatment failure with Starlix AND if the request is for Prandin, the patient has a documented intolerance with generic repaglinide.<br>**Prandimet:** patient has been started and stabilized on Prandimet or on stable doses of the separate agents OR patient has had an inadequate response with repaglinide monotherapy. |
| **PEPTIDE HORMONES** | | |
| ***Preferred Agents After Clinical Criteria Are Met***<br>**Incretin Mimetics**<br>TANZEUM ® (albiglutide)<br>VICTOZA® (liraglutide)<br>*(Quantity Limit=3 pens/30 days)* | Bydureon® (exenatide extended-release)<br>*(Quantity Limit=4 vials/28 days)*<br>Byetta® (exenatide)<br>*(Quantity Limit =1 pen/30 days)*<br>Trulicity® (dulaglutide) | **Bydureon/Byetta/Trulicity:** patient has a diagnosis of type 2 diabetes AND patient is at least 18 years of age AND patient has had a documented side effect, allergy, contraindication or treatment failure with metformin AND patient has a documented side effect, allergy, contraindication, or treatment failure with Victoza or Tanzeum (current users as of 05/29/2015 would be grandfathered) |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **Amylinomimetics** | Symlin® (pramlintide)<br>*No Quantity Limit applies* | **Symlin:** patient has a diagnosis of diabetes mellitus. AND patient is at least 18 years of age. AND patient is on insulin.<br>**Victoza/Tanzeum:** patient has a diagnosis of type 2 diabetes. AND patient is at least 18 years of age. AND patient has had a documented side effect, allergy, contraindication or treatment failure with metformin. |
| **SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS AND COMBINATIONS** | | |
| ***Preferred After Clinical Criteria Are Met***<br>FARXIGA® (dapagliflozin )<br>*(Quantity limit = 1 tablet/day)*<br>INVOKANA® (canagliflozin) §<br>*(Quantity limit = 1 tablet/day)* | Jardiance (empagliflozin)<br>*(Quantity limit = 1 tablet/day)*<br><br>GLYXAMBI® (empagliflozin/ linagliptin) *(Quantity limit = 1 tablet/day)*<br>Invokamet (canagliflozin/metformin)<br>*(Quantity limit = 1 tablet/day)*<br>Synjardy® (empagliflozin/metformin) *(Quantity Limit = 2 tablets/day)*<br>Xigduo XR® (dapagliflozin & metformin ER)<br>*(Quantity limit 5/1000mg = 2/day)*<br>*(Quantity limit All Other Strengths = 1/day)* | Patient is 18 years of age or older AND patient has a diagnosis of type 2 diabetes mellitus and has had an inadequate response to diet and exercise alone AND patient has had a documented side effect, allergy, contraindication OR treatment failure with metformin .<br>**Jardiance additional criteria:**<br>• The patient has had a documented side effect, allergy, contraindication, or treatment failure with Invokana or Farxiga<br>**Invokamet/Xigduo XR® additional criteria:**<br>• The patient has documentation of a failure of therapy with the combination of the single agent drugs Invokana plus metformin<br>**Glyxambi additional criteria:**<br>• The patient has documentation of a failure of therapy with the combination of the preferred SGL2 plus a preferred DPP-4 inhibitor<br>**Synjardy® additional criteria:** the patient has documentation of a failure of therapy with the combination of the single agent drugs Jardiance plus metformin |
| **SULFONYLUREAS 2ND GENERATION** | | |
| GLIMEPIRIDE† (compare to Amaryl®)<br>GLIPIZIDE† (compare to Glucotrol®)<br>GLIPIZIDE ER† (compare to Glucotrol XL®)<br>GLYBURIDE† (compare to Diabeta®, Micronase®) | Amaryl®* (glimepiride)<br>Diabeta®* (glyburide)<br>Glucotrol®* (glipizide)<br>Glucotrol XL®* (glipizide ER)<br>Glynase® PresTab®* (glyburide micronized) | Patient has had a documented side effect, allergy OR treatment failure with glimperiride, AND glimepiride, AND glipizide/glipizide ER, and glyburide/glyburide micronized. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| GLYBURIDE MICRONIZED† (compare to Glynase® PresTab®) | Micronase®* (glyburide) | |
| **THIAZOLIDINEDIONES & COMBINATIONS** | | |
| ***Preferred After Clinical Criteria Are Met***<br>**SINGLE AGENT**<br>PIOGLITAZONE† (compare to Actos®)§<br><br>**COMBINATION**<br>PIOGLITAZONE/GLIMEPIRIDE† (compare to Duetact®) § *(Quantity Limit = 1 tablet/day)*<br>PIOGLITAZONE/METFORMIN† (Compare to Actoplus Met®)§ | Actos® (pioglitazone)<br>Avandia® (rosiglitazone)<br><br>Actoplus Met® (pioglitazone/metformin)<br>Actoplus Met XR (pioglitazone/metformin ER)<br>Avandamet® (metformin/rosiglitazone maleate)<br>Avandaryl® (glimepiride/rosiglitazone maleate)<br>Duetact® (pioglitazone/glimepiride)<br>*(Quantity Limit = 1 tablet/day)* | **Actos (pioglitazone), Actoplus Met, Duetact, Pioglitazone/Metformin:** Patient has been started and stabilized on the requested medication OR patient has had a documented side effect, allergy, contraindication OR treatment failure with metformin AND if the request is for brand Actos Met or Duetact, patient has a documented intolerance to the generic product.<br>**Actoplus Met XR:** patient has been started AND stabilized on the requested medication OR patient has had a documented treatment failure with generic Metformin XR OR patient has had a documented treatment failure OR has been unable to be adherent to a twice daily dosing schedule of Actoplus Met resulting in a significant clinical impact.<br>**Avandia:** patient has been started and stabilized on the requested medication and appears to be benefiting from it and the patient acknowledges that they understand the risks OR patient is unable to achieve glycemic control using other medications (including a documented side effect, allergy, contraindication or treatment failure with metformin). |
| **ANTI-EMETICS** | | |
| **5HT3 ANTAGONISTS:** Length of Authorization: 6 months for chemotherapy or radiotherapy; 3 months for hyperemesis gravadarum, 1 time for prevention of post-op nausea/vomiting: see clinical criteria. Monthly quantity limits apply, PA required to exceed. | | |
| ONDANSETRON† Injection (vial and premix)<br>ONDANSETRON†tablet 4 mg (12 tabs/28 days), 8 mg (6 tabs/28 days)<br>ONDANSETRON† ODT 4 mg (12 tabs/28 days), 8 mg (6 | Akynzeo® (nutupitant/palonosetron)<br>Anzemet® (dolansetron) 50 mg (4 tabs/28 days)<br>Anzemet® (dolansetron) 100 mg (2 tabs/28 days) | **Akynzeo:** Has a diagnosis of nausea and vomiting associated with cancer chemotherapy AND patient has a documented side effect, allergy, or treatment failure of a regimen consisting of a 5-HT3 antagonist, an NK1 antagonist, and |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| tabs/28 days | Granisetron† (formerly Kytril®) 1 mg (6 tabs/28 days)<br>Granisetron† (formerly Kytril®) Injectable<br>Ondansetron† (generic) Oral Solution 4 mg/5 ml<br>Sancuso® 3.1 mg/24 hrs Transdermal Patch (granisetron) (Qty Limit = 1 patch/28 days)<br><br>Zofran®* (ondansetron) Injection<br>Zofran®* (ondansetron) Oral Tablets and ODT 4 mg (12 tabs/28 days),<br>8 mg (6 tabs/28 days)<br>Zofran® (ondansetron) Oral Solution 4 mg/5 ml<br>Zuplenz® (ondansetron) Oral Soluble Film<br>*(Quantity Limit =12 films/28 days (4 mg), 6 films/28 days (8 mg))* | dexamethasone<br>**Anzemet:** has a diagnosis of nausea and vomiting associated with cancer chemotherapy. AND patient has had a documented side effect, allergy, or treatment failure to generic ondansetron.<br>**Granisetron:** patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy or radiotherapy. AND patient has had a documented side effect, allergy, or treatment failure to generic ondansetron.<br>**Zofran:** The patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy, radiotherapy, post-operative nausea and vomiting (1 time only) or hyperemesis gravadarum. AND patient must have a documented intolerance to the corresponding generic ondansetron product (tablets, orally disintegrating tablets (ODT), oral solution or injection). If the request is for oral solution, the patient must be unable to use ondansetron ODT or ondansetron tablets.<br>**Ondansetron Oral Sol:** patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy, radiotherapy, post-operative nausea and vomiting (1 time only) or hyperemesis gravadarum. AND patient is unable to use ondansetron ODT or ondansetron tablets.<br>**Sancuso:** patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy. AND prescriber provides documentation of medical necessity for the transdermal formulation. OR patient has had a documented side effect, allergy or treatment failure with generic ondansetron.<br>**Zuplenz:** patient has a diagnosis of nausea and vomiting associated with cancer chemotherapy or radiotherapy. AND prescriber provides documentation of medical necessity for the specialty dosage form (i.e. inability to swallow tablets, dysphagia) AND a clinical rationale as to why ondansetron ODT is not a suitable option for the patient.<br>**CRITERIA FOR APPROVAL (to exceed quantity limit):**<br>**Ondansetron/Zofran 4 mg and 8 mg tablets and ODT, Zuplenz:** For nausea and vomiting associated with chemotherapy or radiation therapy, 3 tablets for each day of chemotherapy/radiation and 3 tablets for each day for 2 days after completion of chemotherapy/radiation may be approved.<br>**Ondansetron/Zofran 4 mg and 8 mg tablets and ODT:** For hyperemesis |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | gravadarum, three tablets per day of 4 mg or 8 mg may be approved for 3 months.<br>**Anzemet:** For nausea and vomiting associated with chemotherapy, 1 tablet for each day of chemotherapy and 1 tablet for 2 days after completion of chemotherapy may be approved.<br>**Granisetron:** For nausea and vomiting associated with chemotherapy, 2 tablets for each day of chemotherapy and 2 tablets for 2 days after completion of chemotherapy may be approved. OR For nausea and vomiting associated with radiation therapy, 2 tablets for each day of radiation may be approved.<br>**Sancuso:** For nausea and vomiting associated with chemotherapy, 1 patch for each chemotherapy cycle may be approved.<br>**Limitations:** Aloxi and Anzemet injection are not considered outpatient medications and are not covered in the pharmacy benefit. |
| **MISCELLANEOUS (PREGNANCY)** | | |
| | Diclegis® (10 mg doxylamine succinate and 10 mg pyridoxine hydrochloride) DR tablet *(QL= 4 tablets/day)* | Patient has a diagnosis of nausea and vomiting of pregnancy AND Patient has tried and had an inadequate response to conservative management (i.e. change in dietary habits, ginger, or acupressure) AND Patient has tried and had an inadequate response to generic doxylamine and generic pyridoxine (Vitamin B6) AND Patient has tried and had an inadequate response to generic ondansetron. |
| **NK1 ANTAGONISTS** | | |
| ***Preferred After Clinical Criteria Are Met***<br>EMEND® (aprepitant) 40 mg (1 cap/28 days)<br>♣EMEND® (aprepitant) 80 mg (2 caps/28 days)<br>♣EMEND® (aprepitant) 125 mg (1 cap/28 days)<br>♣EMEND® (aprepitant) Tri-fold Pack (1 pack/28 days) | Varubi® (rolapitant) *Quantity Limit = 4 tabs/ 28 days* | **Emend (aprepitant) 80 mg, 125 mg, and Tri-Fold pack:** medication will be prescribed by an oncology practitioner. AND patient requires prevention of nausea and vomiting associated with moderate to highly emetogenic cancer chemotherapy. AND The requested quantity does not exceed one 125 mg and two 80 mg capsules OR one Tri-Fold Pack per course of chemotherapy. Patients with multiple courses of chemotherapy per 28 days will be approved quantities sufficient for the number of courses of chemotherapy.<br>**Emend 40mg:** patient requires prevention of postoperative nausea and vomiting. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| ♣ *To be prescribed by oncology practitioners ONLY* | | AND The requested quantity does not exceed one 40 mg capsule per surgery or course of anesthesia. Patients with multiple surgeries or courses of anesthesia in a 28 day period will be approved quantities sufficient for the number of surgeries or courses of anesthesia.<br>**Varubi:** Medication will be prescribed by an oncology practitioner AND patient requires prevention of nausea and vomiting associated with moderate to highly emetogenic cancer chemotherapy AND the requested quantity does not exceed 4 tablets per 28 days AND the patient has had a documented side effect, allergy, or treatment failure with Emend®. |
| **THC DERIVATIVES** | | |
| | Dronabinol† (compare to Marinol®)<br>Marinol® (dronabinol)<br>Cesamet® (nabilone) | **Pharmacology:** Marinol® is a schedule III cannabinoid agent containing the same active ingredient, tetrahydrocannabinol, as marijuana. While its exact mechanism of action is unknown, it is speculated to inhibit medullary activity as well as suppress prostaglandin and endorphan synthesis. Cesamet® is a schedule II synthetic cannabinoid that acts by activating the endocannabinoid receptors, CB1 and CB2, which are involved in nausea/vomiting regulation. Both Marinol® and Cesamet® are FDA-approved for use in chemotherapy associated nausea and vomiting refractory to conventional antiemetics. In addition, Marinol® is indicated for patients with AIDS-related anorexia or wasting syndrome.<br>**Dronabinol/Marinol:**patient has a diagnosis of chemotherapy-induced nausea/vomiting AND patient has had a documented side effect, allergy, or treatment failure to at least 2 antiemetic agents, of which, one must be a preferred 5HT3 receptor antagonist. If the request is for Marinol, the patient must additionally have a documented intolerance to generic dronabinol. OR patient has a diagnosis of AIDS associated anorexia. AND patient has had an adequate response, adverse reaction, or contraindication to megestrol acetate. If the request is for Marinol, the patient must additionally have a documented intolerance to generic dronabinol.<br>**Cesamet:** patient has a diagnosis of chemotherapy-induced nausea/vomiting AND patient has had a documented side effect, allergy, or treatment failure to at least 2 |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | antiemetic agents, of which, one must be a preferred 5HT3 receptor antagonist. |
| **ANTI-HYPERTENSIVES** | | |
| **ACE INHIBITORS** | | |
| BENAZEPRIL† (compare to Lotensin®)<br>CAPTOPRIL† (formerly Capoten®)<br>ENALAPRIL† (compare to Vasotec®)<br>EPANED® (enalapril) oral solution (age < 12 years old)<br>FOSINOPRIL† (formerly Monopril®)<br>LISINOPRIL† (compare to Zestril®, Prinivil®)<br>MOEXIPRIL† (compare to Univasc®)<br>QUINAPRIL† (compare to Accupril®)<br>RAMIPRIL† (compare to Altace®)<br>TRANDOLAPRIL† (compare to Mavik®) | Accupril®*(quinapril)<br>Aceon® (perindopril)<br>Altace®* (ramipril)<br>Epaned® (enalapril) oral solution (age ≥ 12 years old)<br>Lotensin®* (benazepril)<br>Mavik®* (trandolapril)<br>perindopril† (compare to Aceon®)<br>Prinivil®* (lisinopril)<br>Univasc®* (moexipril)<br>Vasotec®* (enalapril)<br>Zestril®* (lisinopril) | **Epaned Oral Solution (Patients > 12 years old):** patient has a requirement for an oral liquid dosage form (i.e. swallowing disorder, inability to take oral medications).<br>**Other ACE Inhibitors:** patient has had a documented side effect, allergy, or treatment failure to all available preferred generic ACEI. If a medication has an AB rated generic, there must have been a trial of the generic formulation. |
| **ACE INHIBITOR W/ HYDROCHLOROTHIAZIDE** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| BENAZEPRIL/HYDROCHLOROTHIAZIDE† (compare to Lotensin HCT®)<br>ENALAPRIL/HYDROCHLOROTHIAZIDE† (compare to Vaseretic®)<br>FOSINOPRIL/HYDROCHLOROTHIAZIDE† (formerly Monopril HCT®)<br>LISINOPRIL/HYDROCHLOROTHIAZIDE† (compare to Zestoretic®,<br>MOEXIPRIL/HYDROCHLOROTHIAZIDE† (formerly Uniretic®)<br>QUINAPRIL/HYDROCHLOROTHIAZIDE† (compare to Accuretic®) | Accuretic®* (quinapril/HCTZ)<br>Lotensin HCT®* (benazepril/HCTZ)<br>Vaseretic®* (enalapril/HCTZ)<br>Zestoretic®* (lisinopril/HCTZ) | **ACE Inhibitor/Hydrochlorothiazide combinations:** patient has had a documented side effect, allergy, or treatment failure to all available preferred generic ACEI/Hydrochlorothiazide combination. If a medication has an AB rated generic, there must have been a trial of the generic formulation.<br>**Limitations:** Captopril/HCTZ combination not covered. Agents may be prescribed separately |
| **ACE INHIBITOR W/CALCIUM CHANNEL BLOCKER** | | |
| AMLODIPINE/BENAZEPRIL † (compare to Lotrel®)<br>TRANDOLAPRIL/VERAPAMIL (Tarka®) | Lotrel®* amlodipine/(benazepril)<br>Prestalia® (perindopril/amlodipine)<br>Tarka® (trandolopril/verapamil) | **Lotrel, Tarka:** The patient has had a documented side effect, allergy, or treatment failure to the generic formulation.<br>**Prestalia:** The patient has had a documented side effect, allergy, or treatment failure to amlodipine/benazepril AND the patient is unable to take perindopril and amlodipine as the individual separate agents. |
| **ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)** | | |
| ***Preferred After Clinical Criteria Are Met***<br>BENICAR® (olmesartan) §<br>DIOVAN® (valsartan) § | Atacand® (candesartan)<br>Avapro® (irbesartan)<br>candesartan† (compare to Atacand®)§ | **Benicar, Diovan, Irbesartan, Losartan, and Micardis:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

Drugs highlighted in yellow denote a change in PDL status.

To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| IRBESARTAN† (compare to Avapro®) §<br>LOSARTAN† (compare to Cozaar®) §<br>MICARDIS® (telmisartan) | Cozaar® (losartan)<br>Edarbi® (azilsartan) Tablet<br>*(Qty Limit = 1 tablet/day)*<br>Eprosartan† (compare to Teveten®) §<br>Telmisartan† (compare to Micardis®) §<br>Teveten® (eprosartan)<br>valsartan† (compare to Diovan®) | (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination.<br>**Atacand, Avapro, Candasartan, Edarbi, Eprosartan, Telmisartan, and Teveten:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization OR patient has had a documented side effect, allergy, or treatment failure with a preferred Angiotensin Receptor Blocker (ARB) or ARB combination. AND If brand name product with generic available, the patient has had a documented intolerance with the generic product.<br>**Cozaar (Brand):** patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination. AND patient has had a documented intolerance with the generic product.<br>**Valsartan:** patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination. AND patient has had a documented intolerance with the brand product (Diovan) |
| **ANGIOTENSIN RECEPTOR BLOCKER/DIURETIC COMBINATIONS** | | |
| ***Preferred After Clinical Criteria Are Met***<br>BENICAR HCT® (olmesartan/hydrochlorothiazide) § | **Non-** ***Preferred After Clinical Criteria Are Met***<br>Atacand HCT® (candesartan/hydrochlorothiazide)<br>Avalide® (irbesartan/hydrochlorothiazide) | **Benicar HCT, Irbesartan/HCTZ, Losartan/HCTZ, Micardis HCT, and Valsartan/HCTZ:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| IRBESARTAN/HYDROCHLOROTHIAZIDE†<br>(compare to Avalide®)§<br>LOSARTAN/HYDROCHLOROTHIAZIDE †<br>(compare to Hyzaar®)§<br>MICARDIS HCT® (telmisartan/hydrochlorothiazide)<br>VALSARTAN/HYDROCHLOROTHIAZIDE †<br>(compare to Diovan HCT®)§ | candesartan/hydrochlorothiazide † (compare to Atacand HCT®)§<br>Diovan HCT® (valsartan/hydrochlorothiazide)<br>Edarbyclor® (azilsartan/chlorthalidone) Tablet *(Qty Limit = 1 tablet/day)*<br>Hyzaar® (losartan/hydrochlorothiazide)<br>Telmisartan/hydrochlorothiazide † (compare to Micardis HCT®) §<br>Teveten HCT® (eprosartan/hydrochlorothiazide) § | or any other angiotensin receptor blocker (ARB) or ARB combination.<br>**Avalide, Diovan HCT, and Telmisartan HCT:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization OR patient has had a documented side effect, allergy, or treatment failure with a preferred Angiotensin Receptor Blocker (ARB) or ARB combination. AND If brand name product with generic available, the patient has had a documented intolerance with the generic product.<br>**Atacand HCT, candasartan/HCTZ, Teveten HCT:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient has had a documented side effect, allergy, or treatment failure with a preferred ARB/Hydrochlorothiazide combination. AND If the request is for Atacand HCT, the patient has had a documented intolerance with the generic product.<br>**Hyzaar:** patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination. AND patient has had a documented intolerance with the generic product.<br>**Edarbyclor:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient has had a documented side effect, allergy, or treatment failure with a preferred Angiotensin Receptor Blocker (ARB) or ARB combination. AND patient is unable to take the individual components separately |
| **ANGIOTENSIN RECEPTOR BLOCKER/CALCIUM CHANNEL BLOCK COMBINATIONS** | | |
| ***Preferred After Clinical Criteria Are Met***<br>VALSARTAN/AMLODIPINE† (compare to Exforge®)§ *(QL= 1tab/day)* | ***Non- Preferred After Clinical Criteria Are Met***<br>Azor®(olmesartan/amlodipine) *(QL = 1 tablet/day)*<br>amlodipine/telmisartan† (compare to Twynsta® ) | **Valsartan/amlodipine:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| EXFORGE® (valsartan/amlodipine)§ *(QL = 1 tab/day)* | *(QL = 1 tablet/day)*<br>Twynsta® (amlodipine/telmisartan) *(QL = 1 tablet/day)* | combination or any other angiotensin receptor blocker (ARB) or ARB combination.<br>**Exforge:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization OR patient has had a documented side effect, allergy, or treatment failure with a preferred Angiotensin Receptor Blocker (ARB) or ARB combination. AND If brand name product with generic available, the patient has had a documented intolerance with the generic product.<br>**Azor, Amlodipine/Telmisartan, and Twynsta:** The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination. AND patient is unable to take the individual components separately. AND If the request is for Twynsta, the patient has a documented intolerance to generic amlodipine/telmisartan. |
| **ANGIOTENSIN RECEPTOR BLOCKER/DIRECT RENIN INHIBITOR COMBINATIONS** | | |
| | ***Non- Preferred After Clinical Criteria Are Met***<br>Valturna® (aliskiren/valsartan) *(Qty Limit = 1 tablet/day)* | **Valturna:** patient is NOT a diabetic AND patient has a diagnosis of hypertension. AND patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination. OR patient has had a documented treatment failure with Tekturna alone. |
| **ANGIOTENSIN RECEPTOR BLOCKER/CALCIUM CHANNEL BLOCKER/HCTZ COMBO** | | |
| ***Preferred After Clinical Criteria Are Met***<br>EXFORGE HCT®<br>(amlodipine/valsartan/hydrochlorothiazide) §<br>*(Quantity Limit = 1 tablet/day)* | ***Non- Preferred After Clinical Criteria Are Met***<br>Tribenzor®<br>(amlodipine/olmesartan/hydrochlorothiazide) | **Exforge HCT:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| VALSARTAN/AMLODIPINE/HCTZ† (compare to Exforge HCT®) (QL = 1/day) | *(QL = 1 tablet/day)* | other angiotensin receptor blocker (ARB) or ARB combination.<br>**Tribenzor:** The patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination. AND patient is unable to take the individual components separately. |
| **ANGIOTENSIN RECEPTOR BLOCKER/MISCELLANEOUS COMBINATIONS** | | |
| ***Preferred Agent After Clinical Criteria Is Met***<br>ENTRESTO® (valsartan/sacubitril) (QL = 2 tabs/day) | | **Entresto®:** Diagnosis of chronic heart failure NYHA Class II-IV AND Age ≥ 18 years of age AND left ventricular ejection fraction ≤ 40% AND no history of angioedema or unacceptable side effects during receipt of ACE inhibitor or ARB AND not to be used concomitantly with aliskiren in patients with diabetes or concurrently with an ACE inhibitor or other ARB AND no severe hepatic impairment (Child-Pugh C). |
| **BETA BLOCKERS** | | |
| **SINGLE AGENT**<br>ACEBUTOLOL† (compare to Sectral®)<br>ATENOLOL† (compare to Tenormin®)<br>BETAXOLOL† (compare to Kerlone®)<br>BISOPROLOL FUMARATE† (compare to Zebeta®)<br>CARVEDILOL† (compare to Coreg®)<br>INNOPRAN XL® (propranolol SR) | Betapace®* (sotalol)<br>Betapace AF®* (sotalol)<br>Bystolic® (nebivolol) *(QL = 1 tablet/day for 2.5 mg, 5 mg and 10 mg tablet strengths, 2 tablets/day for 20 mg tab)*<br>Coreg®* (carvedilol)<br>Coreg CR® (carvedilol CR) *(QL = 1 tablet/day*<br>Corgard®* (nadolol)<br>Hemangeol® oral solution (propranolol)<br>Inderal LA®* (propranolol ER)<br>Inderal XL® (propranolol SR) | **Non-preferred drugs (except Coreg CR):** patient has had a documented side effect, allergy, or treatment failure to at least three preferred drugs. (If a medication has an AB rated generic, one trial must be the generic formulation.)<br>**Coreg CR:** Indication: Heart Failure: patient has been started and stabilized on Coreg CR. (Note: Samples are not considered adequate justification for stabilization.) OR patient has had a documented side effect, allergy, or treatment failure to metoprolol SR or bisoprolol. AND patient has been unable to be compliant with or tolerate twice daily dosing of carvedilol IR.<br>Indication; Hypertension: patient has been started and stabilized on Coreg CR. (Note: Samples are not considered adequate justification for stabilization.) OR patient has had a documented side effect, allergy, or treatment failure to 3(three) preferred anti-hypertensive beta-blockers. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| LABETALOL† (compare to Trandate®) | | |
| METOPROLOL TARTRATE† (compare to Lopressor®)<br>METOPROLOL SUCCINATE XL† (compare to Toprol XL®)<br>NADOLOL† (compare to Corgard®)<br>PINDOLOL† (formerly Visken®)<br>PROPRANOLOL† (formerly Inderal®)<br>SOTALOL† (compare to Betapace®, Betapace AF®) | Kerlone®* (betaxolol)<br>Levatol® (penbutolol )<br>Lopressor®* (metoprolol tartrate)<br>Propranolol ER† (compare to Inderal LA®)<br>Sectral®* (acebutolol)<br>Sorine® (sotalol)<br>Tenormin®* (atenolol)<br>Timolol† (formerly Blocadren®)<br>Toprol XL®* (metoprolol succinate XL)<br>Trandate®* (labetaolol)<br>Zebeta®* (bisoprolol) | |
| **BETA-BLOCKER/DIURETIC COMBINATION**<br>ATENOLOL/CHLORTHALIDONE † (compare to Tenoretic®)<br>BISOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Ziac®)<br>METOPROLOL/HYDROCHLOROTHIAZIDE† (compare to Lopressor HCT®) | Corzide®* (nadolol/bendroflumethiazide)<br>Lopressor HCT®* (metoprolol/HCTZ)<br>Propranolol/HCTZ† (formerly Inderide®)<br>Tenoretic®* (atenolol/chlorthalidone)<br>Ziac®* (bisoprolol/HCTZ)<br>Dutoprol® (metoprolol succinate XR/hydrochlorothiazide)<br>Nadolol/bendroflumethiazide† (compare to Corzide®) | |
| **CALCIUM CHANNEL BLOCKERS** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

Drugs highlighted in yellow denote a change in PDL status.

To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **SINGLE AGENT**<br>**Dihydropyridines**<br>AFEDITAB® CR † (nifedipine SR, compare to Adalat® CC)<br>AMLODIPINE † (compare to Norvasc®)<br>FELODIPINE ER† (formerly Plendil®)<br>NICARDIPINE † (formerly Cardene®)<br>NIFEDIAC® CC † (nifedipine SR, compare to Adalat® CC)<br>NIFEDICAL® XL † (nifedipine SR osmotic, compare to Procardia® XL)<br>NIFEDIPINE IR † (compare to Procardia®)<br>NIFEDIPINE SR osmotic † (compare to Procardia® XL)<br>NIFEDIPINE SR † (compare to Adalat® CC )<br>NIMODIPINE † (compare to Nimotop®) | Adalat® CC* (nifedipine SR)<br>Isradipine (formerly Dynacirc®)<br>Nisoldipine ER† (compare to Sular®)<br>Norvasc®* (amlodipine)<br>Nymalize® (nimodipine) Oral Solution<br>Procardia®* (nifedipine IR)<br>Procardia XL®* (nifedipine SR osmotic)<br>Sular® (nisoldipine) | **Criteria for approval (except as noted below:)** patient has had a documented side effect, allergy, or treatment failure to at least three preferred drugs. (If a medication has an AB rated generic, one trial must be the generic formulation.)<br>**Nymalize:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient has a medical necessity for a specialty dosage form (i.e. dysphagia, swallowing disorder). |
| **Miscellaneous**<br>CARTIA® XT † (diltiazem SR, compare to Cardizem® CD)<br>DILT-CD® † (diltiazem SR, compare to Cardizem® CD)<br>DILT-XR® † (diltiazem SR)<br>DILTIAZEM† (compare to Cardizem®)<br>DILTIAZEM ER† (formerly Cardizem® SR) | Calan®* (verapamil)<br>Calan® SR* (verapamil CR)<br>Cardizem®* (diltiazem)<br>Cardizem® CD* (diltiazem SR)<br>Cardizem® LA (diltiazem SR)<br>Diltiazem ER†/Matzin LA† (compare to Cardizem® LA) | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

Drugs highlighted in yellow denote a change in PDL status.

To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| DILTIAZEM ER† (compare to Tiazac®)<br>DILTIAZEM SR † (compare to Cardizem®CD)<br>DILTIAZEM SR †<br>TAZTIA® XT † (diltiazem ER, compare to Tiazac®)<br>VERAPAMIL† (compare to Calan®)<br>VERAPAMIL CR† (compare to Calan SR®<br>VERAPAMIL SR† 120 mg, 180 mg 240 mg and 360 mg (compare to Verelan®)<br>VERAPAMIL SR† 100 mg, 200 mg, 300mg (compare to Verelan PM®) | Tiazac®* (diltiazem ER)<br>Verelan®* (verapamil SR 120 mg, 180 mg, 240 mg and 360 mg)<br>Verelan® PM* (100 mg, 200 mg and 300 mg) | |
| **CALCIUM CHANNEL BLOCKER/OTHER COMBINATION**<br>(***Preferred After Clinical Criteria Are Met***)<br><br>EXFORGE HCT® (amlodipine/valsartan/hydrochlorothiazide) §<br>*(Quantity Limit = 1 tablet/day)*<br>VALSARTAN/AMLODIPINE† (compare to Exforge® )§<br>*(Quantity Limit = 1 tablet/day)*<br>VALSARTAN/AMLODIPINE/HCTZ† (compare to Exforge HCT®) (QL = 1/day) | Azor® (olmesartan/amlodipine)<br>*(QL = 1 tablet/day)*<br>amlodipine/telmisartan† (compare to Twynsta® )<br>*(QL = 1 tablet/day)*<br>Tribenzor® (amlodipine/olmesartan/hydrochlorothiazide)<br>*(QL = 1 tablet/day)*<br><br>Twynsta® (amlodipine/telmisartan)<br>*(QL = 1 tablet/day)*<br>Amlodipine/atorvastatin † (compare to Caduet®)<br>*(Qty Limit = 1 tablet/day)*<br>Caduet® (amlodipine/atorvastatin)<br>*(Qty Limit = 1 tablet/day)* | **Azor, Amlodipine/Telmisartan, Tribenzor, and Twynsta:** patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI combination or any other angiotensin receptor blocker (ARB) or ARB combination AND patient is unable to take the individual components separately. AND If the request is for Twynsta, the patient has a documented intolerance to generic amlodipine/telmisartan.<br>**Amlodipine/atorvastatin, Caduet:** prescriber must provide a clinically valid reason for the use of the requested medication. For approval of Caduet, the patient must have also had a documented intolerance to the generic equivalent. For combinations containing 40 mg or 80 mg atorvastatin, the individual generic components are available without PA and should be prescribed.<br>**Exforge, Exforge HCT:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR patient has had a documented side effect, allergy, or treatment failure to an angiotensin converting enzyme inhibitor (ACEI), an ACEI |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | Exforge® (valsartan/amlodipine) *(Quantity Limit = 1 tablet/day)* | combination or any other angiotensin receptor blocker (ARB) or ARB combination. |
| **CENTRAL ALPHA AGONISTS** | | |
| **ORAL**<br>**Tablet**<br>CLONDIDNE IR† Tablets (compare to Catapress®)<br>GUANFACINE IR† Tablets (compare to Tenex®)<br>METHYLDOPA† Tablets<br><br>**Suspension** | Catapres®* (clonidine) Tablet<br>Nexiclon XR® (clonidine) Extended Release Tablets *(Quantity Limit = 3 tablets/day)*<br>Tenex®* (guanfacine) Tablets<br><br>Nexiclon XR® (clonidine) Extended Release Suspension | **Catapres, Tenex:** Patient has a documented intolerance to the generic product.<br>**Nexiclon XR Tabs:** patient has a diagnosis of hypertension. AND patient has had a documented side effect, allergy, or treatment failure to at least TWO agents (either separately or as a combination product) from the following antihypertensive classes: a thiazide diuretic, a beta blocker, an angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or a calcium channel blocker (CCB). AND patient has been unable to be adherent to or tolerate twice daily dosing of the generic clonidine immediate-release tablets.<br>**Nexiclon XR Oral Susp:** patient has a diagnosis of hypertension AND patient has had a documented side effect, allergy, or treatment failure to at least TWO agents (either separately or as a combination product) from the following antihypertensive classes: a thiazide diuretic, a beta blocker, an angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or a calcium channel blocker (CCB). AND patient has a medical necessity for a specialty dosage form (i.e. dysphagia, swallowing disorder. |
| **TRANSDERMAL** | Catapres-TTS® (clonidine) Transdermal Patch *(Qty Limit = 1 patch/7 days)*<br>Clonidine (compare to Catapres-TTS) Transdermal Patch *(Qty Limit = 1 patch/7 days)* | **Clonidine Patches (generic):** patient has a medical necessity for a specialty topical dosage form (i.e. dysphasia, swallowing disorder, compliance, nausea/vomiting).<br>**Catapres-TTS Patches:** patient has a medical necessity for a specialty topical dosage form (i.e. dysphasia, swallowing disorder, compliance, nausea/vomiting). AND patient has a documented intolerance to the generic product. |
| **GANGLIONIC BLOCKERS** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| All products require a PA | Vecamyl®* (mecamylamine) Tablet | **Vecamyl tabs:** Patient has a diagnosis of moderately severe or severe hypertension AND patient has tried and failed, intolerant to, or contraindicated to at least THREE different antihypertension therapies of different mechanism of actions. |
| **RENIN INHIBITOR** | | |
| | SINGLE AGENT<br>Tekturna® (aliskiren) *(Quantity Limit = 1 tablet/day)*<br>COMBINATIONS<br>Amturnide® (aliskiren/amlodipine/hydrochlorothiazide) *(Qty Limit = 1 tab/day)*<br>Tekamlo® (aliskiren/amlodipine) *(Qty Limit = 1 tablet/day)*<br>Tekturna HCT® (aliskiren/hydrochlorothiazide) *(Quantity Limit = 1 tablet/day)* | **Tekturna:** patient is NOT a diabetic who will continue on therapy with an ACEI or ARB AND patient has a diagnosis of hypertension. AND patient has had a documented side effect, allergy, or treatment failure with an angiotensin Receptor Blocker (ARB). Note: Approval of an ARB requires a documented side effect, allergy, or treatment failure with an Angiotensin Converting Enzyme (ACE) inhibitor.<br>**Amturnide, Tekalmo, Tekturna HCT:** patient is NOT a diabetic who will continue on therapy with an ACEI or AND patient has a diagnosis of hypertension. AND patient has had a documented side effect, allergy, or treatment failure with an Angiotensin Receptor Blocker (ARB). Note: Approval of an ARB requires a documented side effect, allergy, or treatment failure with an Angiotensin Converting Enzyme (ACE) inhibitor. OR patient has had a documented treatment failure with Tekturna® alone. |
| **ANTI-INFECTIVES ANTIBIOTICS** | | |
| **CEPHALOSPORINS 1ST GENERATION** | | |
| **CAPSULES/TABLETS**<br>CEFADROXIL† Capsules, Tablets (formerly Duricef®) | Cephalexin® Tablets<br>Keflex®* (cephalexin) Capsules | **Cephalexin Tabs:** patient has had a documented intolerance to cephalexin generic capsules.<br>**Keflex:** patient has had a documented side effect, allergy, or treatment failure to |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| CEPHALEXIN† Capsules (compare to Keflex®)<br>**SUSPENSION**<br>CEFADROXIL† Suspension (formerly Duricef®)<br>CEPHALEXIN† Suspension (formerly Keflex®)<br><br>IV drugs are not managed at this time | | generic cefadroxil and cephalexin.<br>**Limitations:** Cephalexin and Keflex 750 mg dosage strength not covered. Use alternative strengths. |
| **CEPHALOSPORINS 2ND GENERATION** | | |
| **CAPSULES/TABLETS**<br>CEFACLOR† CAPSULE<br>CEFPROZIL† (formerly Cefzil®) TABLET<br>CEFUROXIME † (compare to Ceftin®) TABLET<br><br>**SUSPENSION**<br>CEFACLOR SUSPENSION<br>CEFPROZIL† (formerly Cefzil®) SUSPENSION<br><br>IV drugs are not managed at this time | Cefaclor® ER Tablet<br>Ceftin®* (cefuroxime) tablet<br><br>Ceftin® (cefuroxime) suspension | **Cefaclor ER Tabs:** patient has had a documented intolerance to cefaclor capsules.<br>**Ceftin Tabs:** patient has had a documented side effect, allergy, or treatment failure to at least two of the following medications: cefaclor, cefprozil, and cefuroxime. One trial must be the generic formulation.<br><br>**Ceftin Suspension:** patient has had a documented side effect, allergy, or treatment failure to both of the following suspensions: cefaclor and cefprozil. |
| **CEPHALOSPORINS 3RD GENERATION** | | |
| **CAPSULES/TABLETS**<br>CEFDINIR† (formerly Omnicef®) CAPSULE<br>CEFPODOXIME PROXETIL† (formerly Vantin®) TABLET<br>SUPRAX® (cefixime) TABLET | Cedax® (ceftibuten) capsule<br>ceftibuten†capsule (compare to Cedax®)<br>Suprax® (cefixime) Capsule<br>Suprax® (cefixime) Chewable Tablets | **Spectracef tablet, Cedax® Capsule, Cefditoren tablet, Ceftibuten capsule:** patient is completing a course of therapy which was initiated in the hospital. OR patient has had a documented side effect, allergy, or treatment failure to both cefpodoxime and cefdinir. AND If the request is for Spectracef, the patient has a documented intolerance with generic cefditoren tablets.<br>**Cedax Susp, Ceftibuten Susp:** patient is completing a course of therapy which was |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **SUSPENSION**<br>CEFDINIR† (formerly Omnicef®) SUSPENSION<br>CEFIXIME SUSPENSION<br>CEFPODOXIME PROXETIL† (formerly Vantin®) SUSPENSION<br>SUPRAX® (cefixime) suspension<br><br>IV drugs are not managed at this time | Cedax® (ceftibuten) suspension<br>ceftibuten†suspension (compare to Cedax®) | initiated in the hospital. OR patient has had a documented side effect or treatment failure to both cefdinir and cefpodoxime suspensions. |
| **KETOLIDES** | | |
| | Ketek® (telithromycin) | **Ketek:** member is continuing a course of therapy initiated while an inpatient at a hospital. OR diagnosis or indication for the requested medication is community-acquired pneumonia. AND member is at least 18 years of age at the time of the request. AND member has no contraindication or a history of hypersensitivity or serious adverse event, from any macrolide antibiotic. AND Infection is due to documented Streptococcus pneumoniae (including multi-drug resistant [MDRSP*] s.pneumoniae), Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, or Mycoplasma pneumoniae AND member has had a documented therapeutic failure with all clinically appropriate alternatives. AND member does not have any of the following medical conditions: myasthenia gravis, hepatitis or underlying liver dysfunction, history of arrhythmias (e.g. QTc prolongation, or antiarrhythmic therapy), uncorrected hypokalemia or hypomagnasemia, clinically significant bradycardia, a history of |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | therapy with Class IA (e.g. quinidine or procainamide) or Class III (e.g. dofetilide) antiarrhythmic medications. |
| **MACROLIDES** | | |
| **Azithromycin**<br>AZITHROMYCIN† tabs, liquid (≤ 5 day supply) (compare to Zithromax®)<br>(Maximum 10 days therapy/30 days) | azithromycin† tablets and liquid (if > 5 day supply) (compare to Zithromax®)<br>(Maximum 10 days therapy/30 days)<br>Azithromycin† packet (compare to Zithromax®)<br>*(QL = 2 grams/fill)*<br>Zithromax®* (azithromycin) tablets and liquid<br>*QL = 5 days supply/RX, maximum 10 days therapy/30 days*<br>Zithromax® (azithromycin) packet<br>*(QL=2 grams/fill)*<br>Zmax® Suspension (azithromycin extended release for oral suspension)<br>*QL = 5 days supply/RX, maximum 10 days therapy/30 days* | **Non-preferred agents (except as below):** patient has a documented side-effect, allergy, or treatment failure to at least two of the preferred medications. (If a product has an AB rated generic, one trial must be the generic.) OR patient is completing a course of therapy with the requested medication that was initiated in the hospital.<br>**Azithromycin/Zithromax packets:** A clinically valid reason why the dose cannot be obtained using generic azithromycin tablets AND If the request is for brand Zithromax, the patient has a documented intolerance to the generic product.<br>**Azithromycin > 5 day supply:** patient has a diagnosis of Lyme Disease AND has had a documented side effect, allergy, or treatment failure to at least two of the following: doxycycline, amoxicillin, or a 2nd generation cephalosporin. For early Lyme disease, without neurologic or rheumatologic (arthritis) complications, the length of authorization is up to 10 days. For neurologic or rheumatologic Lyme disease, the length of authorization is up to 28 days OR patient has a diagnosis of Cystic Fibrosis. (length of authorization up to 6 months) OR patient has a diagnosis of HIV/immunocompromised status and azithromycin is being used for MAC or Toxoplasmosis treatment or prevention. (length of authorization up to 6 months) OR patient has a diagnosis of bacterial sinusitis AND has had a documented side effect, allergy, or treatment failure to penicillin, amoxicillin, or sulfamethoxazole/trimethoprim (Bactrim). (length of authorization up to 10 days) OR patient has a diagnosis of severe bronchiectasis with frequent exacerbations (length of authorization up to 6 months)<br>**Dificid:** patient's diagnosis or indication is Clostridium difficile associated diarrhea |
| **Clarithromycin**<br>CLARITHROMYCIN† (compare to Biaxin®) | Biaxin®* (clarithromycin)<br>Clarithromycin SR† (compare to Biaxin® XL) | |
| **Erythromycin** | E.E.S®† (erythromycin ethylsuccinate)<br>ERY-TAB® (erythromycin base, delayed release)<br>ERYTHROMYCIN BASE†<br>ERYTHROMYCIN ETHYLSUCCINATE† (compare | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | to E.E.S®)<br>Eryped® (erythromycin ethylsuccinate)<br>Erythrocin (erythromycin stearate)<br>PCE Dispertab® (erythromycin base) | (CDAD) AND patient has had a side-effect, allergy, treatment failure or contraindication to metronidazole. OR prescriber provides a clinically compelling rationale why metronidazole is not appropriate for the patient. (E.g. patient has severe Clostridium difficile infection, history of recurrent infections). AND patient has had a side-effect, allergy, treatment failure or contraindication to oral vancomycin capsules (Vancocin). |
| **Fidaxomicin**<br><br>IV drugs are not managed at this time | Dificid® (fidaxomicin) tablet *(Quantity limit =2 tablets per day, 10 day supply per 30 days)* | |
| **OXAZOLIDINONES** | | |
| IV form of this medication not managed at this time | Sivextro® (tedizolid) *(Quantity limit = 1 tabs/day)*<br>Zyvox® (linezolid) *(QL = 56 tablets per 28 days)*<br>Zyvox® (linezolid) suspension (*QL = 60 ml/day, maximum 28 days supply)* | **Criteria for Approval:** patient has been started on intravenous or oral linezolid or tedizolid in the hospital and will be finishing the course of therapy in an outpatient setting OR patient has a documented blood, tissue, sputum, or urine culture that is positive for Vancomycin-Resistant Enterococcus (VRE) species. OR patient has a documented blood or sputum culture that is positive for Methicillin-Resistant Staphylococcus species OR patient has a documented tissue or urine culture that is positive for Methicillin-Resistant Staphylococcus AND patient has had a documented treatment failure with trimethoprim/sulfamethoxazole OR there is a clinically valid reason that the patient cannot be treated with trimethoprim/sulfamethoxazole. |
| **PENICILLINS (ORAL)** | | |
| **SINGLE ENTITY AGENTS**<br>**Natural Penicillins**<br>PENICILLIN V POTASSIUM† (formerly Veetids®) tablets, oral solution | | **Augmentin:** patient has had a documented intolerance to the generic formulation of the requested medication. OR patient is < 12 weeks of age and requires the 125 mg/5 mL strength of Augmentin.<br>**Amoxicillin/Clavulanate ER, Augmentin XR, Moxatag**: prescriber must provide a clinically valid reason for the use of the requested medication. Additionally, for |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **Penicillinase-Resistant Penicillins**<br>DICLOXACILLIN† Capsules<br><br>**Aminopenicillins**<br>AMOXICILLIN† (formerly Amoxil®) capsules, tablets, chewable tablets, suspension<br>AMPICILLIN† (formerly Principen®) capsules, suspension<br><br>**COMBINATION PRODUCTS**<br>AMOXICILLIN/CLAVULANATE† (compare to Augmentin ®) tablets, chewable tablets, suspension<br><br>AMOXICILLIN/CLAVULANATE† 600-42.9mg/5ml (formerly Augmentin ES® ) suspension | Moxatag® (amoxicillin extended release) tablet<br>*QL =1 tablet/day*<br><br>Amoxicillin/clavulanate† ER (compare to Augmentin XR®) tablets<br><br>Augmentin®*♣ (amoxicillin/clavulanate) tablets, suspension<br><br>Augmentin XR® (amoxicillin/clavulanate) tablets<br>PA will be granted for 125 mg/5 mL strength for patients < 12 weeks of age | approval of brand Augmentin XR, the patient must have a documented intolerance to generic Amoxicillin/Clavulanate ER<br>**Limitations:** Brand Augmentin® Chewable tablets do not offer Federal Rebate and therefore cannot be provided. |
| **QUINOLONES** | | |
| CIPROFLOXACIN† (compare to Cipro®) tabs, oral suspension<br>LEVOFLOXACIN † (compare to Levaquin®) tabs, sol<br><br>OFLOXACIN† | Avelox® (moxifloxacin HCL)<br>Avelox ABC PACK® (moxifloxacin HCL)<br><br>Cipro® * (ciprofloxacin) tabs, oral suspension<br>Cipro XR® (ciprofloxacin) | **Cipro, Cipro XR, ciprofloxacin ER:** patient has had a documented side effect, allergy, or treatment failure to generic ciprofloxacin immediate-release tablets or oral suspension. AND If the request is for Cipro XR or Cipro the patient has had a documented intolerance to the generic equivalent.<br>**Avelox, Moxifloxacin:** patient is completing a course of therapy with the requested |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| IV drugs are not managed at this time | ciprofloxacin ER† (compare to Cipro XR®)<br>Levaquin®* (levofloxacin) tabs,sol<br>moxifloxacin† (compare to Avelox®) | medication that was initiated in the hospital. OR patient has had a documented side effect, allergy, or treatment failure to levofloxacin. AND If the request is for Avelox, the patient has had a documented intolerance to generic moxifloxacin.<br>**Levaquin (brand):** patient has a documented intolerance with the generic levofloxacin |
| **RIFAMYCINS** | | |
| | Xifaxan ® (rifaximin) 200 mg Tablets *(Qty limit depends on indication)*<br>Xifaxan ® (rifaximin) 550 mg Tablets *(Qty limit depends on indication)* | **Criterial for Approval: Based on Indication:**<br>**Hepatic Encephalopathy (Xifaxan 550 mg Tablets Only):** patient has a diagnosis of hepatic encephalopathy. AND Patient has had a documented side effect, allergy, treatment failure or contraindication to lactulose. AND Quantity limit is 2 tablets/day (550 mg tablets only).<br>**Traveller's Diarrhea (Xifaxan 200 mg Tablets Only**): patient has a diagnosis of traveller's diarrhea caused by noninvasive strains of Escherichia coli. AND Patient has had a documented side effect, allergy, treatment failure or contraindication with a fluoroquinolone. AND Quantity limit is 9 tablets/RX (200 mg tablets only).<br>**Small Intestinal Bacterial Overgrowth (Xifaxan 550 mg or 200 mg Tablets:** patient has a diagnosis of SIBO. AND Patient has attempted dietary modification and has had a documented side effect, allergy, treatment failure or contraindication to (alone or in combination) one of the following: Amoxicillin-clavulanate, cephalosporin, metronidazole, fluoroquinolone, tetracycline, and trimethoprim-sulfamethoxazole. AND Quantity limit is 800 mg to 1,200 mg/day.<br>**Irritable Bowel Syndrome (Xifaxan 550 mg or 200 mg Tablets):** patient has a diagnosis of irritable bowel syndrome without constipation or with symptoms of bloating. AND Patient has attempted dietary modification and has had a documented side effect, allergy, treatment failure or contraindication to two of |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | the following classes (one of which must be an antibiotic): • Antibiotics (alone or in combination: amoxicillin-clavulanate, cephalosporin, metronidazole, fluoroquinolone, tetracycline, trimethoprim-sulfamethoxazole) • SSRIs • TCAs • Antispasmodics • Antidiarrheals • Cholestyramine resin AND Quantity limit is 1,200 mg to 1,650 mg/day.<br>**Inflammatory Bowel Disease: Crohn's Disease (Xifaxan 550 mg or 200 mg Tablets):** patient has a diagnosis of Crohn's Disease. AND Patient has had a documented side effect, allergy, treatment failure or contraindication to two of the following: 6-mercaptopurine, aminosalicylates, azathioprine, corticosteroids, fluoroquinolone and/or metronidazole. AND Quantity limit is 600 mg to 1,600 mg/day.<br>**Inflammatory Bowel Disease: Ulcerative Colitis (Xifaxan 200 mg Tablets):** patient has a diagnosis of Ulcerative Colitis. AND Patient has had a documented side effect, allergy, treatment failure or contraindication to two of the following: 6-mercaptopurine, aminosalicylates, azathioprine, corticosteroids, fluoroquinolone and/or metronidazole. AND Quantity limit is 800 mg/day (4 x 200 mg tablets/day).<br>**Clostridium difficile Diarrhea (Xifaxan 200 mg Tablets):** patient has a diagnosis of C. difficile diarrhea. AND Patient has had a documented side effect, allergy, treatment failure or contraindication to metronidazole. AND Quantity limit is 800 mg/day (4 x 200 mg tablets/day). |
| **VANCOMYCIN** | | |
| IV vancomycin products are not managed at this time | Vancocin® (vancomycin) Capsules<br>Vancomycin† (compare to Vancocin®) Capsules | **Criteria for Approval:** patient's diagnosis or indication is enterocolitis caused by Staphylococcus aureus. OR patient's diagnosis or indication is antibiotic-associated pseudomembranous colitis caused by Clostridium AND patient has had a therapeutic failure, adverse reaction or contraindication to metronidazole OR prescriber provides a clinically compelling rationale why metronidazole is |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | not appropriate for the patient. (e.g. patient has severe Clostridium difficile infection, history of recurrent infections). AND For approval of brand Vancocin, the patient must meet the above criteria and have a documented intolerance to the generic. |
| **ANTI-INFECTIVES ANTIFUNGAL** | | |
| **ALLYLAMINES** | | |
| TERBINAFINE† tabs (compare to Lamisil®) *QL = 30 tablets/month (therapy limit of 90 days)*<br>GRISEOFULVIN MICROSIZE Cap, Tab, Susp, Powder | Griseofulvin Ultramicrosize TabletsLamisil® (terbinafine) granules *(QL: 125 mg packet (1 or 2 per day depending on dose) 187.5 mg packet (1 per day) post PA approval)*<br>Lamisil® tablets (terbinafine HCL) *QL = 30 tablets/month* | **Griseofulvin:** patient had a documented side effect, allergy, or treatment failure with terbinafine tablets.<br>**Lamisil Tabs:** the patient must have a documented intolerance to generic terbinafine.<br>**Lamisil Granules:** patient has a diagnosis of a Tinea capitis infection (confirmed with a positive KOH stain, PAS stain, or fungal culture). AND patient has a requirement for an oral liquid dosage form. AND patient had a documented side effect, allergy, or treatment failure with Griseofulvin suspension |
| **AZOLES** | | |
| FLUCONAZOLE† (compare to Diflucan®) tabs, suspension<br>KETOCONAZOLE† (formerly Nizoral®) tabs<br>CLOTRIMAZOLE Troche† (compare to Mycelex®) | Cresemba® (isavuconazonium) Caps<br>Diflucan®* (fluconazole) tabs, suspension<br>itraconazole† (compare to Sporanox®) caps<br>Noxafil® (posaconazole) oral suspension<br>Noxafil® (posaconazole) DR Tablets | **Cresemba:**<br>• **Diagnosis of either invasive aspergillosis or mucormycosis**<br>• **Age ≥18 years old**<br>• **Documented side effect, allergy, contraindication or treatment failure with voriconazole**<br>• **Completion of regimen started by hospital** |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| IV drugs are not managed at this time. | *(QL=93 tablets/30 days)*<br>Onmel® (itraconazole) 200 mg tablet *(QL=1 tab/day)*<br>Sporanox® (itraconazole) caps, solution<br>VFend® (voriconazole) tabs, suspension<br>voriconazole† (compare to VFend®) tabs, suspension | **Itraconazole 100mg/Sporanox:** patient has a diagnosis of invasive aspergillosis, blastomycosis, or histoplasmosis OR The patient has a diagnosis of a fingernail/toenail onychomycosis infection (confirmed with a positive KOH stain, PAS stain, fungal culture or physician clinical judgment) AND has a documented side-effect, allergy, contraindication, or treatment failure to oral terbinafine AND meets at least 1 of the following criteria: Pain to affected area that limits normal activity, Diabetes Mellitus, Patient is immunocompromised o Patient has diagnosis of systemic dermatosis, Patient has significant vascular compromise OR patient is completing a course of therapy with the requested medication that was initiated in the hospital. OR patient has a documented side-effect, allergy, or treatment failure to at least ONE of the preferred medications. For approval of Sporanox®capsules, the patient must have a documented intolerance to generic itraconazole. For approval of Sporanox solution, the patient must have a medical necessity for a liquid dosage form.<br>**Onmel 200mg:** patient has a diagnosis of a toenail onychomycosis infection (confirmed with a positive KOH stain, PAS stain, fungal culture or physician clinical judgment) AND has a documented side-effect, allergy, contraindication, or treatment failure to oral terbinafine AND there is a clinical reason that itraconazole 100 mg generic capsules cannot be used AND meets at least 1 of the following criteria: Pain to affected area that limits normal activity, Diabetes Mellitus, Patient has significant vascular compromise<br>**Limitations:** Coverage of Onychomycosis agents will NOT be approved solely for cosmetic purposes.<br>**Voriconazole/Vfend:** Patient has a diagnosis of invasive aspergillosis. OR patient is completing a course of therapy with the requested medication that was initiated in the hospital. OR patient has a documented side-effect, allergy, or treatment failure to ONE of the preferred medications AND itraconazole. AND For approval of Vfend® tablets, the patient must have a documented intolerance |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | to generic voriconazole. AND For approval of voriconazole suspenion, the patient must have a medical necessity for a liquid dosage form. For approval of Vfend® suspension, the patient must additionally have a documented intolerance to generic voriconazole suspension.<br>**Noxafil:** patient has a diagnosis of HIV/immunocompromised status (neutropenia secondary to chemotherapy, hematopoietic stem cell transplant recipients) AND Noxafil is being used for the prevention of invasive Aspergillosis/Candida infections. OR patient is completing a course of therapy with the requested medication that was initiated in the hospital. OR Oral Suspension ONLY patient has a documented side-effect, allergy, or treatment failure to ONE of the preferred medications AND itraconazole AND the patient is being treated for oropharyngeal candidiasis.<br>**Diflucan (brand):** For approval of Diflucan brand name product, the patient must have a documented intolerance to generic fluconazole. Oravig: The indication for use is treatment of oropharyngeal candidasis. AND patient has had a documented side effect, allergy, treatment failure/inadequate response to both nystatin suspension and clotrimazole troche. OR patient is unable to be compliant with the nystatin suspension and/or clotrimazole troche dosing schedules. |
| **ANTI-INFECTIVES ANTIMALARIALS: QUININE** | | |
| | Quinine Sulfate † (compare to Qualquin®)<br>Qualaquin® (quinine sulfate) | **Criteria for Approval**: diagnosis or indication is for the treatment of malaria. (Use for leg cramps not permitted.) AND If the request is for brand Qualaquin, the patient has a documented intolerance to the generic equivalent. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | |
| **ANTI-INFECTIVES ANTI-VIRALS** | | |
| **HERPES (ORAL)** | | |
| ACYCLOVIR† (compare to Zovirax®)<br>VALACYCLOVIR † (compare to Valtrex®) | famciclovir † (compare to Famvir®)§<br>Famvir® (famciclovir)<br>Sitavig® (acyclovir) Buccal Tablet *QL = 2 tablets/30 days*<br><br>Valtrex®* (valacyclovir)<br>Zovirax®*(acyclovir) § | **Famciclovir, Zovirax:** patient has a documented side effect or allergy, or treatment failure (at least one course of ten or more days) with acyclovir AND valacyclovir.<br>**Famvir:** patient has a documented side effect or allergy, or treatment failure (at least one course of ten or more days) with acyclovir AND valacyclovir. AND patient has a documented intolerance to generic famciclovir.<br>**Sitavig:** patient has a diagnosis of recurrent herpes labialis (cold sores). AND patient is immunocompetent AND patient has a documented side effect or treatment failure with acyclovir AND valacyclovir.<br>**Valtrex:** patient has a documented intolerance to generic valacyclovir |
| **INFLUENZA MEDICATIONS** | | |
| ***Preferred After Clinical Criteria Are Met***<br>RELENZA® (zanamivir) *QL= 20 blisters / 30 days*<br>TAMIFLU® (oseltamivir) *QL=10 capsules/30 days(45 mg & 75 mg caps) 20 capsules / 30 days (30 mg caps) 180 ml (6 mg/ml) / 30 days (suspension)* | | **Tamiflu, Relenza:** Tamiflu and Relenza will NOT require prior-authorization at this time when prescribed within the following quantity limits:<br>**Relenza:** 20 blisters per 30 days<br>**Tamiflu:** 75mg or 45mg: 10 caps per 30 day<br>**Tamiflu:** 30mg: 20 caps per 30 days<br>**Tamiflu:** Suspension (6mg/ml): 180ml (3 bottles) per 30 days<br>**Limitations:** Amantadine, Flumadine and rimantadine are not CDC recommended for use in influenza treatment or chemoprophylaxis at this time and are not covered for this indication. For information regarding amantadine see |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | "Parkinsons Medications". Flumadine/rimantadine is not covered for any indication. |
| **INFLUENZA VACCINES** | | |
| **SEASONAL Influenza Vaccine INJECTION**<br>**Inactivated Influenza Vaccine, Trivalent (IIV3), Standard Dose (egg based)**<br>AFLURIA® Injection<br>FLUARIX® Injection<br>FLULAVAL® Injection<br>FLUVIRIN® Injection<br>FLUZONE® Injection<br>FLUZONE INTRADERMAL® Injection<br><br>**Inactivated Influenza Vaccine, Trivalent (IIV3), High Dose (egg based)**<br>FLUZONE HIGH-DOSE® Injection<br><br>**Inactivated Influenza Vaccine, Quadrivalent (IIV4), Standard Dose (egg based)**<br>FLUARIX® QUADRIVALENT Injection<br>FLULAVAL® QUADRIVALENT Injection<br>FLUZONE® QUADRIVALENT Injection | **Inactivated Influenza Vaccine, Trivalent (ccIIV3), Standard Dose (cell culture based) (NOT egg free)**<br>Flucelvax® Injection<br><br>**Recombinant Influenza Vaccine, Trivalent (RIV3) (egg FREE)**<br>Flublok® Injection<br><br>**SEASONAL Influenza Vaccine NASAL**<br><br>**Live Attenuated Influenza Vaccine, Quadrivalent (LAIV4) (egg based)**<br>FluMist® Quadrivalent Intranasal | **Flumist:** Flumist is being requested for influenza prophylaxis during flu season AND The patient is between the ages of 19 and 49 years old, AND Prescriber provides documentation of a contraindication to an intramuscular injection (e.g., currently on warfarin; history of thrombocytopenia) or other compelling information to support the use of this dosage form.<br><br>**EXCLUDED FROM APPROVAL:** Hypersensitivity (severe allergy) to any FluMist component including eggs and egg products.<br>Children and adolescents aged 2 – 17 years receiving aspirin therapy (increased risk of Reye's Syndrome).<br>History of Guillain-Barre Syndrome.<br>People with a medical condition that places them at high risk for complications from influenza, including those with chronic heart or lung disease, such as asthma or reactive airways disease; people with medical conditions such as diabetes or kidney failure; or people with illnesses that weaken the immune system, or who take medications that can weaken the immune system.<br>Children <5 years old with a history of recurrent wheezing Pregnant women<br>**Flueclvax:** Flucelvax is being requested for influenza prophylaxis during flu season AND patient is > 18 years old. AND Prescriber provides clinical rationale why one of the preferred influenza vaccines cannot be used.<br>**Flublok:** Flublok is being requested for influenza prophylaxis during flu season AND patient is between the ages of >18 and < 50 years old. AND patient has an egg allergy. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | |
| **VACCINES - OTHER** | | |
| Preferred after Age Limit is met<br>Gardasil<br>Zostavax | | **Gardasil**: Covered for 19 years old to 26 years old (those under 19 should be referred to their pediatrician or PCP for state-supplied vaccine)<br>**Zostavax:** Covered if ≥ 60 years of age<br><br>Vaccines on the Advisory Committee on Immunization Practices (ACIP) list of recommended vaccines for children ≤ 18 years of age are supplied through the Vaccines for Children program administered by the Vermont Department of Health, and are not available through DVHA's pharmacy programs<br>• Vaccines on the ACIP list of recommended vaccines for adults ≥ 19 years of age are available at many primary care provider offices and through the pharmacy programs. Vaccines are subject to the same limitations as the ACIP guideline recommendations. Providers who participate in the Blueprint for Health initiative must enroll in the Vaccines for Adults program administered by the Vermont Department of Health. The ACIP guidelines and information about enrollment in these programs can be found at http://healthvermont.gov/hc/imm/provider.aspx•Vaccines not on the recommended list may require Prior Authorization. |
| **ANTI-MIGRAINE TRIPTANS** | | |
| **Single Agent**<br>**ORAL** | Amerge® (naratriptan) 1 mg, 2.5 mg<br>*Quantity Limit = 9 tablets/month* | **Amerge, Axert, Frova, Imitrex, Maxalt, Maxalt MLT, Naratriptan, Zomig, Zomig ZMT, Zolmitriptan, Zolmitriptan ODT:** patient has had a documented |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| SUMATRIPTAN† (compare to Imitrex®)<br>*Quantity Limit = 18 tablets/month (25 mg), 9 tablets/month (50 mg, 100 mg)*<br><br>**After Sumatriptan Trial**<br><br>RELPAX® (eletriptan) 20 mg, 40 mg<br>*Quantity Limit = 12 tablets/month*<br>RIZATRIPTAN† (compare to Maxalt®)<br>*Quantity Limit = 12 tablets/month*<br>RIZATRIPTAN ODT† (compare to Maxalt-MLT®) §<br>*Quantity Limit = 12 tablets/month* | Axert® (almotriptan)<br>*Quantity Limit = 6 tablets/month*<br>Frova® (frovatriptan) 2.5 mg<br>*Quantity Limit = 9 tablets/month*<br>Imitrex®* (sumatriptan)<br>*Quantity Limit = 18 tablets/month (25 mg), 9 tablets/month (50 mg, 100 mg),*<br>Maxalt® (rizatriptan) 5 mg, 10 mg tablet<br>*Quantity Limit = 12 tablets/month*<br>Maxalt-MLT® (rizatriptan ODT)<br>*Quantity Limit = 12 tablets/month*<br>NARATRIPTAN† (compare to Amerge®) §<br>(*Quantity Limit = 9 tablets/month)*<br>Zomig® (zolmitriptan) tablets<br>*Quantity Limit = 12 tablets/month (2.5 mg), 6 tablets/month (5 mg)*<br>Zomig® ZMT (zolmitriptan ODT)<br>*Quantity Limit = 12 tablets/month (2.5 mg), 6 tablets/month (5 mg)*<br><br>Zolmitriptan† (compare to Zomig®) tablets<br>*Quantity Limit = 12 tablets/month (2.5 mg), 6 tablets/month (5 mg)*<br>Zolmitriptan† ODT (compare to Zomig® ZMT)<br>*Quantity Limit = 12 tablets/month (2.5 mg), 6 tablets/month (5 mg)* | side effect, allergy, or treatment failure to Sumatriptan, Relpax, and Rizatriptan or Rizatriptan ODT. If the request is for brand Maxalt, Zomig, or Zomig ZMT, the patient must also have a documented intolerance to the generic product.<br>**Relpax, Rizatriptan, Rizatriptan ODT:** patient has had a documented side effect, allergy, or treatment failure with Sumatriptan.<br>**Treximet:** patient had a documented side effect, allergy or treatment failure with 2 preferred Triptans, AND patient is unable to take the individual components (sumatriptan and naproxen) separately.<br><br>**Zomig Nasal Spray:** patient has had a documented side effect, allergy or treatment failure of Imitrex Nasal Spray<br>**Sumatriptan Nasal Spray:** patient has had a documented intolerance to brand Imitrex.<br>**Alsuma, Sumatriptan, Sumavel Dose Pro Injections**: patient has had a documented intolerance to brand Imitrex.<br>**Zecuity Transdermal System**: patient has a medical necessity for a specialty topical dosage form (i.e. dysphasia, swallowing disorder, compliance, nausea/vomiting) AND has a documented side effect, allergy or treatment failure with a preferred ODT, nasal, and injectable formulation.<br>**To exceed quantity limits:** patient is taking a medication for migraine prophylaxis. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **NASAL SPRAY**<br>IMITREX® (sumatriptan)<br>*Quantity Limit =12 units/month (5 mg nasal spray),*<br>*6 units/month (20 mg nasal spray)* | Sumatriptan† (compare to Imitrex®)<br>*Quantity Limit =12 units/month (5 mg nasal spray),*<br>*6 units/month (20 mg nasal spray)*<br>Zomig® (zolmitriptan)<br>*Quantity Limit = 12 units/month (2.5 or 5 mg nasal spray)* | |
| **INJECTABLE**<br>IMITREX® (sumatriptan)<br>*Quantity Limit =4 injections/month (4 or 6 mg injection)* | Alsuma® (sumatriptan) 6 mg/0.5ml<br>*Quantity Limit =4 injections/month*<br>sumatriptan (compare to Imitrex®)<br>*Quantity Limit =4 injections/month (4 or 6 mg injection)*<br>Sumavel DosePro® (sumatriptan) 6 mg/0.5ml, 4 mg/0.5 ml<br>*Quantity Limit =4 injections/month* | |
| **TRANSDERMAL** | Zecuity® (sumatriptan succinate) (*Quantity Linit = 4 transdermal systems/28 days)* | |
| **Combination Product (Oral)** | Treximet® (sumatriptan/naproxen)<br>*Quantity Limit = 9 tablets/month* | |
| **ANTI-OBESITY** | | |
| **Effective 10/12/2011, anti-obesity agents (weight loss agents) are no longer a covered benefit for all Vermont Pharmacy Programs. This change is resultant from Drug Utilization Review (DUR) Board concerns regarding safety and efficacy of these agents.** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **ANTI-PSYCHOTIC ATYPICAL & COMBINATIONS (CHILDREN < 18 YEARS OLD)** | | |
| ***Preferred After Clinical Criteria Are Met***<br>**TABLETS/CAPSULES**<br>OLANZAPINE† (compare to Zyprexa®)<br>*FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)*<br><br>RISPERIDONE† (compare to Risperdal®)<br>*FDA maximum recommended dose = 16 mg/day*<br><br>QUETIAPINE† (compare to Seroquel®)<br>*FDA maximum recommended dose = 800 mg/day*<br><br>ZIPRASIDONE† (compare to Geodon®)<br>*FDA maximum recommended dose = 160 mg/day*<br><br>***Preferred After Clinical Criteria Are Met*** | Aripiprazole (compare to Abilify®)<br>FDA maximum recommended dose=30mgday, QL = 1.5 tabs/day (5mg, 10mg, & 15mg)<br>Abilify® (aripiprazole)<br>*FDA maximum recommended dose = 30 mg/day, Quantity limit = 1.5 tabs/day (5 mg, 10 mg & 15 mg tabs)*<br>Clozapine† (compare to Clozaril®)<br>*FDA maximum recommended dose = 900 mg/day*<br>Clozaril® *(clozapine)*<br>*FDA maximum recommended dose = 900 mg/day*<br>Geodon® (ziprasidone)<br>*FDA maximum recommended dose = 160 mg/day*<br>Invega® (paliperidone)<br>*FDA maximum recommended dose = 12 mg/day*<br>*Quantity limit = 1 tab/day (3mg, 9mg), 2 tabs/day (6mg)*<br><br>Risperdal® (risperidone)<br>*FDA maximum recommended dose = 16 mg/day*<br>Seroquel® (quetiapine)<br>*FDA maximum recommended dose = 800 mg/day*<br>Saphris® (asenapine)<br>*FDA maximum recommended dose = 20mg/day QL* | Criteria for approval: (Children < 18 years old) Note: all requests for patients < 5 years old will be reviewed by the DVHA Medical Director.<br>**Target symptoms or Diagnosis that will be accepted for approval:** Target Symptoms - Grandiosity/euphoria/mania; Obsessions/compulsions; Psychotic symptoms; Tics (motor or vocal). Diagnosis- Autism with Aggression and/or irritability; Bipolar Disorder; Intellectual Disability with Aggression and/or Irritability; Obsessive Compulsive Disorder; Schizophrenia/Schizoaffective Disorder; Tourette's Syndrome.<br>***Preferred After Clinical Criteria Are Met*: Tablets & Capsules:**<br><br>**Olanzapine, Risperidone, Ziprasidone:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization). OR medication is being requested for one of the target symptoms or patient diagnoses listed above.<br>**Quetiapine:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization). OR medication is being requested for one of the target symptoms or patient diagnoses listed above. Note: Quetiapine will not be approved for indication of insomnia, for sleep or as a hypnotic.<br><br>**Risperdone Oral Sol:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization). OR medication is being requested for one of the target symptoms |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | *= 2 tabs/ day*<br><br>Seroquel XR® (quetiapine XR)<br>*FDA maximum recommended dose = 800 mg/day*<br>*Quantity Limit = 1 tab/day*<br>*(150 mg & 200 mg tablet strengths), 2 tabs/day (50 mg strength)*<br>Zyprexa® (olanzapine)<br>*FDA maximum recommended dose = 20 mg/day,*<br>*Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)* | or patient diagnoses listed above.<br>**Non-Preferred:**<br>**Invega/Saphris:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization). OR medication is being requested for one of the target symptoms or patient diagnoses listed above AND patient had had a documented side effect, allergy or treatment failure with at least two preferred products after clinical criteria are met with products (typical or atypical antipsychotics) one of which is risperidone.<br>**Cloazaril, Geodon, Risperdal, Seroquel, Zyprezxa:** patient meets clinical criteria for the generic equivalent AND patient has a documented intolerance to the generic equivalent. |
| **ORAL SOLUTIONS**<br>RISPERIDONE† (compare to Risperdal®) oral solution<br>*FDA maximum recommended dose = 16 mg/day* | Abilify® (aripiprazole) oral solution<br>*FDA maximum recommended dose = 25 mg/day*<br>Risperdal® (risperidone) oral solution<br>*FDA maximum recommended dose = 16 mg/day*<br>Versacloz® (clozapine) Oral Suspension<br>*FDA maximum recommended dose = 900 mg/day*<br>*Quantity limit = 18 ml/day* | **Clozapine:** patient has been started and stabilized on the requested medication. (Note samples are not considered adequate justification for stabilization) OR medication is being requested for one of the target symptoms or patient diagnoses listed above AND patient has had a documented side effect, allergy or treatment failure with at least three other antipsychotic medications (typical or atypical antipsychotics), two of which are ***Preferred After Clinical Criteria Are Met*** products (see tables) |
| **ORALLY DISINTEGRATING TABLETS** | Abilify® Discmelt (aripiprazole)<br>*FDA maximum recommended dose = 30 mg/day,*<br>*Quantity limit = 2 tabs/day (10 mg & 15 mg tabs)*<br>clozapine orally disintegrating tablets† (Compare to FazaClo®)<br>*FDA maximum recommended dose = 900 mg/day* | **Seroquel XR:** patient has been started and stabilized on the requested medication. (Note samples are not considered adequate justification for stabilization) OR medication is being requested for one of the target symptoms or patient diagnoses listed above AND patient has not been able to be adherent to a twice daily dosing schedule of quetiapine immediate release resulting in a significant clinical impact.<br><br>**Abilify:** patient has been started and stabilized on the requested medication. (Note samples are not considered adequate justification for stabilization) OR indication |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | FazaClo® (clozapine orally disintegrating tablets)<br>*FDA maximum recommended dose = 900 mg/day*<br>Olanzapine orally disintegrating tablets† (compare to Zyprexa Zydis®)<br>*FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)*<br>Risperdal® M-Tab (risperidone orally disintegrating tablets)<br>*FDA maximum recommended dose = 16 mg/day*<br>Risperidone† ODT (compare to Risperdal® M-Tab)<br>*FDA maximum recommended dose = 16 mg/day*<br>Zyprexa Zydis® (olanzapine orally disintegrating tablets)<br>*FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (5mg&10mg)* | or use is treatment of autism with aggression and/or irritability, intellectual disability with aggression and/or irritability or Tourette's syndrome/tics (motor or vocal) AND the patient has had a documented side effect, allergy or treatment failure with risperidone OR indication or use is treatment of autism with aggression and/or irritability, intellectual disability with aggression and/or irritability or Tourette's syndrome/tics (motor or vocal AND the prescriber feels that risperidone would not be an appropriate alternative for the patient because of pre-existing medical conditions such as obesity or diabetes. OR medication is being requested for one of the other target symptoms or patient diagnoses listed above. AND patient has had a documented side effect, allergy or treatment failure with at least two ***Preferred After Clinical Criteria Are Met*** products (typical or atypical antipsychotic), one of which is risperdone. OR prescriber feels that neither risperidone nor quetiapine would be appropriate alternatives for the patient because of pre-existing medical conditions such as obesity or diabetes.<br>**Abilify Oral Solution:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization), OR medication is being requested for one of the target symptoms or patient diagnoses listed above AND patient has had a documented side effect, allergy or treatment failure with risperidone oral solution OR prescriber feels that risperidone would not be an appropriate alternative for the patient because of pre-existing medical conditions such as obesity or diabetes.<br>**Risperdal:** patient meets clinical criteria for the generic equivalent AND patient has a documented intolerance to the generic product risperidone.<br>**Versacloz Oral Solution:** patient has been started and stabilized on the requested medication (Note: samples are not considered adequate justification for stabilization) OR medication is being requested for one of the target symptoms or patient diagnoses listed above AND patient has had a documented side effect, |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | allergy or treatment failure with at least three other antipsychotic medications (typical or atypical antipsychotics). AND patient is unable to use clozapine orally disintegrating tablets.<br>**Olanzapine ODT, Risperdal M-Tabs, Risperidone ODT, Zyprexa Zydis:** patient meets clinical criteria for non-orally disintegrating oral dosage forms of the same medication AND Medical necessity for a specialty dosage form has been provided AND if the request is for Risperdal M-tabs or Zyprexa Zydis, the patient has a documented intolerance to the generic equivalent.<br>**Clozapine ODT, FazaClo:** patient has been started and stabilized on any form of the requested medication (Note: samples are not considered adequate justification for stabilization) AND Medical necessity for a specialty dosage form has been provided OR medication is being requested for one of the target symptoms or patient diagnoses listed above AND patient has had a documented side effect,<br>allergy or treatment failure with at least three other antipsychotic medications (typical or atypical antipsychotics) AND Medical necessity for a specialty dosage form has been provided AND if the request is for a brand product with a generic equivalent, the patient has a documented intolerance to generic product.<br>**Abilify Discmelt:** patient has been started and stabilized on any form of the requested medication. (Note: samples are not considered adequate justification for stabilization) AND Medical necessity for a specialty dosage form has been provided OR medication is being requested for one of the target symptoms or patient diagnoses listed above AND patient has had a documented side effect, allergy or treatment failure with Risperdal M-tab OR prescriber feels that risperidone would not be an appropriate alternative for the patient because of pre-existing medical conditions such as obesity or diabetes AND Medical necessity for a specialty dosage form has been provided.<br>**Limitations:** Approval for use in Children < 18 years old will not be granted for the |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | following medications or dosage forms due to no FDA approval for use in children and little or no literature to support their use in this population. Exceptions will be made for patients who have been started and stabilized on the requested medication or dosage form (Note: samples are not considered adequate justification for stabilization): Fanapt, Latuda, Geodon Im, Abilify IM, Olanzapine IM, Zyprexa IM, Abilify Maintena, Invega Sustenna, Risperdal Consta, Zyprexa Relprevv, Symbyax, Olanzapine/fluoxetine. |
| **ANTI-PSYCHOTIC ATYPICAL & COMBINATIONS (CHILDREN ≥ 18 YEARS OLD)** | | |
| **TABLETS/CAPSULES**<br><br>CLOZAPINE† (compare to Clozaril®)<br>*FDA maximum recommended dose = 900 mg/day*<br><br>OLANZAPINE† (compare to Zyprexa®)<br>*FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)*<br><br>RISPERIDONE† (compare to Risperdal®)<br>*FDA maximum recommended dose = 16 mg/day*<br>QUETIAPINE† (compare to Seroquel®) > 50 mg/day<br>*FDA maximum recommended dose = 800 mg/day*<br><br>ZIPRASIDONE† (compare to Geodon®) | Aripiprazole (compare to Abilify®)<br>*FDA maximum recommended dose=30mgday, QL = 1.5 tabs/day (5mg, 10mg, & 15mg)*<br>Abilify® (aripiprazole)<br>*FDA maximum recommended dose = 30 mg/day, Quantity limit = 1.5 tabs/day (5 mg, 10 mg & 15 mg tabs)*<br>Clozaril®* *(clozapine)*<br>*FDA maximum recommended dose = 900 mg/day*<br>Fanapt® (iloperidone)<br>*FDA maximum recommended dose = 24 mg/day*<br>*Quantity limit = 2 tablets/day*<br>Geodon®* (ziprasidone)<br>*FDA maximum recommended dose = 160 mg/day*<br>Invega® (paliperidone)<br>*FDA maximum recommended dose = 12 mg/day*<br>*Quantity limit = 1 tab/day (3mg, 9mg), 2tabs/day(6mg)* | **Fanapt:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The indication for use is the treatment of schizophrenia/schizoaffective disorder or bipolar disorder. AND The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics).<br>**Invega:** patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) (Prior therapy with injectable Invega Sustenna® is not considered to be started and stabilized for oral Invega. Patients transferring to oral therapy from Invega Sustenna® should transition to oral risperidone unless patient previously failed such treatment) OR The indication for use is the treatment of schizophrenia/schizoaffective disorder. AND The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics), one of which is risperidone.<br>**Saphris:** patient has been started and stabilized on the requested medication. (Note: |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| *FDA maximum recommended dose = 160 mg/day* | Latuda® (lurasidone)<br>*FDA maximum recommended dose = 160 mg/day*<br>*Quantity limit = 1 tablet/day all strengths except 80 mg = 2 tablets/day*<br>Quetiapine† (compare to Seroquel®) ≤ 50 mg/day (adults ≥ 18 years old)<br>Rexulti® (brexpiprazole)<br>*FDA maximum recommended dose = 3mg (adjunct of MDD) or 5mg (schizophrenia)*<br>Risperdal®* (risperidone)<br>*FDA maximum recommended dose = 16 mg/day*<br>Saphris® (asenapine) sublingual tablet<br>*FDA maximum recommended dose = 20 mg/day*<br>Seroquel® (quetiapine)<br>*FDA maximum recommended dose = 800 mg/day*<br><br>Seroquel XR® (quetiapine XR)<br>*FDA maximum recommended dose = 800 mg/day*<br>*Quantity Limit = 1 tab/day (150 mg & 200 mg tablet strengths), 2 tabs/day (50 mg strength)*<br>ZYPREXA®* (olanzapine)<br>*FDA maximum recommended dose = 20 mg/day,*<br>*Quantity limit = 1.5 tabs/day (2.5 mg, 5 mg, 7.5 mg & 10 mg tabs)* | samples are not considered adequate justification for stabilization.) OR The indication for use is the treatment of schizophrenia/schizoaffective disorder. AND The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics), one of which is risperidone.<br>**Clozaril, Geodon, Risperdal, and Zyprexa:** patient has a documented intolerance to the generic equivalent.<br>**Latuda:** The patient is pregnant and the diagnosis is schizophrenia/schizoaffective disorder or Bipolar I depression. OR The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The indication for use is schizophrenia/schizoaffective disorder. AND The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics), one of which is ziprasidone. OR The indication for use is schizophrenia/schizoaffective disorder. AND The patient has had a documented side effect, allergy or treatment failure with ziprasidone and the prescriber feels that neither risperidone nor quetiapine would be appropriate alternatives for the patient because of pre-existing medical conditions such as obesity or diabetes. OR The indication for use is Bipolar I depression. AND The patient has had a documented side effect, allergy or treatment failure with generic quetiapine. OR The indication for use is Bipolar I depression. AND The prescriber feels that quetiapine would not be an appropriate alternative for the patient because of pre-existing medical conditions such as obesity or diabetes.<br>**Rexulti:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR the indication for use is schizophrenia AND the patient has had a documented side effect, allergy or treatment failure with at least three preferred products, one being Abilify (typical or atypical antipsychotics) OR the indication for use is |
| **ORAL SOLUTIONS**<br>RISPERIDONE† (compare to Risperdal®) oral solution | Abilify® (aripiprazole) oral solution<br>*FDA maximum recommended dose = 25 mg/day* | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| *FDA maximum recommended dose = 16 mg/day* | Risperdal® (risperidone) oral solution<br>*FDA maximum recommended dose = 16 mg/day*<br>Versacloz® (clozapine) Oral Suspension<br>*FDA maximum recommended dose = 900 mg/day*<br>*Quantity limit = 18 ml/day* | adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 3 different antidepressants from two different classes (SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories). Trazodone dosed at < 150mg day would not be considered a trial for indication AND the patient has had a documented side effect, allergy or treatment failure with one preferred atypical antipsychotic product and Abilify being used as adjunctive therapy.<br>**Quetiapine/Seroquel < or = 50mg/day:** The patient is being prescribed > 50 mg/day with combinations of tablet strengths. OR The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories). Trazodone dosed at < 150 mg/day would not be considered a trial for this indication. OR The indication for use is Adjunct treatment of any anxiety disorder (panic, agoraphobia, social phobia, obsessive-compulsive disorder, PTSD, Acute Stress Disorder, Generalized Anxiety Disorder) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories) or at least 2 antidepressants from the SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories and buspirone. Trazodone dosed at < 150 mg/day and bupropion would not be considered trials for this indication. OR The indication for use is a mental health indication (other than the two above indications or a sleep disorder). AND If the request if for brand Seroquel, the patient has a documented intolerance to generic quetiapine.<br>**Note:** Quetiapine in doses of < 50 mg/day will not be approved for indications of insomnia, for sleep or as a hypnotic.<br>**Seroquel XR:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for |
| **SHORT-ACTING INJECTABLE PRODUCTS**<br>GEODON® IM (ziprasidone intramuscular injection)<br>*FDA maximum recommended dose = 40 mg/day* | | |
| **LONG-ACTING INJECTABLE PRODUCTS** | Abilify® IM (aripiprazole intramuscular injection)<br>*FDA maximum recommended dose = 30 mg/day*<br>Olanzapine† intramuscular injection (compare to Zyprexa® IM)<br>*FDA maximum recommended dose = 30 mg/day*<br>Zyprexa® IM (olanzapine intramuscular injection)<br>*FDA maximum recommended dose = 30 mg/day*<br>Abilify Maintena® (aripiprazole monohydrate)<br>*FDA maximum recommended dose = 400 mg/month*<br>*Quantity limit = 1 vial/28 days*<br>Aristada® (aripiprazole lauroxil) *Quantity Limit = 1 syringe/28 days*<br>Invega Sustenna® (paliperidone palmitate)<br>*FDA maximum recommended dose = 234* | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | *mg/month*<br>Invega Trinza ®(paliperidone palmitate)<br>*FDA maximum recommended dose = 819mg/3months*<br>Risperdal® Consta (risperdone microspheres)<br>*FDA maximum recommended dose = 50 mg/14 days*<br>Zyprexa Relprevv® (olanzapine pamoate)<br>*FDA maximum recommended dose = 600 mg/month*<br>*Quantity limit = 1 vial/28 days (405 mg) or 2 vials/month (210 or 300 mg)* | stabilization.) OR The indication for use is schizophrenia/schizoaffective disorder or bipolar disorder (bipolar mania, bipolar depression, and bipolar maintenance). OR The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories). Trazodone dosed at < 150 mg/day would not be considered a trial for this indication. OR The indication for use is Adjunct treatment of any anxiety disorder (panic, agoraphobia, social phobia, obsessive-compulsive disorder, PTSD, Acute Stress Disorder, Generalized Anxiety Disorder) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories) or at least 2 antidepressant from the SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories and buspirone. Trazodone dosed at < 150 mg/day and bupropion would not be considered trials for this indication. AND The patient has not been able to be adherent to a twice daily dosing schedule of quetiapine immediate release resulting in a significant clinical impact |
| **<u>ORALLY DISINTEGRATING TABLETS</u>** | Abilify® Discmelt (aripiprazole)<br>*FDA maximum recommended dose = 30 mg/day,*<br>*Quantity limit = 2 tabs/day (10 mg & 15 mg tabs)*<br><br>clozapine orally disintegrating tablets† (Compare to FazaClo®)<br>*FDA maximum recommended dose = 900 mg/day*<br>FazaClo® (clozapine orally disintegrating tablets)<br>*FDA maximum recommended dose = 900 mg/day*<br>Olanzapine orally disintegrating tablets† (compare to Zyprexa Zydis®)<br>*FDA maximum recommended dose = 20 mg/day,*<br>*Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)*<br><br>Risperdal® M-Tab (risperidone orally disintegrating | **Abilify:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The indication for use is schizophrenia/schizoaffective disorder or bipolar disorder. AND The patient has had a documented side effect, allergy or treatment failure with at least three preferred products (typical or atypical antipsychotics) OR The patient has had a documented side effect, allergy or treatment failure with ziprasidone and the prescriber feels that neither risperidone nor quetiapine would be appropriate alternatives for the patient because of pre-existing medical conditions such as obesity or diabetes. OR The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **COMBINATION PRODUCTS** | tablets)<br>*FDA maximum recommended dose = 16 mg/day*<br>Risperidone† ODT (compare to Risperdal® M-Tab)<br>*FDA maximum recommended dose = 16 mg/day*<br>Zyprexa Zydis® (olanzapine orally disintegrating tablets)<br>*FDA maximum recommended dose = 20 mg/day, Quantity limit = 1.5 tabs/day (5 mg & 10 mg tabs)*<br><br>olanzapine/fluoxetine† (compare to Symbyax®)<br>*FDA maximum recommended dose = 18 mg/75 mg (per day)*<br>Symbyax® (olanzapine/fluoxetine)<br>*FDA maximum recommended dose = 18 mg/75 mg (per day)* | different classes (SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories). Trazodone dosed at <150 mg/day would not be considered a trial for this indication. OR The indication for use is Adjunct treatment of any anxiety disorder (panic, agoraphobia, social phobia, obsessive- compulsive disorder, PTSD, Acute Stress Disorder, Generalized Anxiety Disorder) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories) or at least 2 antidepressant from the SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories and buspirone. Trazodone dosed at <150 mg/day and bupropion would not be considered trials for this indication. AND The patient has had a documented side effect, allergy or treatment failure with one preferred atypical antipsychotic product being used as adjunctive therapy. OR The indication for use is treatment of aggression, psychosis, or agitation secondary to Alzheimer's disease or other dementias AND the patient has had a documented side effect, allergy or treatment failure with two preferred products (typical or atypical antipsychotics). (Note: Please consider FDA Black Box Warning) OR The indication or use is treatment of irritability associated with autistic disorder AND the patient has had a documented side effect, allergy or treatment failure with risperidone. OR The indication or use is treatment of Tourette's syndrome AND the patient has had a documented side effect, allergy or treatment failure with guanfacine or clonidine and also risperidone.<br>**Abilify Oral Solutions:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The indication for use is Adjunct treatment of Major Depressive Disorder (MDD) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories). Trazodone |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | dosed at < 150 mg/day would not be considered a trial for this indication. OR The indication for use is Adjunct treatment of any anxiety disorder (panic, agoraphobia, social phobia, obsessive-compulsive disorder, PTSD, Acute Stress Disorder, Generalized Anxiety Disorder) and the patient has had a documented inadequate response to at least 3 different antidepressants from 2 different classes (SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories) or at least 2 antidepressant from the SSRI, SNRI, tricyclic and/or Miscellaneous Antidepressant categories and buspirone. Trazodone dosed at <150 mg/day and bupropion would not be considered trials for this indication. AND The patient has had a documented side effect, allergy or treatment failure with preferred risperidone oral solution being used as adjunctive therapy. OR The indication for use is schizophrenia/schizoaffective disorder or bipolar disorder. OR The indication for use is treatment of aggression, psychosis, or agitation secondary to Alzheimer's disease or other dementias. (Note: Please consider FDA Black Box Warning) OR The indication or use is treatment of irritability associated with autistic disorder. OR The indication or use is treatment of Tourette's syndrome AND the patient has had a documented side effect, allergy or treatment failure with guanfacine or clonidine. AND The patient has had a documented side effect, allergy or treatment failure with preferred risperidone oral solution.<br>**Risperdal Oral Solution:** The patient has a documented intolerance to the generic product risperidone.<br>**Versacloz Oral Solution**: The patient has a medical necessity for a non-solid oral dosage form and is unable to use clozapine orally disintegrating tablets.<br>**NON-PREFERRED SHORT-ACTING INJECTABLE PRODUCTS**: Medical necessity for a specialty dosage form has been provided. AND The patient has had a documented side effect, allergy, or treatment failure with Geodon IM. In addition, for approval of Zyprexa® IM, the patient must have had a documented intolerance to generic olanzapine IM. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | **Risperdal Consta Inj:** The patient has been started and stabilized on the medication OR Medical necessity for a specialty dosage form has been provided (non-compliance with oral medications) AND Tolerability has been established previously with oral risperidone.<br>**Invega Sustenna Inj:** The patient has been started and stabilized on the medication OR Medical necessity for a specialty dosage form has been provided (non-compliance with oral medications) AND Tolerability has been established previously with oral/injectable risperidone or oral paliperidone.<br>**Invega Trinza:** The patient has been started and stabilized on the medication OR medical necessity for a specialty dosage form has been provided (noncompliance with oral medications) AND tolerability has been established previously with oral/injectable risperidone or oral paliperidone AND Invega Sustenna for at least four months AND only when the dose has been stable over the prior two months.<br>**Zyprexa Relprevv:** The patient has been started and stabilized on the medication OR Medical necessity for a specialty dosage form has been provided (non-compliance with oral medications) AND Tolerability has been established previously with oral olanzapine.<br>**Abilify Maintena:** The patient has been started and stabilized on the medication OR Document clinically compelling information supporting the choice of a non-preferred agent on a General Prior Authorization Request Form. Medical necessity for a specialty dosage form has been provided (non-compliance with oral medications) AND Tolerability has been established previously with oral aripiprazole for at least 2 weeks.<br>**Aristada®:** The patient has been started and stabilized on the medication OR Document clinically compelling information supporting the choice of a non-preferred agent on a General Prior Authorization Request Form. Medical necessity for a specialty dosage form has been provided (non-compliance with oral medications) AND Tolerability has been established previously with oral |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | aripiprazole for at least 2 weeks AND the patient has documented treatment failure with Abilify Maintena<br>**ORALLY DISINTEGRATING TABLETS:** Medical necessity for a specialty dosage form has been provided. AND If the request is for FazaClo, Risperdal M-Tab or Zyprexa Zydis, the patient has a documented intolerance to the generic equivalent.<br>**COMBINATION PRODUCTS:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient has had a documented side effect, allergy or treatment failure with two preferred products (ziprasidone, risperidone, and quetiapine). OR The prescriber provides a clinically valid reason for the use of the requested medication. AND If the request is for brand product, the patient has a documented intolerance to the generic product. |
| **ANTI-PSYCHOTIC: TYPICALS** | | |
| **ORAL TABLETS/CAPSULES**<br>CHLORPROMAZINE† (formerly Thorazine®)<br>FLUPHENAZINE† (formerly Prolixin®)<br>HALOPERIDOL† (compare to Haldol®)<br>LOXAPINE† (compare to Loxitane®)<br>NAVANE® (thiothixene) (20 mg ONLY)<br>PERPHENAZINE† (formerly Trilafon®)<br>THIORIDAZINE† (formerly Mellaril®)<br>THIOTHIXENE† (compare to Navane®)<br>TRIFLUOPERAZINE† (formerly Stelazine®)<br><br>**LONG ACTING INJECTABLE PRODUCTS** | Haldol®* (haloperidol)<br>Loxitane®* (loxapine)<br>Navane®* (thiothixene) 2 mg, 5 mg, 10 mg<br><br>Haldol® decanoate* (haloperidol decanoate) | **Criteria for Approval**<br>**Oral:** patient has had a documented side effect, allergy or treatment failure with at least two preferred products (If a product has an AB rated generic, one trial must be the generic)<br><br>**Long Acting Injectable Products:** for approval of haldol decanoate, the patient has a documented intolerance to the generic product. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| FLUPHENAZINE DECANOATE† (formerly Prolixin® decanoate)<br>HALOPERIDOL DECANOATE † (compare to Haldol® decanoate) | | |
| **BONE RESORPTION INHIBITORS** | | |
| **ORAL BISPHOSPHONATES TABLETS/CAPSULES**<br><br>ALENDRONATE† (compare to Fosamax®)<br><br>**INJECTABLE BISPHOSPHONATES**<br>All products require PA | Actonel® (risedronate)<br>Atelvia (risedronate) Delayed Release Tablet *(Quantity Limit = 4 tablets/28 days)*<br>Binosto® (alendronate) 70 mg effervescent tablet *(Quantity Limit=4 tablets/28 days)*<br>Boniva® (ibandronate) *(Quantity Limit = 150 mg tablet/1 tablet per 28 days )*<br>Didronel® (etidronate)<br>Etidronate† (compare to Didronel®)<br>Fosamax®* (alendronate)<br>Fosamax Plus D® (alendronate/vitamin D)<br>Ibandronate† (compare to Boniva®) *(Quantity Limit = 150 mg tablet/1 tablet per 28 days)*<br>Risedronate† (compare to Actonel®)<br>Skelid® (tiludronate)<br>Boniva® Injection (ibandronate) *(QL = 3 mg/3 months (four doses)/year)*<br>ibandronate Injection† (compare to Boniva®) | **Actonel, Risedronate:** patient has a diagnosis/indication of Paget's Disease AND patient has had a documented side effect, allergy, or treatment failure (at least a six-month trial) to generic alendronate OR patient has a diagnosis/indication of postmenopausal osteoporosis, osteoporosis in men or glucocorticoid induced osteoporosis AND patient has had a documented side effect, allergy, or treatment failure** to generic alendronate. AND if the request is for brand Actonel, the patient has also had a documented intolerance to generic risedronate<br>**Atelvia, Boniva Oral, Ibandronate:** patient has a diagnosis/indication of postmenopausal osteoporosis AND patient has had a documented side effect, allergy or treatment failure** to generic alendronate. AND if the request if for brand Boniva oral, the patient has also had a documented intolerance to generic Ibandronate<br>**Binosto:** patient has a diagnosis/indication of postmenopausal osteoporosis or osteoporosis in men. AND prescriber provides documentation of medical necessity for the specialty dosage form (i.e. inability to swallow tablets, dysphagia).<br>**Calcitonin Nasal Spray (generic), Fortical, Miacalcin Nasal Spray:** patient is started and stabilized on the requested medication. If the request is for generic Calcitonin Nasal Spray, the patient has had a documented intolerance to brand Miacalcin. Note: Calcitonin Nasal Spray (brand and generic) no longer |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | *(QL=3 mg/3 months (four doses)/year)*<br><br>Reclast® Injection (zoledronic acid) *(Quantity Limit = 5 mg (one dose)/year)*<br>Zoledronic Acid Injection† (compare to Reclast®) 5mg/100ml*(QL=5 mg (one dose)/year)*<br>Zometa® (zoledronic acid) Injection 4mg/100ml or conc. 4mg/5ml | recommended for osteoporosis.<br>**Miacalcin Injection:** patient has a diagnosis/indication of Paget's Disease<br>**Evista Tablets:** patient has had a documented intolerance to generic raloxifene.<br>**Fosamax Tablets:** patient has had a documented intolerance to generic alendronate.<br>**Fosamax Plus D:** there is a clinical reason why the patient is unable to take generic alendronate and vitamin D separately. |
| **ESTROGEN AGONIST/ANTAGONIST**<br>RALOXIFENE† (compare to Evista®) Tablet *(QL=1 tablet/day)* | Evista® (raloxifene) Tablet *(QL = 1 tablet/day)* | **Didronel, Etidronate, and Skelid:** patient has a diagnosis/indication of Paget's Disease AND patient has had a documented side effect, allergy, treatment failure (at least a six-month trial) to generic alendronate. If a medication has an AB rated generic, there must have also been a trial of the generic formulation. |
| **INJECTABLE RANKL INHIBITOR**<br>All products require PA | Prolia® Injection (denosumab) *(QL=60 mg/6 months (two doses)/year)*<br><br>Xgeva® (denosumab) *(QL=120 mg/28 days)* | **Forteo:** patient has a diagnosis/indication of postmenopausal osteoporosis in females, primary or hypogoandal osteoporosis in males or glucocorticoid induced osteoporosis AND patient has had a documented side effect, allergy, or treatment failure** to an oral bisphosphonate. AND prescriber has verified that the patient has been counseled about osteosarcoma risk AND the quantity requested does not exceed 1 pen (3ml) per 28 days with a lifetime maximum duration of treatment of 2 years. |
| **CALCITONIN NASAL SPRAY**<br>All products require PA | Calcitonin† Nasal Spray (compare to Miacalcin®)<br>Fortical®† (calcitonin) Nasal Spray<br>Miacalcin® (calcitonin) Nasal Spray | **Boniva Injection, Ibandronate Injection:** patient has a diagnosis/indication of postmenopausal osteoporosis AND patient has had a documented side effect or treatment failure** to a preferred bisphosphonate. **Prolia Injection:** diagnosis or indication is osteopenia in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer OR diagnosis or indication is osteopenia in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer OR patient has a diagnosis/indication of postmenopausal osteoporosis AND patient has had a documented side effect, allergy, or treatment failure** to a preferred bisphosphonate.. |
| **CALCITONIN INJECTION**<br>All products require PA | Miacalcin® (calcitonin) Injection | |
| **PARATHYROID HORMONE INJECTION**<br>All products require PA | Forteo® (teriparatide) *(Quantity Limit = 1 pen (3 ml)/28 days)*<br>*(Lifetime max duration of treatment = 2 years)* | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | **Reclast Injection, Zoledronic Acid Injection (5mg):** patient has a diagnosis/indication of Paget's disease of bone OR patient has a diagnosis/indication of postmenopausal osteoporosis OR patient is male with a diagnosis of osteoporosis OR patient has a diagnosis of glucocorticoid induced osteoporosis AND patient has had a documented side effect or treatment failure** to a preferred bisphosphonate.<br>AND if the request is for Reclast, the patient has a documented intolerance to generic zoledronic acid injection.<br>**Zometa Injection, Zoledronic Acid Injection (4mg):** Diagnosis or indication is bone metastases from solid tumors, multiple myeloma, osteopenia or treatment of hypercalcemia of malignancy<br>**Xgeva Injection:** diagnosis or indication is bone metastases from solid tumors (e.g. prostate, breast, thyroid, non-small lung cancer)<br>**Treatment failure is defined as documented continued bone loss or fracture after one or more years despite treatment with an oral bisphosphonate. |
| **BOTULINUM TOXINS** | | |
| | BOTOX® (onabotulinumtoxinA)<br>Myobloc® (rimabotulinumtoxinB)<br><br>**Available after a BOTOX® trial for select indications:**<br>Dysport® (abobotulinumtoxinA)<br>Xeomin® (incobotulinumtoxinA) | **BOTOX (onabotulinumtoxinA):** The indication for use is: o Strabismus and blepharospasm associated with dystonia, including essential blepharospasm, VII cranial nerve disorders/hemifacial spasm or Focal dystonias, including cervical dystonia, spasmodic dystonia, oromandibular dystonia o Limb spasticity (e.g., due to cerebral palsy, multiple sclerosis, or other demyelinating CNS diseases) o Focal spasticity (e.g., due to hemorrhagic stroke, anoxia, traumatic brain injury) o Axillary Hyperhidrosis (if member has failed an adequate trial of topical |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | therapy) o Overactive bladder or detrusor overactivity (if member has failed an adequate trial of at least TWO urinary antispasmodics (either short- or long-acting formulations) o Chronic migraine (>15 days per month with headache lasting 4 hours a day or longer) and the member has failed or has a contraindication to an adequate trial of at least TWO medications for migraine prophylaxis from at least two different classes (tricyclic antidepressants, beta-blockers, calcium channel blockers or anticonvulsants). For re-approval after 3 months, the patient must have had an improvement in symptoms. AND The patient is >12 years of age if for blepharospasm or strabismus, >16 years of age for cervical dystonia, and >18 years of age for hyperhidrosis, chronic migraine or overactive bladder/detrusor overactivity.<br>**Dysport (abobotulinumtoxinA):** The patient has a diagnosis of cervical dystonia or spasmodic torticollis AND The patient is >18 years of age AND The patient has had a treatment failure with BOTOX.<br>**Myobloc (rimabotulinumtoxinB):** The patient has a diagnosis of focal dystonia, including cervical dystonia, spasmodic dystonia, oromandibular dystonia AND The patient is >16 years of age<br>**Xeomin (incobotulinumtoxinA):** The patient has a diagnosis of cervical dystonia or blepharospasm. AND The patient is >18 years of age AND The patient has had a documented intolerance or treatment failure with BOTOX.<br>**LIMITATIONS:** Coverage of botulinum toxins will not be approved for cosmetic use (e.g., glabellar lines, vertical glabellar eyebrow furrows, facial rhytides, horizontal neck rhytides, etc.). (BOTOX Cosmetic (onabotulinumtoxinA) is not covered)<br>**IMPORTANT NOTE:** Botulinum neurotoxins are used to treat various disorders of focal muscle spasm and excessive muscle contractions, such as focal dystonias. When injected intramuscularly, botulinum neurotoxins produce a presynaptic neuromuscular blockade by preventing the release of acetylcholine from the |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | nerve endings. As a consequence of the chemistry and clinical pharmacology of each botulinum neurotoxin product, botulinum neurotoxins are not terchangeable, even among same sterotype products. Units of biological activity are unique to each preparation and cannot be compared or converted into units of another. It is important that providers recognize there is no safe dose conversion ratio—i.e., one unit of BOTOX (onabotulinumtoxinA, formerly type A) does not equal one unit of Myobloc (rimabotulinumtoxinB, formerly type B) does not equal one unit of Dysport (abobotulinumtoxinA) does not equal one unit of Xeomin (incobotulinumtoxinA). Failure to understand the unique characteristics of each formulation of botulinum neurotoxin can result in under or over dosage. It is expected that use of these products will be based on each product's individual dosing, efficacy and safety profiles. |
| **BPH AGENTS** | | |
| **ALPHA BLOCKERS**<br>DOXAZOSIN† (compare to Cardura®)<br>TAMSULOSIN† (compare to Flomax®)<br>*Quantity Limit = 2 capsules/day*<br>TERAZOSIN† (formerly Hytrin®) | alfuzosin ER† (compare to Uroxatral®)<br>Quantity Limit = 1 tablet/dayCardura®* (doxazosin)<br>Cardura XL® (doxazosin)<br>*Quantity Limit = 1 tablet/day*<br>Flomax®* (tamsulosin)<br>*Quantity Limit = 2 capsules/day*<br>Rapaflo® (silodosin) *Quantity Limit = 1 capsule/day*<br>Uroxatral® (alfuzosin)<br>*Quantity Limit = 1 tablet/day* | **Cardura, Cardura XL:** The patient has had a documented side effect, allergy or treatment failure with two alpha blockers, one of which must be generic doxazosin.<br>**Flomax:** The patient has had a documented side effect, allergy or treatment failure with two preferred alpha blockers, one of which must be generic tamsulosin.<br>**alfuzosin ER, Rapaflo, Uroxatral:** The patient has had a documented side effect, allergy or treatment failure with two preferred alpha blockers. In addition, for approval of Uroxatral, the patient must have a documented intolerance to generic alfuzosin ER.<br>**Avodart:** The patient has a diagnosis of BPH (benign prostatic hypertrophy) AND |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **ANDROGEN HORMONE INHIBITORS**<br>FINASTERIDE† (compare to Proscar®) *(QL = 1 tablet/day)*<br><br>**COMBINATION PRODUCT** | Avodart® (dutasteride) (*QL = 1 capsule/day)*<br>finasteride† (compare to Proscar®) females; males age < 45 *(QL = 1 tablet/day)*<br>Proscar® *(finasteride) *(QL = 1 tablet/day)*<br><br>Jalyn® (dutasteride/tamsulosin) (*QL = 1 capsule/day)* | the patient has a documented side effect, allergy or treatment failure to generic finasteride.<br>**Proscar:** The patient has a diagnosis of BPH (benign prostatic hypertrophy) AND the patient has a documented intolerance to generic finasteride.<br>**Finasteride for males age < 45:** The patient has a diagnosis of BPH (benign prostatic hypertrophy)<br>**Jalyn:** The patient has a diagnosis of BPH (benign prostatic hypertrophy) AND the patient has a documented treatment failure/inadequate response to combination therapy with generic tamsulosin and finasteride.<br>**LIMITATIONS:** Coverage of androgen hormone inhibitors will not be approved for cosmetic use in men or women (male-pattern baldness/alopecia or hirsutism). (This includes Propecia (finasteride) and its generic equivalent whose only FDA approved indication is for treatment of male pattern hair loss.) Current clinical guidelines recommend the use of Cialis (tadalafil) only in men with concomitant erectile dysfunction or pulmonary hypertension. Medicaid programs do not receive Federal funding for drugs used in the treatment of erectile dysfunction so Cialis will not be approved for use in BPH. |
| **CARDIAC GLYCOSIDES** | | |
| DIGOXIN†<br>DIGOXIN† Oral Solution<br>LANOXIN® (digoxin) | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **CHEMICAL DEPENDENCY** | | |
| **ALCOHOL DEPENDENCY** | | |
| ACAMPROSATE† (compare to Campral®)<br>DISULFIRAM† 250 mg, 500 mg tab (compare to Antabuse®)<br><br>NALTREXONE oral † (compare to Revia®) | Antabuse®* (disulfiram)<br>Campral®* (acamprosate)<br>Revia®* (naltrexone oral)<br><br>Vivitrol® (naltexone for extended-release injectable suspension)<br>*(QL = 1 injection (380 mg) per 30 days)* | **Revia, Antabuse, Campral**: The patient has had a documented intolerance to the generic equivalent product |
| **OPIATE DEPENDENCY** | | |
| NALTREXONE oral † (compare to Revia®)<br><br>**<u>Preferred Agent after Clinical Criteria are Met</u>**<br>SUBOXONE® sublingual FILM (buprenorphine/nalaxone)<br>*QL = 2 films per day (8 mg strength), 3 films per day (2 mg strength)or*<br>*1 film per day (4 mg and 12 mg strengths)*<br>*(Maximum daily Dose = 16 mg/day)*<br><br>***Maximum days supply for Suboxone is 14 days***<br><br>Note: Methadone for opiate dependency can only be | buprenorphine† sublingual TABLET(formerly Subutex®)<br>*QL = 3 tablets per day (2 mg strength) or 2 tablets/day (8 mg strength)*<br>*(Maximum Daily Dose = 16 mg/day)*<br>Revia®* (naltrexone oral)<br>buprenorphine/nalaxone† (formerly Suboxone®) sublingual TABLET<br>*QL = 2 tablets per day (8 mg strength) or 3 tablets per day (2 mg strength)*<br>*(Maximum daily Dose = 16 mg/day)*<br>Bunavail® (*QL= 1film per day(2.1/0.3mg, 6.1/1mg), 2films per day (4.2/0.7mg)*<br>Zubsolv® *(QL=1 film per day of all strengths)*<br><br>**Maximum days supply for buprenorphine/naloxone or buprenorphine is 14 days** | **Suboxone, Buprenorphine/Naloxone, Buprenorphine:** Diagnosis of opiate dependence confirmed (will not be approved for alleviation of pain) AND Prescriber has a DATA 2000 waiver ID number ("X-DEA license") in order to prescribe AND A "Pharmacy Home" for all prescriptions has been selected (Pharmacy located or licensed in VT) AND Requests for Buprenorphine/Naloxone SL tablet, Bunavail or Zubsolv after documented intolerance of Suboxone Film must include a completed MedWatch form that will be submitted by DVHA to the FDA. AND If buprenorphine (formerly Subutex) is being requested, Patient is either pregnant and history (copy of positive pregnancy test) has been submitted (duration of PA will be one 1 month post anticipated delivery date) OR Patient is breastfeeding a methadone or morphine dependent baby and history from the neonatologist or pediatrician has been submitted.<br>**Vivitrol:** There must be a documented trial of oral naltrexone AND Patient should |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| prescribed through a Methadone Maintenance Clinic | **For Prevention of Relapse to Opioid Dependency**<br>Vivitrol® (naltrexone for extended-release injectable suspension) (QL = 1 injection (380 mg) per 30 days) | be opiate free for > 7 -10 days prior to initiation of Vivitrol. If the diagnosis is alcohol dependence, there must be a clinically compelling reason for use (e.g. multiple hospital admissions for alcohol detoxification). |
| **OVERDOSE TREATMENT** | | |
| NALOXONE HCL Prefilled luer-lock needleless syringe plus intranasal mucosal atomizing device (Rescue kit)<br>NARCAN® (naloxone hcl) Nasal Spray<br>Quantity Limit = 4 single-use sprays/28days | Evzio® (naloxone hcl autoinjector) | Compelling clinical reason why a rescue kit comprised of naloxone plus atomizer or Narcan NS cannot be used. |
| **GASTROINTESTINAL AGENTS: CONSTIPATION/DIARRHEA, IRRITABLE BOWEL SYNDROME-CONSTRIPATION, SHORT BOWEL SYNDROME, OPIOID INDUCED CONSTIPATION** | | |
| **Preferred Agents (No PA Required)** | **Non-preferred Agents (PA Required)** | **Criteria** |
| **Constipation: Chronic, IBS_C, or Opioid-Induced (Amitiza, Linzess, & Movantik length of approval: Initial PA of 3 months and & 12 months thereafter; Relistore: 3 months** | | |
| **Bulk-Producing Laxatives**<br>PSYLLIUM†<br>**Osmotic Laxatives**<br>LACTULOSE†<br>POLYETHYLENE GLYCOL 3350 (PEG)† ( | Amitiza® (lubiprostone) *(Qty Limit = 2 capsules/day)*<br>Linzess® (linaclotide) *(Qty limit = 1 capsule/day)*<br>Movantik (naloxegol) *(Qty limit=1 tablet/day)*<br>Relistor® (methylnatrexone) | **Amitiza:** The patient has a diagnosis of chronic idiopathic constipation (CIC) (24 mcg capsules) OR The patient is a woman and has a diagnosis of irritable bowel syndrome with constipation (IBS-C) (8 mcg capsules) OR opioid-induced constipation AND The patient has had documented treatment failure to lifestyle and dietary modification (increased fiber and fluid intake and increased physical |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **Stimulant Laxative**<br>BISACODYL†<br>SENNA†<br>**Stool Softener**<br>DOCUSATE†<br><br>**Miscellaneous**<br>DICYCLOMINE | | activity). AND The patient has had documented side effect, allergy or treatment failure to a 1 week trial each of at least 2 preferred laxatives from the Bulk-Producing Laxative or Osmotic Laxative categories (see below).<br>**Linzess:** The patient is 18 years of age or older. AND The patient has a diagnosis of chronic idiopathic constipation (CIC) (145 mcg capsules) OR The patient has a diagnosis of irritable bowel syndrome with constipation (IBS-C) (290 mcg capsules) AND The patient has had documented treatment failure to lifestyle and dietary modification (increased fiber and fluid intake and increased physical activity). AND The patient has had documented side effect, allergy or treatment failure to a 1 week trial each of at least 2 preferred laxatives from the Bulk-Producing Laxative or Osmotic Laxative categories (see below).<br>**Movantik:** The patient must have documented opioid-induced constipation AND The patient has had documented side effect, allergy or treatment failure to a 1 week trial of at least 2 preferred laxatives from Bulk-Producing Laxative or Osmotic Laxative categories..<br>**Relistor:** The patient must have documented opioid-induced constipation and be receiving palliative care AND The patient must have had documented treatment failure to a 1 week trial of at least 2 preferred laxatives from 2 different laxative classes (see below) used in combination. |
| Short Bowel Syndrome (SBS) (length of approval: 6 Months) | | |
| | Gattex® (teduglutide) Vials Maximum days' supply = 30 days | **Gattex:** Patient has a diagnosis of short bowel syndrome AND Patient is receiving specialized nutritional support administered intravenously (i.e. parenteral nutrition) AND Patient is 18 years of age or older AND Patient does not have an active gastrointestinal malignancy (gastrointestinal tract, hepatobiliary, pancreatic), colorectal cancer, or small bowel cancer. AND After preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval. Note: Re-approval requires evidence of |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | decreased parenteral nutrition support from baseline. |
| Antidiarrheal: HIV/AIDs (length of approval: initial approval 3 months, subsequent 1 year) | | |
| DIPHENOXYLATE/ATROPINE†<br>LOPERAMIDE† | Fulyzaq® (crofelemer) 125 mg DR Tablets<br>*QL = 2 tablets/day* | **Fulyzaq:** Patient has HIV/AIDS and is receiving anti-retroviral therapy AND Patient is at least 18 years of age AND Patient requires symptomatic relief of noninfectious diarrhea AND Infectious diarrhea (e.g. cryptosporidiosis, c. difficile, etc.) has been ruled out AND Patient has tried and failed at least one anti-diarrheal medication (i.e. loperamide or atropine/diphenoxylate) |
| **CONTRACEPTIVES** | | |
| **SELECT PRODUCTS (length of approval: 1 year)**<br>**MONOPHASIC AGENTS:** | | |
| Due to the extensive list of products, any monophasic BCP not listed as non-preferred is considered preferred. | Brevicon-28 (norethindrone/ethinyl estradiol)<br>Gildesse fe (norethindrone/ ethinyl estradiol/FE)<br>Lo-Estrin (norethindrone/ethinyl estradiol)<br>Lo-Estrin FE (norethindrone/ ethinyl estradiol/FE)<br>LoEstrin (norethindrone/ ethinyl estradiol)<br>LoMedia FE (norethindrone/ ethinyl estradiol/FE)<br>Lo/Ovral 21<br>Lo/Ovral 28<br>Modicon (norethindrone/ethinyl estradiol)<br>Nordette-28<br>Norinyl 1/35 (norethindrone/ethinyl estradiol)<br>Ogestrel (norgestrel/ ethinyl estradiol) | **Non-preferred agents:** Trial with at least three preferred contraceptive products including the preferred formulation of the requested non-preferred agent |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | Ortho-Ccept 28 (desogestrel/ethinyl estradiol)<br>Ortho-Cyclen-28 (norgestimate/ethinyl estradiol)<br>Ovcon-35/28 (norethindrone/ethinyl estradiol)<br>Yaz (drospirenone/ ethinyl estradiol)<br>Yasmin 28 (drospirenone/ ethinyl estradiol)<br>Zovia 1-50(ethynodiol D/ ethinyl estradiol) | |
| **BIPHASIC AGENTS** | | |
| AZURETTE (desogestrel/ ethinyl estradiol)<br>DESOGESTREL ETHINYL ESTRADIOL<br>KARIVA (desogestrel/ ethinyl estradiol)<br>MINASTRIN FE (norethindrone ethinyl estradiol)<br>NORETHIDRONE/ETHINYL ESTRADIOL 0.5/1-35<br>PIMTREA (desogestrel/ ethinyl estradiol)<br>VIORELE (desogestrel/ ethinyl estradiol) | Mircette (desogestrel/ ethinyl estradiol)<br>Necon 10/11-28 (norethindrone/ ethinyl estradiol) | **Non-preferred agents:** Trial with at least three preferred contraceptive products including the preferred formulation of the requested non-preferred agent |
| **TRPHASIC AGENTS** | | |
| ALYACEN (norethindrone ethinyl estradiol)<br>ARANELLE (norethindrone/ethinyl estradiol)<br>CAZIANT (desogestrel/ ethinyl estradiol)<br>CYCLAFEM (norethindrone/ethinyl estradiol)<br>DASETTA (norethindrone/ethinyl estradiol)<br>ENPRESSE (levonorgestrel/ ethinyl estradiol)<br>LEENA (norethindrone/ethinyl estradiol)<br>LEVONEST (levonorgestrel/ ethinyl estradiol))<br>MYZILRA (levonorgestrel/ ethinyl estradiol)<br>NATAZIA (dienogest/estradiol valerate)<br>NECON 7/7/7 (norethindrone/ethinyl estradiol)<br>Norgestimate ethinyl estradiol | Cyclessa (desogestrel/ ethinyl estradiol)<br>Estrostep FE (norethindrone/ethinyl estradiol/FE)<br>Ortho-Novum 7/7/7 (norethindrone/ethinyl estradiol)<br>Ortho Tri-Ccyclen (norgestimate/ ethinyl estradiol)<br>Tri-Norinyl (norethindrone/ethinyl estradiol) | **Non-preferred agents:** Trial with at least three preferred contraceptive products including the preferred formulation of the requested non-preferred agent |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| NORTREL 7/7/7 (norethindrone/ethinyl estradiol)<br>ORTHO TRI-CYCLEN LO (norgestimate/ ethinyl estradiol)<br>PIRMELLA (norethindrone/ethinyl estradiol)<br>TILIA FE (norethindrone/ethinyl estradiol/FE)<br>TRI-ESTARYLLA (norgestimate/ ethinyl estradiol)<br>TRI-LEGEST FE (norethindrone/ethinyl estradiol/FE)<br>TRI-LINYAH (norgestimate/ ethinyl estradiol)<br>TRINESSA (norgestimate/ ethinyl estradiol)<br>TRI-PREVIFEM (norgestimate/ ethinyl estradiol)<br>TRI-SPRINTEC (norgestimate/ ethinyl estradiol)<br>TRIVORA (levonorgestrel/ ethinyl estradiol)<br>VELIVET (desogestrel/ ethinyl estradiol) | | |
| **EXTENDED CYCLE** | | |
| AMETHIA (levonorgestrel/ ethinyl estradiol)<br>AMETHIA LO (levonorgestrel/ ethinyl estradiol)<br>AMETHYST (levonorgestrel/ ethinyl estradiol)<br>ASHLYNA (levonorgestrel/ ethinyl estradiol)<br>CAMRESE (levonorgestrel/ ethinyl estradiol)<br>CAMRESE LO (levonorgestrel/ ethinyl estradiol)<br>DAYSEE (levonorgestrel/ ethinyl estradiol)<br>INTROVALE (levonorgestrel/ ethinyl estradiol 3MTH)<br>JOLESSA (levonorgestrel/ ethinyl estradiol 3MTH)<br>LEVONORGESTREL ETHINYL ESTRADIOL TBDSPK 3 month<br>LEVONORGESTREL ETHESTRAD ETHINYL ESTRADIOL TBDSPK 3 month<br>LO-SEASONIQUE (levonorgestrel/ ethinyl estradiol) | | **Non-preferred agents:** Trial with at least three preferred contraceptive products including the preferred formulation of the requested non-preferred agent |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| QUASENSE (levonorgestrel/ ethinyl estradiol 3MTH)<br>QUARTETTE (levonorgestrel/ ethinyl estradiol)<br>SEASONIQUE (levonorgestrel/ ethinyl estradiol) | | |
| **PROGESTIN ONLY CONTRACEPTIVES** | | |
| CAMILA (norethindrone)<br>DEBLITANE (norethindrone)<br>ERRIN (norethindrone)<br>HEATHER (norethindrone)<br>JENCYCLA (norethindrone)<br>JOLIVETTE(norethindrone)<br>LYZA (norethindrone)<br>NORA-BE (norethindrone)<br>NORETHINDRONE 0.35MG<br>NORLYROC (norethindrone)<br>SHAROBEL (norethindrone) | Nor-QD (norethindrone)<br>Ortho Micronor (norethindrone) | **Non-preferred agents:** Trial with at least three preferred contraceptive products including the preferred formulation of the requested non-preferred agent |
| **INJECTABLE CONTRACEPTIVES** | | |
| MEDROXYPROGESTERONE ACETATE 150MG (IM) VIAL/SYRINGE<br>DEPO-PROVERA 104 (SUB-Q) SYRINGE (medroxyprogesterone acetate) | Depo-Provera (IM) (medroxyprogesterone acetate) 150mg Susp vial/syringe | |
| **VAGINAL RING** | | |
| NUVARING® (etonogestrel/ethinyl estradiol vaginal ring) | | |
| **TOPICAL CONTRACEPTIVE** | | |
| ORTHO EVRA PATCH (norelgestromin/ethinyl estradiol)<br>XULANE PATCH (norelgestromin/ ethinyl estradiol) | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **EMERGENCY CONTRACEPTIVE** | | |
| AFTERA (levonorgestrel)<br>ECONTRA EZ (levonorgestrel)<br>FALLBACK (levonorgestrel)<br>LEVONORGESTREL<br>MY WAY (levonorgestrel)<br>NEXT CHOICE (levonorgestrel)<br>OPCICON ONE-STEP (levonorgestrel)<br>TAKE ACTION (levonorgestrel)<br>ELLA (ulipristal) | Plan B One-step (levonorgestrel) | |
| **CORONARY VASODILATORS/ANTIANGINALS/SINUS NODE INHIBITORS** | | |
| **ORAL** | | |
| ISOSORBIDE DINITRATE† tablet(compare to Isordil®)<br>ISOSORBIDE DINITRATE† ER tablet<br>ISOSORBIDE MONONITRATE† tablet (compare to Ismo®,Monoket®)<br><br>ISOSORBIDE MONONITRATE† ER tablet (compare to Imdur®)<br>NITROGLYCERIN† SL tablet<br>NITROGLYCERIN† ER capsule<br>NITROLINGUAL PUMP SPRAY®<br>NITROGLYCERIN SPRAY LINGUAL† (compare to Nitroglycerin Pump Spray®) | Dilatrate-SR® (isosorbide dinitrate SR capsule)<br>Imdur®* (isosorbide mononitrate ER tablet)<br>Ismo®* (isosorbide mononitrate tablet)<br>Isosorbide dinitrate SL tablet<br>Isordil®* (isosorbide dinitrate tablet)<br>Monoket®* (isosorbide mononitrate tablet)<br><br>BiDil® (isosorbide dinitrate/hydralazine)<br>Ranexa® (ranolazine) *(Quantity Limit = 3 tablets/day (500 mg), 2 tablets/day (1000 mg)))* | **Dilatrate-SR, Imdur:** The patient has had a side effect, allergy, or treatment failure to at least two of the following medications: isosorbide dinitrate ER tablet, isosorbide mononitrate ER tablet, nitroglycerin ER capsule or Nitro-time. If a product has an AB rated generic, one trial must be the generic formulation.<br><br>**Ismo, Isordil, Monoket, Isosorbide dinitrate SL tablet:** The patient has had a side effect, allergy, or treatment failure to at least two of the following medications: isosorbide dinitrate tablet or isosorbide mononitrate tablet. If a product has an AB rated generic, one trial must be the generic formulation<br>**Bidil:** The prescriber provides a clinically valid reason why the patient cannot use isosorbide dinitrate and hydralazine as separate agents.<br>**Ranexa:** The patient has had a diagnosis/indication of chronic angina. AND The patient has had a documented side effect, allergy, or treatment failure with at |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| NITROMIST® Lingual Spray<br>NITROQUICK® (nitroglycerin SL tablet)<br>NITROSTAT® (nitroglycerin SL tablet)<br>NITRO-TIME® (nitroglycerin ER capsule) | | least one medication from two of the following classes: beta-blockers, maintenance nitrates, or calcium channel blockers. AND The patient does not have any of the following conditions: Hepatic insufficiency, Concurrent use of medications which may interact with Ranexa: CYP450 3A4 inducers (rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, St.John's wort) CYP450 3A4 inhibitors (diltiazem, verapamil, ketoconazole, protease inhibitors, grapefruit juice, macrolide antibiotics) Note: doses of digoxin or drugs metabolized by CYP450 2D6 (TCAs, some antipsychotics) may need to be adjusted if used with Ranexa. AND The dose requested does not exceed 3 tablets/day (500 mg) or 2 tablets/day (1000 mg). |
| **TOPICAL** | | |
| NITREK® (nitroglycerin transdermal patch)<br>NITRO-BID® (nitroglycerin ointment)<br>NITROGLYCERIN TRANSDERMAL PATCHES† (compare to Nitro-Dur®) | Nitro-Dur®* (nitroglycerin transdermal patch) | **Nitro-Dur:** patient has had a side effect, allergy, or treatment failure to Nitrek or generic nitroglycerin transdermal patches. |
| **SINUS NODE INHIBITORS** | | |
| | Corlanor® (ivabradine) (QL=60 tabs/30 days) | **Corlanor Clinical Criteria:**<br>• Diagnosis of stable, symptomatic heart failure AND<br>• Left ventricular ejection fraction of ≤ 35% AND<br>• Resting heart rate ≥ 70 bpm AND<br>• In sinus rhythm AND<br>• Persisting symptoms despite maximally tolerated doses of beta blockers or who have contraindication to beta blocker therapy |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **CORTICOSTEROIDS: ORAL** | | |
| CORTISONE ACETATE tablets<br>DEXAMETHASONE† tablets, elixir, intensol, solution<br>DEXPAK® tabs (dexamethasone taper pack)<br>HYDROCORTISONE† tab (compare to Cortef®)<br>MEDROL® (methylprednisolone) 2mg tablets<br>METHYLPREDNISOLONE† (compare to Medrol®) tabs<br>METHYLPREDNISOLONE DOSE PACK† (compare to Medrol Dose<br>Pack®) tabs<br>ORAPRED® ODT (prednisolone sod phosphate) (age < 12 yrs)<br>PREDNISOLONE† 3 mg/ml oral solution, syrup (compare to Prelone®)<br><br>PREDNISOLONE SODIUM PHOSPHATE† 3 mg/ml oral solution<br>(compare to Orapred®)<br>PREDNISOLONE SOD PHOSPHATE ORAL SOLUTION† 6.7mg/5ml<br>(5mg/5ml base) (compare to Pediapred®)<br>PREDNISONE† intensol, solution, tablets | Celestone® (betamethasone) oral solution<br>Cortef®* (hydrocortisone) tablets<br>Flo-Pred® (prednisolone acetate) oral suspension<br><br>Medrol®* (methylprednisolone) tablets<br>Medrol Dose Pak®* (methylprednisolone) tabs<br>Millipred® (prednisolone) tablets<br>Millipred® (prednisolone sodium phos) oral solution<br>Millipred DP® (prednisolone) dose pack tablets<br>Orapred®* oral solution* (prednisolone sod phos)<br>Orapred® ODT (prednisolone sod phos) (age ≥ 12 yrs)<br>Pediapred®* (prednisolone sod phosphate) oral solution<br>prednisolone sodium phosphate oral solution 25 mg/5ml<br>Rayos® (prednisone) Delayed Release Tablet<br>*(Quantity limit = 1 tablet/day)*<br>Veripred® 20 oral solution (prednisolone sodium phosphate) | **Rayos:** The patient has had a trial of generic immediate release prednisone and has documented side effects that are associated with the later onset of activity of immediate release prednisone taken in the morning.<br><br>**All Others:** The patient has been started and stabilized on the requested medication. OR The patient has a documented side effect, allergy, or treatment failure to at least two preferred medications. If a product has an AB rated generic, one trial must be the generic formulation. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **COUGH AND COLD PREPARATIONS** | | |
| All generics<br>MUCINEX ® (guaifenesin) | Hydrocodone/chlorpheniramine (compare to Tussionex® ) *(QL = 60 ml/RX)*<br><br>Tussionex® (hydrocodone/chlorpheniramine) *(QL = 60 ml/RX)*<br>TussiCaps® (hydrocodone/chlorpheniramine) *(QL = 12 capsules/RX)*<br>All other brands | **Tussionex, TussiCaps, Hydrocodone/chlorpheniramine suspension (generic):** The patient has had a documented side effect, allergy, or treatment failure to two of the following generically available cough or cough/cold products: hydrocodone/homatropine (compare to Hycodan), promethazine/codeine (previously Phenergan with Codeine), guaifenesin/codeine (Cheratussin AC) or benzonatate. AND patient is 6 years old of age or greater. AND The quantity requested does not exceed 60 ml (Tussionex) or 12 capsules (TussiCaps). AND If the request is for Tussionex, the patient has a documented intolerance to generic hydrocodone/chlorpheniramine suspension.<br>**All Other Brands:** The prescriber must provide a clinically valid reason for the use of the requested medication including reasons why any of the generically available preparations would not be a suitable alternative. |
| **CYSTIC FIBROSIS MEDICATIONS** | | |
| ***Preferred After Clinical Criteria Are Met***:<br>KITABIS® (tobramycin sol)<br>*(QL= 56vials/56days; maximum days' supply = 56 days; 2 vials/day for 28 days, then 28 days off)*<br>TOBI® (tobramycin PODHaler capsules for inhalation)<br>*(QL = 224 capsules/56 days; maximum days' supply = 56 days) (4 capsules twice daily for 28 days, then 28 days off)* | Cayston® (aztreonam) inhalation solution<br>(Quantity Limit = 84 vials/56 days; maximum days supply = 56 days)<br>(3 vials/day for 28 days, then 28 days off)<br><br>Bethkis® (tobramycin) inhalation solution<br>(Quantity Limit = 56 vials/56 days; maximum days' supply = 56 days) | **Kitabis, Pulmonzyme:** diagnosis or indication is cystic fibrosis<br>**Bethkis, TOBI, tobramycin inhalation solutions:** Diagnosis or indication is cystic fibrosis and the patient has a documented failure or intolerance to Kitabis.<br>**Cayston:** diagnosis or indication is cystic fibrosis and the patient has had a documented failure, intolerance or inadequate response to inhaled tobramycin therapy alone<br>.<br>**Kalydeco:** The patient has a diagnosis of Cystic Fibrosis. AND Patient has one of the following mutations on at least one allele in the cystic fibrosis |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | (2 vials/day for 28 days, then 28 days off)<br>Kalydeco® (ivacaftor) tablets<br>(Quantity Limit = 2 tablets/day, maximum days' supply = 30 days)<br>Kalydeco® (ivacaftor) packets<br>(Quantity Limit = 2 packets/day, maximum days' supply = 30 days)<br><br>Orkambi® (lumacaftor/ivacaftor) (Quantity Limit= 120/30 days; max days supply=30 days)<br><br>Pulmozyme® (dornase alfa) inhalation solution<br>(Quantity Limit =60/30 days; maximum days supply=30 days)<br><br>TOBI® (tobramycin) inhalation solution<br>(Quantity Limit = 56 vials/56 days; maximum days supply = 56 days)<br>(2 vials/day for 28 days, then 28 days off)<br><br>Tobramycin inhalation solution† (compare to Tobi®)<br>(Quantity Limit = 56 vials/56 days; maximum days' supply = 56 days)(2 vials/day for 28 days, then 28 days off) | transmembrane conductance regulator gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R and who have an R117H mutation in the CFTR gene (documentation provided). AND The patient is ≥2 years old. Note: Renewal of Prior Authorization will require documentation of member response.<br>**TOBI PODHALER:** allowed after a trial of another form of inhaled tobramycin<br>**Orkambi:** The patient has a diagnosis of Cystic Fibrosis AND<br>Initial Criteria<br>• ≥ 12 years of age<br>• Patient must be determined to be homozygous for the *F508del* mutation in the CFTR gene as confirmed by an FDA-approved CF mutation test AND<br>• Patient has a baseline forced expiratory volume in one second (FEV1) of 40 percent of the predicted normal value AND<br>• If the patient is between the ages of 12-18, they must have undergone a baseline ophthalmic examination to monitor for lens opacities/cataracts<br>• Prescriber is a CF specialist or pulmonologist<br>Ongoing Approval Criteria<br>• Patient has stable or improved FEV1<br>• Patient has LFTs/bilirubin monitored every 3 months for the first year of therapy and annually after the first year<br>• ALT or AST ≤ 5 X the upper limit of normal or ALT/AST ≤ 3 X the upper limits of normal and bilirubin is ≤ 2 X the upper limit of normal<br>• Between the ages of 12 and 18, have follow up ophthalmic exam at least annually |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **DERMATOLOGICAL AGENTS** | | |
| **ACTINIC KERATOSIS THERAPY** | | |
| ALDARA® (imiquimod) 5 % Cream<br>EFUDEX®* (fluorouracil) 5% cream, solution<br>FLUOROURACIL (compare to CARAC®) 0.5% cream<br>CARAC® (fluorouracil) 0.5% cream<br><br>*C=cream, F=foam, G=gel, L=lotion, O=ointment, S=solution* | Diclofenac Sodium 3 % Gel (compare to Solaraze®)<br>*Qty Limit = 1 tube/30 days*<br>Fluorouracil† (compare to Efudex®) 5% cream, 5%, 2% solution<br>Imiquimod† (compare to Aldara®) 5 % cream<br>Picato® (ingenol mebutate) 0.015 % Gel<br>*Qty Limit = 3 tubes*<br>Picato® (ingenol mebutate) 0.05 % Gel<br>*Qty Limit = 2 tubes*<br>Solaraze® (diclofenac sodium) 3 % Gel<br>*Qty Limit = 1 tube/30 days*<br>Zyclara (imiquimod) 3.75 % Cream<br>*Qty Limit = 56 packets/6 weeks*<br>Zyclara (imiquimod) 2.5%, 3.75 % Cream Pump<br>*Qty Limit = 2 pumps/8 weeks* | **Imiquimod (generic) cream:** The patient has had a documented intolerance to brand Aldara<br>**Picato:** The diagnosis or indication is actinic keratosis AND The patient has had a documented side effect, allergy, contraindication or treatment failure with a generic topical fluorouracil product. OR The patient has had a documented side effect, allergy, contraindication or treatment failure with preferred brand Aldara<br>**Solaraze Gel, Diclofenac Gel:** The diagnosis or indication is actinic keratosis AND The patient has had a documented side effect, allergy, contraindication or treatment failure with generic topical fluorouracil product.<br>**Zyclara Cream:** The diagnosis or indication is actinic keratosis on the face or scalp AND The patient has had a documented side effect, allergy, or treatment failure with 5-fluorouracil and Aldara or generic imiquimod 5% cream. OR The treatment area is greater than 25 cm2 on the face or scalp. AND The patient has had a documented side effect, allergy, or treatment failure with 5-fluorouracil. |
| **ANTIOBIOTICS TOPICAL** | | |
| **Single Agent**<br>BACITRACIN†<br>MUPIROCIN OINTMENT† (compare to Bactroban®) | Altabax® (retapamulin) *QL = 1 tube*<br>Bactroban® (mupirocin) Cream<br>Bactroban®* (mupirocin) Ointment<br>Centany® Ointment (mupirocin)<br>Gentamicin Cream or Ointment | **Altabax:** The patient is being treated for impetigo. AND The patient has had a documented side effect, allergy, or treatment failure with mupirocin ointment AND MRSA (methicillin resistant staph aureus) has been ruled out by culture<br>**Bactroban Cream or Ointment, mupirocin cream, Centany Ointment:** The patient has had a documented intolerance with generic mupirocin ointment AND If the request is for brand Bactroban Cream, the patient has also had a |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **Combination Products**<br>BACITRACIN-POLYMYXIN†<br>NEOMYCIN-BACITRACIN-POLYMYXIN†<br>Note: Bactroban® Nasal Ointment is not included in this managed category<br><br>*C=cream, F=foam, G=gel, L=lotion, O=ointment, S=solution* | Mupirocin cream† (compare to Bactroban®)<br><br>Cortisporin® Cream (neomycin-polymyxin-hydrocortisone)<br>Cortisporin® Ointment(bacitracin-neomycin-polymyxin-hydrocortisone)<br><br>**All other branded products** | documented intolerance to the generic equivalent.<br>**Cortisporin Cream or Ointment, Gentamicin Cream or Ointment:** The patient has had a documented side-effect, allergy or treatment failure with at least one preferred generic topical antibiotic |
| **ANTIFUNGALS: ONYCHOMYCOSIS** | | |
| CICLOPRIOX † 8 % solution (compare to Penlac® Nail Lacquer) QL =6.6 ml/90 days | Penlac® Nail Lacquer (ciclopirox 8 % solution) QL = 6.6 ml/90<br>Kerydin®<br>Jublia® QL=48 weeks treatment | **Jublia, Kerydin, Penlac Sol:** The patient meets at least 1 of the following criteria: Pain to affected area that limits normal activity, Diabetes Mellitus, Patient is immunocompromised, Patient has diagnosis of systemic dermatosis, Patient has significant vascular compromise AND Documented intolerance to generic ciclopirox 8% solution.<br>**LIMITATIONS:** Coverage of Onychomycosis agents will NOT be approved solely for cosmetic purposes. Kits with multiple drug products or non-drug items not covered. |
| **ANTIFUNGALS: TOPICAL** | | |
| **Single Agent**<br>CICLOPIROX † (compare to Loprox®) 0.77% C, Sus, | Ertaczo® (sertaconazole) 2% C<br>Exelderm® (sulconazole) 1% C, S | **All Brands (except Vusion):** The patient has had a documented side effect, allergy, or treatment failure to at least TWO different preferred generic topical antifungal |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| G; 1%Sh<br>CLOTRIMAZOLE†(formerly Lotrimin®) 1% C, S<br>ECONAZOLE † (formerly Spectazole®) 1% C<br>KETOCONAZOLE † (compare to Kuric®, Nizoral®) 2% C, 2% Sh<br>MICONAZOLE † all generic/OTC products<br>NYSTATIN † O, C, P (compare to Mycostatin®, Nystop®, Pedi-Dri®, Nyamyc®)<br>TOLNAFTATE † (compare to Tinactin®) 1% C, P, Sp, S<br><br>**Combination Products**<br>CLOTRIMAZOLE W/BETAMETHASONE † (compare to Lotrisone®) C, L<br>NYSTATIN W/TRIAMCINOLONE † (formerly Mycolog II®) C, O<br>*C=cream, F=foam, G=gel, L=lotion, P=powder, S=solution, Sh=shampoo, Sp=spray, Sus=suspension* | Extina® (ketoconazole) 2% F<br>Ketoconazole† (compare to Extina®) 2 % Foam<br>Lamisil RX/OTC® (terbinafine) 1% C, S, Sp, G<br>Luzu® (luliconazole) 1% Cream<br>Mentax®) 1% C<br>Naftin® (naftifine) 1% & 2% C, 1%, 2% G<br>Nizoral®* (ketoconazole) 2% Sh<br>Nystop®, Pedi-Dri®, Nyamyc®* (nystatin) P<br>Oxistat® (oxiconazole) 1% C, L<br>Lotrisone®* (clotrimazole w/betamethasone) C, L<br>Vusion® (miconazole w/zinc oxide) O<br>*(QL=50 g/30 days)*<br>**All other branded products**<br><br>**Note**: Please refer to "Dermatological: Antifungals: Onychomycosis" for ciclopirox solution and Penlac® Nail Lacquer | agents. (If a product has an AB rated generic, one trial must be the generic equivalent of the requested product.) OR The patient has a contraindication that supports the need for a specific product or dosage form of a brand topical antifungal.<br>**Ketoconazole Foam:** The patient has had a documented side effect, allergy, or treatment failure to at least TWO different preferred generic topical antifungal agents.<br>**Vusion:** The patient has a diagnosis of diaper dermatitis complicated by documented candidiasis AND The patient is at least 4 weeks of age. AND The patient has had two trials (with two different preferred antifungal agents) used in combination with a zinc oxide diaper rash product resulting in documented side effects, allergy, or treatment failures.<br>**Limitations:** Foam products (e.g. Ecoza (econazole nitrate)) not covered. Other topical dosage preparations preferred. |
| **ANTIVIRALS: TOPICAL** | | |
| ABREVA OTC (docosanol) 10% C<br>*C=cream, O=ointment*<br>Note: See Anti-Infectives: Antivirals: Herpes: Oral for Sitavig® | Acyclovir (compare to Zovirax®) 5 % O<br>Denavir® (penciclovir) 1% C<br>Zovirax® (acyclovir) 5% C, O<br>Xerese® (acyclovir 5%/hydrocortisone 1%) C | **Denavir:** The patient has a diagnosis of oral herpes simplex infection and a failure of both oral antiviral and Abreva OTC.<br>**Acyclovir, Zovirax:** If prescribed for the treatment of oral herpes simplex infection, the patient has had a documented side effect, allergy, or treatment failure (at least one course of four or more days) with Denavir.<br><br>** Topical antiviral therapy offers minimal clinical benefit in the treatment of genital herpes and its use is discouraged by the CDC so topical antiviral therapy |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | will not be approved for this indication. ** |
| **CORTICOSTEROIDS: LOW POTENCY** | | |
| ALCLOMETASONE 0.05% C, O† (compare to Aclovate®)<br>FLUOCINOLONE 0.01% C, S, oil† (compare to Derma-Smoothe, Synalar®)<br>HYDROCORTISONE†<br>0.5%, 1%, 2.5% C; 1%, 2.5% L, 0.5%, 1%, 2.5% O<br>*C=cream, F=foam, G=gel, L=lotion, O=ointment, S=solution* | Capex® (fluocinolone) 0.01% shampoo<br>Derma-Smoothe®* (fluocinolone 0.01%) oil<br>Desonate® (desonide) 0.05% G<br>Desonide† 0.05% C,L,O (compare to DesOwen®)<br>DesOwen®* (desonide) 0.05% C, L<br>Synalar®* (fluocinolone) 0.01% S<br>**All other brands** | **CRITERIA FOR APPROVAL (NON-PREFERRED AGENTS):** The patient has a documented side effect, allergy, or treatment failure to at least two different preferred agents of similar potency. (If a product has an AB rated generic, one trial must be the generic.) |
| **CORTICOSTEROIDS: MEDIUM POTENCY** | | |
| BETAMETHASONE DIPROPIONATE† 0.05% C, L, O (formerly Diprosome®)<br>BETAMETHASONE VALERATE† 0.1% C, L, O (formerly Beta-Val®)<br>BETAMETHASONE VALERATE†0.12% (compare to Luxiq®) F<br>CLOCORTOLONE 0.1% C (compare to Cloderm®)<br>FLUOCINOLONE† 0.025% C, O (compare to Synalar®)<br>FLUTICASONE † 0.05% C; 0.005% O (compare to Cutivate®)<br>HYDROCORTISONE BUTYRATE† 0.1% C, O, S<br>MOMETASONE FUROATE† 0.1% C, L, O, S | Cloderm® (clocortolone) 0.1% C<br>Cordran® (all products)<br>Cutivate® (fluticasone) 0.05% L<br>Dermatop® (prednicarbate) 0.1% C, O<br>desoximetasone 0.05% C, O (compare to Topicort®)<br>Elocon®* (all products)<br>Fluticasone† (compare to Cutivate®) 0.05%, L<br>Hydrocortisone Valerate† 0.2% C,O<br>Kenalog® (triamcinolone) Aerosol Spray<br>Luxiq® (betamethasone valerate) F<br>prednicarbate† (compare to Dermatop®) 0.1% C, O<br>Synalar®* (fluocinolone) 0.025% C, O | **CRITERIA FOR APPROVAL (NON-PREFERRED AGENTS):** The patient has a documented side effect, allergy, or treatment failure to at least two different preferred agents of similar potency. (If a product has an AB rated generic, one trial must be the generic.) |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| (compare to Elocon®)<br>TRIAMCINOLONE ACETONIDE† 0.025%, 0.1% C, L, O (formerly Aristocort® or Kenalog®) | Topicort®* (desoximetasone) 0.05% C, O<br>Triamcinolone Aerosol Spray<br>Trianex®* (triamcinolone) 0.05% O<br><br>**All other brands** | |
| **CORTICOSTEROIDS: HIGH POTENCY** | | |
| AUGMENTED BETAMETHASONE† 0.05% C, L(compare to Diprolene® AF)<br>BETAMETHASONE VALERATE† 0.1% C, O (formerly Beta-Val®)<br><br>DESOXIMETASONE† 0.05% C, G, O; 0.25% C, O (compare to Topicort®)<br>FLUOCINONIDE† 0.05% C, G, O, S (formerly Lidex®)<br><br>TRIAMCINOLONE ACETONIDE† 0.5% C, O (formerly Aristocort®)<br>*C=cream, F=foam, G=gel, L=lotion, O=ointment, S=solution* | Amcinonide† (formerly Cyclocort®)<br>Apexicon E® (diflorasone) 0.05% C<br>Diflorasone diacetate† 0.05% C, O (compare to Apexicon E®)<br><br>Diprolene® AF* (augmented betamethasone) 0.05% C, L<br>Halog® (halcinonide) all products<br>Topicort®* (desoximetasone) 0.05% G; 0.25% C, O, Spray<br><br>**All other brands** | **CRITERIA FOR APPROVAL (NON-PREFERRED AGENTS):** The patient has a documented side effect, allergy, or treatment failure to at least two different preferred agents of similar potency. (If a product has an AB rated generic, one trial must be the generic.) |
| **CORTICOSTEROIDS: VERY HIGH POTENCY** | | |
| AUGMENTED BETAMETHASONE† 0.05% C,L, O (compare to Diprolene®) 0.05% G<br>DIFLORASONE DIACETATE† 0.05% O (compare to Apexicon®, formerly Psorcon E®)<br>HALOBETASOL PROPRIONATE† (compare to | Clobetasol propionate† (compare to Clobex®) 0.05% L, Sh, Spray<br>Clobetasol propionate (compare to Temovate®/Cormax®) 0.05% C,G,O,S<br>Clobetasol 0.05% F (compare to Oulux®)<br>clobetasol propionate emulsion† (compare to Olux E®) | **CRITERIA FOR APPROVAL (NON-PREFERRED AGENTS)**: The patient has a documented side effect, allergy, or treatment failure to at least two different preferred agents of similar potency. (If a product has an AB rated generic, one trial must be the generic.) |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| Ultravate®)<br>*C=cream, F=foam, G=gel, L=lotion, O=ointment, S=solution* | 0.05% F<br>Clobex® (clobetasol propionate) 0.05% L, shampoo, spray<br>Diprolene®* (augmented betamethasone) 0.05% L, O<br>Diprolene®AF 0.05% C<br>fluocinonide † (compare to Vanos®)0.1% C<br>Olux® * /Olux E® (clobetasol propionate) 0.05% F<br>Temovate®* (clobetasol propionate) 0.05% C, , O,<br>Vanos® (fluocinonide) 0.1% C<br>Ultravate®* (halobetasol propionate) 0.05% C, O<br>**All other brands** | |
| **GENITAL WART THERAPY** | | |
| ALDARA® (imiqumod 5%)<br><br>PODOFILOX SOLUTION† (compare to Condylox®) | Imiquimod† 5 % (compare to Aldara®) cream<br>Condylox® Gel (podofilox gel)<br><br>Condylox®* solution (podofilox solution)<br>Veregan® (sinecatechins ointment) (Quantity limit = 15 grams (1 tube)/per 30 days)<br><br>Zyclara® (imiquimod 3.75%) Cream<br>(Quantity limit = 56 packets)/per 8 weeks)<br>Zyclara® (imiquimod 3.75%) Cream Pump | **Condylox gel, Veregan:** The patient has had a documented side effect, allergy, or treatment failure with Aldara<br>**Condylox Solution:** The patient has had a documented intolerance to generic podofilox solution.<br><br>**Imiquimod (generic) cream:** The patient has had a documented intolerance to brand Aldara |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | (Quantity limit = 2 pumps/per 8 weeks) | |
| **IMMUNOMODULATORS** | | |
| **Effective 11/1/06: PA required for Elidel / Protopic/tacrolimus for children < 2 years. Quantity Limit = 30 gm / fill, 90 gm / 6 mos. Step Therapy required (previous trial of topical steroid for patients ≥ 2 yrs). Protopic/tacrolimus ointment concentration limited to 0.03% for age < 16 years old.** | | |
| ELIDEL® (pimecrolimus) §<br>PROTOPTIC® (tacrolimus) § | Elidel® (pimecrolimus) (age < 2 yrs)<br>Protopic® (tacrolimus) (age < 2 yrs)<br>Tacrolimis Ointment† (compare to Protopic®) All Patient | **Criteria for Approval Age < 2 years** (requests will be approved for up to 6 months): The patient has a diagnosis of atopic dermatitis (eczema). AND The patient has had a documented side effect, allergy, or treatment failure with at least one moderate to high potency topical corticosteroid within the last 6 months. AND The quantity requested does not exceed 30 grams/fill and 90 grams/6 months. AND If the request is for generic tacrolimus ointment, the patient has a documented intolerance to brand Protopic.<br>**Criteria for Approval Age > 2 years** (requests will be approved for up to 1 year): The patient has a diagnosis of atopic dermatitis (eczema). AND The patient has had a documented side effect, allergy, or treatment failure with at least one moderate to high potency topical corticosteroid within the last 6 months. AND The quantity requested does not exceed 30 grams/fill and 90 grams/6 months. AND If the request is for generic tacrolimus ointment, the patient has a documented intolerance to brand Protopic. |
| **SCABICIDES AND PEDICULOCIDES** | | |
| **SCABICIDES**<br>PERMETHRIN† 5 % (compare to Elimite®) *C*<br><br>**PEDICULICIDES (lice treatment)**<br>PERMETHRIN† 1 % *CR, L*<br>PIPERONYL BUTOXIDE AND PYRETHRINS† *G,* | Eurax® (crotamiton 10 %) *C, L*<br>Lindane† *L*<br><br>Lindane† *Sh* | **NON-PREFERRED SCABICIDES:** The patient has had a documented side effect or allergy to permethrin cream or treatment failure with two treatments of permethrin cream.<br>**Natroba:** The patient has had a documented side effect or allergy to OTC permethrin and piperonyl butoxide and pyrethrins or treatment failure with one |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| *S, Sh*<br>***Preferred After Clinical Criteria Are Met* (1 OTC step via electronic PA)**<br>NATROBA® (spinosad 0.9 %) *Ss*§<br><br>*C=cream, CR=crème rinse, G=gel, L=lotion, S=solution, Sh=shampoo, Sp=spray, Ss=suspension* | Malathion †*L* (compare to Ovide®)<br>Ovide® (malathion) *L*<br>Sklice® (Ivermectin 0.5 %) *L*<br>Spinosad† (compare to Natroba) *Ss*<br>Ulesfia® (benzyl alcohol 5%) *L*<br>All other brand and generic Scabicides and Pediculicides | treatment of OTC permethrin or piperonyl butoxide and pyrethrins.<br>**Non-Preferred Pediculicides:** The patient has had a documented side effect or allergy to OTC permethrin and piperonyl butoxide and pyrethrins and Natroba or treatment failure with two treatments of OTC permethrin and/or piperonyl butoxide and pyrethrins and one treatment of Natroba. For approval of Ovide® Lotion, the patient must also have a documented intolerance to the generic equivalent product. |
| **DESMOPRESSIN: INTRANASAL/ORAL** | | |
| **Intranasal**<br><br>**Oral**<br><br>DESMOPRESSIN† | DDAVP® (desmopressin) Nasal Solution or Spray 0.01%<br>Desmopressin † Nasal Solution or Spray 0.01 % (compare to DDAVP®)<br>Minirin † (desmopressin) Nasal Spray 0.01%<br>Stimate® (desmopressin) Nasal Solution 1.5 mg/ml<br><br>DDAVP®* (desmopressin) tablets | **CRITERIA FOR APPROVAL:** Intranasal: The diagnosis or indication for the requested medication is (1) Diabetes Insipidus, (2) hemophilia type A, or (3) Von Willebrand disease AND If the request is for brand DDAVP, the patient has a documented intolerance to generic desmopressin spray or solution.<br>**CRITERIA FOR APPROVAL:** non-preferred oral: The diagnosis or indication for the requested medication is (1) Diabetes Insipidus and/or (2) primary nocturnal enuresis AND The patient has had a documented intolerance to generic desmopressin tablets<br>**LIMITATIONS:** Desmopressin intranasal formulations will not be approved for the treatment of primary nocturnal enuresis (PNE) due to safety risks of hyponatremia. Oral tablets may be prescribed for this indication. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **DIABETIC TESTING SUPPLIES** | | |
| **MONITORS/METERS** | | |
| Please refer to the DVHA website for covered Diabetic testing supplies. | | **CRITERIA FOR APPROVAL:** The prescriber demonstrates that the patient has a medical necessity for clinically significant features that are not available on any of the preferred meters/test strips.<br>**LIMITATIONS:** Talking monitors are not covered under the pharmacy benefit. |
| **TEST STRIPS/LANCETS** | | |
| **DIABETIC TEST STRIPS**<br><br>Please refer to the DVHA website for covered Diabetic testing supplies.<br><br>**LANCETS**<br><br>All brands and store brands | | **CRITERIA FOR APPROVAL:** The prescriber demonstrates that the patient has a medical necessity for clinically significant features that are not available on any of the preferred meters/test strips.<br>**LIMITATIONS:** Talking monitors are not covered under the pharmacy benefit. |
| **EPINEPHRINE: AUTO-INJECTOR** | | |
| EPIPEN® 2-PAK INJ 0.3 MG (epinephrine 0.3 mg/0.3 ml (1:1000))<br><br>EPIPEN-JR® 2-PAK INJ 0.15 MG (epinephrine 0.15 mg/0.3 ml (1:2000)) | All other branded and generic products. | **CRITERIA FOR APPROVAL:** The patient has a documented intolerance to the preferred product. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **ESTROGENS: VAGINAL** | | |
| **Estradiol**<br>ESTRACE VAGINAL® Cream<br><br>ESTRING® Vaginal Ring<br>VAGIFEM® Vaginal Tablets<br><br>**Conjugated Estrogens**<br>PREMARIN VAGINAL® Cream<br><br>**Estradiol Acetate**<br>FEMRING® Vaginal Ring | | |
| **FIBROMYALGIA AGENTS** | | |
| | Savella® (milnacipran) tablet, titration pack<br>*Quantity Limit = 2 tablets/day*<br>Cymbalta® (duloxetine)<br>Duloxetine† (compare to Cymbalta®)<br>Lyrica® (pregabalin) | **Savella:** The diagnosis or indication is treatment of fibromyalgia AND The patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine or Lyrica.<br>**Cymbalta/Duloxetine:** The patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine, Lyrica® or Savella® (this indication not processed via automated step therapy) AND if the request is for duloxetine, the patient has had a documented intolerance with brand Cymbalta. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | **Lyrica:** The patient has had a documented side effect, allergy, or treatment failure to TWO drugs from the following: gabapentin, tricyclic antidepressant, SSRI antidepressant, SNRI antidepressant, miscellaneous antidepressant, cyclobenzaprine or Savella®, if medication is being used for fibromyalgia (this indication not processed via automated step therapy) AND If the request is for the oral solution, the patient is unable to use Lyrica capsules (eg. swallowing disorder). |
| **GASTROINTESTINAL** | | |
| **INFLAMMATORY BOWEL DISEASE INJECTABLES (**Initial approval is 3 months, renewals are 1 year) | | |
| ***Preferred After Clinical Criteria Are Met***<br>HUMIRA® (adalimumab)<br>*Quantity limit = 6 syringes/28 days for the first month (Crohn's starter kit);2 syringes/28 days subsequently*<br>REMICADE® (infliximab) | Cimzia® (certolizumab pegol)<br>*Quantity limit = 1 kit/28 days* Entyvio® (vedolizumab)<br>*Quantity limit = 300mgX 3/42 days, 300mg X 1 every 56 days thereafter*<br>Simponi® (golimumab) SC<br>*3 of 100mg prefilled syringe or autoinjector X 1, then 100mg/28days*<br>Tysabri® (natalizumab) | **NOTE:** Crohn's Disease Self-Injectables (Humira and Cimzia) must be obtained and billed through our specialty pharmacy vendor, Briova. Please see the Humira and Cimzia Prior Authorization/Patient Enrollment Form for instructions. Briova may supply Remicade upon request or you may continue to obtain through your usual supplier. Briova will not be supplying Tysabri at this time – please continue to obtain through your usual supplier.<br>**Clinical Criteria (Crohn's Disease)**<br>**Humira, Remicade, Cimzia, Tysabri, Entyvio:**<br>• Patient has a diagnosis of Crohn's disease and has already been stabilized on the medication. OR<br>• Diagnosis is moderate to severe Crohn's disease and at least 2 of the following drug classes resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure (i.e. resistant or intolerant to steroids or immunosuppressants): aminosalicylates, antibiotics, |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | corticosteroids, and immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate. Note: Humira and Cimzia have been shown to be effective in patients who have been treated with infliximab but have lost response to therapy.<br>**Cimzia additional criteria:**<br>• Patient age > 18 years AND<br>• The prescriber must provide a clinically valid reason why Humira cannot be used.<br>**Tysabri additional criteria:**<br>• The patient has a documented side effect, allergy, treatment failure, or contraindication to BOTH, Remicade and Humira.<br>**Entyvio additional criteria:**<br>• Patient age > 18 years AND<br>• The patient has a documented side effect, allergy, treatment failure (including corticosteroid dependence despite therapy), or contraindication to BOTH Remicade and Humira<br>**Clinical Criteria (Ulcerative Colitis)**<br>**Humira, Remicade:**<br>• Patient has a diagnosis of Ulcerative Colitis and has already been stabilized on the medication. OR<br>• The patient has a diagnosis of Ulcerative Colitis and has had a documented side effect, allergy or treatment failure with at least 2 of the following 3 agents: aminosalicylates (e.g. sulfasalazine, mesalamine, etc), corticosteroids, or immunomodulators (e.g. azathioprine, 6-mercaptopurine, cyclosporine, etc.).<br>**Entyvio, Simponi:**<br>• Patient has a diagnosis of ulcerative colitis and has already been stabilized |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | on the drug OR<br>• Age > 18 years AND a diagnosis of ulcerative colitis AND<br>• has demonstrated corticosteroid dependence or has had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine AND the prescriber must provide a clinically valid reason why Humira and Remicade cannot be used. |
| **H.PYLORI COMBINATION THERAPY** | | |
| | Helidac® (bismuth subsalicylate, metronidazole, tetracycline) *(Quantity limit=224 caps & tabs/14 days)*<br>Lansoprazole, amoxicillin, clarithromycin (compare to Prevpac®)<br>*(Quantity limit = 112 caps & tabs/14 days)*<br><br>Omeclamox-Pak® (omeprazole, clarithromycin, amoxicillin)<br>*(Quantity limit = 80 caps & tabs/10 days)*<br><br>Prevpac® (lansoprazole, amoxicillin, clarithromycin)<br>*(Quantity limit = 112 caps & tabs/14 days)*<br>Pylera® (bismuth subcitrate, metronidazole, tetracycline) capsules<br>*(Quantity limit=120 capsules/10 days)* | **CRITERIA FOR APPROVAL:** The patient has a documented treatment failure with combinations of individual proton pump inhibitors or H2 antagonists given together with two appropriate antibiotics OR The patient has been unable to be compliant with individual agents prescribed separately. AND For approval of brand Prevpac®, the patient has a documented intolerance to the generic equivalent combination product. |
| **H-2 BLOCKERS** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| FAMOTIDINE† (compare to Pepcid®) tablet<br>RANITIDINE† (compare to Zantac®) tablet<br><br>**SYRUPS AND SPECIAL DOSAGE FORMS**<br>CIMETIDINE † ORAL SOLUTION<br>RANITIDNE† syrup (compare to Zantac®) | Cimetidine† (compare to Tagamet®) tablet<br>Pepcid®* (famotidine) tablet §<br>ranitidine† capsule §<br>Tagamet®* (cimetidine) tablet §<br>Zantac®* (ranitidine) tablet §<br>famotidine† (compare to Pepcid®) oral suspension §<br>Nizatidine †Oral Solution (compare to Axid®)<br>Pepcid® (famotidine) Oral Suspension § | **Nizatidine capsule, Pepcid tablet, ranitidine capsule, Tagamet tablet, Zantac tablets:** The patient has had a documented side effect, allergy, or treatment failure to at least one preferred medication. If a medication has an AB rated generic, the trial must be the generic formulation. For approval of ranitidine capsules, the patient must have had a trial of ranitidine tablets.<br><br>**Famotidine Oral Suspension, Nizatidine Oral Solution, Pepcid Oral Suspension:** The patient has had a documented side effect, allergy, or treatment failure to ranitidine syrup or cimetidine oral solution. If a medication has an AB rated generic, there must have been a trial of the generic formulation.<br>**Cimetidine tablet** current users as of 05/29/2015 would be grandfathered |
| **INFLAMMATORY BOWEL AGENTS (ORAL & RECTAL PRODUCTS)** | | |
| **MESALAMINE PRODUCTS**<br>**Oral**<br>APRISO® (mesalamine capsule extended-release)<br>ASACOL® (mesalamine tablet delayed-release)<br>DELZICOL® (mesalamine capsule delayed-release)<br>*(QL = 6 capsules/day)*<br><br>LIALDA® (mesalamine tablet extended-release)<br>PENTASA ER 250mg® (mesalamine cap CR) | Asacol HD® (mesalamine tablet delayed release)<br><br>Pentasa ER 500mg® (mesalamine cap CR)<br>Sfrowasa® (mesalamine enema sulfite free) | **Azulfidine, Colazal:** patient has had a documented intolerance to the generic equivalent of the requested medication.<br>**Asacol HD:** The patient has had a documented side effect, allergy, or treatment failure with two (2) preferred oral mesalamine products.<br>**Entocort EC/Uceris ER tab:** The patient had a documented intolerance to the generic budesonide 24 hr capsules.<br><br>**Giazo:** The diagnosis is ulcerative colitis AND The patient is male and > 18 years old. AND The patient has a documented intolerance to generic balsalazide.<br>**Pentasa 500mg current users as of 8/7/2015 will be grandfathered**<br><br>**Sfrowasa:** The patient has had a documented intolerance to mesalamine enema.<br>**LIMITATIONS:** Kits with non-drug products are not covered. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **Rectal**<br>CANASA® (mesalamine suppository)<br>MESALAMINE ENEMA† (compare to Rowasa®) | Entocort EC®* (budesonide 24 hr cap)<br>*QL = 3 capsules/day*<br>Uceris® (budesonide ) ER Tablet<br>*QL = 1 tablet/day* | |
| **CORTICOSTEROIDS**<br>**ORAL**<br>BUDESONIDE 24HR (compare to Entocort EC®)<br>*QL = 3 capsules/day*<br>**RECTAL**<br>UCERIS RECTAL FOAM (budesonide)<br>**OTHER**<br>BALSALAZIDE† (compare to Colazal®)<br>DIPENTUM® (olsalazine)<br>SULFAZINE<br>SULFAZINE EC<br>SULFASALAZINE† (compare to Azulfidine®)<br>SULFASALAZINE DR | Azulfidine®* (sulfasalazine)<br>Colazal®* (balsalazide)<br>Giazo® (balsalazide disodium) tablet<br>*QL = 6 tablets/day* | |
| **PROKINETIC AGENTS** | | |
| **Tablets**<br>METOCLOPRAMIDE† tabs (compare to Reglan®)<br>**Oral Solution**<br>METOCLOPRAMIDE† (formerly Reglan®) oral sol | Reglan®* (metoclopramide) | **Reglan:** The patient has had a documented intolerance to generic metoclopramide tablets. |
| **Orally Disintegrating Tablets** | Metozolv ODT® (metoclopramide) *(QL= 4 tabs/day)* | **Metozolv ODT:** The patient has a medical necessity for a disintegrating tablet formulation (i.e. swallowing disorder, inability to take oral medications) AND |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | Generic metoclopramide oral solution cannot be used |
| **PROTON PUMP INHIBITORS** | | |
| **ORAL CAPULES/TABLETS**<br>OMEPRAZOLE† RX capsules (compare to Prilosec®) *(Quantity limit = 1 capsule/day)*<br><br>PANTOPRAZOLE† tablets (compare to Protonix®) *(Quantity limit=1 tab/day)*<br><br>LANSOPRAZOLE† generic RX capsules (compare to Prevacid®) § *(Quantity limit = 1 cap/day)* | Aciphex® (rabeprazole) tablets *(Quantity limit=1 tab/day)*<br>Dexilant® (dexlansoprazole) capsules *(Quantity limit=1 cap/day)*<br>Esomeprazole® Strontium capsules *(Quantity limit = 1 cap/day)*<br><br>Nexium® (esomeprazole) capsules § *(Quantity limit=1 cap/day)*<br>omeprazole † generic OTC tablets *(Quantity limit=1 tab/day)*<br>omeprazole magnesium† generic OTC 20 mg capsules § *(Quantity limit=1 cap/day)*<br>omeprazole/sodium bicarb capsules RX (compare to Zegerid®) § *(Quantity limit=1 cap/day)*<br>Prevacid® RX (lansoprazole) capsules *(Quantity limit=1 cap/day)*<br>Prevacid® 24 hr OTC (lansoprazole) capsules *(Quantity limit=1 cap/day)*<br>Prilosec OTC® 20mg (omeprazole magnesium) tablets *(Quantity limit = 1 tablet/day)*<br>Prilosec®* RX (brand) (omeprazole) capsules *(Quantity limit=1 cap/day)*<br>Protonix®* (pantoprazole) tablets *(Quantity limit=1 tab/day)*<br>rabeprazole (compare to Aciphex®) tablets *(Quantity* | **Nexium powder for suspension, Prevacid Solutabs (for patients > 12 years old), Prilosec packet, and Protonix packet:** The patient has a requirement for a non-solid oral dosage form (e.g. an oral liquid, dissolving tablet or sprinkle).<br>**Aciphex Sprinkle:** The patient has a requirement for a non-solid oral dosage form AND The member has had a documented side effect, allergy, or treatment failure to omeprazole capsule opened and sprinkled omeprazole or lansoprazole suspension or Prevacid solutab.<br>**Other non-preferred medications:** The member has had a documented side effect, allergy, or treatment failure to Omeprazole RX generic capsules, Lansoprazole RX generic capsules, and Pantoprazole generic tablets. If the request is for Prevacid 24 hr OTC or Prevacid RX, the patient must also have a documented intolerance to lansoprazole generic RX capsules. If the request is for brand Zegerid RX capsules, the patient must also have a documented intolerance to the generic equivalent.<br>**CRITERIA FOR APPROVAL (twice daily dosing):**<br>**Gastroesophageal Reflux Disease (GERD)** – If member has had an adequate trial (e.g. 8 weeks) of standard once daily dosing for GERD, twice daily dosing may be approved.<br>**Zollinger-Ellison (ZE) syndrome** – Up to triple dose PPI may be approved.<br>**Hypersecretory conditions (endocrine adenomas or systemic mastocytosis)** – Double dose PPI may be approved.<br>**Erosive Esophagitis, Esophageal stricture, Barrett's esophagitis (complicated GERD)** – Double dose PPI may be approved.<br>**Treatment of ulcers caused by H. Pylori** – Double dose PPI may be approved for |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | *limit = 1 tab/day)*<br>Zegerid RX ® (omeprazole/sodium bicarb) caps, oral, suspension *(Quantity limit=1 cap/day)*hex® Sprinkle (rabeprazole) DR Capsule *(Quantity limit=1 cap/day)* | up to 2 weeks.<br>**Laryngopharyngeal reflux** – Double dose PPI may be approved.<br>**LIMITATIONS:** First-Lansoprazole® and First-Omeprazole Suspension Kits ered as Federal Rebate no longer offered. Nexium 24HR OTC (esomeprazole) capsules OTC Plan Exclusion - these products are not covered |
| **SUSPENSION & SPECIAL DOSAGE FORMS** | Nexium® (esomeprazole) powder for suspension § *(Quantity limit=1 packet/day)*<br>Prevacid Solutabs® (lansoprazole) *(Quantity limit=1 tab/day)*<br>Prilosec® (omeprazole magnesium) packet *(Quantity limit=2 packets/day)*<br>Protonix® (pantoprazole) packet *(Quantity limit=1 packet/day)* | |
| **GAUCHER'S DISEASE MEDICATIONS** | | |
| | Cerdelga *(Quantity limit=2 caps/day)*<br>Cerezyme® (imiglucerase for injection)<br>Elelyso® (taliglucerase alfa for injection)<br>Vpriv® (velaglucerase alfa for injection)<br>Zavesca® (miglustat) (*QL = max 3 caps/daily)*<br><br>****Maximum days supply per fill for all drugs is 14 days**** | **CRITERIA FOR APPROVAL:** The diagnosis or indication is Gaucher disease (GD) type I. AND The diagnosis has been confirmed by molecular or enzymatic testing.<br>**Age Limits**<br>**Elelyso, Vpriv:** for patients ≥ 4 years old<br>**Cerezyme:** for patients ≥ 2 years old<br>**Cerdelga, Zavesca:** for patients ≥ 18 years old<br><br>**Cerdelga/Vpriv additional criteria:** Failure, intolerance or other contraindication |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | to enzyme replacement therapy with Elelyso<br><br>**Cerdelga additional criteria:**<br>• For whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access)<br>• Testing to verify if CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM), ultra-rapid metabolizer (URM), or if CYP2D6 genotype cannot be determined<br>  ○ Dose max: 84mg twice/day if EM or IM<br>  ○ Dose max: 84mg/day if PM<br>  ○ Not indicated or URM<br>  ○ Case by case determination if CYP2D6 cannot be determined<br><br>**Zavesca additional criteria:**<br>• For whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access) |
| **GOUT AGENTS** | | |
| **SINGLE INGREDIENT COLCHICINE**<br><br>**SINGLE INGREDIENT URICOSURIC AGENTS**<br>PROBENECID†<br><br>**XANTHINE OXIDASE INHIBITORS**<br>ALLOPURINOL† (compare to Zyloprim®) | Colcrys® (colchicine) tablet<br>*QL = 3 tablets/day (gout) or 4 tablets/day (FMF)*<br>Colchicine tablets (compare to Colcrys®)<br>Colchicine capsules | **Colcrys, colchicine tablets** The diagnosis or indication for the requested medication is Familial Mediterranean Fever (FMF) OR The diagnosis or indication for the requested medication is gout AND The patient has had a documented side effect or treatment failure with at least one drug from the NSAID class. OR The patient is not a candidate for therapy with at least one drug from the NSAID class due to one of the following: The patient is 60 years of age or older, Patient has a history of GI bleed, Patient is currently taking an anticoagulant (warfarin or heparin), Patient is currently taking an oral corticosteroid, Patient is currently taking methotrexate |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **COMBINATION PRODUCTS**<br>COLCHICINE/PROBENECID†<br><br>**PEG-URICASE AGENTS** | Zyloprim®* (allopurinol)<br><br>Uloric® (febuxostat) *QL (40 mg tablets) = 1 tablet/day* | **Colchicine capsules:** the diagnosis or indication for the requested medication is prophylaxis of gout flares in adults AND the patient has had a documented side effect or treatment failure with at least one drug from the NSAID class OR the patient is not a candidate for therapy with at least one drug from the NSAID class due to one of the following: the patient is 60 years of age or older, patient has a history of GI bleed, patient is currently taking an anticoagulant (warfarin or heparin), patient is currently taking an oral corticosteroid, patient is currently taking methotrexate<br>**Note:** after preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.<br>**Uloric:** The diagnosis or indication is treatment of gout AND The patient has had a documented side effect, allergy, treatment failure or a contraindication to allopurinol. NOTE: Treatment failure is defined as inability to reduce serum uric acid levels to < 6 mg/dl with allopurinol doses of 600 mg/day taken consistently. Additionally, renal impairment is not considered a contraindication to allopurinol use.<br>**Zyloprim:** The patient has had a documented intolerance to generic allopurinol |
| **GROWTH STIMULATING AGENTS** | | |
| *****Must be obtained through Specialty Pharmacy Provider, Briova*** (Please see Growth Stimulating Agents Prior Authorization/Enrollment Form for instructions.)** | | |
| NORDITROPIN® | Genotropin®<br>Humatrope®<br>Nutropin® AQ<br>Omnitrope®<br>Saizen®<br>Tev-Tropin®<br>Zomacton® | **Criteria for Approval Pediatric:** 1) The patient must have one of the following indications for growth hormone: Turner syndrome confirmed by genetic testing. Prader-Willi Syndrome confirmed by genetic testing. Growth deficiency due to chronic renal failure. Patient who is Small for Gestational Age (SGA) due to Intrauterine Growth Retardation (IUGR)and catch up growth not achieved by age 2 (Birth weight less than 2500g at gestational age of <37 |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | **Specialized Indications – See Specific Criteria**<br>Increlex® (mecasermin)<br>Serostim®<br>Zorbtive® | weeks or a birth weight or length below the 3rd percentile for gestational age). OR  Pediatric Growth Hormone Deficiency confirmed by results of two provocative growth hormone stimulation tests (insulin, arginine, levodopa, propranolol, clonidine, or glucagon) showing results (peak level) <10ng/ml. 2) The requested medication must be prescribed by a pediatric endocrinologist (or pediatric nephrologist if prescribed for growth deficiency due to chronic renal failure). 3) Confirmation of non-closure of epiphyseal plates (x-ray determining bone age) must be provided for females > age 12 and males > age 14. 4) Initial requests can be approved for 6 months. Subsequent requests can be approved for up to 1 year with documentation of positive response to treatment with growth hormone.<br>**Criteria for Approval Adult:** The patient must have one of the following indications for growth hormone: Panhypopituitarism due to surgical or radiological eradication of the pituitary. OR Adult Growth Hormone Deficiency confirmed by one growth hormone stimulation test (insulin, arginine, levodopa, propranolol, clonidine, or glucagon) showing results (peak level) <5ng/ml. Growth hormone deficient children must be retested after completion of growth.<br>**LIMITATIONS:** Coverage of Growth Hormone products will not be approved for patients who have Idiopathic Short Stature.<br>**GENOTROPIN, HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN, TEV-TROPIN, ZOMACTON:** The patient has a documented side effect, allergy, or treatment failure to Norditropin<br>**Increlex:** Member has growth hormone gene deletion AND neutralizing antibodies to growth hormone, OR primary insulin-like growth factor (IGF-1) deficiency (IGFD), defined by the following: o Height standard deviation score < -3 AND Basal IGF-1 standard deviation score < -3 AND Normal or elevated growth hormone level Member is ≥ 2 years old (safety and efficacy has not been established in patients younger than 2), AND Member has open epiphysis, AND |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | Member is under the care of an endocrinologist or other specialist trained to diagnose and treat growth disorders.<br>**Serostim:** A diagnosis of AIDS associated wasting/anorexia<br>**Zorbtive:** A diagnosis of short bowel syndrome. Concomitant use of specialized nutritional support (specialty TPN) Prescription must be issued by gastroenterologist (specialist) |
| **HEMOPHILIA FACTORS** | | |
| **AHF-Factor VII**<br>*****Must be obtained through Specialty Pharmacy Provider, Briova***** | | |
| NOVOSEVEN® VIAL | | |
| **AHF-Factor VIII**<br>*****Must be obtained through Specialty Pharmacy Provider, Briova***** | | |
| ADVATE® VIAL<br>HELIXATE FS® VIAL<br>HEMOFIL® M VIAL<br>KOGENATE FS® VIAL<br>MONOCLATE-P® KIT<br>OBIZUR® VIAL<br>RECOMBINATE® VIAL | Adynovate® Vial<br>Eloctate® Vial<br>Novoeight® Vial<br>Nuwiq® Vial<br>Xyntha® Syringe | **All Non-Preferred Products:** The prescriber must provide a clinically compelling reason for the use of the requested medication including reasons why any of the preferred products would not be suitable alternatives. |
| **AHF-Factor IX**<br>*****Must be obtained through Specialty Pharmacy Provider, Briova***** | | |
| ALPHANINE® SD VIAL<br>BEBULIN® VIAL<br>BENEFIX® KIT<br>MONONINE® KIT | Alprolix® Vial<br>Ixinity® Vial<br>Kcentra® Vial<br>Profilnine® Vial | **All Non-Preferred Products:** The prescriber must provide a clinically compelling reason for the use of the requested medication including reasons why any of the preferred products would not be a suitable alternative |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | Rixubis® Vial | |
| **AHF-Von Willebrand Factor**<br>*****Must be obtained through Specialty Pharmacy Provider, Briova***** | | |
| ALPHANATE® VIAL<br>HUMATE-P® VIAL<br>KOATE®-DVI KIT<br>WILATE® KIT | | |
| **HEPATITIS C AGENTS** | | |
| *****Must be obtained through Specialty Pharmacy Provider, Briova*** Initial PA: 3 months; subsequent maximum 3 months** | | |
| RIBASPHERE† 200 mg tabs<br>RIBAVIRINn† 200 mg tablets<br><br>***<u>Preferred After Clinical Criteria Are Met</u>***<br><br>HARVONI® (ledipasvir/sofosbuvir)<br>OLYSIO® (simeprevir) 150 mg Capsules<br>*(QL = 1capsule/day)(Maximum 12 weeks/lifetime)*<br><br>TECHNIVIE® (ombitasvir, paritaprevir, ritonavir)<br>PEG-INTRON/PEG-INTRON REDIPEN (peginterferon alfa-2b) *(QL= I kit(4 pens per) 28 days)*<br>PEG-INTRON REDIPEN PAK 4 (peginterferon alfa-2b) *(QL= I kit(4 pens per) 28 days)*<br>SOVALDI® (sofosbuvir) 400 mg Tablet<br>*(QL = 1 tablet/day)(Maximum 24 weeks/lifetime* | ***<u>Non-Preferred After Clinical Criteria Are Met</u>***<br><br>Copegus® (ribavirin 200 mg tabs)<br>Daklinza® (daclatasvir)<br>Infergen (interferon alfacon-1)<br>Moderiba® 200 mg/400 mg Dose Pak (ribavirin)<br>Pegasys® (peginterferon alfa-2a)*(QL=4 vials/28 days)*<br>Pegasys Convenience PAK®(peg-interferon alfa-2a)*(QL=1 kit/28 days)*<br>Pegasys Proclick (peginterferon alfa-2a)<br>Rebetp;® (ribavirin 200mg capsule)<br><br>Rebetol Oral Solution® (ribavirin 40 mg/ml)<br>Ribapak Dose Pack® (ribavirin)<br>ribavirin † 200 mg capsules<br>Ribasphere† 400 and 600 mg tabs(ribavirin)<br>Viekira PAK® (ombitasvir, paritaprevir, ritonavir | **Direct Acting Agents: Daklinza, Harvoni, Olysio, Sovaldi, Technivie and Viekira pak:**<br>• Hep C PA form must be completed and clinical documentation supplied. All requests will be reviewed on a case by case basis by the DVHA Medical Director. Combination therapy will be either approved or denied in its entirety.<br>• Member must have Metavir fibrosis score of 3 or 4<br>• Prescriber must be a hepatologist, gastroenterologist or infectious disease specialist<br>• See PA form for detailed requirements and for documentation required<br><br>**Pegasys:** Diagnosis is hepatitis C AND the patient has a documented side effect, allergy or treatment failure to Peg-Intron<br>**Non-preferred Ribavirin Brands/strengths:** The patient is unable to use generic ribavirin 200 mg tablets<br>**Quantity Limits**<br>Peg-Intron Redipen-4 pens per 28 days |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| *unless hepatocellular carcinoma (48 weeks))*<br>(sofosbuvir) | tablet with dasabuvir tablet) | |
| **HEREDITARY ANGIOEDEMA MEDICATIONS** | | |
| ***Preferred After Clinical Criteria Are Met***<br>KALBITOR® (ecallantide)<br>*(QL = 6 vials (2 packs) per fill* | Berinert® (human C1 inhibitor)<br>Cinryze® (human C1 inhibitor)<br>*(QL = 16 vials/28 days for prophylaxis; 4 vials per fill for acute attacks)*<br>Firazyr® (icatibant) Prefilled Subcutaneous Syringe<br>*(QL = 3 syringes (9 ml)/fill)*<br>Ruconest® (recombinant C1 esterase inhibitor)<br>*(QL = 4 vials/fill)* | **Berinert:** The diagnosis or indication is treatment of an acute Hereditary Angioedema (HAE) attack. (Approval may be granted so that 2 doses may be kept on hand).<br>**Cinryze:** The diagnosis or indication is prophylaxis of Hereditary Angioedema (HAE) attacks. AND The patient has had a documented side effect, allergy, treatment failure or a contraindication to androgen therapy (i.e. danazol). OR The medication is to be used for the treatment of an acute Hereditary Angioedema (HAE) attack.<br>**Firazyr:** The diagnosis or indication is treatment of an acute Hereditary Angioedema (HAE) attack.<br>**Kalbitor:** The diagnosis or indication is treatment of an acute Hereditary Angioedema (HAE) attack. (Approval may be granted so that 2 doses may be kept on hand).<br>**Ruconest:** The diagnosis or indication is treatment of an acute Hereditary Angioedema (HAE) attack AND the patient has had a documented side effect, allergy, treatment failure or a contraindication to Berinert® or Cinryze® (Approval may be granted so that 2 doses may be kept on hand) |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **IDIOPATHIC PULMONARY FIBROSIS (IPF)** | | |
| | Esbriet® (pirfenidone) (*QL = 270 tabs/month)*<br>Ofev® (nintedanib) (*QL = 60 tabs/month)* | **Clinical Criteria: Esbriet, Ofev**<br>○ Age ≥ 18<br>○ Diagnosis of idiopathic pulmonary fibrosis (IPF-ICD-9 Code 516.31 or ICD-10 code J84.112) as well as exclusion of other known causes of Interstitial Lung Disease.<br>○ May not be used in combination with Ofev® or Esbriet® respectively.<br>○ The prescriber is a pulmonologist.<br>○ Clinical documentation that the member is a non-smoker or has not smoked in 6 weeks.<br>○ FVC≥ 50% of predicted<br>○ AND one of the following<br>  ○ High-resolution computed tomography (HRCT) revealing IPF or probable IPF.<br>  ○ Surgical lung biopsy consistent with IPF or probable IPF.<br>**Reauthorization Criteria:**<br>○ Documentation the patient is receiving clinical benefit to Esbrit® or Ofev® therapy as evidenced by < 10% decline in percent predicted FVC of < 200mL decrease in FVC AND<br>○ There is clinical documentation that the member has remained tobacco-free. |
| **IMMUNOLOGIC THERAPIES FOR ASTHMA** | | |
| **(Initial 3 months, Renewal 1 year)** | | |
| | Xolair® (omalizumab) 150 mg subcutaneous injection | **Xolair®:** Patient must have a diagnosis of moderate to severe persistent asthma. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | vial *Quantity limit = 6 vials every 28 days*<br>Nucala® (mepolizumab) 100mg subcutaneous injection *Quantity limit = 1 vial every 28 days* | AND patient is 12 years of age or older AND Patient has tried and failed an inhaled oral corticosteroid (with or without chronic oral corticosteroid therapy) or has a contraindication to an inhaled corticosteroid. AND Patient has tried and failed a leukotriene receptor antagonist or has a contraindication to a leukotriene receptor antagonist. AND Patient has tried and failed a long acting beta-agonist or has a contraindication to a long acting beta-agonist. AND A pulmonologist/allergist/immunologist consult has been obtained within the past year. AND Patient has tested positive to at least one perennial aeroallergen by a skin or blood test (i.e.: RAST, CAP, intracutaneous test). AND Patient has an IgE level ≥ 30 and ≤ 700 IU/ml prior to beginning therapy with Xolair. This drug must be billed through the DVHA POS prescription processing system using NDC values. J codes will NOT be accepted.<br>**Limitations:** Xolair use will not be approved if requested for prevention of peanut related allergic reaction.<br>**Nucala®:**<br>• The patient must be 12 years of age or older AND<br>• The patient must have a diagnosis of severe persistent asthma with an eosinophilic phenotype as defined by pre-treatment blood eosinophil count of ≥ 150 cells per mcL within the previous 6 weeks or ≥ 300 cells per mcL within 12 months prior to initiation of therapy AND<br>• The patient has a history of 2 or more exacerbations in the previous year despite regular use of high dose inhaled corticosteroids (ICS) AND inadequate symptom control when given in combination with another controller medication (long-acting beta agonist {LABA} or leukotriene receptor antagonist {LTRA}) for a minimum of 3 consecutive months, with or without oral corticosteroids. Pharmacy claims will be evaluated to assess compliance with therapy. AND |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | • The patient has a pre-treatment $FEV_1$ < 80% predicted AND<br>• The prescriber is an allergist, immunologist, or pulmonologist. AND<br>• The patient has a documented side effect, allergy, or treatment failure to Xolair.<br>For continuation of therapy after the initial 3 month authorization, the patient must continue to receive therapy with both an ICS and a controller medication (LABA or LTRA) AND have either a decreased frequency of exacerbations OR decreased use of maintenance oral corticosteroids OR reduction in the signs and symptoms of asthma OR an increase in predicted $FEV_1$ from baseline.<br>**Limitations:** Nucala® will not be considered in patients who are currently smoking, in combination with omalizumab, OR for treatment of other eosinophilic conditions. |
| **INTERLEUKIN (IL)-1 RECEPTOR BLOCKERS** | | |
| ***Preferred After Clinical Criteria Are Met***<br>ILARIS® (canakinumab)<br>*(QL = 1 vial/56 days)(CAPS diagnosis)*<br>*(QL = 2 vials/28 days)(sJIA diagnosis* | Arcalyst® (rilonacept) *(QL = 2 vials for loading dose, then 1 vial per week)* | **Ilaris:** The diagnosis is Cryopyrin-Associated Periodic Syndrome (CAPS) OR The diagnosis is Familial Cold Autoinflammatory Syndrome (FCAS) OR The diagnosis or indication for the requested medication is Muckle-Wells Syndrome (MWS) AND The patient is > 4 years old OR The diagnosis is systemic juvenile idiopathic arthritis (sJIA) with active systemic features and varying degrees of synovitis with continued disease activity after initial therapy (Initial therapy defined as 1 month of anakinra (Kineret), 2 weeks of glucocorticoid monotherapy (oral or IV) or one month of NSAIDs). AND patient is > 2 years of age.<br>**Arcalyst:** The diagnosis is Cryopyrin-Associated Periodic Syndrome (CAPS) OR The diagnosis is Familial Cold Autoinflammatory Syndrome (FCAS) OR The |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | diagnosis is Muckle-Wells Syndrome (MWS) AND The patient is > 12 years old AND The patient must have a documented side effect, allergy, treatment failure or a contraindication to Ilaris (canakinumab)<br>**Note:** Medical Records to support the above diagnosis must accompany the Prior Authorization request. Authorization for continued use shall be reviewed at least every 12 months to confirm patient has experienced disease stability or improvement while on therapy. |
| **IRON CHELATING AGENTS** | | |
| EXJADE® (deferasirox)<br>FERRIPROX® (deferiprone) | Jadenu®(deferasirox) | **Jandenu®:** patient has had a documented side effect allergy or treatment failure to Exjade®; Jadenu® will not be approved without compelling clinical reason why Exjade® cannot be used as they are different forms of the same medication |
| **LIPOTROPICS:** | | |
| **BILE ACID SEQUESTRANTS** | | |
| CHOLESTYRAMINE† powder (compare to Questran®)<br>CHOLESTYRAMINE LIGHT† powder (compare to Questran Light®)<br>PREVALITE† powder (cholestyramine light)<br>COLESTIPOL† tablets, granules (compare to | Questran®* powder (cholestyramine)<br>Questran Light®* powder (cholestyramine light)<br>Colestid®* tablets, granules (colestipol)<br>Welchol® (colesevelam) | **Questran:** The patient has had a documented intolerance to cholestyramine powder<br>**Questran Light:** The patient has had a documented intolerance to cholestyramine light powder<br>**Colestid:** The patient has had a documented intolerance to colestipol tablets or granules<br>**Welchol:** If being prescribed for lipid reduction, the patient has had a documented side effect, allergy, or treatment failure to cholestyramine and colestipol. OR If being prescribed for lipid reduction, the patient has had a documented side effect, |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| Colestid®) | | allergy, or treatment failure to cholestyramine and colestipol. |
| **FIBRIC ACID DERIVATIVES** | | |
| GEMFIBROZIL† (compare to Lopid®) 600 mg<br><br>**On statin concurrently or after gemfibrozil trial**<br><br>TRICOR® (fenofibrate nanocrystallized) § 48 mg, 145 mg<br>*Quantity Limit = 1 tablet/day*<br>TRILIPIX (fenofibric acid) §45 mg, 135 mg delayed release capsule<br>*Quantity Limit = 1 capsule/day* | Antara® (fenofibrate micronized) 43 mg, 30 mg, 90 mg, 130 mg<br>fenofibrate tablets†(compare to Lofibra® tablets) § 54 mg, 160 mg<br>fenofibrate capsule† (compare to (Lipofen®) § 50 mg, 150 mg<br>fenofibrate micronized capsule†(compare to Lofibra® capsules) 67 mg, 134 mg, 200 mg<br>fenofibrate micronized† (compare to Antara®) § 43 mg, 130 mg<br>fenofibrate nanocrystallized† (compare to Tricor®) 48 mg, 145 mg<br><br>fenofibric acid § 35 mg, 105 mg<br>*Quantity Limit = 1 capsule/day*<br><br>fenofibric acid (compare to Trilipix®) 45 mg, 135 mg delayed release capsule<br>*Quantity Limit = 1 capsule/day*<br>Fenoglide® (fenofibrate MeltDose) 40 mg, 120 mg<br><br>Fibricor® (fenofibric acid) § 35 mg, 105 mg<br>*Quantity Limit = 1 capsule/day*<br>Lipofen® (fenofibrate) 50 mg, 150 mg | **Lopid:** The patient has had a documented intolerance to generic gemfibrozil.<br>**Tricor, Trilipix:** The patient has been started and stabilized on either Tricor or TriLipix (Note: samples are not considered adequate justification for stabilization.) OR The patient is taking a statin concurrently. OR The patient has had a documented side effect, allergy, or treatment failure to gemfibrozil.<br>**Antara, fenofibrate, fenofribrate micronized, fenofibric acid, Fenoglide, Fibricor, Lipofen, Lofibra and Triglide:** The patient is taking a statin concurrently and has had a documented side effect, allergy, or treatment failure with Tricor or TriLipix. (If a product has an AB rated generic, there must have been a trial with the generic formulation.) OR The patient has had a documented side effect, allergy, or treatment failure to gemfibrozil and Tricor or TriLipix. (If a product has an AB rated generic, there must have been a trial with the generic formulation.)<br>**Fenofibrate nanocrystallized (generic for Tricor), fenofibric acid (generic for Trilipix):** The patient is taking a statin concurrently, OR The patient has had a documented side effect, allergy, or treatment failure to gemfibrozil. AND The patient has had a documented intolerance with the brand equivalent.<br><br>**Note regarding fibrates:** For patients receiving statin therapy, fenofibrate appears less likely to increase statin levels and thus may represent a safer choice than gemfibrozil for co-administration in this group of patients - Am J Med 2004;116:408- |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | Lofibra® (fenofibrate micronized) Capsules 67mg, 134 mg, 200 mg<br><br>Lofibra® (fenofibrate) Tablets 54 mg, 160 mg<br>Lopid®* (gemfibrozil) 600 mg<br>Triglide® (fenofibrate ) 50 mg, 160 mg | |
| **HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMA (HoFH) AGENTS** | | |
| All products require a PA | Juxtapid® (lomitapide) Capsule<br>*QL = 5 and 10 mg caps (1 per day), 20 mg cap (3 per day)*<br>Kynamro® (mipomersen) Syringe for Subcutaneous Injection<br>*QL = 4 syringes(4 ml)/28 days*<br>Maximum days' supply per fill for all drugs is 28 days | **CRITERIA FOR APPROVAL:** Patient has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND Medication will be used as adjunct to a low-fat diet and other lipid-lowering treatments AND Patient does not have any of the following contraindications to therapy: ▪ Pregnancy (Juxtapid) ▪ Concomitant use with strong or moderate CYP3A4 inhibitors (Juxtapid) ▪ Moderate or severe hepatic impairment or active liver disease including unexplained persistent abnormal liver function tests (Juxtapid, Kynamro) AND Patient has tried and had an inadequate response, intolerance or contraindication<br><br>to BOTH atorvastatin and Crestor AND  After preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval. Note: Re-approval requires confirmation that the patient has responded to therapy (i.e. decreased LDL levels) AND the patient does not have any contraindications to therapy. |
| **NICOTINIC ACID DERIVATIVES** | | |
| **IMMEDIATE RELEASE PRODUCTS**<br>NIACIN†<br>NIACOR®† (niacin) | | **CRITERIA FOR APPROVAL:** The patient has a documented intolerance to the branded product. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| **EXTENDED RELEASE PRODUCTS**<br>NIASPAN® (niacin extended release) | Niacin extended release† (compare to Niaspan®) | |
| **HIGH INTENSITY STATINS** | | |
| ATORVASTATIN† 40 or 80 mg (compare to Lipitor®)<br>*(QL = 1 tablet/day)*<br>CRESTOR® 20 or 40 mg (rosuvastatin calcium)<br>*(QL = 1 tablet/day)* | Lipitor®* (atorvastatin) 40 or 80 mg<br>*(QL = 1 tablet/day)* | **Lipitor 40 or 80 mg:** The patient has had a documented intolerance to generic atorvastatin. |
| **MODERATE INTENSITY STATINS** | | |
| ATORVASTATIN† 10 or 20 mg (compare to Lipitor®) *(QL = 1 tablet/day)*<br>CRESTOR® 5 or 10 mg (rosuvastatin calcium)<br>*(QL = 1 tablet/day)*<br>LOVASTATIN† 40 mg (compare to Mevacor®) *(QL = 1 tablet/day)*<br>PRAVASTATIN† 40 or 80 mg (compare to Pravachol®) ) *(QL = 1 tablet/day*<br>SIMVASTATIN† 20 or 40 mg (compare to Zocor®) *(QL = 1 tablet/day* | Altoprev® 40 or 60 mg (lovastatin SR) *(QL = 1 tablet/day)*<br>fluvastatin† 40 mg (compare to Lescol® ) *(QL = 2 tabs/day)*<br>Lescol® 40 mg (fluvastatin) *(QL = 2 tabs/day)*<br>Lescol® XL 80 mg (fluvastatin XL) *(QL = 1 tablet/day)*<br>Lipitor® (atorvastatin) 10 or 20 mg *(QL = 1 tablet/day)*<br>Livalo® 2 or 4 mg (pitavastatin) *(QL = 1 tablet/day)*<br>Mevacor®* 40 mg (lovastatin) ) *(QL = 1 tab/day)*<br>Pravachol®* 40 or 80 mg (pravastatin)*(QL = 1 tab/day)*<br>Zocor®* (simvastatin) 20 or 40 mg *(QL = 1 tablet/day)* | **Lipitor 10 or 20 mg:** The patient has had a documented side effect, allergy, or contraindication to generic simvastatin OR The patient has had an inadequate response to a six week trial of simvastatin 40 mg/day AND If the request is for Lipitor, the patient has had a documented intolerance to generic atorvastatin.<br>**Altoprev 40 or 60 mg, fluvastatin 40 mg BID, Lescol 40 mg BID, Lescol XL, Livalo 2 or 4 mg:** The patient has had a documented side effect, allergy, or contraindication to all 3 of generic lovastatin, pravastatin and simvastatin. OR The patient has had inadequate responses to six week trial of each of lovastatin 40 mg/day, pravastatin 80mg/day, simvastatin 40 mg/day and Crestor 10 mg/day. AND If the request is for Lescol, the patient has had a documented intolerance to generic fluvastatin.<br>**Mevacor 40 mg, Pravachol 40 or 80 mg, Zocor 20 or 40 mg:** The patient has had documented intolerance to the generic equivalent<br>**LIMITATIONS: Simvastatin 80 mg:** initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA due to the increased risk of myopathy, including rhabdomyolysis. Patients may only continue on this dose when new to |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | Medicaid if the patient has been taking this dose for 12 or more months without evidence of muscle toxicity. If the request is for Zocor 80 mg, the patient must have met the prior treatment length requirement and have a documented intolerance to the generic equivalent |
| **LOW INTENSITY STATINS** | | |
| LOVASTATIN† 10 or 20 mg (compare to Mevacor®) *(QL = 1 tablet/day)*<br><br>PRAVASTATIN† 10 or 20 mg (compare to Pravachol®) ) *(QL = 1 tablet/day*<br><br>SIMVASTATIN† 5 or 10 mg (compare to Zocor®) *(QL = 1 tablet/day)* | Altoprev® 20 mg (lovastatin SR) *(QL = 1 tablet/day)*<br>fluvastatin† 20 or 40 mg (compare to Lescol® ) *(QL = 1 tab/day (20mg) or 2 tabs/day (40 mg))*<br>Lescol® 20 or 40 mg(fluvastatin) *(QL = 1 tab/day (20mg) or 2 tabs/day (40 mg))*<br>Livalo® 1 mg (pitavastatin) *(QL = 1 tablet/day)*<br>Mevacor®* 10 or 20 mg (lovastatin) ) *(QL = 1 tablet/day)*<br>Pravachol®* 20 mg (pravastatin) *(QL = 1 tab/day)*<br>Zocor®* (simvastatin) 5 or 10 mg *(QL = 1 tablet/day)* | **Altoprev 20 mg, fluvastatin 20 or 40 mg, Lescol 20 or 40 mg, Livalo 1 mg:** The patient has had a documented side effect, allergy, or contraindication to all 3 of generic lovastatin, pravastatin and simvastatin. OR The patient has had inadequate responses to six week trial of each of lovastatin 20 mg/day, pravastatin 20 mg/day and simvastatin 10 mg/day. AND If the request is for Lescol, the patient has had a documented intolerance to generic fluvastatin.<br>**Mevacor 10 or 20 mg, Pravachol 20 mg, Zocor 5 or 10 mg:** The patient has had documented intolerance to the generic equivalent. |
| **MISCELLANEOUS/COMBOS** | | |
| | **<u>Miscellaneous</u>**<br>Lovaza® (omega-3-acid ethyl esters)<br>Omega-3-acid ethyl esters† (compare to Lovaza®)<br>Vascepa® (icosapent ethyl)<br>*(QL = 4 capsules/day)*<br>**<u>Cholesterol Absorption Inhibitors/Combinations</u>**<br>*Liptruzet® (ezetimibe/atorvastatin)*<br>*(QL = 1 tablet/day)*<br>*Vytorin® (ezetimibe/simvastatin)*<br>*(QL = 1 tablet/day)* | **Lovaza, Vascepa, Omega-3-acid ethyl esters:** The patient has been started and stabilized on this medication (Note: samples are not considered adequate justification for stabilization.) OR The patient has triglyceride levels > 500 mg/dL AND The patient has a documented contraindication, side effect, allergy, or treatment failure to a fibric acid derivative and niacin. AND If the request is for brand Lovaza, the patient has a documented intolerance to the generic equivalent.<br>**Amlodipine/atorvastatin, Caduet:** The prescriber must provide a clinically valid reason for the use of the requested medication. For approval of Caduet, the patient must have also had a documented intolerance to the generic equivalent. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| SIMCOR® (simvastatin/extended release niacin)<br>*(Qty Limit = 1 tablet/day)*<br>*Zetia® (ezetimibe)*<br>*(Qty Limit = 1 tablet/day)* | **Other Statin Combinations**<br>Advicor® (lovastatin/extended release niacin)<br>*(Qty Limit = 1 tablet/day)*<br>Amlodipine/atorvastatin † (compare to Caduet®)<br>*(Qty Limit = 1 tablet/day)*<br>Caduet® (atorvastatin/amlodipine)<br>*(Qty Limit = 1 tablet/day)* | For combinations containing 40mg or 80 mg atorvastatin, the individual generic components are available without PA and should be prescribed.<br>**Advicor:** The patient is unable to take the individual drug components separately.<br>.<br>**Liptruzet, Vytorin:** The patient has had an inadequate response to atorvastatin or Crestor. AND If the request is for Vytorin 10/80, the patient has been taking this dose for 12 or more months without evidence of muscle toxicity. |
| **PCSK9 INHIBITORS** | | |
| | Praluent® (alirocumab)<br>Repatha® (evolocumab) | **Criteria for approval:**<br>• Age > 18 years of age **or** > 13 and dx of homozygous familial hypercholesterolemia (HoFH)<br>• Concurrent use with statin therapy<br>• Documented adherence to prescribed lipid lowering medications for the previous 90 days<br>• Recommended or prescribed by a lipidologist or cardiologist<br>• Diagnosis of heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease or (Repatha only) homozygous familial hypercholesterolemia<br>  ○ with additional criteria for each as outlined below<br>**Additional criteria for the diagnosis of heterozygous familial hypercholesterolemia (HeFH): (both are required)**<br>• Total cholesterol > 290 mg/dL OR LDL-C > 190 mg/dL AND one of the following<br>  ○ Presence of tendon xanthomas **OR**<br>  ○ In 1st or 2nd degree relative-documented tendon xanthomas, MI at age ≤ 60 years or TC > 290 mg/dL **OR**<br>  ○ Confirmation of diagnosis by gene or receptor testing **AND**<br>• Unable to reach goal LDL-C with maximally tolerated dose of statin and ezetimibe 10 mg daily + another concurrently administered lipid lowering |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | agent<br>○ A trial of 2 or more statins, at least one of which must be either atorvastatin or rosuvastatin is required.<br>**Additional criteria for the diagnosis of clinical atherosclerotic cardiovascular disease: (both are required)**<br>• History of MI, angina, coronary or other arterial revascularization, stroke, TIA, or PVD of atherosclerotic origin **AND**<br>• Unable to reach goal LDL-C with maximally tolerated doses of stain + ezetimibe 10 mg daily<br>○ A trial of 2 or more statins, at least one of which must be either atorvastatin or rosuvastatin is required.<br><br>**Additional criteria for the diagnosis of homozygous familial hypercholesterolemia (Repatha only): (both are required)**<br>• Total cholesterol and LDL-C > 600 mg/dL and TG within reference range **OR**<br>• Confirmation of diagnosis by gene testing **AND**<br>• Unable to reach goal LDL-C with maximally tolerated dose of statin and ezetimibe 10 mg daily + another concurrently administered lipid lowering agent<br>○ A trial of 2 or more statins, at least one of which must be either atorvastatin or rosuvastatin is required. |
| **MISCELLANEOUS** | | |
| **Pyridostigmine bromide (Compare to Mestinon)**<br><br>***PREFERRED AFTER CLINICAL CRITERIA ARE*** | Mestinon®<br><br>Benlysta® (belimumab) Vials | **Benylsta:** The diagnosis or indication is active systemic lupus erythematosus (SLE) AND The patient is positive for autoantibodies (anti-nuclear antibody (ANA) and/or anti-double-stranded DNA (anti-dsDNA). AND The patient has had a |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| ***MET***<br><br>CARBAGLU® dispersible tablets (carglumic acid)<br>*(Maximum days supply per fill = 14 days)*<br><br>GLYCOPYRROLATE 1 mg, 2 mg tablets (compare to Robinul®, Robinul Forte®)<br><br>***Preferred After Clinical Criteria Are Met***<br>MAKENA® (hydroxyprogesterone caproate) injection 250 mg/ml 5 ml vials<br>Maximum fill = 5 ml/fill (35 day supply) | *(Maximum days supply per fill = 28 days)*<br>Elaprase® (idursulfase) *(QL = calculated dose/week)*<br><br>Cuvposa® oral solution (glycopyrrolate)*<br>**Maximum days supply per fill is 30 days**<br><br>Glycate® 1.5 mg tablet (glycopyrrolate)<br>*Quantity limit = 5 tablets/day*<br>Robinul® 1 mg tablet (glycopyrrolate)<br>Robinul® Forte 2 mg tablet (glycopyrrolate)<br><br>Hetlioz® (tasimelteon) 20 mg oral capsule<br>*Quantity limit =1 capsule/day* * Maximum days supply per fill is 30 days*<br>Korlym® tablets (mifepristone)<br>*Quantity limit = 4 tablets/day*<br>Otrexup® or Rasuvo® Single-dose auto-injector for subcutaneous use<br>(methotrexate)<br>*(Quantity Limit = 4 syringes/28 days)*<br>Myalept® (metreleptin) vial for subcutaneous injection<br>*QL = one vial/day (Maximum days' supply per fill = 30 days)*<br>Nuedexta® capsules (dextromethorphan/quinidine)<br>*Quantity limit = 2 capsules/day*<br>Samsca® tablets (tolvaptan) *Quantity limit = 15 mg tablets (1 tablet/day), 30 mg tablets (2 tablets/day)*<br>Signifor® (pasireotide) Ampules *QL (all strengths)* | documented inadequate response or intolerance to at least TWO of the following agents: NSAIDs, hydroxychloroquine, prednisone, azathioprine, methotrexate, mycophenolate.<br>**Note:** The efficacy of Benlysta® has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of Benlysta is not recommended in these situations.<br>**Carbaglu:** The diagnosis or indication for the requested medication is hyperammonemia due to N-acetylglutamate synthetase (NAGS) deficiency AND The prescriber is a specialist in metabolic disorders (e.g., medical geneticist) or prescriber is in consultation with a specialist. Note: after preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.<br>**Elaprase (Hunter's Syndrome Injectable**): The diagnosis or indication for the requested medication is Hunter's Syndrome<br>**Cuvposa:** The diagnosis or indication for the requested medication is Sialorrhea or a neurologic condition associated with excessive drooling (e.g. cerebral palsy, mental retardation, Parkinson's disease). AND The dose cannot be obtained from the tablet formulation. AND (For patients >18 years of age) The patient has had a documented side effect, allergy, treatment failure, or a contraindication to scopolamine patches.<br>**Glycate:** The indication for use is adjunctive therapy in the treatment of peptic ulcer. AND The patient has had a documented intolerance to generic glycopyrrolate.<br><br>**Robinul, Robinul Forte:** The patient has had a documented intolerance to generic glycopyrrolate.<br>**Hetlioz:** Patient has documentation of Non-24-Hour Sleep-Wake Disorder (Non- |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | *= 2 ml (2 amps)/day* Maximum days' supply = 30 days<br>Solesta® submucosal injection gel 50 mg/15 ml *(Quantity Limit = 4 syringes/28 days)*<br>Soliris® (eculizumab) *(Quantity Limit = 12 vials(360 ml) /28 days) Maximum days' supply per fill = 28 days*<br>Somatuline® Depot Injection (lanreotide) *(Quantity Limit = 0.2 ml/28 days (60 mg syringe), 0.3 ml/28 days (90 mg syringe) and 0.5 ml/28 days (120 mg syringe))*<br>Lysteda® tablets (tranexamic acid) *Quantity limit = 30 tablets/28 days tranexamic acid† (compare to Lysteda®)*<br>*Quantity limit = 30 tablets/28 days*<br>Xenazine® tablets (tetrabenazine) *(Maximum 1 month supply per fill Quantity limit = 50 mg/day at initial approval (12.5 mg tablets ONLY), up to100 mg/day at subsequent approvals (12.5 mg or 25 mg tablets)* | 24) AND Patient has documentation of total blindness AND Patient has had a documented side effect, allergy or treatment failure with Rozerem and at least one OTC melatonin product.<br>**Korlym:** Patient is ≥18 years of age AND Patient has a diagnosis of endogenous Cushing's syndrome AND Patient is diagnosed with type 2 diabetes mellitus or glucose intolerance AND Patient has hyperglycemia secondary to hypercortisolism AND Patient has failed or is not a candidate for surgery AND Patient has a documented side effect, allergy, treatment failure or contraindication to at least 2 adrenolytic medications (eg. ketoconazole, etomidate) AND Patient does not have any of the following contraindications to Korlym: Pregnancy (pregnancy must be excluded before the initiation of therapy or if treatment is interrupted for >14 days in females of reproductive potential. Nonhormonal contraceptives should be used during and one month after stopping treatment in all women of reproductive potential) OR Patient requires concomitant treatment with systemic corticosteroids for serious medical conditions/illnesses (immunosuppression for organ transplant) OR Patient has a history of unexplained vaginal bleeding OR Patient has endometrial hyperplasia with atypia or endometrial carcinoma OR Patient is concomitantly taking simvastatin, lovastatin, or a CYP3A substrate with a narrow therapeutic index (e.g., cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, or tacrolimus). Note: after preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.<br>**Makena:** Patient is 16 years of age or older AND Patient has a history of singleton spontaneous preterm birth AND Patient is having a singleton (single offspring) pregnancy AND Therapy will be started between 16 weeks, 0 days and 27 weeks, 0 days of gestation AND Therapy will be continued until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | **Otrexup, Rasuvo:** The patient has a diagnosis of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA) or psoriasis. AND The patient has been intolerant to oral methotrexate AND The patient has been unable to be compliant with a non-auto-injector form of injectable methotrexate (includes difficulty with manual dexterity).<br>**Myalept:** Patient has a diagnosis of congenital or acquired generalized lipodystrophy AND Patient has one or more of the following metabolic abnormalities AND is refractory to current standards of care for lipid and diabetic management: Insulin resistance (defined as requiring > 200 units per day), Hypertriglyceridemia, Diabetes AND Prescription is written by or in consultation with an endocrinologist AND The prescriber is registered in the MYALEPT REMS program. Note: after preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval.<br>Reauthorization for continued use criteria: Patient has experienced an objective response to therapy • Sustained reduction in hemoglobin A1c (HbA1c) level from baseline OR • Sustained reduction in triglyceride (TG) levels from baseline<br>**Nuedexta:** The patient must have a diagnosis of pseudobulbar affect (PBA) secondary to a neurological condition **AND** the patient has had a trial and therapy failure at a therapeutic dose with a tricyclic antidepressant (TCA) or an SSRI **AND** the patient has documentation of a current EKG (within the past 3 months) without QT prolongation **AND** initial authorizations will be approved for 6 months with a baseline Center for Neurologic Studies Lability Scale (CNS-LS) questionnaire **AND** subsequent prior authorizations will be considered at 6 month intervals with documented efficacy as seen in an improvement in the CNS-LS questionnaire<br>**Samsca:** The agent is being used for the treatment of euvolemic or hypervolemic hyponatremia AND Despite optimal fluid restriction, the patient's serum sodium |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | < 120 mEq/L or the patient is symptomatic with a serum sodium < 125 mEq/L. AND The treatment will be initiated or is being reinitiated in a hospital setting where serum sodium can be monitored<br>**Signifor:** Patient has a diagnosis of (pituitary) Cushing's disease AND Patient is 18 years of age or older AND Pituitary surgery is not an option or has not been curative AND After preliminary review by the Clinical Call Center, the request will be forwarded to the DVHA Medical Director for final approval. Note: Re-approval requires confirmation that the patient has experienced an objective response to therapy (i.e., clinically meaningful reduction in 24-hour urinary free cortisol levels and/or improvement in signs or symptoms of the disease).<br>**Solesta:** The diagnosis or indication is treatment of fecal incontinence. AND The patient is 18 years of age or older AND The patient has had an inadequate response with conservative therapy, including diet, fiber supplementation, and anti-diarrheal medication<br>**Soliris:** The patient has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) documented by flow cytometry. AND The patient has received the meningococcal vaccine at least 2 weeks prior to therapy initiation. OR The patient has a diagnosis of atypical hemolytic uremic syndrome (aHUS). AND The patient has received the meningococcal vaccine at least 2 weeks prior to therapy initiation. Authorization for continued use shall be reviewed to confirm that the patient has experienced an objective response to the therapy.<br>**Somatuline:** The diagnosis or indication for the requested medication is Acromegaly.<br>**Lysteda, Tranexamic acid:** The diagnosis or indication is clinically significant heavy menstrual bleeding AND The patient has been started and stabilized on oral tranexamic acid within the previous 360 days OR The patient does not have a contraindication to therapy with oral tranexamic acid (i.e., active thrombotic disease, history of thrombosis/thromboembolism, or an intrinsic risk of |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | thrombosis/thromboembolism), and if oral tranexamic acid is to be used concomitantly with an estrogen containing hormonal contraceptive product, the risks of combination therapy have been discussed with the patient. AND The patient has had a documented side effect, allergy, contraindication, or an inadequate response with at least one oral contraceptive or progestin containing product despite an adequate trial of at least 90 days, or a rationale for why these products cannot be used (e.g. actively attempting to conceive). AND The patient has had a documented side effect, allergy, contraindication, or an inadequate response with at least one regularly scheduled (not PRN) NSAID or a rationale for why these products cannot be used (e.g. actively attempting to conceive). AND If the request is for brand Lysteda, the patient has had a documented intolerance to the generic product.<br>**Xenazine:** The diagnosis or indication for the requested medication is Huntington's disease with chorea. AND Age > 18 years. |
| **MOOD STABILIZERS** | | |
| LITHIUM CARBONATE† (formerly Eskalith®)<br>LITHIUM CARBONATE SR† (compare to Lithobid®, formerly Eskalith CR®)<br>LITHIUM CITRATE SYRUP† | Equetro® (carbamazepine SR)<br>Lithobid®* (lithium carbonate SR) | **Lithobid:** The patient has had a documented side effect, allergy, or treatment failure with the generic equivalent of the requested medication.<br>**Equetro:** The patient has had a documented side effect, allergy, or treatment failure with a carbamazepine product from the anticonvulsant therapeutic drug category |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **MUCOSAL COATING AGENTS** | | |
| ALUMINUM HYDROXIDE†(formerly Amphojel®)<br>EPISIL® (wound barrier)<br>GELCLAIR® (povidone sodium hyaluronate glycyrrhetinic acid gel)<br>MYLANTA/DIPHENYDRAMINE/LIDOCAINE VISCOUS (aka "Magic Mouthwash")<br><br>Or other similar single or combination products | MuGard® (mucoadhesive oral wound rinse)<br>*(QL = 4 bottles/month)* | **MuGard:** Patient is receiving radiation and/or chemotherapy. AND The patient has had a documented side effect, allergy or treatment failure with at least one oral mucosal coating agent<br>(e.g. aluminum hydroxide suspension, Mylanta) or a topical anesthetic (e.g. viscous lidocaine or diphenhydramine solutions) or combinations of similar agents.<br>**Additional criteria for viscous lidocaine:**<br>• Due to a FDA safety alert, viscous lidocaine will require prior authorization for children ≤3 years of age. |
| **MULTIPLE SCLEROSIS MEDICATIONS** | | |
| **Self-injectables (Avonex®, Betaseron®, Copaxone® ,Extavia® Glatopa®, Plegridy®, &Rebif®) & Aubagio®, Gilenya® & Tecfidera® must be obtained through Specialty Pharmacy Provider, Briova** | | |
| **INJECTABLES**<br>**Interferons**<br><br>AVONEX® (interferon *B*-1a)<br>BETASERON® (interferon *B*-1b)<br>REBIF® (interferon *B*-1a) | Extavia® (interferon beta-1b)<br><br>Copaxone® 40 mg (glatiramer)*(QL = 12 syringes(12 ml)/28 days)*<br>Plegridy® (peginterferon beta-1a) | **Ampyra:** Patient has a diagnosis of multiple sclerosis. AND Patient age > 18 years.<br>**Aubagio:** Patient is at least 18 years of age or older AND Patient has a diagnosis of relapsing forms of multiple sclerosis (relapsing-remitting multiple sclerosis and progressive-relapsing multiple sclerosis) AND Patient does not have any of the following contraindications to teriflunomide: Severe hepatic impairment Current treatment with leflunomide (Arava) Patients who are pregnant or women of childbearing potential not using reliable contraception |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **Other**<br>COPAXONE® 20 mg (glatiramer acetate) *(QL = 1 kit/30 days)*<br><br>**ORAL**<br>TECFIDERA® (dimethyl fumarate)<br>*(QL = 2 capsules/day, maximum 30 day supply per fill)*<br>GILENYA® (fingolimod) capsule<br>*(QL = 1 capsule/day, maximum 30 day supply per fill)*<br><br>***Preferred After Clinical Criteria Are Met***<br>AMPYRA® (dalfampridine) tablet *(QL = 2 tablets/day, maximum 30 day supply per fill)* | Tysabri® (natalizumab)<br><br>Aubagio® (teriflunamide) tablet<br>*(QL = 1 tablet/day, maximum 28 day supply per fill)*<br>Glatopa® 20mg (glatiramer acetate) (QL=1 carton (30 syringes/30 days)) | **Copaxone 40 mg Syringe:** Patient has a diagnosis of multiple sclerosis. AND The patient has a documented side effect, allergy, treatment failure, or contraindication to at least one preferred drug (not Copaxone 20 mg). AND The patient is unable to tolerate or be compliant with Copaxone 20 mg daily dosing.<br>**Extavia:** Patient has a diagnosis of multiple sclerosis. AND The provider provides a clinical reason why Betaseron cannot be prescribed.<br>**Glatopa 20mg:** Patient is ≥ 18 years AND diagnosis of relapsing forms of Multiple Sclerosis AND the provider provides a clinical reason why Copaxone 20mg cannot be prescribed.<br>**Plegridy:** Patient is ≥ 18 years. Diagnosis of relapsing form of Multiple Sclerosis. Documented side effect, allergy, treatment failure or contraindication to at least three preferred drugs including at least one preferred form of interferon.<br>**Tysabri:** Patient has a diagnosis of relapsing multiple sclerosis and has already been stabilized on Tysabri OR Diagnosis is relapsing multiple sclerosis and the patient has a documented side effect, allergy, treatment failure, or contraindication to at least two preferred drugs. OR Diagnosis of relapsing multiple sclerosis and the patient has a documented side effect, allergy, treatment failure, or contraindication to one preferred drug and has tested negative for anti-JCV antibodies. |
| **MUSCLE RELAXANTS, SKELETAL** | | |
| **Musculoskeletal Agents**<br><br>**Single Agent**<br>CHLORZOXAZONE† 500 mg tablets<br>(compare to Parafon Forte DSC®) | Amrix®(cyclobenzaprine sustained-release) 15 mg, 30 mg capsule<br>*(Quantity limit = 1 capsule/day)*<br>carisoprodol 250 mg tablets<br>*(Quantity limit = 4 tablets/day)* | **Amrix, cyclobenzaprine 7.5 mg, Fexmid**: The prescriber must provide a clinically valid reason why a preferred generic cyclobenzaprine cannot be used. For approval of Fexmid, the patient must also have a documented intolerance to the generic equivalent.<br>**Brand skeletal muscle relaxants with generics available (Flexeril, Parafon Forte** |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| *(Quantity limit = 4 tablets/day)*<br>CYCLOBENZAPRINE†5 mg, 10 mg tablets (compare to Flexeril®)<br>*(Quantity limit = 6 tablets/day (5 mg), 3 tablets/day (10 mg))*<br>METHOCARBAMOL† 500mg, 750 mg tablets (compare to Robaxin®)<br>*(Quantity limit = 8 tablets/day)*<br>ORPHENADRINE CITRATE ER† (previously Norflex®) 100 mg tablet<br>*(Quantity limit = 2 tablets/day)*<br><br>**<u>Combination Product</u>**<br><br>*ASA = aspirin*<br><br>**Maximum duration of therapy all musculoskeletal agents = 90 days**<br><br>**<u>Antispasticity Agents</u>** | carisoprodol†350 mg (compare to Soma®) tablets<br>*(Quantity limit = 4 tablets/day)*<br>cyclobenzaprine 7.5 mg† tab (compare to Fexmid®)<br>*(Quantity limit = 3 tablets/day)*<br>Fexmid® (cyclobenzaprine) 7.5 mg tablet<br>*(Quantity limit = 3 tablets/day)*<br>Lorzone® (chlorzoxazone) 375 mg, 750 mg tablets<br>*(Quantity limit = 4 tablets/day)*<br>metaxalone† (compare to Skelaxin®) 800 mg tablets<br>*(Quantity limit = 4 tablets/day)*<br>Parafon Forte DSC®* (chlorzoxazone) 500 mg tablets<br>*(Quantity limit = 4 tablets/day)*<br>Robaxin®* (methocarbamol) 500mg, 750 mg tablets<br>*(Quantity limit = 8 tablets/day)*<br>Skelaxin® (metaxalone) 800 mg tablets<br>*(Quantity limit = 4 tablets/day)*<br>Soma® (carisoprodol) 250 mg, 350 mg tablets<br>*(Quantity limit = 4 tablets/day)*<br>carisoprodol, ASA† (previously Soma Compound®)<br>*(Quantity limit = 4 tablets/day)*<br>carisoprodol, ASA, codeine† (previously Soma Compound with Codeine®)<br>*(Quantity limit = 4 tablets/day)*<br><br>Dantrium®* (dantrolene)<br>tizanidine† (compare to Zanaflex®) capsules | **DSC, Robaxin):** The patient has had a documented side effect, allergy or treatment failure with two different preferred musculoskeletal agents (One trial must be the AB rated generic).<br>**carisoprodol, carisoprodol/ASA, carisoprodol/ASA/codeine, Soma, metaxolone, Skelaxin:** The patient has had a documented side effect, allergy or treatment failure with two different preferred musculoskeletal agents. Additionally, if a brand name product is requested where an AB rated generic exists, the patient must also have had a documented intolerance to the generic product.<br>**Lorzone:** The patient has had a documented side effect, allergy or treatment failure with two different preferred musculoskeletal agents.<br>**Dantrium, Zanaflex tablets:** The patient must have a documented intolerance with the AB rated generic product.<br>**Tizanadine capsules, Zanaflex capsules:** The prescriber must provide a clinically valid reason why generic tizanidine tablets cannot be used. AND If the request is for Zanaflex capsules, the patient must have a documented intolerance to generic tizanadine capsules |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| BACLOFEN† (formerly Lioresal®)<br>DANTROLENE† (compare to Dantrium®)<br>TIZANIDINE† (compare to Zanaflex®) tablets | Zanaflex® (tizanidine) capsules<br>Zanaflex®* (tizanidine) tablets | |
| **NEUROGENIC ORTHOSTATIC HYPOTENSION** | | |
| FLUDROCORTISONE†<br>MIDODRINE† | Northera® | **Quantity Limits:**<br>• Initial 2 weeks approval<br>• Continued therapy approvals based on documentation of continued benefit clinically and as evidenced by positional blood pressure readings<br><br>**Clinical Criteria:**<br>• diagnosis of neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy, AND<br>• the presentation of symptoms including dizziness, lightheadedness, and the feeling of "blacking out" AND<br>• Failure of multiple non-pharmacologic measures as appropriate(e.g. removal of offending medications, compression stockings, increased fluid and salt intake) AND<br>• Failure, intolerance or contra-indication to fludrocortisone AND midodrine |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **NUTRITIONALS, LIQUID ORAL SUPPLEMENTS** | | |
| | ALL<br>Note: Nutritional supplements administered via tube feeds may be provided through the Medical Benefit | **EleCare, EleCare Jr:** The patient is an infant or child who needs an amino acid-based medical food or who cannot tolerate intact or hydrolyzed protein. AND The product is being requested for the dietary management of protein maldigestion, malabsorption, severe food allergies, short-bowel syndrome, eosinophilic GI disorders, GI-tract impairment, or other conditions for which an amino acid-based diet is required.<br>**All Others:** Requested nutritional supplement will be administered via tube feeding. OR Patient has one of the following conditions where feeding is difficult or malabsorption or maldigestion occurs: AIDS, Cancer, Celiac Disease, Cerebral Palsy, Chronic Diarrhea, Cognitive Impairment, Cystic Fibrosis, Dementia (includes Alzheimer's), Developmental Delays, Difficulty with chewing/swallowing food, Inflammatory Bowel Disease, Parkinson's, Short Gut. OR Patient has experienced unplanned weight loss or is extremely low weight (see further definitions below) OR Patient has demonstrated nutritional deficiency identified by low serum protein levels (albumin or pre-albumin levels to be provided) (albumin <3.5 g/dL /pre-albumin <15 mg/dL)<br>**Unplanned Weight Loss/Low Weight Table:**<br>**Adult:** □ Involuntary loss of > 10 % of body weight within 6 months □ Involuntary loss of > 5% of body weight within 1 month □ Loss of > 2% of body weight within one week □ BMI of < 18.5 kg/m2<br>**Elderly:** (>65): □ Involuntary loss of > 10 % of body weight within 6 months □ Involuntary loss of > 5 % of body weight within 3 months □ Loss of > 2 % of body weight within one month □ BMI of < 18.5 kg/m2<br>**Children:** □ < 80 % of expected weight-for-height □ < 90 % of expected height- |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | for-age  Mid-upper arm circumference/head circumference ratio < 0.25<br>**Limitations:** Infant formulas are not covered under the pharmacy benefit. Please contact WIC. |
| **ONCOLOGY: ORAL (select)** | | |
| ALL – see Oncology: Oral order form for details of medication that must be obtained through Briova, DVHA's specialty pharmacy provider | | |
| **OPHTHALMICS** | | |
| **ANTIBIOTICS** | | |
| **QUINOLONES**<br>BESIVANCE® (besifloxacin) suspension<br>CILOXAN® (ciprofloxacin) ointment<br>CIPROFLOXACIN HCL† (compare to Ciloxan®) solution<br>MOXEZA® (moxifloxacin 0.5%) (preservative free) solution<br>OCUFLOX®*(ofloxacin) solution<br>OFLOXACIN† (compare to Ocuflox®) solution<br>VIGAMOX® (moxifloxacin 0.5%) (preservative free) solution | gatifloxacin 0.5% solution (compare to Zymaxid®)<br>levofloxacin† 0.5 % solution<br><br>Zymaxid® (gatifloxacin 0.5%) solution<br><br>Azasite®(azithromycin) solution<br>All other brands | **Aminoglycosides: Single and Combination Agents:** The patient has had a documented side effect, allergy or treatment failure with TWO preferred ophthalmic aminoglycosides or aminoglycoside combination, one of wich must be Tobradex<br>**Macrolides:** The patient has had a documented side effect, allergy or treatment failure with erythromycin<br>**Miscellaneous Antibiotics:** The patient has had a documented side effect, allergy or treatment failure with at least TWO preferred ophthalmic miscellaneous antibiotics. (If a product has an AB rated generic, there must have also been a trial of the generic formulation)<br>**Quinolones:** The patient has had a documented side effect, allergy or treatment |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | Tobramycin w/Dexamethasone† (compare to Tobradex®) suspension | failure with TWO preferred ophthalmic quinolones. |
| | Pred-G® S.O.P. (gentamicin/prednisolone) ointment | |
| **MACROLIDES**<br>ERYTHROMYCIN† ointment<br>ILOTYCIN† (erythromycin) ointment | Bleph-10®* (sulfacetamide) solution | |
| **AMINOGLYCOSIDES**<br>**Single Agent**<br>AK-TOB† (tobramycin) solution<br>GARAMYCIN® (gentamicin) ointment, solution<br>GENTAK† (gentamicin) ointment, solution<br>GENTAMICIN† ointment, solution<br>TOBRAMYCIN † solution (compare to Tobrex®)<br>TOBREX® ointment,solution (tobramycin)<br>**Combination**<br>PRED-G® (gentamicin/prednisolone) ointment, suspension<br>TOBRADEX®* (tobramycin/dexamethasone) suspension , ointment<br>TOBRADEX ST®(tobramycin/dexamethasone) suspension<br>ZYLET® (tobramycin/loteprednol) suspension | Blephamide® (sulfacetamide/prednisolone acetate) suspension<br>Blephamide® S.O.P. (sulfacetamide/prednisolone acetate) ointment<br>Maxitrol®* (neomycin/polymyxin/dexamethasone) suspension, ointment<br>Neomycin/Polymyxin w/Hydrocortison ointment<br>Polytrim®* (polymyxin B/trimethoprim) soln | |
| **MISCELLANEOUS**<br>**Single Agent**<br>BACITRACIN ointment | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| SULFACETAMIDE SODIUM† (compare to Bleph-10®) solution<br>SULFACETAMIDE SODIUM ointment<br>**Combination**<br>BACITRACIN ZINC W/POLYMYXIN B† ointment<br><br>NEOMYCIN/BACITRACIN/POLYMYXIN ointment<br>NEOMYCIN/POLYMYXIN W/DEXAMETHASONE† (compare to Maxitrol®) ointment, suspension<br>NEOMYCIN/POLYMYXIN W/GRAMICIDIN† solution (compare to Neosporin®)<br>NEOMYCIN/POLYMYXIN W/HYDROCORTISONE suspension<br>NEOMYCIN/POLYMYXIN/BACITRACIN/ HYDROCORTISONE† ointment<br>NEOSPORIN®* (neomycin/polymyxin/gramicidin) solution<br>POLYMYXIN B W/TRIMETHOPRIM† (compare to Polytrim®) solution<br>SULFACETAMIDE W/PREDNISOLONE SOD PHOSPHATE solution | | |
| **ANTIHISTAMINES** | | |
| KETOTIFEN† 0.025 % (eg. Alaway®, Zaditor® OTC, others) | Azelastine † (compare to Optivar®) *(QL = 1 bottle/month)*<br>Bepreve® (bepotastine besilate) *(QL = 1 bottle/month)* | **Pataday/Patanol:** The patient has had a documented side effect, allergy, or treatment failure to ketotifen.<br>**Azelastine, Bepreve, Elestat, Epinastine, Olopatadine, Pazeo:** The patient has |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| *(Quantity Limit = 1 bottle/month)*<br>**<u>After trial of ketotifen 0.025 %</u>**<br><br>PATADAY® § (olopatadine 0.2%)/PATANOL®§ (olopatadine 0.1%)<br>*(Quantity Limit = 1 bottle/month)* | Elestat® (epinastine) *(Quantity Limit = 1 bottle/month)*<br>Epinastine† (compare to Elestat®) *(QL = 1 bottle/month)*<br>Emadine® (emedastine) *(Quantity Limit = 2 bottles/month)*<br>Lastacaft® (alcaftadine) *(QL = 1 bottle/month)*<br>Olopatdine 0.1% (compare to Patanol®) *(QL=1 bottle/month)*<br>Pazeo® (olopatadine 0.7%) *(QL= 1 bottle/month)* | had a documented side effect, allergy, or treatment failure to Pataday or Patanol. If the product has a generic equivalent, the patient must also have had a documented intolerance to the generic equivalent.<br>**Lastacaft, Emadine:** The patient is pregnant and the diagnosis is allergic conjunctivitis OR The patient has had a documented side effect, allergy, or treatment failure to ketotifen. AND The patient has had a documented side<br><br>effect, allergy, or treatment failure to Patanol/Pataday |
| **CORTICOSTEROIDS: TOPICAL** | | |
| ALREX® (loteprednol) 0.2% suspension<br>DEXAMETHASONE SODIUM PHOSPHATE 0.1% solution†<br>FLAREX® (fluorometholone acetate) 0.1% suspension<br>FLUOROMETHOLONE 0.1% suspension†<br>FML® (fluorometholone) 0.1% ointment<br>Lotemax® (loteprednol) 0.5% ointment (pres. free)<br>Lotemax® (loteprednol) 0.5% gel, suspension,<br>MAXIDEX® (dexamethasone) suspension<br>PRED MILD® (prednisolone acetate) 0.12% suspension<br>PREDNISOLONE ACETATE 1%suspensionS†<br>VEXOL® (rimexolone) 1% suspension<br>*E=emulsion, G=gel,O=ointment, S=suspension, Sol=solution* | Durezol® (difluprednate) 0.05% emulsion<br>FML Forte® (fluorometholone) 0.25% suspension<br>FML Liquifilm® (fluorometholone) 0.1% suspension<br>Pred Forte®/Omnipred® (prednisolone acetate) 1% suspension<br>All other brands | **All Others:** The patient has had a documented side effect, allergy, or treatment failure with TWO preferred ophthalmic corticosteroid. (If a product has an AB rated generic, there must have been a trial of the generic formulation) |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **CYSTARAN** | | |
| | Cystaran® (cysteamine) 0.44% ophthalmic solution<br>*(QL=4 bottles (60 ml)/ 28 days)*<br>*Maximum days' supply/RX = 28 days* | **Cystaran:** The indication for use is corneal cystine accumulation in patients with cystinosis. |
| **DRY EYE SYNDROME** | | |
| **Generic OTC Ocular Lubricants**<br>ARTIFICIAL TEARS† Ointment<br>ARTIFICIAL TEARS† Solution<br>REFRESH TEARS† Solution<br>TEARS NATURALE† Solution<br>LUBRIFRESH P.M.† Ointment<br><br>And all other generics | Restasis® (cyclosporine ophthalmic emulsion) 0.05% (*QL=60 vials per 30 days).* | **CRITERIA FOR APPROVAL:** The patient has a diagnosis of moderate to severe keratoconjunctivitis sicca (dry eye syndrome) or Sjogren syndrome with suppressed tear production due to ocular inflammation AND The member does not have any of the following contraindications or exclusions to therapy: A) An active ocular infection B) Concurrent topical anti-inflammatory drugs C) Concurrent punctal plug use AND The patient has had a documented side effect, allergy, or treatment failure to two ocular lubricants (e.g., artificial tears, lubricant gels, etc.).<br>**Limitations:** OTC branded ocular lubricants are not covered (as part of DVHA's comprehensive OTC policy). There is no PA opportunity for branded OTC ocular lubricants. |
| **GLAUCOMA AGENTS/MIOTICS** | | |
| **ALPHA-2 ADRENERGIC**<br>**Single Agent**<br>ALPHAGAN P® 0.1 %, 0.15 % (brimonidine tartrate)<br>BRIMONIDINE TARTRATE† 0.2 % ( formerly Alphagan®)<br><br>**Combination**<br>COMBIGAN® (brimonidine tartrate/timolol maleate)<br>SIMBRINZA® | apraclonidine† (compare to Iopidine®)<br>brimonidine tartrate 0.15 % † (compare to Alphagan P®)<br>Iopidine® (apraclonidine) | **ALPHA 2 ADRENERGIC AGENTS:** Single Agent: The patient has had a documented side effect, allergy or treatment failure with at least one preferred ophthalmic alpha 2 adrenergic agent. If the request is for brimonidine tartrate 0.15%, the patient must have a documented intolerance of brand name Alphagan P 0.15%.<br><br>**BETA BLOCKERS:** The patient has had a documented side effect, allergy or treatment failure with at least one preferred ophthalmic beta blocker.<br>**PROSTAGLANDIN INHIBITORS** |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| (brinzolamide 1% and brimonidine 0.2%) Suspension<br><br>**BETA BLOCKER**<br>BETAXOLOL HCL† (formerly Betoptic®)<br>CARTEOLOL HCL† (formerly Ocupress®)<br><br>LEVOBUNOLOL HCL† (compare to Betagan®)<br>TIMOLOL MALEATE† (compare to Timoptic®)<br>TIMOLOL MALEATE †gel (compare to Timotic XE®)<br><br>**PROSTAGLANDIN INHIBITORS**<br>LATANOPROST† (compare to Xalatan®)<br>TRAVATAN Z® (travoprost) (BAK free)<br><br>**CARBONIC ANHYDRASE INHIBITOR**<br>**Single Agent**<br>DORZOLAMIDE 2 % (compare to Trusopt®)<br><br>**Combination**<br>DORZOLAMIDE w/TIMOLOL (compare to Cosopt®) | Betagan®* (levobunolol)<br>Betimol® (timolol)<br>Betoptic S® (betaxolol suspension)<br>Istalol®* (timolol)<br><br>Metipranolol (formerly Optipranolol®)<br>Timoptic®* (timolol maleate)<br>Timoptic XE®* (timolol maleate gel)<br><br>Bimatoprost 0.3% (Lumigan®)<br>Lumigan® 0.01 %/0.03 % (bimatoprost)<br>Travoprost® (Xalatan®* (latanoprost)<br>Zioptan® (tafluprost)<br><br>Azopt® (brinzolamide 1%)<br>Trusopt®* (dorzolamide 2 %)<br><br>Cosopt®* (dorzolamide w/timolol)<br>Cosopt PF® (dorzolamide w/timolol) (pres-free)<br>Simbrinza® (brinzolamide 1% and brimonidine 0.2%) Susp | **Lumigan, Bimatoprost:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient has had a documented side effect, allergy or treatment failure with generic latanoprost and Travatan Z.<br><br>**Travoprost:** The patient has had a documented intolerance to Travatan Z.<br>**Zioptan:** The patient has been started and stabilized on the requested medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient has had a documented side effect, allergy or treatment failure with generic latanoprost and Travatan Z. OR The patient has a sensitivity to preservatives used in ophthalmic preparations<br>**Xalatan:** The patient has a documented intolerance to the generic product. AND The patient has had a documented side effect, allergy or treatment failure with Travatan Z.<br>**CARBONIC ANHYDRASE INHIBITORS**<br>**Single Agent:** The patient has had a documented side effect, allergy or treatment failure with a preferred carbonic anhydrase inhibitor.<br>**Combination Product:**<br>**Cosopt:** The patient has had a documented intolerance to the generic equivalent product.<br>**Cosopt PF:** The patient has had a documented intolerance to the preservatives in the generic combination product. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **MISCELLANEOUS**<br><br>ISOPTO® CARPINE (pilocarpine)<br>PILOCARPINE HCL† PHOSPHOLINE IODIDE® (echothiophate) | Miochol-E® (acetylcholine) | **Miscellaneous:** The patient has had a documented side effect, allergy or treatment failure with a preferred miscellaneous ophthalmic agent. If a product has an AB rated generic, there must have also been a trial of the generic formulation) |
| **MAST CELL STABILIZERS** | | |
| CROMOLYN SODIUM† (formerly Crolom®) | Alocril® (nedocromil sodium)<br>Alomide® (lodoxamide) | **Criteria for Approval:** The patient has had a documented side effect, allergy, or treatment failure with generic cromolyn sodium |
| **NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)** | | |
| ACULAR® (ketorolac 0.5% ophthalmic solution)<br><br>FLURBIPROFEN † 0.03% ophthalmic solution<br>ILEVRO® ophthalmic suspension (nepafenac 0.3%)<br>NEVANAC® ophthalmic suspension (nepafenac 0.1%) | Acular LS ® (ketorolac 0.4% ophthalmic solution)<br>Acuvail (ketorolac 0.45 %) Ophthalmic Solution<br>*(Quantity Limit = 30 unit dose packets/15 days)*<br>Bromday® ophthalmic solution (bromfenac 0.09%)<br>Bromfenac† 0.09 % ophthalmic solution (formerly Bromday®) (once daily)<br>Diclofenac† 0.1% ophthalmic solution (Voltaren®)<br>Ketorolac† 0.4 % ophthalmic solution (compare to | **Acuvail:** The patient has had a documented side effect, allergy, or treatment failure to Acular OR The patient has a documented hypersensitivity to the preservative benzalkonium chloride.<br>**Acular LS, Bromday, Bromfenac, Diclofenac, Prolensa,:** The patient has had a documented side effect, allergy, or treatment failure to Acular. In addition, if a product has an AB rated generic, there must have also been a trial of the generic formulation.<br>**Ketorolac 0.4 %/0.5 %:** The patient has had a documented intolerance to brand |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | Acular LS®)<br>Ketorolac† 0.5 % ophthalmic solution (compare to Acular®)<br>Ocufen®* ophthalmic solution (flurbiprofen 0.03%)<br>Prolensa® ophthalmic solution (bromfenac 0.07%) | Acular ophthalmic solution.<br><br>**Ocufen:** The patient has had a documented intolerance to generic flurbiprofen ophthalmic solution. |
| **OTIC ANTI-INFECTIVES** | | |
| **Anti-infective Single Agent**<br><br>CIPRO-HC® (ciprofloxacin 0.2%/hydrocortisone 1%) otic suspension<br><br>**Anti-infective/Corticosteroid Combination**<br><br>CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) otic suspension<br><br>NEOMYCIN/POLYMYXIN B SULFATE/HYDROCORTISONE† (compare to Cortisporpin otic®)<br><br>**Miscellaneous Agents**<br>ACETIC ACID† Otic solution<br>ACETIC ACID-ALUMINUM ACETATE† Otic solution | Ciprofloxacin† 0.2% (compare to Cetraxal®) otic solution *(Qty limit = 14 unit dose packages/ 7 days)*<br>Ofloxacin† 0.3% Otic solution (formerly Floxin®)<br><br>Coly-Mycin S®/Cortisporin TC® (neomycin/colistin/thonzium/hydrocortisone)<br><br>Acetasol HC† (acetic acid 2%/hydrocortisone 1% otic solution)<br>Acetic Acid/Hydrocortisone† Otic Solution | **Ciprofloxacin 0.2%:** The patient has a documented side effect, allergy, contraindication or treatment failure to both of the following: any generic neomycin/polymyxin B/hydrocortisone product, AND Ciprodex otic suspension.<br>**Coly-Mycin S, Cortisporin TC:** The patient has had a documented side effect, allergy, or treatment failure to neomycin/polymyxin B sulfate/hydrocortisone and one other preferred product.<br>**Acetasol HC, Acetic Acid/Hydrocortisone:** The patient has had a documented side effect, allergy, or treatment failure to at least TWO preferred otic anti-infectives. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **OVER THE COUNTER (OTC) MEDICATIONS** | | |
| **Please refer to the DVHA website for covered OTC categories not already managed on the PDL. Many categories limited to generics ONLY and other categories not covered. No PA process for non-covered OTCs.** | | |
| **PANCREATIC ENZYME PRODUCTS** | | |
| CREON® DR Capsule<br>ZENPEP® DR Capsule | Pancreaze® DR Capsule<br>Pancrelipase† 5,000 (compare to Zenpep® 5,000)<br>Pertzye® DR Capsule<br>Ultresa® DR Capsule<br>Viokace® DR Capsule | **Pancrelipase 5,000 (generic):** The patient has a documented intolerance to brand Zenpep 5,000<br>**All others:** The patient has been started and stabilized on the requested product. OR The patient has had treatment failure or documented intolerance with both Creon and Zenpep. |
| **PARATHYROID AGENTS** | | |
| | Natpara® (parathyroid hormone) (max dosage = 2 cartridges per 28 days) | **Natpara clinical criteria** (length of authorization 1 year)<br>▪ Natpara: diagnosis of hypocalcemia secondary to hypoparathyroidism (but NOT acute post-surgical hypoparathyroidism within 6 months of surgery) **AND**<br>▪ Natpara PA form must be completed and clinical and lab documentation supplied **AND**<br>▪ Must be prescribed by an endocrinologist **AND**<br>▪ Must be documented by **ALL** of the following:<br>○History of hypoparathyroidism >18 months **AND**<br>○Biochemical evidence of hypocalcemia **AND**<br>○Concomitant serum intact parathyroid hormone (PTH) |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | concentrations below the lower limit of the normal laboratory reference range on 2 test dates at least 21 days apart within the past 12 months **AND**<br>▪ No history of the following:<br>○mutation in CaSR gene **OR**<br>○pseudohypoparathyroidism **OR**<br>○a condition with an increased risk of osteosarcoma **AND**<br>▪ Hypocalcemia is not corrected by calcium supplements and preferred active forms of vitamin D alone **AND**<br>▪ Patients must be taking vitamin D metabolite/analog therapy with calcitriol ≥0.25 µg per day OR equivalent **AND**<br>▪ Must be taking supplemental oral calcium treatment ≥ 1000 mg per day over and above normal dietary calcium intake **AND**<br>▪ Serum calcium must be ≥ 7.5 mg/dl prior to starting Natpara **AND**<br>▪ Serum thyroid function tests and serum magnesium levels must be within normal limits **AND**<br>▪ Documentation of creatinine clearance > 30 mL/min on two separate measurements **OR** creatinine clearance > 60 mL/min AND serum creatinine < 1.5 mg/dL |
| **PARKINSON'S: NON ERGOT DOPAMINE RECEPTOR AGONIST** | | |
| **DOPAMINE PRECURSOR**<br>CARBIDOPA/LEVODOPA† (compare to Sinemet®)<br>CARBIDOPA/LEVODOPA† ER (compare to Sinemet® CR)<br>CARBIDOPA/LEVODOPA† ODT (compare to Parcopa®) | Parcopa®* (carbidopa/levodopa ODT)<br>Rytary® (carbidopa/levodopa ER caps)<br>Sinemet®* (carbidopa/levodopa)<br>Sinemet CR®*(carbidopa/levodopa ER) | **Sinemet, Sinemet CR, Mirapex, Parcopa, Parlodel, Requip, Eldepryl:** The patient has had a documented intolerance to the generic product.<br>**Rytary:** The patient has a diagnosis of Parkinson's disease, post-encephalitic parkinsonism, or parkinsonism following intoxication from carbon monoxide or manganese AND the prescriber is a neurologist AND the patient is having breakthrough symptoms despite a combination of concurrent IR and ER formulations of carbidopa/levodopa |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **DOPAMINE AGONISTS (ORAL)**<br>BROMOCRIPTINE† (compare to Parlodel®)<br>PRAMIPEXOLE † (compare to Mirapex®)<br>ROPINIROLE† (compare to Requip®)<br><br>**DOPAMINE AGONISTS (TRANSDERMAL)**<br>Neupro® (rotigotine) transdermal patch<br>*(Quantity Limit = 1 patch/day)*<br>*(2mg, 4 mg, 6 mg and 8 mg patches)*<br><br>**COMT INHIBITORS**<br>COMTAN® (entacapone)<br>ENTACAPONE† (compare to Comtan®)<br><br>**MAO-B INHIBITORS**<br>SELEGILINE† (compare to Eldepryl®)<br><br>**OTHER** | Mirapex®* (pramipexole)<br>Mirapex ER® (pramipexole ER)<br>*QL = 1 tab/day*<br>Requip®* (ropinirole)<br>Requip XL® (ropinirole XL)<br>*QL = 1 tab/day (all strengths except 12 mg), QL = 2 tabs/day (12 mg)*<br>ropinirole XL† (compare to Requip XL®)<br>*QL = 1 tab/day (all strengths except 12 mg), QL = 2 tabs/day (12 mg)*<br>Tasmar® (tolcapone)<br><br>Azilect® (rasagiline) (QL = 1 mg/day)<br>Eldepryl® (selegiline)<br>Zelapar® (selegiline ODT) *(QL = 2.5 mg/day)* | **Amantadine tablets:** The patient has had a documented intolerance to generic amantadine capsules.<br>**Azilect:** The diagnosis or indication is Parkinson's disease. AND The patient has had a documented side effect, allergy, or treatment failure with selegiline. AND The dose requested does not exceed 1 mg/day<br>**carbidopa/levodopa/entacapone**: The patient has had a documented intolerance to brand Stalevo.<br>**Mirapex ER, Requip XL, ropinirole:** The diagnosis or indication is Parkinson's disease. Requests will not be approved for Restless Leg Syndrome (RLS) AND The patient has had an inadequate response (i.e. wearing off effect or "off" time) with the immediate release product. OR The patient has not been able to be adherent to a three times daily dosing schedule of the immediate release product resulting in a significant clinical impact. AND If the requested product has an AB rated generic, the patient has a documented intolerance to the generic product.<br>**Tasmar:** The diagnosis or indication is Parkinson's disease. AND The patient has had a documented side effect, allergy, or treatment failure with Comtan.<br>**Zelapar:** The diagnosis or indication is Parkinson's disease. AND The patient is on current therapy with levodopa/carbidopa. AND Medical necessity for disintegrating tablet administration is provided (i.e. inability to swallow tablets or drug interaction with oral selegiline). AND the dose requested does not exceed 2.5mg/day<br><br>**Limitations:** To prevent the use of amantadine in influenza treatment/prophylaxis, days supply < 10 days will require PA. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| AMANTADINE† capsules (formerly Symmetrel®)<br>(PA required for ≤ 10 day supply)<br>STALEVO® (carbidopa/levodopa/entacapone) | Amantadine† tablets (formerly Symmetrel®)<br><br>(Quantity limit PA also required for ≤ 10 day supply)<br>carbidopa/levodopa/entacapone† (compare to Stalevo®) | |
| **PHOSPHODIESTERASE-4 (PDE-4) INHIBITORS** | | |
| | Daliresp® tablet (roflumilast)<br>*Quantity limit = 1 tablet/day*<br><br>Otezla® tablet (apremilast)<br>*(Starter pack – Quantity limit = 27 tablets/14 days)*<br>*( 30 mg tablets – Quantity limit = 2 tablets/day)*<br>*** Maximum days' supply per fill = 30)** | **Daliresp:** The indication for the requested medication is treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. AND The patient has had a documented side effect, allergy, treatment failure, or a contraindication to at least one inhaled long-acting anticholinergic AND at least one inhaled long-acting beta-agonist. AND The patient has had a documented side effect, allergy, treatment failure, or a contraindication to at least one inhaled corticosteroid.<br>**Otezla:** The patient has a diagnosis of psoriatic arthritis AND The patient is 18 years of age or older AND The patient has had inadequate response to, intolerance to, or contraindication to methotrexate. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **PHOSPHODIESTERASE-5 (PDE-5) INHIBITORS** | | |
| **Effective 7/1/06, phosphodiesterase-5 (PDE-5) inhibitors are no longer a covered benefit for all Vermont Pharmacy Programs for the treatment of erectile dysfunction. This change is resultant from changes set into effect January 1, 2006 and as detailed in Section 1903 (i)(21)(K) of the Social Security Act (the Act), precluding Medicaid Federal Funding for outpatient drugs used for the treatment of sexual or erectile dysfunction. Sildenafil will remain available for coverage via prior-authorization for the treatment of Pulmonary Arterial Hypertension.** | | |
| | Adcirca® (tadalafil) *(Quantity Limit = 2 tablets/day)*<br>Revatio® (sildenafil) Tabs (*Quantity Limit = 3 tablets/day)*<br>Revatio® (sildenafil citrate) vial<br>*(Quantity Limit = 3 vials/day, maximum 14 days supply per fill)*<br>sildenafil citrate† (compare to Revatio® ) tablet<br>*(Quantity Limit = 3 tablets/day)*<br>Viagra® (sildenafil) (*Quantity Limit = 3 tablets/day)* | **Adcirca (tadalafil) 20 mg, Revatio (sildenafil citrate) 20 mg, sildenafil citrate 20 mg:** Clinical diagnosis of pulmonary hypertension AND No concomitant use of organic nitrate-containing products AND For approval of Revatio, the patient has a documented intolerance to the generic equivalent.<br>**Viagra (sildenafil citrate) 25 mg, 50 mg, and 100 mg:** Clinical diagnosis of pulmonary hypertension AND No concomitant use of organic nitrate-containing products AND Inadequate response to Revatio (sildenafil) 20 mg or currently maintained on a sildenafil dose of 25 mg TID or higher<br>**Revatio IV:** Clinical diagnosis of pulmonary hypertension AND No concomitant use of organic nitrate-containing products AND The patient has a requirement for an injectable dosage form. AND Arrangements have been made for IV bolus administration outside of an inpatient hospital setting. |
| **PLATELET INHIBITORS** | | |
| **AGGREGATION INHIBITORS**<br>BRILINTA® (ticagrelor) Tablet *QL = 2 tablets/day*<br>CILOSTAZOL† (compare to Pletal®) | Plavix®* 75 mg (clopidogrel bisulfate)<br>Pletal®* (cilostazol)<br>Zontivity® (vorapaxar) Tablet *QL = 1 tablet/day* | **Agrylin, Persantine, Plavix, Pletal:** The patient has had a documented intolerance to the generic formulation of the medication.<br>**Dipyridamole/Aspirin:** The patient has had a documented intolerance to the brand formulation of the medication. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| CLOPIDOGREL†75 mg (compare to Plavix®)<br>EFFIENT® (prasugrel) Tablet *QL = 1 tablet/day*<br><br>TICLOPIDINE† (formerly Ticlid®)<br><br>**OTHER**<br>AGGRENOX® (dipyridamole/Aspirin)<br>ANAGRELIDE† (compare to Agrylin®)<br>ASPIRIN†<br>DIPYRIDAMOLE† (compare to Persantine®) | Agrylin®* (anagrelide)<br>Persantine®* (dipyridamole)<br><br>Dipyridamole/Aspirin (compare to Aggrenox®)<br>Durlaza® (asprin extended release) capsules | **Durlaza:** The patient is ≥ 18 years of age AND the indication for use is to reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease (history of MI, unstable angina pectoris, or chronic stable angina) OR to reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack AND the patient is unable to use at least 4 preferred products, one of which must be enteric coated aspirin.<br>**Zontivity:** The patient is started and stabilized on the medication. (Note: samples are not considered adequate justification for stabilization.) OR The patient has a history of myocardial infarction (MI) or peripheral arterial disease (PAD) AND The indication for use is reduction of thrombotic cardiovascular events. AND The medication is being prescribed in combination with aspirin and/or clopidogrel.<br>**Limitations:** Plavix/clopidogrel 300mg is not an outpatient dose and is not covered in the pharmacy benefit. |
| **POST-HERPETIC NEURALGIA AGENTS** | | |
| | Gralise® (gabapentin) tablet, starter pack<br>*Quantity Limit = 3 tablets/day*<br>*(Maximum 30 day supply per fill)* | **Gralise:** The patient has a diagnosis of post-herpetic neuralgia (PHN) AND The patient has had a documented side effect, allergy, contraindication or treatment failure with at least one drug from the tricyclic antidepressant class. AND The patient has had an inadequate response to the generic gabapentin immediate-release. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **PSORIATIC** | | |
| **INJECTABLES** (Initial approval is 3 months, renewals are 1 year) | | |
| T | | |
| ***Preferred After Clinical Criteria Are Met***<br><br>COSENTYX® (secukinumab) *(Quantity limit=8 pens or vials month one, then 4 pens or vials monthly)*<br><br>ENBREL® (etanercept)<br>*Quantity limit = 8 syringes/28 days for the first 3 months; then 4 syringes/28 days(50 mg) or 8 syringes/28 days (25 mg) subsequently*<br>HUMIRA® (adalimumab)<br>*Quantity limit = 4 syringes/28 days for one month; 2 syringes/28 days subsequently* | Remicade® (infliximab)<br>Stelara® (ustekinumab)<br>*(Quantity limit = 45 mg (0.5 ml) or 90 mg (1 ml) per dose)*<br>*(90 mg dose only permitted if pt weight > 100 kg)* | **Clinical Criteria:**<br>**For all drugs:**<br>The prescription must be written by a dermatologist AND The patient has a documented diagnosis of moderate to severe plaque psoriasis and has already been stabilized on the drug being requested OR The prescription must be written by a dermatologist AND The patient has a documented diagnosis of moderate to severe plaque psoriasis affecting > 10% of the body surface area (BSA) and/or has involvement of the palms, soles, head and neck, or genitalia and has had a documented side effect, allergy, inadequate treatment response, or treatment failure to at least 2 different categories of therapy [i.e. at least 2 topical agents and at least 1 oral systemic agent, (unless otherwise contraindicated)] from the following categories: Topical agents: emollients, keratolytics, corticosteroids, calcipotriene, tazarotene, etc. Systemic agents: methotrexate, sulfasalazine, azathioprine, cyclosporine, tacrolimus, mycophenolate mofetil, etc. Phototherapy: ultraviolet A and topical psoralens (topical PUVA), ultraviolet A and oral psoralens (systemic PUVA, narrow band ultraviolet B (NUVA), etc.<br><br>**Additional Criteria for Cosentyx:** The prescriber must provide evidence of a trial and failure or contraindication to Humira®.<br>**Additional Criteria for Remicade:** The prescriber must provide a clinically valid reason why either Humira® or Cosentyx® cannot be used.<br>**Additional criteria for Stelara:** The prescriber must provide a clinically valid |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | reason why either Humira® or Cosentyx® cannot be used. |
| **NON-BIOLOGICS** | | |
| **ORAL**<br>CYCLOSPORINE † (all brand and generic)<br>METHOTREXATE † (all brand and generic)<br>METHOXSALEN† (compare to Oxsoralen-Ultra®)<br>SORIATANE® (acitretin) capsules<br><br>**TOPICAL**<br>CALCIPOTRIENE† Solution (compare to Dovonex®)<br>CALCIPOTRIENE® Ointment (formerly Dovonex®)<br>DOVONEX® (calcipotriene cream)<br>PSORIATEC®, DRITHO-SCALP® (anthralin cream)<br>TAZORAC® (tazarotene cream, gel) | Acitretin† (compare to Soriatane®) capsules<br>Oxsoralen-Ultra® (methoxsalen)<br><br>Calcipotriene† cream (compare to Dovonex®)<br>Calcitrene® (calcipotriene) ointment<br>calcitriol† (compare to Vectical®) Ointment<br>*(Quantity Limit = 200 g (2 tubes)/week)*<br>Calcipotriene/betamethasone ointment† (compare to Taclonex®)<br>*(QL for initial fill = 60 grams)*<br>Dovonex®* solution (calcipotriene)<br>Sorilux® (calcipotriene) foam<br>Taclonex® (calcipotriene/betamethasone ointment/scalp suspension)<br>*(QL for initial fill = 60 grams)*<br>Vectical® Ointment (calcitriol)<br>*(Quantity Limit = 200 g (2 tubes)/week)* | **Acritretin Capsules:** The patient has a documented intolerance to brand Soriatane capsules.<br>**Calcitrene Ointment:** The patient has a documented intolerance to Calcipotriene ointment.<br>**Calcipotriene Cream:** The patient has a documented intolerance to the brand Dovonex cream.<br>**Dovonex Solution:** The patient has a documented intolerance to the generic product.<br><br>**Oxsoralen-Ultra:** The patient has a documented intolerance to the generic equivalent.<br>**Taclonex or calcipotriene/betamethasone diproprionate Ointment or Scalp Suspension:** The patient has had an inadequate response to a 24 month trial of a betamethasone dipropionate product and Dovonex (or generic calcipotriene), simultaneously, with significant non-adherence issues. AND The patient has had a documented side effect, allergy, or treatment failure with Tazorac 0.05% or 0.1% cream or gel. Note: If approved, initial fill of Taclonex® or calcipotriene/betamethasone diproprionate will be limited to 60 grams.<br>**Vectical Ointment, Calcitriol Ointment:** The patient ≥ 18 years of age AND The patient has a diagnosis of mild-to-moderate plaque psoriasis AND The patient has demonstrated inadequate response, adverse reaction or contraindication to calcipotriene AND If the request is for brand Vectical, the patient has had a documented intolerance to the generic product.<br>**Sorilux:** The patient ≥ 18 years of age AND The patient has a diagnosis of plaque psoriasis AND The patient has demonstrated inadequate response or |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | intolerance to other dosage forms of calcipotriene (brand or generic)<br>**Limitations:** Kits with non-drug or combinations of 2 drug products are not covered. |
| **PULMONARY AGENTS** | | |
| **ANTICOLINERGICS: INHALED** | | |
| METERED DOSE INHALER (SINGLE AGENT)<br>**Short Acting**<br><br>ATROVENT HFA® (ipratropium)<br>*Quantity Limit = 2 inhalers/25 days*<br><br>**Long Acting**<br>SPIRIVA® HANDIHALER (tiotropium)<br>*Quantity Limit = 1 capsule/day*<br><br>NEBULIZER (SINGLE AGENT)<br>IPRATROPIUM SOLN FOR INHALATION<br><br>METERED DOSE INHALER (COMBO PRODUCT)<br>**Short Acting**<br>COMBIVENT® (ipratropium/albuterol)<br>*Quantity Limit = 2 inhalers/30 days*<br><br>COMBIVENT® RESPIMAT (ipratropium/albuterol)<br>*Quantity Limit = 1 inhaler (4 grams)/30 days*<br>**Long Acting** | Incruse Ellipta® (umeclidinium bromide) *(Quantity Limit= 1 inhaler/30 days)*<br><br>Tudorza® Pressair (aclidinium bromide)<br>*Quantity Limit = 1 inhaler/30 days*<br><br>Spiriva® Respimat (tiotropium)<br>*QL = 1 inhaler/30days*<br><br>Anoro® Ellipta (umeclidinium/vilanterol)<br>*Quantity Limit = 1 inhaler (60 blisters)/30 days* | **Anoro Ellipta/Stiolto Respimat:** patient has a diagnosis of COPD (not FDA approved for asthma). AND<br>○ Mild-Moderate COPD- failure of individual and combination therapy of one preferred Long Acting Beta Adrenergic (LABA) and a preferred Long Acting Anticholinergic OR<br>○ Severe COPD- failure of one preferred Inhaled Corticosteroid/LABA combination product and the preferred Long Acting Anticholinergic.<br><br>**Incruse Ellipta/Tudorza:** The patient has had documented side effect, allergy or treatment failure to Spiriva®<br><br>Spiriva Respimat: patient has a diagnosis of COPD and a compelling clinical reason why they cannot use Spiriva Handihaler |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **All require PA.**<br>NEBULIZER (COMBINATION PRODUCT)<br>IPRATROPIUM/ALBUTEROL† | *Stiolto Respimat® (tiotropium/olodaterol) (QL = 1 inhaler/30 days)* | |
| **ANTIHISTAMINES: INTRANASAL** | | |
| | SINGLE AGENT<br><br>Astelin® (azelastine) Nasal Spray<br>*Quantity Limit = 1 bottle (30 ml)/30 days*<br><br>Astepro® (azelastine 0.15 %) Nasal Spray<br>*Quantity Limit = 1 bottle (30 ml)/30 days*<br><br>azelastine (compare to Astelin®) Nasal Spray<br>*Quantity Limit = 1 bottle (30 ml)/30 days*<br><br>azelastine 0.15 % (compare to Astepro®) Nasal Spray<br>*Quantity Limit = 1 bottle (30 ml)/30 days*<br><br>Olopatadine † 0.6% (compare to Patanase®) Nasal Spray<br>*Quantity Limit = 1 bottle (31 gm)/30 days*<br><br>Patanase® (olopatadine 0.6%) Nasal Spray<br>*Quantity Limit = 1 bottle (31 gm)/30 day*<br><br>COMBO WITH CORTICOSTEROID<br>Dymista® (azelastine/fluticasone) Nasal Spray<br>*Quantity Limit = 1 bottle (23 gm)/30 days* | **ASTELIN, ASTEPRO, AZELASTINE, DYMISTA, OLOPATADINE,**<br><br>**PATANASE:** The diagnosis or indication for the requested medication is allergic rhinitis. AND The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) OR cetirizine (OTC) AND a preferred nasal corticosteroid used in combination. AND If the request is for Astepro, the patient has a documented intolerance to the generic equivalent. |
| **ANTIHISTAMINES: 1ST GENERATION** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| All generic antihistamines<br><br>All generic antihistamine/decongestant combinations | All brand antihistamines (example: Benadryl®)<br><br>All brand antihistamine/decongestant combinations (example: Deconamine SR®, Rynatan®, Ryna-12®) | **CRITERIA FOR APPROVAL:** The prescriber must provide a clinically valid reason for the use of the requested medication including reasons why any of the generically available products would not be a suitable alternative. |
| **ANTIHISTAMINES: 2ND GENERATION** | | |
| **SINGLE AGENT TABLET**<br><br>LORATADINE † (OTC) (Allergy Relief®, Alavert®)<br>CETIRIZINE† OTC (formerly Zyrtec®) 5 mg, 10 mg tablets<br><br>**After loratadine OTC and cetirizine OTC trials**<br>FEXOFENADINE † 60 mg, 180 mg (OTC) tablets (formerly Allegra®)<br><br>**COMBINATION WITH PSEUDOEPHEDRINE**<br><br>LORATADINE/PSEUDOEPHEDRINE SR 12hr 5 mg/120 MG † (OTC)<br>(Alavert Allergy/Sinus®)<br>LORATADINE/PSEUDOEPHEDRINE SR 24hr 10 mg/240 MG †(OTC)<br><br>**SINGLE AGENT ORAL LIQUID** | Clarinex® (desloratadine) 5 mg tablet<br>desloratadine† (compare to Clarinex®) 5 mg tablet<br>Levocetirizine† (compare to Xyzal®) 5 mg tablet<br>Xyzal® (levocetirizine) 5 mg tablet<br><br>All other brands<br><br>Cetirizine/Pseudoephedrine SR 12hr 5 mg/120 mg OTC†<br>Clarinex-D® 12 hr (desloratadine/pseudoephedrine 2.5 mg/120 mg)<br><br>Clarinex Syrup® (desloratadine) | **FEXOFENADINE 60MG/180 MG TABLETS:** The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria. AND The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) AND cetirizine (OTC).<br>**CLARINEX TABLETS, DESLORATADINE TABLETS, LEVOCETIRIZINE TABLETS, XYZALTABLETS:** The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria AND The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) AND cetirizine (OTC) AND The patient has had a documented side effect, allergy, or treatment failure to fexofenadine. AND If the request is for Clarinex or Xyzal, the patient must also have a documented intolerance to the generic equivalent tablets.<br>**CERTIRIZINE CHEWABLE TABLETS, CLARINEX REDITABS, DESLORATADINE ODT:** The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria AND The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) rapidly disintegrating tablets or requires less than a 10 mg dose of loratadine. AND If the request is for Clarinex Reditabs, the patient must also have a documented intolerance to the generic equivalent tablets |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| LORATADINE † (OTC) syrup (Allergy Relief®)<br><br>CETIRIZINE † (OTC, RX) syrup<br><br>**CHEWABLE/ORALLY DISINTEGRATING TABLET**<br><br>LORATADINE † (OTC) (Allergy Relief®, Alavert®) rapidly disintegrating tablet (RDT) (compare to Claritin®) 10 mg | Levocetirizine (compare to Xyzal®) Solution<br>Xyzal® (levocetirizine) Solution<br><br>Certirizine † OTC Chewable Tablets 5 mg, 10 mg<br>Clarinex Reditabs®§ (desloratadine) 2.5 mg, 5 mg<br>Desloratadine ODT (compare to Clarinex Reditabs®) 2.5 mg, 5 mg<br><br>All other brands | **CLARINEX SYRUP, LEVOCETIRIZINE SOLUTION, XYZAL SOLUTION**<br><br>**ORAL LIQUID:** The diagnosis or indication for the requested medication is allergic rhinitis or chronic idiopathic urticaria AND the patient has had a documented side effect, allergy, or treatment failure to loratadine syrup AND cetirizine syrup. AND If the request is for Xyzal, the patient must also have a documented intolerance to levocetirizine solution.<br>**CETIRIZINE D, CLARINEX-D:** The diagnosis or indication for the requested medication is allergic rhinitis. AND The patient has had a documented side effect, allergy, or treatment failure to loratadine-D (OTC).<br>**LIMITATIONS:** Many Allegra® and Zyrtec® brand products as well as Claritin capsules are not covered as no Federal Rebate is offered. Fexofenadine suspension not covered as no Federal Rebate is offered. Fexofenadine/pseudoephedrine combination products) (brand and generic) are not covered – individual components may be prescribed separately. |
| **BETA-ADRENERGIC AGENTS** | | |
| **METERED-DOSE INHALERS (SHORT-ACTING)**<br>PROAIR® HFA (albuterol)<br>PROVENTIL® HFA (albuterol)<br><br>MAXAIR® Autohaler (pirbuterol)<br><br>**METERED-DOSE INHALERS (LONG-** | Ventolin® HFA (albuterol)<br>Xopenex® HFA (levalbuterol)<br>ProAir® Respiclick (albuterol)<br><br>Arcapta® Neohaler (indacaterol) *(criteria for LABA must also be met)*<br>*Quantity Limit = 1 capsule/day*<br><br>Striverdi Respimat® | **Metered Dose Inhalers (Long-Acting):** Effective 11/1/06, prior-authorization will be required for long-acting beta-adrenergic (LABA) MDIs for patients who have not been on a controller medication in the past 6 months or who do not have a diagnosis of COPD.<br>ProAir® Respiclick: documented side effect, allergy, or treatment failure to ONE preferred short acting metered dose inhaler.<br>**Foradil, Serevent:** The patient has a diagnosis of COPD OR The patient has a diagnosis of asthma and is prescribed an inhaled corticosteroid as a controller medication. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **ACTING)**<br><br>FORADIL® (formoterol) *(after criteria for LABA are met)*<br>*Quantity Limit = 60 capsules/month*<br>SEREVENT® DISKUS (salmeterol xinafoate) *(after criteria for LABA are met)*<br>*Quantity Limit = 60 blisters/30 days*<br><br>**NEBULIZER SOLUTIONS (SHORT-ACTING)**<br><br>ALBUTEROL † 0.63 mg/3 ml and 1.25 mg/3 ml neb solution<br>ALBUTEROL † 2.5 mg/3 ml neb solution<br>ALBUTEROL † 5 mg/ml neb solution<br>XOPENEX® neb solution (levalbuterol HCL) (age ≤ 12 yrs)<br><br>**NEBULIZER SOLUTIONS (LONG-ACTING)**<br><br>**TABLETS/SYRUP (SHORT-ACTING)**<br><br>ALBUTEROL † tablets/syrup<br><br>**TABLETS (LONG-ACTING)**<br>ALBUTEROL ER † tablets | Levalbuterol † neb solution (compare to Xopenex® ) (all ages)<br>Xopenex® neb solution (age > 12 yrs)<br><br>Brovana® (arformoterol) *QL = 2 vial/day*<br>Perforomist® (formoterol) *QL = 2 vial/day*<br>metaproterenol tablets/syrup †<br>terbutaline tablets †<br><br>Vospire ER®* (albuterol) | **Arcapta, Striverdi :** The patient has a diagnosis of COPD (not FDA approved for asthma). AND The patient has a documented side effect, allergy, or treatment failure to either Foradil or Serevent.<br>**Levalbuterol nebulizer solution (age < 12 years):** The patient must have had a documented intolerance to the brand Xopenex nebulizer solution.<br>**Levalbuterol nebulizer solution (age > 12 years):** The patient must have had a documented side effect, allergy, or treatment failure to albuterol nebulizer. AND The patient must have had a documented intolerance to the brand Xopenex nebulizer solution.<br>**Xopenex nebulizer solution (age >12 years):** The patient must have been started and stabilized on the requested medication. OR The patient must have had a documented side effect, allergy, or treatment failure to albuterol nebulizer.<br>**Brovana or Perforomist Nebulizer Solution:** The patient must have a diagnosis of COPD. AND The patient must be unable to use a non-nebulized long-acting bronchodilator or anticholinergic (Foradil, Serevent or Spiriva) due to a physical limitation<br>**Metaproterenol tablets/syrup:** The patient has had a documented side effect, allergy or treatment failure with generic albuterol tablets/syrup.<br>**Terbutaline tablets:** The medication is not being prescribed for the prevention/treatment of preterm labor. AND If Brethine is requested, the patient must have had a documented side effect, allergy, or treatment failure to generic terbutaline tablets.<br>**Ventolin HFA, Xopenex HFA:** The patient must have had a documented side effect, allergy, or treatment failure to ONE preferred short acting metered dose inhaler.<br>**Vospire ER tablets:** The patient must have had a documented side effect, allergy, or treatment failure to generic albuterol ER tablets. |
| **CORTICOSTEROIDS/COMBINATIONS: INHALED** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **METERED DOSE INHALERS (SINGLE AGENT)**<br>AEROSPAN® (flunisolide HFA)<br>*(QL = 6 inhalers (53.4 gm)/90 days)*<br>ASMANEX® 110 or 220 mcg/inh (mometasone furoate)<br>*(QL =3 inhalers/90 days)*<br>FLOVENT® DISKUS (fluticasone propionate)<br>*(QL = 3 inhalers/90 days)*<br>FLOVENT® HFA (fluticasone propionate)<br>*(QL = 36 gm(3 inhalers)/90 days)*<br>PULMICORT FLEXHALER® (budesonide)<br>*(QL = 6 inhalers/90 days)*<br>QVAR® 40 mcg/inh (beclomethasone)<br>*(QL = 17.4 gm (2 inhalers)/90 days)*<br>QVAR® 80 mcg/inh (beclomethasone)<br>*(QL = 58.4 gm (8 or 6 inhalers)/90 days)* | Alvesco® (ciclesonide)<br>*(QL = 18.3 gm (3 inhalers)/90 days)) (80 mcg/inh)*<br>*(QL =36.6 gm (6 inhalers)/90 days)) (160 mcg/inh)*<br><br>Arnuity Ellipta 100 or 200mcg/inh (fluticasone furoate) (QL= 90 blisters/90 days)<br>Asmanex HFA 100 or 200mcg (mometasone furoate)<br>*(QL=3 inhalers/90 days)* | **Metered-dose inhalers (single agent):** The patient has been started and stabilized on the medication. OR The patient has had a documented side effect, allergy, or treatment failure to at least two preferred agents. |
| **METERED DOSE INHALERS (COMBINATION PRODUCT)**<br>ADVAIR® HFA (fluticasone/salmeterol)<br>*(QL = 36 gm (3 inhalers)/90 days)*<br>DULERA® (mometasone/formoterol)<br>*(QL = 39 gm (3 inhalers)/90 days)*<br>SYMBICORT® (budesonide/formoterol)<br>*(QL = 30.6 gm (3 inhalers)/90 days)* | ADVAIR® DISKUS (fluticasone/salmeterol)<br>*(QL = 3 inhalers/90 days)*<br><br>Breo Ellipta® (fluticasone furoate/vilanterol)<br>*(QL = 180 blisters(3 inhalers)/90 days)* | **ADVAIR® DISKUS** : current users as of 01/01/2016 will be allowed a 90 day grace period to transition to preferred ADVAIR® HFA. Advair Diskus will be approved for patients with asthma or COPD who have difficulty using MDIs due to lack of hand-breath coordination AND/OR have a history or develop thrush with MDI formulations of inhaled corticosteroids AND/OR are 4-11 years old<br>**Breo Ellipta:** The patient has a diagnosis of COPD or Asthma AND The patient has had a documented side effect, allergy, or treatment failure to Advair or Symbicort. |
| **NEBULIZER SOLUTIONS** | Budesonide Inh Suspension (compare to Pulmicort | **Budesonide Inh Suspension (all ages):** The patient requires a nebulizer formulation. AND The patient has a documented intolerance to the brand |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| PULMICORT RESPULES® (budesonide) (age ≤ 12 yrs) | Respules®) (all ages)<br>Pulmicort Respules® (budesonide) (age > 12 years) | product.<br>**Pulmicort Respules (age > 12 years):** The patient requires a nebulizer formulation. |
| **CORTICOSTEROIDS: INTRANASAL** | | |
| **SINGLE AGENT**<br>FLUTICASONE Propionate† (compare to Flonase®)<br>*QL = 16 gm (1 inhaler)/30 days*<br>OMNARIS® (ciclesonide)<br>*QL = 12.5 gm (1 inhaler)/30 days*<br>ZETONNA® (ciclesonide)<br>*QL = 6.1 gm (1 inhaler)/30 days* | Beconase AQ® (beclomethasone)<br>*QL =50 gm (2 inhalers)/30 days*<br>budesonide † (compare to Rhinocort Aqua®)<br>*QL = 8.6 gm (1 inhaler)/30 days*<br>Flonase®* (fluticasone propionate)<br>*QL = 16 gm (1 inhaler)/30 days*<br>flunisolide † 25 mcg/spray (formerly Nasalide®)<br>*QL = 50 ml (2 inhalers)/30 days*<br>flunisolide† 29 mcg/spray (formerly Nasarel®)<br>*QL = 50 ml (2 inhalers)/30 days*<br>*QL = 16.5 gm (1 inhaler)/30 days*<br>NASONEX® (mometasone)<br>*QL = 17 gm (1 inhaler)/30 days*<br>QNASL® (beclomethasone diproprionate) HFA<br>*QL = 8.7 gm (1 inhaler)/30 days*<br>Rhinocort Aqua® (budesonide)<br>*QL = 8.6 gm (1 inhaler)/30 days*<br>triamcinolone † (compare to Nasacort AQ®)<br>*QL = 16.5 gm (1 inhaler)/30 days*<br>Veramyst® (fluticasone furoate)<br>*QL = 10 gm (1 inhaler)/30 days*<br>**COMBINATION WITH ANTIHISTAMINE**<br>Dymista® (azelastine/fluticasone)<br>*QL = 23 gm (1 inhaler)/30 days* | **Beconase AQ, Budesonide, Flonase, Flunisolide 25 mcg/spray, Flunisolide 29 mcg/spray, Nasonex, QNASL, Rhinocort Aqua, triamcinolone, Veramyst:** The patient has had a documented side effect, allergy, or treatment failure of two preferred nasal glucocorticoids. If the request is for Rhinocort Aqua®, the patient has also had a documented intolerance to the generic equivalent.<br>**Dymista:** The diagnosis or indication is allergic rhinitis. AND The patient has had a documented side effect, allergy, or treatment failure to loratadine (OTC) OR cetirizine (OTC) AND a preferred nasal corticosteroid used in combination.<br>**Limitations:** Nasacort Allergy OTC not covered as no Federal Rebate is offered. Nasacort AQ RX available after PA obtained. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **LEUKOTRIENE MODIFIERS** | | |
| ***Preferred After Clinical Criteria Are Met***<br><br>MONTELUKAST SODIUM† (compare to Singulair®) tablets§<br><br>MONTELUKAST SODIUM† (compare to Singulair®) chews§ 4mg for ages 2-5, 5mg for age 6-14<br><br>MONTELUKAST SODIUM† (compare to Singulair®) granules§ ages 6months-23months | Accolate® (zafirlukast) **§**<br>*Quantity Limit = 2 tablets/day*<br>Singulair® (montelukast sodium) **§** tablets, chew tabs, granules<br>*Quantity Limit = 1 tablet or packet per day*<br>zafirlukast (compare to Accolate®) **§**<br>Zyflo (zileuton)<br>*Quantity Limit = 2 tablets/day*<br>Zyflo CR® (zileuton SR)<br>*Quantity Limit = 4 tablets/day* | **Montelukast:**<br>• The diagnosis or indication for the requested medication is asthma.<br>• The diagnosis or indication for the requested medication is allergic rhinitis. The patient has had a documented side effect, allergy, or treatment failure to a second generation non-sedating antihistamine and a nasal corticosteroid.<br>• The diagnosis or indication for the requested medication is urticaria. The patient has had a documented side effect, allergy, or treatment failure to at least TWO preferred 2nd generation antihistamines (i.e. loratadine (OTC), cetirizine (OTC), fexofenadine).<br>• If the request is for brand Singulair tablets, chew tablets or granules; the patient has a documented intolerance to the generic equivalent montelukast preparation.<br>**Zafirlukast, Accolate:** The diagnosis or indication for the requested medication is asthma. AND If the request is for Accolate, the patient has a documented intolerance to generic zafirlukast.<br>**Zyflo/Zyflo CR:** The diagnosis or indication for the requested medication is asthma. AND The patient has had a documented side effect, allergy, or treatment failure to Accolate or Singulair/Montelukast.<br>**Montelukast chewable and granules:** Will only be approved for appropriate FDA approved age and indications. |
| **SYNAGIS** | | |
| | SYNAGIS® (palivizumab)<br>*Quantity Limit = 1 vial/month (50 mg) or 2 vials/month (100 mg)* | **CRITERIA FOR APPROVAL:**<br>Infants born at 28 weeks of gestation or earlier (i.e., ≤ 28 weeks, 6 days) and |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | under twelve months of age at the start of the RSV season (maximum 5 doses).<br>Infants born at 29-32 weeks (i.e., between 29 weeks, 0 days and 31 weeks, 6 days) of gestation and under 1 year of age at the start of the RSV season who develop chronic lung disease of prematurity defined as a requirement for >21% oxygen for at least the first 28 days after birth (maximum 5 doses).<br>Children under 24 months of age with chronic lung disease of prematurity defined as born at 31 weeks, 6 days or less who required >21% oxygen for at least the first 28 days after birth and continue to require medical support (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) during the 6-month period before the start of the second RSV season (maximum 5 doses).<br><br>Children under 12 months of age with hemodynamically significant congenital heart disease (CHD) (dosing continues in the RSV season through the end of the month the infant reaches 12 months old -maximum 5 doses): Acyanotic heart disease and receiving medication to control congestive heart failure and will require cardiac surgical procedures, Moderate to severe pulmonary hypertension , Cyanotic heart disease and recommended for Synagis therapy by Pediatric Cardiologist<br>Infants under 12 months of age with either: (dosing continues in the RSV season through the end of the month the infant reaches 12 months old -maximum 5 doses) Congenital abnormalities of the airways that impairs the ability to clear secretions from the upper airway because of ineffective cough, Neuromuscular condition that impairs the ability to clear secretions from the upper airway because of ineffective cough<br>Infants and children less than 24 months of age who will undergo a heart transplant during the RSV season<br>Infants and children less than 24 months of age who are profoundly immunocompromised during the RSV season (e.g. undergoing organ or stem cell |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | transplant or receiving chemotherapy).<br>**EXCLUDED FROM APPROVAL:**<br>Infants and children with hemodynamically insignificant heart disease.<br>Infants with cardiac lesions adequately corrected by surgery, unless they continue to require medication for congestive heart failure.<br>Infants with mild cardiomyopathy who are not receiving medical therapy.<br>Breakthrough hospitalization for RSV disease (Synagis therapy should be discontinued for the season once hospitalization for RSV has occurred).<br>Infants and children with Down syndrome unless other indications above are present.<br>Infants and children with cystic fibrosis unless other specific conditions are present<br>This drug must be obtained and billed through our specialty pharmacy vendor for Synagis, Wilcox Home Infusion, and processed through the DVHA POS prescription processing system using NDC values. Under no circumstances will claims processed through the medical benefit be accepted. |
| **PULMONARY ARTERIAL HYPERTENSION MEDICATIONS** | | |
| **ENDOTHELIAN RECEPTOR ANTAGONISTS**<br><br>LETAIRIS® (ambrisentan) Tablet<br>*Quantity Limit = one tablet/day*<br><br>TRACLEER® (bosentan) Tablet<br>*Quantity Limit = 2 tablets/day* | Opsumit® (macitentan) Tablet<br>*Quantity Limit = one tablet/day* | **Adempas:** The patient has a diagnosis of pulmonary arterial hypertension (PAH) WHO Group I with New York Heart Association (NYHA) Functional Class II or III. OR The patient has a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) AND the patient has persistent or recurrent disease after surgical treatment (e.g., pulmonary endarterectomy) or has CTEPH that is inoperable AND The patient is 18 years of age or older AND The patient will not use Adempas concomitantly with the following: Nitrates or nitric oxide donors (such as amyl nitrate) in any form. Phosphodiesterase (PDE) |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **PROSTANOIDS**<br><br>**Injection**<br>EPOPROSTENOL † ( compare to Flolan®)<br>REMODULIN® (treprostinil sodium injection)<br>VELETRI® (epoprostinil)<br><br>**Inhalation**<br>TYVASO® (treprostinil inhalation solution)<br>VENTAVIS® (iloprost inhalation solution)<br><br>**Oral**<br>ORENITRAM® (treprostinil) ER Tablet<br><br>**sGC STIMULATOR**<br><br>****Maximum days supply for all drugs is 30 days**** | Flolan®* (epoprostenol)<br><br>Adempas® (riociguat) Tablets<br>*Quantity Limit = 3 tablets/day* | inhibitors, including specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or non-specific PDE inhibitors (such as dipyridamole or theophylline) AND The patient is not pregnant AND Female patients are enrolled in the Adempas REMS Program<br>**Flolan:** Clinical diagnosis of pulmonary hypertension AND The patient has had a documented intolerance to the generic epoprostenol.<br>**Opsumit:** Patient has a diagnosis of PAH WHO Group 1 with NYHA Functional Class II or III AND Patient is not pregnant AND Female patients have been enrolled in the Opsumit REMS Program |
| **RENAL DISEASE: PHOSPHATE BINDERS** | | |
| CALCIUM ACETATE † (compare to Phos Lo®) capsule<br>CALCIUM ACETATE † (compare to Eliphos®) tablet<br>FOSRENOL® (lanthanum carbonate)<br>RENAGEL® (sevelamer) | Auryxia® (ferric citrate) *(QL= 12/day)*<br>Eliphos® (calcium acetate) tablet<br>Phos Lo®* (calcium acetate) capsule<br>Renvela® (sevelamer carbonate) Oral Suspension Packet<br>*(QL = 2 packs/day (0.8 g strength only))*<br>Renvela® (sevelamer carbonate) tablets | **Eliphos, PhosLo:** The patient must have a documented intolerance to the generic equivalent calcium acetate tablet or capsule.<br>**Renvela Oral Suspension Packet:** The patient has a requirement for a liquid dosage form.<br>**Renvela tablet, Sevelamer 800 mg Tablet:** The patient must have a documented side effect, allergy, or inadequate response to Renagel (sevelamer hydrochloride). |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| **ORAL SOLUTIONS**<br>PHOSLYRA® (calcium acetate) oral solution | Sevelamer carbonate (compare to Renvela®) 800 mg tablet<br>Velphoro® (sucroferric oxyhydroxide) Chew Tablet | **Velphoro Chew Tablet/Auryxia Tablet:** The patient must have a documented side effect, allergy, or inadequate response to one preferred phosphate binder. |
| **RESTLESS LEG SYNDROME MEDICATIONS** | | |
| **DOPAMINE AGONISTS (ORAL)**<br>PRAMIPEXOLE † (compare to Mirapex®)<br>ROPINIROLE† (compare to Requip®)<br><br>**DOPAMINE AGONISTS (TRANSDERMAL)**<br>NEURPO® (rotigotine) transdermal patch<br>*(Quantity Limit = 1 patch/day)*<br>*(1mg, 2 mg and 3 mg patches ONLY)*<br><br>**GAMMA-AMINOBUTYRIC ACID ANALOG**<br>GABAPENTIN IR | Mirapex®* (pramipexole)<br>Requip®* (ropinirole)<br><br>Horizant® (gabapentin enacarbil) ER Tablet<br>*(Quantity Limit = 1 tablet/day)* | **Mirapex, Requip:** The patient has had a documented intolerance to the generic product.<br>**Horizant:** The patient has a diagnosis of restless legs syndrome (RLS). AND The patient has had a documented side effect, allergy, contraindication or treatment failure to two preferred dopamine agonists (pramipexole IR, ropinirole IR, Neupro) AND gabapentin IR. **Limitations:** Requests for Mirapex ER and Requip XL will not be approved for Restless Leg Syndrome (RLS). |
| **RHEUMATOID, JUVENILE & PSORIATIC ARTHRITIS: IMMUNOMODULATORS** | | |
| **Self-injectables/Oral (Enbrel®, Humira®, Cimzia®, Kineret®, Orencia® Subcutaneous, Simponi®, Stelara® & Xeljanz®) must be obtained through Specialty Pharmacy Provider, Briova** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

EFFECTIVE
Version
Updated: 06/03/16

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| ***Preferred After Clinical Criteria Are Met***<br>**Injectable**<br>ENBREL® (etanercept)<br>*(Quantity limit = 4 syringes/28 days(50 mg) and 8 syringes/28 days (25 mg))*<br>HUMIRA® (adalimumab)<br>*(Quantity limit = 4 syringes/28 days)*<br><br>**Oral** | Actemra® (tocilizumab) Intravenous Infusion<br>*(Qty limit = 4 vials/28 days (80 mg vial), 3 vials/28 days (200 mg vial) or 2 vials/28 days (400 mg vial))*<br>Actemra® (tocilizumab) Subcutaneous<br>*(Qty limit = 4 prefilled syringes (3.6ml)/28 days)*<br>Cimzia® (certolizumab pegol)<br>*(Quantity limit = 1 kit/28 days)* Kineret® (anakinra)<br>*(Quantity limit = 1 syringe/day)*<br>Orencia® (abatacept) Subcutaneous Injection<br>*(Quantity limit = 4 syringes/28 days)*<br>Orencia® (abatacept) Intravenous Infusion<br>Remicade® (infliximab)<br><br>Simponi® (golimumab) Subcutaneous<br>*Qty Limit = 1 of 50 mg prefilled syringe or autoinjector/28 days)*<br>Simponi Aria® (golimumab) 50 mg/4 ml Vial for Intravenous Infusion<br>Stelara® (ustekinumab)<br>*(Quantity limit = 45 mg (0.5 ml) or 90 mg (1 ml) per dose)*<br>*(90 mg dose only permitted for pt weight > 100 kg)*<br><br>Xeljanz® (tofacitinib) tablet<br>*(Qty limit = 2 tablets/day)*<br>*Maximum 30 days supply* | **Clinical Criteria for all drugs:** Patient has a diagnosis of rheumatoid arthritis (RA), juvenile idiopathic arthritis* or psoriatic arthritis and has already been stabilized on the drug being requested OR Diagnosis is RA, juvenile idiopathic arthritis or psoriatic arthritis, and methotrexate therapy resulted in an adverse effect, allergic reaction, inadequate response, or treatment failure. If methotrexate is contraindicated, another DMARD should be tried prior to approving therapy. Other DMARDs include leflunomide, sulfasalazine, gold, antimalarials, minocycline, D-penicillamine, azathioprine, cyclophosphamide and cyclosporine. Additional note for Humira: Approval should be granted in cases where patients have been treated with infliximab, but have lost response to therapy.<br><br>**Actemra Intravenous Infusion additional criteria:** The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used. For RA, patient must have had an inadequate response to one or more TNF inhibitors.<br>**Actemra Subcutaneous additional criteria:** The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used. The patient must have had an inadequate response to one or more TNF inhibitors.<br>**Cimzia additional criteria:** The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used.<br>**Remicade additional criteria** The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used.<br>**Simponi (subcutaneous) additional criteria:** The patient must be ≥ 18 years of age AND The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used.<br>**Simponi Aria additional criteria :** The patient has not responded adequately to Simponi subcutaneous. AND The prescriber must provide a clinically valid |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | reason why both Humira and Enbrel cannot be used.<br>**Kineret additional criteria:** Note: Kineret may be used as monotherapy or concomitantly with DMARDs, other than TNF antagonists. Kineret should not be administered concomitantly with any TNF antagonists (i.e. Enbrel, Humira, or Remicade). AND The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used.<br>**Xeljanz additional criteria** The patient must be ≥ 18 years of age AND The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used.<br>**Orencia Intravenous Infusion additional criteria:** Orencia may be used as monotherapy or concomitantly with DMARDs, other than TNF antagonists. Orencia® should not be administered concomitantly with TNFantagonists (i.e. Enbrel, Humira, or Remicade) and is not recommended for use with Kineret. AND The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used. AND If the diagnosis is RA, there is a clinically valid reason why Orencia Subcutaneous cannot be used.<br>**Orencia Subcutaneous additional criteria:** . Orencia should not be administered concomitantly with TNFantagonists (i.e. Enbrel, Humira, or Remicade) and is not recommended for use with Kineret. AND The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used.<br>**Stelara additional criteria:** The prescriber must provide a clinically valid reason why both Humira and Enbrel cannot be used.<br>**Patients with systemic juvenile arthritis (SJRA/SJIA)** and fever are not required to have a trial of a DMARD, including methotrexate. Patients with systemic juvenile arthritis without fever should have a trial of methotrexate, but a trial of another DMARD in the case of a contraindication to methotrexate is not required before Enbrel, Humira, Actemra, or Orencia is approved. * Patients with psoriatic arthritis with a documented diagnosis of active axial involvement |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| | | should have a trial of NSAID therapy, but a trial with DMARD is not required before a TNF-blocker is approved. If no active axial skeletal involvement, then an NSAID trial and a DMARD trial are required (unless otherwise contraindicated) prior to receiving Humira, Enbrel, Remicade, Cimzia, Stelara or Simponi |
| **SILIVA STIMULANTS** | | |
| PILOCARPINE (compare to Salagen®)<br>CEVIMELINE† (compare to Evoxac®)<br>EVOXAC® (cevimeline) | Salagen®* (pilocarpine) | Salagen: The patient has had a documented side effect, allergy, or treatment failure to generic pilocarpine |
| **SEDATIVE/HYPNOTICS** | | |
| **BENZODIAZEPINE** | | |
| ESTAZOLAM† (compare to Prosom®)<br>TEMAZEPAM† 15 mg, 30 mg (compare to Restoril®) | Doral® (quazepam)<br>flurazepam† (formerly Dalmane®)<br>Halcion® (triazolam)<br>Prosom®* (estazolam)<br>Restoril®* (temazepam)<br>temazepam† 7.5 mg, 22.5 mg (compare to Restoril®)<br>triazolam† (compare to Halcion®) | **Criteria for Approval:** The patient has had a documented side effect, allergy, or treatment failure with two preferred benzodiazepine sedative/hypnotics. If a product has an AB rated generic, one trial must be the generic. |
| **NON BENZODIAZEPINE, NON BARBITURATE** | | |
| | Ambien®* (zolpidem) *(Quantity Limit = 1 tab/day)* | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| ZOLPIDEM † (compare to Ambien®)*(Quantity Limit = 1 tab/day)*<br>ZALEPLON † (compare to Sonata®)<br>*(Quantity Limit = 1 cap/day (5 mg) or 2 caps/day (10 mg))* | Ambien CR® (zolpidem) *(Quantity Limit = 1 tab/day)*<br>Belsomra® (suvorexant) (*Quantity Limit = 1 tab/day)*<br>Edluar® (zolpidem) sublingual tablet *(Quantity Limit = 1 tab/day)*<br>eszopiclone† (compare to Lunesta® )<br>*(Quantity Limit = 1 tab/day)*<br>Intermezzo® (zolpidem) Sublingual Tablet *(Quantity Limit = 1 tab/day)*<br>Lunesta® (eszopiclone) *(Quantity Limit = 1 tab/day)*<br>Rozerem® (ramelteon) *(Quantity Limit = 1 tab/day)*<br>Silenor® (doxepin) *(Quantity limit = 1 tab/day)*<br>Sonata®* (zaleplon) *(Quantity Limit = 1 cap/day (5 mg) or 2 caps/day (10 mg))*<br>Zolpidem CR† (compare to Ambien CR®) *(Quantity Limit = 1 tab/day)* | **Ambien:** The patient has had a documented intolerance to generic zolpidem.<br>**Ambien CR, Belsomra, Lunesta, eszopiclone, Zolpidem CR:** The patient has had a documented side effect, allergy or treatment failure to generic zolpidem. If the request is for brand Ambien CR, there has also been a documented intolerance to the generic. If the request is for generic eszopiclone, there has also been a documented intolerance to the brand Lunesta. Belsomra will be available to the few patients who are unable to tolerate or who have failed on preferred medications.<br>**Edluar:** The patient has a medical necessity for a disintegrating tablet formulation (i.e. swallowing disorder). **Intermezzo:** The patient has insomnia characterized by middle-of-the night awakening followed by difficulty returning to sleep AND The patient has had a documented inadequate response to zolpidem IR AND zaleplon.<br>**Rozerem:** The patient has had a documented side effect, allergy, contraindication or treatment failure to generic zolpidem. OR There is a question of substance abuse with the patient or family of the patient. Note: If approved, initial fill of Rozerem will be limited to a 14 day supply.<br>**Silenor:** The patient has had a documented side effect, allergy, contraindication or treatment failure to generic zolpidem AND The patient has had a documented intolerance with generic doxepin or there is another clinically valid reason why a generic doxepin (capsule or oral solution) cannot be used.<br>**Sonata:** The patient has had a documented intolerance to generic zaleplon |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | |
| **SMOKING CESSATION THERAPIES** | | |
| **NICOTINE REPLACEMENT: maximum duration is 16 weeks (2 x 8 weeks)/365 days for non-preferred. For approval of therapy beyond the established maximum duration, the prescriber must provide evidence that the patient is engaged in a smoking cessation counseling program.** | | |
| NICOTINE GUM†<br>NICOTINE PATCH OTC†<br>NICORETTE LOZENGE®<br>**ORAL THERAPY**<br>BUPROPION SR† (compare to Zyban®)<br>CHANTIX® (varenicline) (Limited to 18 years and older, Quantity Limit = 2 tabs/day, max duration 24 weeks (2x12 weeks )/365 days) | Nicoderm CQ Patch®<br>Nicorette Gum®<br>nicotine lozenge†<br>Nicotrol Inhaler®<br>Nicotrol Nasal Spray®<br>Zyban®* (bupropion SR)<br>(maximum duration 24 weeks (2 x 12 weeks)/365 days) | **Nicoderm CQ patch:** The patient has had a documented intolerance to generic nicotine patch.<br>**Nicorette gum:** The patient has had a documented intolerance to generic nicotine gum.<br>**nicotine lozenge:** The patient has had a documented side effect or allergy to Nicorette lozenge<br>**Nicotrol Inhaler:** The patient has had a documented treatment failure with BOTH generic nicotine patch and generic nicotine gum.<br>**Nicotrol Nasal Spray:** The prescriber must provide a clinically valid reason for the use of the requested medication.<br>**Zyban:** The patient has had a documented intolerance to generic bupropion SR.<br>*Smoking Cessation Counseling is encouraged with the use of smoking cessation therapies*<br>*The combined prescribing of long acting (patch) and faster acting (gum or lozenge) nicotine replacement therapy is encouraged for greater likelihood of quit success.<br>**Vermont QUIT LINE** (available free to all patients) 1-800-QUIT-NOW (1-800-784-8669)<br>**GETQUIT™** Support Plan available free to all Chantix® patients 1-877-CHANTIX (242-6849)<br>**Limitations:** Nicotine System Kit® not covered – prescribe multiple strengths separately |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| **TESTOSTERONE: TOPICAL** | | |
| **Nasal** | | |
| | Natesto® (testosterone) nasal (QL = 1 pump/30 days) | **Natesto:** The patient has had a documented side effect, allergy, or treatment failure to AndroGel® Gel. |
| **Topical** | | |
| ANDROGEL® GEL (testosterone 1% gel packets)<br>*Quantity limit = 2.5 gm packet (1 packet/day)*<br>*5 gm packet (2 packets/day)* | Androderm® Transdermal 2mg, 4 mg (testosterone patch)<br>ANDROGEL® GEL (testosterone 1.62% gel packets)<br>*Quantity limit = 1.25 gm packet (1.62%) (1 packet/day)*<br>*2.5 gm packet (1.62%) (2 packets/day)*<br>ANDROGEL® PUMP (testosterone pump bottles)<br>*Quantity limit = 1 % (4 bottles/30 days)*<br>*1.62% (2 bottles/30 days)*<br>*Quantity limit = 1 patch/day/strength*<br><br>Axiron (testosterone 2% solution) 90 ml Pump Bottle<br>*Quantity limit = 2 bottles/30 days*<br>Fortesta® (testosterone 2 % Gel) 60 gm Pump Bottle<br>*Quantity limit = 2 bottles/30 days*<br>Testim® Gel 5 gm (testosterone 1% gel tube)<br>*Quantity limit = 2 tubes/day* | **Andoderm, Axiron, Fortesta, Testim Testosterone Gel 1%, Testosterone Gel 2 %, Androgel 1.62% packets, Androgel Pump:** The patient has had a documented side effect, allergy, or treatment failure to AndroGel® 1% Gel Packets<br>**Limitations:** Coverage of testosterone products is limited to males. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | Testosterone 1% Gel Packets (compare to Androgel®, Vogelxo®)<br>*Quantity Limit = 2.5gm packet (1 packet/day)*<br>*Quantity Limit= 5gm packet (2 packets/day)*<br>Testosterone 1% gel tube (compare to Testim® Gel 5 gm, Vogelxo®, Androgel®)<br>*Quantity limit = 2 tubes/day*<br>Testosterone† 1% Gel Pump (compare to Androgel®, Vogelxo®)<br>*Quantity limit = 4 bottles/30 days*<br>Testosterone 2% gel 60 gm pump bottle (compare to Fortesta® )<br>*Quantity limit = 2 bottles/30 days*<br>Vogelxo® 1% (testosterone 1%) gel, pump<br>*Quantity limit = 2 tubes/day (5 gm gel tubes)*<br>*Quantity limit = 4 bottles/30 days (gel pump bottle)*<br><br>*Maximum day supply all products is 30 days* | |
| **THROMBOPOIETIN RECEPTOR AGONISTS** | | |
| | Nplate® (romiplostim)<br><br>Promacta® (eltrombopag) | **FOR APPROVAL:** The patient is at least 18 years of age. AND The diagnosis or indication is chronic immune (idiopathic) thrombocytopenic purpura (ITP). AND The patient's platelet count is less than 30,000/µL (< 30 x 109/L) or the patient is actively bleeding. AND The patient has had a documented side effect, allergy, treatment failure or a contraindication to therapy with corticosteroids. OR The |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| | | patient has a documented insufficient response following splenectomy. |
| **URINARY ANTISPASMODICS** | | |
| **SHORT-ACTING AGENTS**<br>OXYBUTYNIN† (formerly Ditropan®) | Flavoxate † (formerly Urispas®) | **CRITERIA FOR APPROVAL:** (for patients >21 and <65 years of age): Please note: Patients <21 years of age are exempt from all ORAL ANTIMUSCARINIC Urinary Antispasmodics PA requirements (Exception: An adequate trial of oxybutynin/oxybutynin XL will be required before approval of Ditropan/Ditropan XL and an adequate trial of tolterodine SR will be required before approval of Detrol LA will be granted for all patients) and patients ≥ 65 years of age are exempt from the short acting oxybutynin trial requirement. |
| **LONG-ACTING AGENTS (after clinical criteria are met)**<br>**ANTIMUSCARINIC**<br>**Twice Daily Oral *(Qty Limit = 2 per day)*** | Detrol® (tolterodine)<br>tolterodine† (compare to Detrol®)<br>trospium† (formerly Sanctura®) | **flavoxate, Enablex, Vesicar:** The patient has had a documented side effect, allergy, or treatment failure with generic oxybutynin |
| | Detrol LA® (tolterodine SR) | |
| **Once Daily Oral *(Qty Limit = 1 per day)***<br>ENABLEX® (darifenacin)<br>VESICARE® (solifenacin) | Ditropan XL® (oxybutynin XL)<br>oxybutynin XL† (compare to Ditropan® XL)<br>tolterodine SR† (compare to Detrol LA®) | **Detrol, Detrol LA, Ditropan XL, Oxybutynin XL, tolterodine (generic), tolterodine SR (generic), trospium (generic), trospium ER (generic), Toviaz:** The patient has had a documented side effect, allergy, or treatment failure with generic oxybutynin. AND The patient has had a documented side effect, allergy, or treatment failure with 2 preferred long-acting agents. If a medication has an AB rated generic, there must have also been a trial of the generic formulation. |
| **Transdermal/Topical** | Toviaz® (fesoterodine<br>trospium ER† (formerly Sanctura XR®) | |
| **BETA-3 ADRENERGIC AGONISTS** | | |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS (No PA required unless otherwise noted) | NON-PREFERRED AGENTS (PA required) | PA CRITERIA |
|---|---|---|
| *>NOTE:*<br>▪ *Patients under the age of 65 must fail an adequate trial of generic oxybutynin before approval will be granted for either Vesicare® or Enablex®.*<br>▪ *A therapeutic failure on two long acting preferred products is required before a PA will be approved on any non-preferred long acting medication.*<br>*Recipients < 21 years of age are exempt from all ORAL ANTIMUSCARINIC PA Requirements.(Exception: An adequate trial of oxybutynin/ XL will be required before approval of Ditropan® XL and tolterodine SR before approval of Detrol LA® will be granted)* | Gelnique 3%® (oxybutynin topical gel)<br>*(Qty limit = 1 pump bottle (92gm)per 30 days)*<br>Gelnique 10%® (oxybutynin topical gel)<br>*(Qty limit = 1 sachet/day)*<br>Oxytrol® (oxybutinin transdermal) *(Qty Limit = 8 patches/28 days)*<br><br>Myrbetriq® (mirabegron) ER Tablet<br>*(Qty limit = 1 tablet/day)* | **Gelnique 3%, 10%, Oxytrol:** The patient is unable to swallow a solid oral formulation (e.g. patients with dysphagia) OR The patient is unable to be compliant with solid oral dosage forms.<br>**Myrbetriq:** The patient has had a documented side effect, allergy, treatment failure, or contraindication with one preferred long-acting urinary antimuscarinic agent.<br>**Limitations:** Oxytrol (for Women) OTC not covered. Oxytrol RX is available but subject to prior authorization. |
| **VAGINAL ANTI-INFECTIVES** | | |
| **CLINDAMYCIN**<br>CLINDAMYCIN VAGINAL† (clindamycin vaginal cream 2%)<br><br>**METRONIDAZOLE** | Cleocin®* (clindamycin vaginal cream 2%)<br><br>Cleocin® Vaginal Ovules (clindamycin vaginal | **Cleocin, Clindesse:** The patient has had a documented side effect, allergy, or treatment failure to generic clindamycin vaginal (clindamycin vaginal)<br><br>**Metrogel Vaginal, Nuvessa Vaginal:** The patient has had a documented side effect, allergy, or treatment failure to generic metronidazole vaginal gel 0.75 % |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F

# Department of Vermont Health Access
# Pharmacy Benefit Management Program

## Vermont Preferred Drug List and Drugs Requiring Prior Authorization
## (includes clinical criteria)

| PREFERRED AGENTS<br>(No PA required unless otherwise noted) | NON-PREFERRED AGENTS<br>(PA required) | PA CRITERIA |
|---|---|---|
| METRONIDAZOLE VAGINAL GEL 0.75%†<br>VANDAZOLE† (metronidazole vaginal 0.75%) | suppositories)<br>Clindesse® (clindamycin vaginal cream 2%)<br>Metrogel Vaginal®* (metronidazole vaginal gel 0.75%)<br>Nuvessa Vaginal® (metronidazole vaginal gel 1.3%) (1 pre-filled applicator/30 days) | or Vandazole. |
| **VITAMINS: PRENATAL MULTIVITAMINS** | | |
| PRENATAL PLUS IRON<br>PRENATAL VITAMINS PLUS<br>PRENATE AM TAB<br>PRENATE CAP ENHANCE<br>PRENATE CAP ESSENTIAL<br>PRENATE CAP RESTORE<br>PRENATE CHEW .6-.4<br>PRENATE DHA CAP<br>PRENATE MINI CAP<br>PREPLUS<br>VIRT-PN DHA CAP<br>VIRT-PN PLUS CAP<br>VOL-PLUS | All others | **All Non-Preferred:** The prescriber must provide a clinically valid reason for the use of the requested medication including reasons why any of the preferred products would not be a suitable alternative. |



This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
Drugs highlighted in yellow denote a change in PDL status.
To search the PDL, press CTRL + F